Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)
Date: 04 February, 2025

Episode Summary

• “Making America healthy again” begins with personal responsibility, because a nation cannot be treated like a patient, and health improves only when individuals change their daily habits.
• Modern healthcare often reacts to disease instead of preventing it, with insurance and medical spending focused on procedures and prescriptions rather than exercise, nutrition, and foundational care that keep people well.
• Hormones, peptides, and other therapies can support vitality when used thoughtfully and monitored carefully, while rushed or profit-driven protocols often ignore individual needs and create unnecessary risk.
• Breakthrough drugs and aggressive cancer treatments are frequently marketed as major advances, yet real-world benefits may be small while costs, side effects, and disruptions to daily life remain significant, which calls for careful evaluation before agreeing to intervention.
• Long-term health depends on prevention, including lowering toxin exposure, questioning invasive procedures such as unnecessary biopsies, and taking steady control of lifestyle decisions that protect strength, energy, and independence over time.

Quick Decision Checklist

Use this checklist as a simple self-review. These points help you confirm that your daily choices support prevention, personal responsibility, and long-term vitality rather than relying only on treatment after problems appear.

☐ You set aside time and resources for prevention such as regular movement, balanced meals, quality sleep, and routine health monitoring.

☐ Your daily habits support steady energy, healthy weight, and metabolic stability throughout the year.

☐ Your spending supports wellness through fitness, clean food, and foundational care alongside your insurance coverage.

☐ Your environment reflects lower exposure to avoidable risks such as smoking and unnecessary toxin contact.

☐ Your focus remains on consistent, everyday behaviors that protect strength, clarity, and independence over the long term.

00:00 Introduction

When you check the internet, you will see headlines like, “Only 12% of American adults are metabolically healthy.” After reading something like that, it is hard not to wonder where you stand. Are you actually healthy, or simply moving through life without obvious symptoms?

The idea of “making America healthy again” sounds straightforward, yet it raises a deeper question. When exactly were we healthy to begin with? Every period people look back on carried its own risks, from fatal infections before antibiotics, to pandemic disease, to waves of heart attacks and chronic illness. Health has never been a perfect state that disappeared. It has always required consistent effort and personal responsibility.

Waiting for a system, a policy, or the next medical breakthrough to fix things rarely leads anywhere. A country cannot be treated like a patient, and no one from outside is coming to manage your daily habits for you. Years of studying human behavior has showed us one thing: Real improvement begins at the individual level. The choices you make about how you eat, move, rest, and protect your body will eventually make a lot of differences.

02:52 The Reality of Health Insurance

Health insurance takes a significant share of personal income each year, and the national numbers show just how large that share has become. In 2024, U.S. healthcare spending grew 7.2% to $5.3 trillion, which averages $15,474 per person, with private insurance accounting for 31% of total expenditures. That amount of money represents a major financial commitment for families, employers, and the system as a whole.

With spending at that level, many people assume the structure is designed to keep them healthy, yet most coverage is centered on paying for care after illness has already developed. The system reimburses hospital visits, procedures, imaging, and medications, while the everyday habits that protect long-term health such as regular exercise, nutrition guidance, hormone support, and preventive programs usually come out of pocket. As a result, treatment is financially supported, while prevention often becomes a personal expense.

This arrangement quietly influences behavior. Once premiums, deductibles, and co-pays are paid each month, there is less room left to invest in proactive steps that build strength and resilience. Over time, it becomes normal to spend thousands managing disease and hesitate to spend a fraction of that on maintaining health. The focus shifts toward reacting to problems rather than reducing risk in advance.

Seeing the system this way brings the responsibility back to the individual. Insurance can help with unexpected events and major interventions, yet day-to-day vitality still depends on steady choices around movement, food, sleep, stress, and foundational care. Those small decisions, repeated consistently, have a greater impact on long-term outcomes than any policy document or insurance card.

03:22 Hormone Therapy

Hormones regulate how the body produces energy, builds muscle, maintains bone strength, stabilizes mood, and supports clear thinking, so changes in these levels show up in daily life in ways that are easy to notice. When testosterone, thyroid hormones, or other key signals decline, the effects often appear as fatigue, weight gain, reduced strength, slower recovery, and loss of focus. These symptoms are commonly dismissed as “just aging,” yet they reflect measurable physiologic changes rather than an unavoidable loss of health.

Clinical evidence shows that hormone levels influence long-term outcomes, which is why balance is important. Lowering hormone levels too far produced clear harm to brain health, which demonstrates that hormones affect far more than appearance or performance and play a direct role in how the brain and body function.

The same principle applies when levels are too low. If excessive suppression creates risk, maintaining healthy physiologic ranges helps protect strength, metabolism, and mental clarity. The focus remains on correcting deficiency rather than pushing levels beyond normal. Blood work, symptoms, and regular follow-up guide each adjustment so care reflects the individual instead of a preset protocol.

A steady and monitored approach treats hormone care as part of preventive medicine. Stable levels support muscle mass, protect bone density, maintain cardiovascular function, and preserve cognitive performance, all of which influence independence and quality of life over time. When these systems remain supported, daily movement feels easier, thinking stays sharper, and energy remains more consistent.

Viewed this way, hormone therapy becomes a practical tool for maintaining function year after year, with the goal of keeping the body operating efficiently and reducing the gradual decline that many people accept as normal.

05:40 Understand Peptides

Peptides are often presented as something new or experimental, yet the term simply describes short chains of amino acids that act as signaling molecules inside the body. In practical terms, they are small proteins that help regulate communication between cells. Many familiar therapies already fall into this category. Insulin is a peptide. Several naturally occurring hormones are peptides. These compounds have been used in medicine for decades, which means the concept itself is not exotic or futuristic. It is basic biology.

Understanding this definition removes much of the mystery. A peptide is not automatically a miracle treatment or a shortcut to better health. It is simply a tool that influences a specific pathway. Each peptide has a different target and a different purpose. Some affect metabolism, some influence healing and inflammation, and others act on brain function or body composition. The effect depends on the molecule and the context, not the label.

This is why careful evaluation matters. A thoughtful approach starts with a clear clinical goal and works backward. The question is not whether someone wants peptides. The question is what problem needs to be addressed and what mechanism makes sense for that problem. Symptoms, lab results, and overall health status guide the decision. When care is individualized, treatment becomes deliberate and measured. When care is reduced to a preset package or a quick sale, outcomes become unpredictable.

Using peptides responsibly follows the same principles as any other therapy. The body is assessed first, the target is defined, and the response is monitored over time. This keeps the focus on physiology rather than marketing and keeps the patient from chasing trends that sound advanced but add little real value.

09:43 The Quicks and Mentality

Many people judge their health by looking around and comparing themselves to others their age. If everyone feels tired, gains weight, and slows down, those changes begin to look normal. Decline becomes something expected instead of something to question. This mindset creates a quiet form of resignation. When everyone around you is sinking at the same rate, the situation feels acceptable even though the overall direction is downward.

This way of thinking shows up clearly in lab interpretation. Results are often described as normal for a certain age group, which gives the impression that falling performance is natural and therefore harmless. A lower hormone level, weaker metabolism, or rising blood sugar may still fit inside a wide reference range, yet that does not mean the body is functioning well. It simply means many other people share the same decline.

Medicine provides many examples where accepting the average leads to missed opportunities. Studies of prostate cancer treatment show that aggressive intervention does not automatically improve survival. In the large STAMPEDE randomized trial, adding radiotherapy to the prostate in men with newly diagnosed metastatic disease did not improve overall survival for the full study population. More treatment did not translate into longer life. This finding reinforces a broader lesson: Doing something simply because it is customary does not guarantee benefit.

A proactive mindset looks different. Instead of asking whether a result is typical for an age group, the focus shifts to whether it supports strength, energy, and long-term function. Health is treated as something to maintain intentionally rather than something that fades with time. Small corrections made early often prevent larger problems later.

11:55 The ‘Breakthrough Drug’

The phrase breakthrough drug carries a strong emotional pull. It suggests a major advance and a clear improvement in outcomes. In practice, many new therapies offer modest gains that sound impressive in headlines yet look far less dramatic when the numbers are examined closely. A treatment may extend survival by only a few months, require intensive monitoring, and bring a high rate of side effects, yet still be marketed as a major step forward.

Looking at real outcome data helps put these claims in context. Cancer trials often measure survival in months rather than years, and adverse reactions are common. Radiation-based therapies, for example, carry documented risks that affect daily life. Reports of brachytherapy show persistent rectal and bowel complications in a meaningful percentage of patients, which can include bleeding, pain, and long-term functional issues. These effects illustrate a simple reality. Every intervention has a cost.

This does not mean treatment has no place. It means the benefit must clearly outweigh the burden. Extending life slightly while reducing quality of life through repeated hospital visits, isolation, or severe side effects is a tradeoff that deserves careful thought. Numbers such as survival time, complication rates, and financial cost should be examined plainly rather than wrapped in optimistic language.

A clear view of the data leads to steadier decisions. New does not automatically mean better and expensive does not mean effective. The goal remains practical and grounded, which is to protect function, preserve energy, and choose interventions that offer meaningful value rather than symbolic action.

16:52 Isolation After the Treatment

Some treatments are presented as precise and targeted, yet the practical consequences tell a different story. A therapy may be described as localized radiation or a focused intervention, but the precautions that follow often reveal that the effect is not limited to a small area. When patients are instructed to avoid close contact with family members, sleep separately, or isolate themselves for days after each dose, it becomes clear that the treatment reaches beyond the intended target.

These instructions carry weight because they change daily life in very real ways. Time that would normally be spent with a spouse or family is replaced with separation. Normal routines are interrupted. Weeks of recovery and restricted contact accumulate across multiple cycles. When this pattern repeats over several treatments, a large portion of the remaining time is spent managing side effects rather than living normally.

This practical burden deserves the same attention as the survival statistics. Extending life by a short interval has a different meaning when a significant share of that time involves isolation, hospital visits, and recovery. Quality of life becomes just as important as duration. A treatment plan should be evaluated not only by what it promises on paper, but by how a person will actually live during those months.

Looking at care this way encourages a steadier and more deliberate decision process. Instead of reacting to the word breakthrough or assuming that more treatment automatically equals better outcomes, the focus shifts to the full picture, which includes time, comfort, independence, and daily function. A choice that preserves connection and strength may carry more value than one that simply adds days under heavy medical supervision.

19:46 Cadmium Is Everywhere

Environmental exposure rarely receives the same attention as drugs or procedures, yet long-term contact with toxins can quietly shape health over decades. Cadmium is one of those exposures. It is a heavy metal found in soil, food, cigarette smoke, and industrial pollution, and small amounts accumulate gradually in the body over time. Because it builds up slowly, most people are unaware of how much they carry.

Research shows that this exposure is not trivial. A pooled analysis of multiple studies found that cadmium levels in prostate tissue and blood were significantly higher in men with prostate cancer than in healthy controls. This association does not depend on symptoms or headlines. It is measured directly in tissue and plasma. The closer the proximity to a known carcinogen, the greater the potential for cellular damage.

This finding supports a simple preventive principle. Reducing exposure and lowering body burden where possible is a practical step toward lowering long-term risk. Attention to food sources, smoking status, occupational contact, and detoxification strategies becomes part of routine health maintenance rather than an afterthought. Prevention often looks quiet and unremarkable, yet these small adjustments accumulate just as steadily as the exposure itself.

Focusing on environmental load also shifts the conversation away from waiting for disease to appear. Instead of reacting after a diagnosis, the goal becomes lowering risk factors before they create harm. This approach aligns with the broader theme of taking responsibility for what can be controlled today rather than relying solely on treatment tomorrow.

21:33 Never Biopsy a Prostate

A biopsy is often treated as a routine next step after an abnormal screening result, yet the procedure is still invasive and carries biological consequences. Passing a needle repeatedly through tissue disrupts the structure of the gland and creates a path through which cells can move. The act of sampling is not neutral. It alters the environment it is trying to measure.

Laboratory research has demonstrated that tumor cells can be displaced along the needle track during core needle biopsy. This mechanical spread has been documented in several cancers and supports the concern that puncturing a tumor may increase the chance of local dissemination. Even if the risk is small, it highlights that a biopsy is not simply a harmless diagnostic step.

At the same time, outcome data from prostate cancer management show that detecting and treating more disease does not always translate into longer life. Aggressive intervention often carries side effects such as incontinence, sexual dysfunction, and chronic discomfort, while survival differences remain limited in many early cases. When the benefit is uncertain and the harms are clear, the decision deserves careful thought.

Seeing these pieces together leads to a more cautious mindset. Information is valuable only when it changes management in a meaningful way. If the result will not alter the plan or improve outcomes, adding an invasive step may create more harm than clarity. A deliberate approach that weighs necessity, risk, and long-term impact helps protect both health and quality of life.

23:40 Trust Generic Drugs

Medication decisions are often shaped by marketing and headlines instead of long-term evidence. New drugs arrive with big promises and strong promotion, while older medicines continue to work quietly in everyday practice. A drug that has been used for many years carries something valuable, which is a long record of real-world results. Doctors understand how it behaves, what doses work, and what side effects to expect because millions of patients have already used it.

Generic drugs come from this history. They contain the same active ingredients and must meet the same safety and quality standards as brand-name versions, yet they cost less because the research and branding expenses have already been paid. That lower cost makes treatment easier to access and easier to sustain over time.

This trend will continue. Many high-cost brand-name drugs are losing patent protection between 2025 and 2033, which opens the door for more affordable and complex generic alternatives. As those patents expire, more treatments will move into the generic space, giving patients dependable options without the high price tag.

25:39 Take Control of Your Health

Daily health is shaped by consistent habits rather than occasional treatments. Steady decisions around food, movement, sleep, and medical care influence long-term outcomes far more than reacting after a problem appears. A practical plan begins with simple actions you can apply every day.

What to Do:

1. Maintain a healthy body weight and waist size through regular physical activity and balanced meals built around whole foods, since stable body composition supports metabolism, hormone balance, and cardiovascular health.
2. Check your labs at regular intervals and review trends over time so you understand how your body is changing and can address small shifts before they grow into larger issues.
3. Correct hormone, thyroid, blood sugar, and nutrient imbalances early with proper evaluation and follow-up, because early adjustment helps preserve energy, strength, and mental clarity.
4. Reduce exposure to environmental toxins by avoiding smoking, improving indoor air quality, and paying attention to food and water sources, since long-term accumulation of harmful substances increases disease risk.
5. Ask clear questions before agreeing to procedures or medications and make sure each step has a meaningful benefit that justifies the cost and potential side effects.
6. Use established treatments with long safety records, including generic medications when appropriate, so care remains predictable, affordable, and supported by years of real-world experience.
7. Protect the basics each day by prioritizing consistent sleep, daily movement, and stress control, because these habits support nearly every system in the body and strengthen long-term resilience.

Taking these steps keeps control in your hands and builds health gradually through deliberate, informed action.

Key Takeaway

Health rarely improves through one dramatic change. It improves through steady, informed decisions repeated every day. Insurance, prescriptions, and procedures all have a role, yet they do not replace the basics that keep the body strong. Energy, strength, and long-term resilience come from maintaining healthy weight, balanced hormones, clean nutrition, regular movement, reduced toxin exposure, and thoughtful medical choices grounded in evidence.

The common thread across each topic in this episode remains simple and practical. Question interventions that add risk without clear benefit, rely on treatments with a long record of safety, pay attention to environmental exposures that accumulate quietly over time, and address small imbalances before they grow into larger problems. This approach shifts the focus away from reacting to disease and toward protecting function.

Call to Action

If you found this episode helpful, take a moment to rate and subscribe to the Intellectual Medicine podcast so you never miss future discussions grounded in evidence and practical decision-making. For a deeper look at the research, clinical reasoning, and preventive strategies behind this vitality-focused approach, you can explore Fight Cancer Like a Man, which walks through these concepts in clear, step-by-step detail you can apply to your own health. Member notes, clinical summaries, and extended guides are added regularly, so stay engaged and continue building your understanding with each new episode.

Join the Intellectual Medicine Community

• Membership (exclusive educational content and clinical resources): https://tinyurl.com/DrPetterutiMember
• Sign up for Dr. Steve’s Email Newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com 

Connect with Dr. Petteruti

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
• Instagram: https://www.instagram.com/dr.stephenpetteruti
• Facebook: https://www.facebook.com/dr.stephenpetteruti 

Subscribe to the Intellectual Medicine Podcast

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast 
• Spotify:  https://tinyurl.com/DrPetterutiSpotifyPodcast

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

References:

Hoffman, Karen E et al. “Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.” JAMA vol. 323,2 (2020): 149-163. doi:10.1001/jama.2019.20675

Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14, 2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005

Ladjevardi, Sam et al. “Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.” Disease Markers vol. 2014 (2014): 707529. doi:10.1155/2014/707529

Lane, Janet Athene et al. “Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).” BJU international vol. 130,3 (2022): 370-380. doi:10.1111/bju.15739

Parker, Christopher C et al. “Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.” Lancet (London, England) vol. 392,10162 (2018): 2353-2366. doi:10.1016/S0140-6736(18)32486-3

Zhang, Liang et al. “Cadmium Levels in Tissue and Plasma as a Risk Factor for Prostate Carcinoma: a Meta-Analysis.” Biological trace element research vol. 172,1 (2016): 86-92. doi:10.1007/s12011-015-0576-0

Other Links:

https://www.unc.edu/posts/2018/11/28/only-12-percent-of-american-adults-are-metabolically-healthy-carolina-study-finds/#:~:text=Only%2012%20percent%20of%20American,study%20finds%20%7C%20UNC%2DChapel%20Hill 

https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet 

https://www.pcmanet.org/rx-research-corner/generic-drugs-are-an-american-success-story-heres-why/06/10/2022/#:~:text=Indeed%2C%20peer%2Dreviewed%20research%20concludes,BACK%20TO%20RX%20RESEARCH%20CORNER 

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)
Date: 11 February, 2025

Episode Summary

• Human beings naturally carry higher body fat from birth, which means energy storage is built into normal biology, and controlling percent body fat requires structure rather than short-term dieting.
• Percent body fat and muscle mass provide a clearer measure of health than body weight alone, because excess fat increases metabolic and cardiovascular risk while preserved muscle supports strength, glucose control, and long-term function.
• Regular feeding times, adequate protein intake, and simple repeatable meals help regulate hunger hormones such as ghrelin, reduce overeating, and make daily intake predictable.
• Exercise improves strength, bone density, heart health, and mental well-being, yet fat loss depends primarily on consistent nutrition habits, with medication used only as supportive therapy when appropriate.
• Sustainable weight management comes from organized daily behaviors that can be repeated long term rather than temporary diets or extreme restrictions.

Quick Decision Checklist

Use this checklist to confirm that daily habits support healthy body composition and long-term health.

☐ Percent body fat or body composition tracked regularly
☐ Consistent feeding times maintained throughout the day
☐ Adequate protein included at each meal
☐ Fruit intake controlled and limited to structured meals
☐ Strength training performed weekly to protect muscle and bone
☐ Exercise used for fitness and conditioning rather than to offset excess intake
☐ Daily routine focused on prevention and long-term function

00:00 Introduction

Human beings are the fattest animals at the time of birth. There is no other organism on the planet that carries as much body fat when it enters the world. In most mammals, only about 2 to 3% of birth weight is fat, and chimpanzee newborns average about 3%. Humans begin life with substantially higher fat stores, which means energy conservation is part of normal human biology from day one.

A body designed to conserve energy does not lose fat easily. When energy intake exceeds energy use, the excess is stored as fat. Repeating that pattern day after day increases the percent body fat over time. That is just one of the many reasons why a lot of people are now dealing with obesity issues, even when they are putting in conventional efforts to lose weight.

Now the big question is: What can be done differently to get rid of obesity issues?

01:20 Two Main Things We Do

Human behavior follows two consistent drives. We seek pleasure, and we avoid pain. Nearly everything we do each day connects back to one of those two goals.

Eating fits directly into both.

Food removes the discomfort of hunger, which satisfies the drive to avoid pain, and at the same time, food activates reward pathways in the brain that release dopamine and other neurotransmitters, which creates a sense of pleasure. The brain quickly learns this connection, so eating becomes a behavior the body encourages again and again.

There is also a metabolic reason behind this pattern. The brain accounts for only about 2% of body weight, yet it uses close to 20% of the body’s daily energy. That high demand keeps appetite signals active throughout the day and explains why most people rarely feel “done” eating for long.

02:57 What Is a Calorie?

A calorie is a unit of energy used in thermodynamics. In scientific terms, one dietary calorie, which is technically a kilocalorie, represents the amount of energy required to raise one kilogram of water by one degree Celsius. The term helps researchers measure heat and energy output, yet it does not describe food in a practical or physical way.

People do not eat energy units. They eat portions of food. The stomach responds to the weight and volume of what is consumed, along with the balance of protein, fat, and carbohydrate. For that reason, translating every meal into numbers often creates a system that feels disconnected from normal eating behavior.

Long-term data reflect this problem. Large reviews that combine results from multiple diet trials report that calorie-restricted diets rarely lead to durable weight loss. Many participants regain lost weight within the first year, and most return to baseline within several years. The outcome appears repeatedly across different diet styles.

Managing intake through planned portions and structured meals fits daily life more naturally and allows eating habits to remain consistent over time, which supports better control of percent body fat.

04:32 What Happens With Diets

Dieting usually lowers body weight at first, yet the number on the scale does not tell you what was actually lost. Weight includes fat, muscle, water, and bone. When intake drops sharply, the body does not remove fat alone. It often breaks down muscle tissue and sheds water along with it.

Losing muscle creates a problem. Muscle drives daily energy use and supports metabolic rate. When muscle mass declines, the body burns fewer calories at rest, which makes future fat storage easier even if food intake stays the same. At that point, weight loss slows while fat regain becomes more likely.

Bone can also be affected. Rapid weight loss without adequate protein and resistance training has been associated with measurable reductions in bone density, particularly during aggressive restriction or drug-only approaches. Bone tissue does not rebuild quickly, which means that short-term weight loss can carry long-term consequences.

For this reason, focusing only on total weight can be misleading. Health improves when fat decreases and muscle is preserved. Any plan that reduces muscle or bone while lowering the scale moves the body in the wrong direction.

06:04 Cornerstone Elements

Once you understand how the body stores energy and how dieting affects muscle and metabolism, the next step becomes practical. Fat loss works better when eating follows structure instead of appetite.

Hunger is not a reliable guide. The body produces hunger signals throughout the day whether energy is needed or not, which means waiting until you feel hungry often leads to irregular eating and oversized portions. A more predictable approach comes from scheduling intake in advance.

This is where feeding times come in. A feeding time simply means a planned moment to fuel the body. It does not need to be a large sit-down meal. It can be small and simple, yet it occurs at a consistent time. Planning meals this way creates stable energy levels and reduces impulsive eating later in the day.

Protein becomes the foundation of each feeding time. The body relies on amino acids to maintain muscle tissue, produce hormones, and support basic metabolic functions. When protein intake is too low, the body breaks down muscle to supply those needs. Losing muscle lowers metabolic rate and makes fat control more difficult, which is why preserving muscle mass remains a priority during weight loss.

Consistency matters more than variety. Repeating similar foods and portions each day simplifies decisions and makes intake easier to control. When meals are predetermined, adherence improves and eating becomes a routine process rather than something driven by mood or convenience.

This structured approach turns fat loss into a controlled system. Scheduled feeding times, adequate protein, and predictable portions provide the foundation that supports healthier body composition over the long term.

10:08 The Perfect Body Fat

Body weight alone does not tell you whether someone is healthy. The number on a scale combines fat, muscle, water, and bone into one total, so it cannot show what actually improved or what declined. Two people can weigh the same and still have very different health profiles depending on how much of that weight comes from fat and how much comes from lean tissue.

Percent body fat gives a clearer picture. Excess body fat, especially around the abdomen, is associated with insulin resistance, cardiovascular disease, type 2 diabetes, joint degeneration, and shorter lifespan. Large population studies consistently report higher rates of metabolic disease as body fat rises, even when total weight falls within a “normal” range.

Clinical guidelines place healthy body fat ranges for men at roughly 10 to 20% and for women at roughly 18 to 28%, with some variation by age and activity level. Values that rise far above these ranges correlate with higher inflammation markers, poorer glucose control, and reduced physical performance.

Muscle tissue supports daily energy use, strength, and joint stability. When dieting leads to muscle loss, resting metabolic rate declines because the body burns fewer calories at rest. Lower energy use makes fat regain more likely. A program that reduces scale weight but reduces muscle can leave someone lighter while also weaker and less metabolically efficient.

Tracking body composition prevents this problem. Tools such as bioelectrical impedance analysis, DEXA scans, or skinfold measurements identify what is actually changing. Fat loss with preserved muscle indicates progress. Muscle loss signals the need for adjustment.

11:34 The Hormone Called Ghrelin

Hunger is controlled by hormones. One of the primary signals is ghrelin, which is produced in the stomach and communicates with the brain to stimulate appetite.

Ghrelin rises when the stomach is empty and falls after eating. This cycle repeats throughout the day and follows a predictable rhythm. Research also shows that ghrelin responds to timing. When meals occur at regular hours, the body prepares in advance and appetite remains moderate. When meals are skipped or delayed, ghrelin levels climb higher and hunger becomes intense, which often leads to overeating.

The speed of eating also influences intake. After food enters the stomach, it takes about 20 to 30 minutes for hormonal signals to reduce appetite. Eating too quickly during this period allows more food to be consumed before fullness registers.

Scheduled meals reduce these extremes. Regular feeding times limit long gaps, keep hunger signals controlled, and make portion sizes easier to manage. Consistency works with normal physiology rather than against it.

13:13 Food Variety Is Nonsense

The idea that every meal needs to be different sounds attractive, yet it often makes weight control harder. Constant variety increases decision-making and creates uncertainty about portion sizes and ingredients. Each new option introduces small changes that add up over time.

Repetition simplifies eating. Similar meals each day stabilize intake and remove unnecessary choices. Many structured nutrition programs use this approach. Athletes, military units, and clinical weight-management plans often rely on standardized menus because predictable meals produce predictable results.

Consistency also improves accuracy. Repeating portions makes it easier to understand how the body responds and allows small adjustments without recalculating everything. Protein intake, carbohydrate limits, and total food volume remain controlled with less effort.

This structure supports everyday eating while still allowing planned flexibility. Most body composition changes come from routine habits repeated across the week rather than occasional special events.

Taken together, monitoring body fat, managing hunger hormones, and using simple, repeatable meals create a practical system. The body responds well to predictable inputs, and that predictability makes fat loss easier to maintain over time.

16:22 Knowing Someone Is Healthy

Health cannot be judged by body size alone. A lower number on the scale does not automatically mean better health because weight includes fat, muscle, bone, and water all combined into one total. The scale cannot tell you what improved and what declined.

Objective measurements give clearer answers. Percent body fat, muscle mass, strength, blood pressure, fasting glucose, and cholesterol levels describe how well the body is actually working. These markers connect directly to disease risk and daily performance.

Muscle tissue plays a central role in this process. Muscle handles most of the glucose your body uses after meals and supports insulin sensitivity. More muscle improves blood sugar control and lowers the risk of metabolic disease. Bone density protects posture and reduces fracture risk as you age.

Body fat location also influences risk. Fat stored around the abdomen surrounds internal organs and releases inflammatory signals that contribute to heart disease and diabetes. Studies consistently link increasing waist size with higher cardiometabolic risk.

Health therefore comes down to function. Strength, energy, and stable lab values give a more reliable picture than appearance.

16:51 Hedonistic Eating

Food does more than provide fuel. It also connects people to family, culture, and celebration. Removing every enjoyable food often creates frustration and leads to overeating later.

Behavioral research supports this pattern. Strict restriction increases cravings and lowers long-term adherence. When people feel deprived, they tend to compensate with larger portions or unplanned snacks. That cycle disrupts progress.

Planning enjoyable foods works better. Choosing the time and portion ahead of time keeps intake controlled while still allowing enjoyment. A defined treat fits into the week without throwing off the entire routine.

This method replaces impulsive eating with deliberate eating. Impulsive choices happen when food appears suddenly and emotions guide the decision. Deliberate choices follow a plan. A plan creates consistency, and consistency keeps body fat under control.

18:50 The Real Benefits of Fruits

Fruit contains fiber, vitamins, minerals, and plant compounds that support overall health. These nutrients are valuable. Fruit also contains natural sugars, which add to total carbohydrate intake.

Carbohydrates influence insulin release. Frequent large spikes in insulin encourage the body to store energy as fat. This process does not change simply because the sugar comes from fruit.

Portion size determines the effect. A small serving of berries with a meal provides nutrients with modest carbohydrate intake. Multiple servings of high-sugar fruits throughout the day can equal the carbohydrate load of snack foods or desserts.

Clinical nutrition guidance often recommends limiting fruit to one serving at a time and pairing it with protein or fiber. This slows absorption and helps keep blood sugar steady.

Fruit supports health when used thoughtfully. Large or frequent portions add extra energy that the body stores.

20:43 The Role of Exercise

Exercise improves heart health, strength, balance, and mood. Regular activity lowers blood pressure, improves insulin sensitivity, and supports mental well-being. These benefits are well established.

Exercise alone does not remove large amounts of body fat. A typical 30-minute brisk walk burns about 150 to 200 calories, which can be replaced quickly with one snack or drink. The body also adapts by conserving energy later in the day, which reduces the total effect.

Most fat loss comes from controlling intake. Exercise protects muscle and improves health markers, but it does not offset excess eating.

Exercise should therefore support your structure rather than act as compensation for food.

What to Do

Use these habits to guide daily behavior:

1. Schedule 3 to 5 feeding times and include protein at each meal.
2. Measure percent body fat periodically instead of relying only on scale weight.
3. Plan one or two controlled treats per week.
4. Keep fruit portions small and pair them with protein or fiber.
5. Perform strength training 2 to 3 times per week to protect muscle and bone.
6. Use walking or light cardio for heart health, not to cancel out overeating.
7. Keep meals simple and repeatable so intake stays predictable.

These steps create structure and make progress easier to maintain.

21:30 Pharmacology Influence

Obesity is recognized medically as a chronic metabolic condition. Some people benefit from medication support when lifestyle changes alone are not enough.

Certain medications reduce appetite or increase fullness. Older options such as phentermine have been used for decades and remain inexpensive. Newer GLP-1 medications, including semaglutide, slow stomach emptying and reduce hunger signals. Clinical trials report average weight reductions of about 10 to 15% over one year.

Medication still requires structure. Reduced appetite can lead to skipped meals and low protein intake, which increases the risk of muscle and bone loss. Studies have documented declines in lean mass when weight loss occurs without adequate nutrition.

Medication works best when combined with planned meals and strength training. Drugs assist the process. Daily habits determine the outcome.

Key Takeaway

Health is built through daily structure, not occasional effort. Percent body fat, muscle mass, and metabolic stability provide a clearer picture of wellness than body weight alone, which is why tracking body composition offers more useful guidance than watching the scale.

Planned meals, controlled portions, and consistent eating times help regulate hunger hormones and reduce overeating, while simple and repeatable food choices keep intake predictable. Enjoyable foods can still fit into the week when they are scheduled and limited rather than impulsive.

Exercise supports strength, bone health, and cardiovascular function, yet food intake remains the primary driver of fat loss. Medication can assist selected individuals, but it works best when paired with disciplined habits rather than used as a substitute for them.

Call to Action

For a broader explanation of the reasoning behind this perspective, Fight Cancer Like a Man by Dr. Stephen Petteruti presents these principles in a structured and practical format, outlining how to approach cancer prevention, screening, and treatment decisions with clarity.

Fight Cancer Like a Man by Dr. Petteruti: https://www.amazon.com/dp/B0GLZ9TL8N/

If you would like continued access to extended clinical notes and member-only discussions, you can join the Intellectual Medicine Community here:

• Membership: https://tinyurl.com/DrPetterutiMember
• Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
  Instagram: https://www.instagram.com/dr.stephenpetteruti
  Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
• Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To support deeper reflection, referenced studies explore the long-term outcomes of observation compared with intervention. These data examine survival, treatment-related complications, and the biological consequences of biopsy and hormone suppression. Reviewing this literature allows patients and clinicians to move beyond habit and consider a more individualized approach to prostate health.

Selected References

The following peer‑reviewed studies and reviews provide background evidence for the concepts discussed in Episode 02: “Obesity and Aging: The Secrets to Sustainable Weight Loss.” These references explore the biological role of body fat in humans from birth, the metabolic adaptations that promote fat preservation, and strategies that support healthy, sustainable fat loss through metabolism management rather than short‑term dieting. Together, they highlight how energy balance, muscle preservation, and hormonal regulation influence long‑term body composition and aging.

Brennan CS. Dietary fibre, glycaemic response, and diabetes. Mol Nutr Food Res. 2005;49(6):560‑570. doi:10.1002/mnfr.200500025
PubMed: https://pubmed.ncbi.nlm.nih.gov/15926172/

Center for Academic Research and Training in Anthropogeny (CARTA). Fatness at Birth. CARTA Website. https://carta.anthropogeny.org/moca/topics/fatness-birth. Accessed February 11, 2025. 

Chen Y, Yang Y, Jiang H, Liang X, Wang Y, Lu W. Associations of BMI and Waist Circumference with All‑Cause Mortality: A 22‑Year Cohort Study. Obesity (Silver Spring). 2019;27(4):662‑669. doi:10.1002/oby.22423
PubMed: https://pubmed.ncbi.nlm.nih.gov/30807694/

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714‑1719. doi:10.2337/diabetes.50.8.1714
PubMed: https://pubmed.ncbi.nlm.nih.gov/11473029/

Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity (Silver Spring). 2016;24(8):1612‑1619. doi:10.1002/oby.21538
PubMed: https://pubmed.ncbi.nlm.nih.gov/27136388/

Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: advances in models and methods. Annu Rev Nutr. 1997;17:527‑558. doi:10.1146/annurev.nutr.17.1.527
PubMed: https://pubmed.ncbi.nlm.nih.gov/9240939/

Kuzawa CW. Adipose tissue in human infancy and childhood: an evolutionary perspective. Am J Phys Anthropol. 1998;(Suppl 27):177‑209. doi:10.1002/(SICI)1096‑8644(1998)107:27+<177::AID‑AJPA7>3.0.CO;2‑B
PubMed: https://pubmed.ncbi.nlm.nih.gov/9881522/

Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6 Suppl):1320S‑1329S. doi:10.3945/ajcn.114.084038
PubMed: https://pubmed.ncbi.nlm.nih.gov/25926512/

Leonard WR, Robertson ML, Snodgrass JJ, Kuzawa CW. Metabolic correlates of hominid brain evolution. Comp Biochem Physiol A Mol Integr Physiol. 2003;136(1):5‑15. doi:10.1016/S1095‑6433(03)00132‑6
PubMed: https://pubmed.ncbi.nlm.nih.gov/14527624/

Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare's search for effective obesity treatments: diets are not the answer. Am Psychol. 2007;62(3):220‑233. doi:10.1037/0003‑066X.62.3.220
PubMed: https://pubmed.ncbi.nlm.nih.gov/17469900/

Phillips SM, Van Loon LJ. Dietary protein for athletes: from requirements to optimum adaptation. J Sports Sci. 2011;29 Suppl 1:S29‑S38. doi:10.1080/02640414.2011.619204
PubMed: https://pubmed.ncbi.nlm.nih.gov/22150425/

Raynor HA, Epstein LH. Dietary variety, energy regulation, and obesity. Psychol Bull. 2001;127(3):325‑341. doi:10.1037/0033‑2909.127.3.325
PubMed: https://pubmed.ncbi.nlm.nih.gov/11316011/

Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127(6):547‑553. doi:10.1016/j.amjmed.2014.02.007
PubMed: https://pubmed.ncbi.nlm.nih.gov/24561114/

Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Church TS. The role of exercise and physical activity in weight loss and maintenance. Prog Cardiovasc Dis. 2014;56(4):441‑447. doi:10.1016/j.pcad.2013.09.012
PubMed: https://pubmed.ncbi.nlm.nih.gov/24438736/

Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med. 2011;364(13):1218‑1229. doi:10.1056/NEJMoa1008234
PubMed: https://pubmed.ncbi.nlm.nih.gov/21449785/

Wells JC. The evolution of human fatness and susceptibility to obesity: an ethological approach. Biol Rev Camb Philos Soc. 2006;81(2):183‑205. doi:10.1017/S1464793105006974
PubMed: https://pubmed.ncbi.nlm.nih.gov/16573852/

Wilding JPH, Batterham RL, Calanna S, et al. Once‑Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989‑1002. doi:10.1056/NEJMoa2032183
PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/

Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84(3):475‑482. doi:10.1093/ajcn/84.3.475
PubMed: https://pubmed.ncbi.nlm.nih.gov/16960159/

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are intended to support thoughtful decision-making and improve health literacy. They are not a substitute for individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Members Version)

Date: 08 February, 2026

Episode Summary

• Early stage prostate cancer often progresses slowly, and long-term studies report little or no survival difference between immediate conventional treatment and careful observation, while surgery and radiation carry clear risks such as urinary leakage, erectile dysfunction, and bowel complications.
• PSA tests, biopsies, and imaging provide limited predictive certainty, and invasive procedures can introduce their own harms, so decisions work best when guided by trends, overall health, and thoughtful evaluation rather than reacting to a single result.
• A structured, prevention-focused approach that includes watchful waiting, immune support, lowering toxic exposures, and maintaining healthy body composition helps protect quality of life while allowing time to choose treatment only when it is truly necessary.

Quick Decision Checklist

Use this checklist to confirm that your daily choices support careful monitoring, prevention, and long-term prostate health.

☐ PSA levels tracked over time instead of reacting to one isolated result

☐ Abnormal PSA values repeated after rest and recovery to rule out temporary causes such as illness, stress, or recent activity

☐ Clear understanding of how a biopsy result would change management before agreeing to the procedure

☐ Regular follow-up visits are scheduled for monitoring rather than rushing into treatment

☐ Percent body fat and waist size are kept within healthy ranges to lower metabolic and cancer risk

☐ Sleep, nutrition, and physical activity are used daily to support immune function

☐ Environmental exposures, such as heavy metals or toxins evaluated when appropriate

☐ Decisions made calmly with complete information and personal values guiding the process

00:00 Introduction

A prostate cancer diagnosis can make anyone feel like they need to act fast. The word “cancer” carries weight, and the first instinct is often to remove it or treat it immediately before it spreads. Many people believe that earlier treatment always leads to better results.

Prostate cancer does not always behave that way. Research over many years has found that a large number of early prostate cancers grow slowly and stay inside the gland without causing symptoms or shortening life. At the same time, common treatments such as surgery and radiation can lead to urine leakage, sexual dysfunction, bowel problems, and other lasting complications. In some cases, the treatment creates more measurable harm than the cancer itself.

That creates an important question: If early treatment does not clearly improve survival, and the side effects can permanently change daily life, is rushing into surgery or radiation always the right move?

02:09 New Discoveries About Prostate Cancer

For many years, prostate cancer was treated with one basic idea in mind. If cancer is found early, remove it quickly. The assumption was that early surgery or radiation would naturally save lives.

Long-term research began to question that belief. As more men were followed over time, doctors noticed something unexpected. Many early prostate cancers grew very slowly and stayed confined to the prostate for years without causing symptoms. Some never affected lifespan at all. In other words, detection did not automatically mean danger.

Clinical trials helped clarify this pattern. One of the better-known examples is the PIVOT trial, where men with localized prostate cancer were split into two groups. One group had the prostate removed through surgery, and the other group received observation without immediate treatment. After more than a decade of follow-up, overall survival between the two groups looked nearly the same, and deaths specifically from prostate cancer were also similar. Removing the gland did not produce a clear survival advantage.

At the same time, the men who underwent surgery experienced higher rates of complications. Urinary leakage, erectile dysfunction, and surgical risks appeared more often in the treated group. These side effects affected daily life in ways that could not be reversed, while the expected survival benefit remained small or uncertain.

These findings changed how many specialists think about early disease. Prostate cancer often behaves differently from aggressive cancers such as pancreatic or lung cancer. Instead of spreading rapidly, it may remain slow and contained for long periods. Treating every early tumor as an emergency can lead to harm without a matching benefit.

This shift in understanding explains why some medical guidelines now accept observation, often called watchful waiting or active surveillance, as a reasonable first step for many men with early-stage prostate cancer. The goal becomes careful monitoring rather than immediate intervention, which allows treatment to be reserved for cases that show clear signs of progression.

When you look at the data this way, the decision starts to feel less urgent. Early detection still has value, yet immediate treatment does not always improve outcomes. Knowing that difference gives you room to think clearly and weigh the real risks and benefits before moving forward.

05:00 Potential Damage from Radiation

Radiation therapy is often presented as an option for men who want to avoid surgery. The idea sounds straightforward. The prostate remains in place, and the cancer is targeted and destroyed with focused radiation. Many people assume this approach avoids the risks that come with an operation.

Radiation still carries its own set of risks, and those risks can appear months or even years later. Radiation affects cancer cells and nearby healthy tissue because the prostate sits next to the bladder and the rectum. When those tissues absorb radiation, they can become inflamed or damaged over time.

Damage to the rectum is known as radiation proctitis. Men can develop chronic irritation, bleeding, pain, or difficulty controlling bowel movements. Damage to the bladder, called radiation cystitis, can lead to burning with urination, bleeding, or increased urgency and frequency. These problems may persist long after treatment ends and can interfere with daily comfort.

There is also a broader biological concern. Radiation itself is carcinogenic, which means it has the potential to damage DNA and increase the risk of future cancers. Studies that follow patients for many years have reported small but measurable increases in secondary malignancies after pelvic radiation, including bladder and blood-related cancers. The risk is not immediate, yet it exists because radiation works by injuring cells at a genetic level.

When the survival benefit is unclear or ambiguous, these trade-offs become important. Some treatments extend life, and people accept side effects as part of the cost. Long-term survival for early-stage prostate cancer often appears similar across different treatment paths, so side effects carry greater weight because they may reduce quality of life without adding measurable time.

Radiation can cause lasting bowel, bladder, and sexual problems. These complications may continue for years and can affect daily comfort and independence. At the same time, research has not established a clear survival benefit for early-stage prostate cancer. Many men at this stage feel completely well and have cancer that remains confined to the prostate. Starting radiation in that situation can introduce new health problems that did not previously exist, even though the person had no symptoms to begin with.

07:17 Prostate Cancer Found During Cadaveric Studies

Some of the clearest insights about prostate cancer came from autopsy research rather than hospital treatment rooms. Pathologists examined the prostate glands of men who died from unrelated causes such as heart disease, infections, or accidents. These men lived their entire lives without symptoms or treatment for prostate cancer, yet their tissues told a different story under the microscope.

When those glands were analyzed carefully, many contained small areas of prostate cancer that had never been detected while the men were alive. The tumors were often tiny, localized, and completely silent. They caused no pain, no urinary problems, and no limitation in daily life, which means the disease existed without creating noticeable harm.

The numbers reported in these studies are striking. Research has found incidental prostate cancer in roughly 20 to 30% of men over age fifty, and the rate increases steadily with age. In men in their seventies and eighties, more than half show microscopic cancer within the gland, and in very elderly groups the majority carry these small lesions.

These findings change how the disease should be interpreted. Prostate cancer appears to be common at the cellular level, especially as men grow older. Many tumors grow slowly and remain confined to the gland for years or decades without spreading or threatening life expectancy.

This helps explain the old medical saying that many men die with prostate cancer rather than from it. The presence of cancer cells alone does not guarantee danger, and detecting every small focus does not automatically improve survival. A diagnosis may create anxiety, yet the biological behavior of the tumor may remain quiet for a very long time.

This context becomes important when screening tests identify an elevated PSA or a small abnormality on imaging. The natural reaction is urgency, because the word “cancer” carries emotional weight. Autopsy data suggest that many early findings represent slow, contained disease that might never affect lifespan or function.

08:37 Cancer Patients Who Survived

Statistics and research papers help guide decisions, yet real clinical stories often make the point more clearly. Over the years, many men diagnosed with prostate cancer have chosen to avoid immediate surgery or radiation and have continued living full, active lives. These cases remind us that a diagnosis does not automatically equal rapid decline or shortened survival.

One example involved a man with a significantly elevated PSA who underwent a biopsy that confirmed prostate cancer. He declined surgery because he felt well and wanted to protect his daily function and independence. More than two decades later, he remained alive, active, and symptom-free, even though his PSA stayed high throughout that time.

Another case moved in the opposite direction. A man underwent early surgery to remove the prostate gland, and his PSA dropped to nearly zero after treatment. Despite that reassuring number, the cancer later spread to his spine and caused severe complications, which shows that a low PSA does not always guarantee protection from progression.

A third patient had biopsy-confirmed cancer and chose observation rather than immediate treatment. Years later, repeat testing showed no detectable cancer in the sampled tissue. This outcome highlights how some prostate lesions can remain quiet or even regress without aggressive intervention.

Stories like these do not replace research, yet they reflect what long-term studies also report. PSA values do not always predict behavior accurately, and early treatment does not always determine survival. The relationship between test results and real-world outcomes remains inconsistent, which makes automatic intervention difficult to justify.

These examples support a central idea that runs throughout this topic. Prostate cancer behaves differently from person to person, and many cases move slowly enough that immediate treatment does not change the long-term picture.

10:56 Biopsy Reliability and Risks

A biopsy sounds simple in theory. A small needle enters the prostate, collects tissue, and the lab checks for cancer cells. Many people assume the result gives a clear yes-or-no answer and makes the next step obvious. In practice, the process carries uncertainty, and that uncertainty affects both accuracy and safety.

The prostate is not sampled in its entirety during a biopsy. Multiple needles are inserted into different areas of the gland in a pattern that resembles random sampling. This method means some areas are tested while others remain untouched, so a small tumor can be missed, and a quiet or contained lesion can be detected even though it may never cause symptoms. The result depends heavily on where the needle happens to land.

Because of this sampling method, false negatives and false positives both occur. A negative result does not guarantee the absence of cancer, and a positive result does not automatically indicate a dangerous or fast-growing disease. Research has documented both underdiagnosis and overdiagnosis with prostate biopsies, which creates confusion and often leads to repeated procedures.

The procedure itself also carries physical risks. Passing needles through the rectal wall into the prostate introduces bacteria into deeper tissue, which can lead to infection. Some men develop fever, urinary retention, or bloodstream infections that require hospitalization and intravenous antibiotics. Bleeding in the urine, stool, or semen is also common for days or weeks after the procedure.

There is another concern that receives less attention. Inserting needles into a tumor disturbs the local environment of the gland. Some laboratory and surgical literature has documented the presence of cancer cells along needle tracks after biopsies in certain cancers, which raises questions about whether mechanical disruption can contribute to cell spread. The evidence does not provide absolute proof for prostate cancer, yet the possibility deserves careful thought before proceeding.

Decision-making becomes important at this point. A biopsy only makes sense when the result will change what you plan to do next. If a person has already decided against surgery or radiation, then confirming the presence of cancer may add anxiety without altering the treatment plan.

This is why many clinicians recommend stepping back before scheduling a biopsy. Clarifying your goals first helps determine whether the information will be useful or simply stressful. Testing should serve a clear purpose, and that purpose should align with how you intend to manage your health moving forward.

13:14 Consequences of Sticking Needles Inside

Placing a needle into any organ creates more than a simple sample. It disrupts tissue, causes local inflammation, and triggers a healing response. That reaction may be minor on the skin, yet it carries greater significance inside an organ that contains a known tumor. The prostate has a dense network of blood vessels and lymphatic channels, so any disturbance spreads fluid and cells through those pathways.

During a standard prostate biopsy, multiple cores are taken in one session. In many practices, 10 to 12 needle passes occur in different parts of the gland. Each pass creates a small channel that cuts through tissue and temporarily opens a pathway between the inside of the prostate and the surrounding circulation. From a mechanical standpoint, this process fragments tissue and releases cells into nearby spaces.

Cancer biology adds another layer to consider. Tumor cells already have the ability to detach and migrate. When tissue is punctured repeatedly, some cells can be dislodged from their original location. In other areas of medicine, pathologists have documented tumor cells deposited along needle tracks after biopsies of breast and liver lesions. This phenomenon is called needle-track seeding. It remains uncommon, yet it demonstrates that mechanical spread can occur under certain conditions.

Direct proof in prostate cancer remains limited, yet the concept remains biologically plausible. The prostate sits next to veins and lymphatic vessels that drain into the pelvis. Any disruption in that environment creates an opportunity for cellular movement. Even a small theoretical risk becomes relevant when the disease itself often grows slowly and may never threaten life.

The transcript emphasizes a practical question. If the next step after a positive biopsy involves surgery or radiation that may not improve survival, then the biopsy may introduce risk without offering clear benefit. Testing should help guide a decision. Testing that does not change management creates exposure without purpose.

There are also immediate complications to consider. Studies report infection rates of about 2 to 5% after transrectal prostate biopsy, with a smaller percentage requiring hospital care. Urinary retention, bleeding, and significant discomfort also occur. These events may sound rare on paper, yet they affect real people and can disrupt weeks of daily life.

The broader issue comes down to intent. When a test is ordered, it should answer a question that changes action. If the plan already involves monitoring and preserving quality of life, then repeated needle procedures may add stress and physical risk without moving care forward. Careful thought before intervention protects both the body and peace of mind.

15:44 PSA Monitoring and Its Limitations

PSA stands for prostate-specific antigen. It is a protein made by prostate cells and released into the bloodstream. The test measures how much of that protein is present in a small blood sample. On paper, it looks simple. A higher number appears to suggest a problem inside the gland.

In practice, PSA is a nonspecific signal. It rises for many different reasons that have nothing to do with dangerous cancer. Infection, inflammation, recent sexual activity, cycling, urinary retention, and even a routine digital exam can temporarily increase the value. Normal day-to-day biological variation also causes small fluctuations. A single elevated result often reflects irritation rather than disease.

Large screening studies help clarify this issue. When PSA testing became widespread, diagnosis rates increased sharply, yet mortality from prostate cancer changed only modestly. Many men were labeled with cancer that never progressed to symptoms. This pattern is called overdiagnosis. Autopsy studies support it, with microscopic prostate cancer found in a significant percentage of men who died from unrelated causes and never knew they had it.

The number itself also lacks a clear boundary. There is no natural line where PSA suddenly shifts from safe to dangerous. A value of 2, 4, or 6 does not automatically predict outcome. Some men with low PSA still harbor aggressive disease, while others live decades with high levels and no clinical impact. This overlap limits the test’s ability to guide life-changing decisions.

The typical response to a rising PSA often follows a predictable chain. The number increases, concern grows, and a biopsy is scheduled. That biopsy may lead to surgery or radiation. Each step introduces risk, yet the original signal may have been temporary or harmless. When the starting point is unreliable, every downstream step inherits that uncertainty.

Trend tracking sounds logical, yet it carries similar problems. Small changes over time may reflect laboratory variation or short-term inflammation. Treating every upward movement as an emergency can create repeated procedures without improving outcomes. Many clinicians now recommend repeating the test after several weeks under calm conditions before making any decision.

Monitoring still has a role. Used thoughtfully, PSA can provide background information while a person remains symptom-free. It works best as one piece of context rather than a trigger for immediate intervention. Numbers should inform reflection, not rush action.

17:22 The Watchful Waiting Process

Watchful waiting is a planned approach to care. It means treatment is not started immediately after a prostate cancer finding. Life continues as usual while the condition is monitored at regular intervals. Decisions are made gradually with new information gathered over time.

This approach was developed because early prostate cancer often progresses slowly. Many tumors remain confined to the gland for years without causing symptoms. Autopsy studies have identified small prostate cancers in a large number of older men who died from unrelated causes, which indicates that the disease can exist quietly without affecting lifespan. In these situations, the cancer was present but never became clinically important.

Clinical research reflects the same pattern. Long-term studies that compared immediate surgery with observation reported similar overall survival between the groups. The difference appeared in side effects. Men who underwent treatment experienced higher rates of urinary leakage, erectile dysfunction, and bowel complications. The men who were monitored avoided those complications while maintaining similar life expectancy.

Monitoring follows a clear structure. PSA levels are checked at scheduled times. Physical exams or imaging are performed when needed. Symptoms are reviewed during follow-up visits. Trends across months or years guide decisions rather than a single number or one test result. This method keeps care organized and reduces unnecessary procedures.

Quality of life remains a central part of the plan. Urinary control, sexual function, and daily comfort influence independence and well-being. Preserving these functions has practical value. Many men prefer to maintain normal activity while continuing observation and reserving intervention for situations where clear progression appears.

Time also supports better thinking. A cancer diagnosis can create fear and pressure to act quickly. A slower, structured process allows space to review evidence and consider personal priorities. Health decisions made with patience often align better with long-term goals.

20:01 Addressing Other Carcinogens

Cancer risk does not come from a single source. Cells change over time when they are exposed to repeated stress, inflammation, and toxic substances. Prostate tissue responds to the same biological forces that affect the rest of the body, which means overall health habits influence what happens inside the gland.

Environmental exposure plays a measurable role. Heavy metals such as cadmium, arsenic, and lead have been classified as carcinogenic in toxicology research. Cadmium receives special attention because it accumulates in the prostate and can remain in tissue for years. Occupational studies in industrial workers have linked higher cadmium exposure with increased rates of prostate cancer, which supports the idea that long-term buildup carries risk.

Testing for toxic burden provides useful information. Blood, urine, or provocative chelation testing can estimate how much of these metals are stored in the body. Identifying elevated levels gives you a clear target for intervention. Removing or lowering those exposures reduces one source of chronic cellular stress.

Body composition also fits into this picture. Excess body fat acts as active tissue that releases inflammatory chemicals and hormones. Higher inflammation creates an internal environment that favors cellular damage over time. Waist circumference and percent body fat correlate with higher rates of several cancers, including prostate cancer, which means fat reduction becomes part of prevention rather than appearance.

Nutrient status supports immune surveillance. The immune system identifies and removes abnormal cells every day. Vitamin D plays a role in immune regulation, and blood levels in the adequate range have been associated with improved immune function in many studies. Zinc concentrates heavily in prostate tissue and contributes to normal prostate biology, which explains why maintaining sufficient levels remains a common clinical recommendation.

These steps do not involve cutting or radiating tissue. They focus on strengthening the body’s natural defenses and lowering known stressors. Improving nutrition, reducing toxins, maintaining healthy body fat, and supporting immune function create conditions that favor stability inside the gland.

Addressing carcinogens becomes a practical prevention. Each small correction removes one burden from the system. Over time, those changes build a healthier internal environment that supports long-term function and lowers avoidable risk.

22:17 Pause and Contemplate

A prostate cancer diagnosis often triggers urgency. The phone rings, a number comes back high, or a biopsy report includes the word “cancer,” and the next thought quickly turns into action. Appointments get scheduled, procedures get discussed, and decisions start to feel rushed. Fear pushes the process forward faster than understanding.

Prostate cancer rarely behaves like an emergency. In many men, it grows slowly over years rather than weeks. That time window gives you space to think clearly, review the evidence, and decide what truly supports your long-term health. Slowing the process protects you from making permanent decisions based on temporary anxiety.

Deliberate thinking leads to better outcomes. When you step back and look at survival data, treatment risks, and your current quality of life, the picture becomes practical instead of emotional. The goal becomes preserving function and longevity together, not reacting to a single lab result.

What to Do

1. Review your PSA trend over time instead of reacting to a single reading.
2. Repeat abnormal tests when appropriate to rule out temporary causes such as infection, stress, or recent activity.
3. Ask how any proposed procedure will change management before agreeing to it.
4. Focus on daily health habits that support immune function, including sleep, nutrition, and regular movement.
5. Measure and reduce excess body fat, since abdominal fat correlates with higher cancer and metabolic risk.
6. Maintain adequate vitamin D and zinc levels as part of general immune support.
7. Schedule follow-ups at planned intervals so monitoring remains organized rather than reactive.

These steps keep you involved in your care and give you control over what can be controlled today. Thoughtful action replaces panic, and steady, informed decisions protect both quality of life and long-term health.

Key Takeaway

Early-stage prostate cancer often grows slowly and may remain confined to the prostate for many years without affecting daily function or life expectancy. At the same time, surgery, radiation, biopsies, and hormone therapy carry well-documented risks that can permanently affect urinary control, sexual function, bowel comfort, muscle mass, and overall quality of life. When the survival benefit of immediate treatment remains uncertain, those risks deserve careful thought.

Clear decisions come from understanding the numbers and the biology, not from fear. Tracking PSA trends, reviewing imaging carefully, and addressing modifiable risk factors such as body fat, toxic exposures, sleep, and immune support gives you a practical way to protect your health while you evaluate your options. A measured, informed approach allows you to preserve function, maintain strength, and choose treatment only when it truly serves your long-term well-being.

Continue the Conversation

If this discussion raised new questions for you, there are related episodes that expand on these themes in greater detail:

EP10 – Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies

E16 - Prostate Cancer Prevention Is Not About Fear | What Most Doctors Miss

For a broader explanation of the reasoning behind this perspective, Fight Cancer Like a Man by Dr. Stephen Petteruti presents these principles in a structured and practical format, outlining how to approach cancer prevention, screening, and treatment decisions with clarity.

Fight Cancer Like a Man by Dr. Petteruti: https://www.amazon.com/dp/B0GLZ9TL8N/

If you would like continued access to extended clinical notes and member-only discussions, you can join the Intellectual Medicine Community here:

• Membership: https://tinyurl.com/DrPetterutiMember
• Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
  Instagram: https://www.instagram.com/dr.stephenpetteruti
  Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
• Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To support deeper reflection, referenced studies explore the long-term outcomes of observation compared with intervention. These data examine survival, treatment-related complications, and the biological consequences of biopsy and hormone suppression. Reviewing this literature allows patients and clinicians to move beyond habit and consider a more individualized approach to prostate health.

Selected References

Wilt TJ, Jones KM, Barry MJ, et al. Follow‑up of prostatectomy versus observation for early prostate cancer. N Engl J Med. 2017;377(2):132‑142. doi:10.1056/NEJMoa1615869

Hamdy FC, Donovan JL, Lane JA, et al. 15‑year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(10):798‑809. doi:10.1056/NEJMoa2214122

Donovan JL, Hamdy FC, Lane JA, et al. Patient‑reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425‑1437. doi:10.1056/NEJMoa1606221

Klotz L. Active surveillance for low‑risk prostate cancer. N Engl J Med. 2020;383:81‑82. doi:10.1056/NEJMe2011155

Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate‑cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320‑1328. doi:10.1056/NEJMoa0810084

Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicity after conformal radiotherapy for prostate cancer: Dose‑response relationships. Int J Radiat Oncol Biol Phys. 2008;70(4):1124‑1129. doi:10.1016/j.ijrobp.2007.11.044

Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1994;152(2 Pt 1):1011‑1014. doi:10.1016/S0022‑5347(17)32573‑4

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER‑Medicare. J Urol. 2011;186(5):1830‑1834. doi:10.1016/j.juro.2011.07.005

Volanis D, Neal DE, Warren AY, Kelly JD. Incidence of needle‑tract seeding following prostate biopsy: a literature review. Urol Int. 2015;95(1):117‑121. doi:10.1159/000366175

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are intended to support thoughtful decision-making and improve health literacy. They are not a substitute for individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine By Dr. Stephen Petteruti (Member Version)

Date: 04 March, 2025

Episode Summary

• A prior cancer diagnosis increases the risk of recurrence, and treatments such as chemotherapy and radiation can add long-term carcinogenic exposure, which makes ongoing prevention necessary even after the tumor is gone.
• Environmental toxins, excess body fat, and weakened immune function create conditions that allow abnormal cells to grow, while reducing heavy metals, lowering percent body fat, and maintaining adequate nutrition help strengthen the body’s natural defenses.
• Consistent daily habits, including proper sleep, balanced meals, immune support, and evidence-based preventive therapies, provide practical protection and reduce the likelihood of secondary cancer over time.

Quick Prevention Checklist

Use this checklist to confirm that daily habits support long-term cancer prevention and overall health.

☐ Percent body fat is kept within a healthy range while muscle is preserved

☐ 7–8 hours of sleep maintained each night consistently

☐ Regular meals eaten with adequate protein and whole foods

☐ Vitamin C, vitamin D, and zinc levels monitored and supported

☐ Heavy metals such as cadmium or lead are tested and addressed when needed

☐ Daily stress managed through movement and recovery

☐ A structured prevention plan was followed instead of waiting for symptoms

00:00 Introduction

We must be diligent in the daily battle that takes place inside the body, because cancer rarely begins with a loud warning and often develops quietly while life feels normal. Many people go through periods of heavy stress, such as divorce, financial problems, or the loss of someone close, and during those months, their sleep worsens, their eating habits change, and their overall resilience declines. A year or two later, they receive a cancer diagnosis that feels sudden, yet the groundwork had already been laid long before the first symptom appeared.

The reason is simple biology. The immune system monitors the body every day and removes abnormal cells before they become dangerous, yet when stress, poor nutrition, environmental toxins, or metabolic strain weaken that protection, those same cells gain the chance to multiply. Once they begin dividing repeatedly, they build momentum, and the body has a harder time keeping them under control. What looks like a new disease is often the result of small changes that accumulated over time.

There is another reality that deserves clear attention. One of the strongest predictors of future cancer is a history of cancer. If malignant cells formed once, they can form again, which means finishing treatment does not automatically remove the risk. Being declared cancer-free only means that nothing is visible on imaging today. It does not mean the underlying environment that allowed cancer to develop has been corrected.

So, when you have been declared cancer-free, what should be done next?

01:20 Making Thoughtful Action

After someone finishes cancer treatment, there is often a quiet assumption that the job is done. The surgery is over, the chemotherapy sessions are complete, the scans look clear, and life slowly returns to normal. Family members celebrate, friends say congratulations, and everyone hopes the chapter has closed for good. Emotionally, that moment brings relief, yet biologically, it is only the beginning of the next phase.

Cancer care usually focuses on removing or shrinking what can be seen, which means attention stays on the tumor itself. Once the visible disease is gone, the medical system often steps back and shifts to periodic checkups and imaging. You wait for the next scan, the next blood test, or the next appointment. During that waiting period, very little changes inside the body unless you actively change it.

This is where thoughtful action becomes important. Waiting is passive, while prevention is active. Waiting means hoping nothing returns. Prevention means deliberately shaping the internal environment so that abnormal cells have a harder time surviving in the first place. One approach depends on chance. The other depends on daily behavior.

Thoughtful action does not require extreme measures or complicated programs. It means making consistent choices that support normal physiology. You strengthen the immune system, reduce inflammation, lower toxic exposures, protect muscle, and keep body fat within healthy limits. Each of these steps improves how the body repairs DNA, removes damaged cells, and maintains balance at the cellular level.

The key idea is simple and practical. You do not need to live in fear of recurrence, and you do not need to assume that nothing can be done. You focus on controllable factors and handle them one by one. Over time, these small actions accumulate, and that accumulation shifts risk in your favor in a quiet and steady way.

01:45 Risk of Cancer Recurrence

One of the most uncomfortable facts about cancer is that a history of cancer remains one of the strongest risk factors for developing cancer again. Once the body has formed one malignancy, it has already demonstrated that the environment for abnormal cell growth exists. Removing a tumor or finishing chemotherapy does not erase that underlying vulnerability. It only addresses what was visible at the time.

Many people hear the phrase “cancer-free” and assume the danger has passed. In medical terms, it simply means that no detectable tumor is present on current tests. Imaging and blood work identify masses that are large enough to be measured, yet cancer begins at the level of single cells long before it forms a visible growth. During that early period, nothing feels different, and routine scans can appear normal while microscopic changes continue quietly.

Long-term follow-up data reflect this reality. Early-stage breast cancer, for example, carries very low mortality within the first five years, yet relapse rates rise when patients are tracked for ten or fifteen years. Some recurrences appear decades later. These patterns tell us that cancer biology operates on a long timeline and that short-term success does not guarantee long-term protection.

Large follow-up research tells the same story in plain numbers. A meta-analysis that pooled 31 clinical studies tracked 24,328 people who had already been treated for cancer and followed them for a combined 85,784 person-years. During that time, new cancers continued to appear year after year. Depending on the treatment group, recurrence ranged from 35 to 56 cancers for every 1,000 person-years of observation. These numbers appeared regardless of whether patients received immunosuppressive drugs, biologic therapy, or no additional medication at all.

03:42 Known Risks of Chemotherapy and Radiation

Primary cancer treatment often involves chemotherapy, radiation, or both. These treatments are designed to shrink tumors, control spread, and save lives. For someone facing an active or aggressive cancer, these tools are often necessary and appropriate.

It also helps to understand what these treatments do at a biological level. Chemotherapy damages rapidly dividing cells. Radiation injures DNA, so cells cannot reproduce. Cancer cells are affected, and healthy cells are exposed as well. Blood cells, bone marrow, the gut lining, and immune cells all sit in the path of that damage.

This exposure carries long-term consequences that are often overlooked after treatment ends. Both chemotherapy drugs and radiation are classified as carcinogenic, which means they can damage DNA and increase the risk of future cancers. Medical literature documents higher rates of leukemias, lymphomas, and other secondary malignancies in survivors years after therapy. The original cancer receives treatment, and the same treatment can create new risks later in life.

Large follow-up studies document this pattern clearly. Survivors who received chemotherapy or radiation carry a measurable lifetime increase in secondary blood cancers. These risks may appear five, ten, or even fifteen years after therapy. By that time, many people believe their cancer journey has ended, so the connection often goes unrecognized.

Treatment still plays an important role during the initial phase of care. At the same time, the story continues after the tumor disappears. Once someone completes chemotherapy or radiation, the body has carried two separate burdens. One came from the original cancer. The other came from the therapy used to control it.

05:07 Understanding What Is a Tumor

When most people hear the word cancer, they picture a tumor. They imagine a mass that can be seen on a scan or felt during an exam. That image feels concrete and immediate, so it becomes the focus of attention. The problem is that a tumor represents a late stage in the process, not the beginning.

A tumor forms only after cancer cells have been growing quietly for a long time. A single abnormal cell divides into two, then four, then eight, and the process continues. Each division is called a doubling time. Research in oncology shows that it can take roughly 30 doubling cycles before a cluster becomes large enough to measure about one centimeter and appear on imaging. By the time a tumor reaches that size, the cells have already been multiplying for years.

This timeline changes how early detection should be understood. When a scan finds a one-centimeter mass, the disease has already progressed through many rounds of growth. The earlier cellular changes happened long before anything could be seen or felt. Waiting for a tumor to appear means reacting late in the biological timeline.

This is why secondary prevention focuses on the internal environment rather than chasing visible masses. Cancer cells likely form in the body from time to time, and a healthy immune system removes them before they grow. Strengthening that internal defense gives the body a chance to stop problems at the cellular level, long before a tumor ever develops.

07:04 Environmental Factors

Genetics plays a role in cancer risk, yet research consistently shows that most risk comes from the environment around us and the exposures we accumulate over time. Large epidemiologic studies estimate that roughly 80 to 90% of cancer risk relates to environmental and lifestyle factors rather than inherited genes. That number gives people more control than they realize.

Environmental exposure happens daily. Metals, chemicals, and pollutants enter through the air we breathe, the water we drink, and the food we eat. Industrial processes release substances that settle into soil and dust. Over the years, small amounts build up inside tissues. The body stores many of these compounds instead of clearing them quickly.

Some of these substances are classified as carcinogens, which means they can damage DNA or interfere with normal cell repair. Heavy metals such as cadmium and lead fall into this category. Once inside cells, they create oxidative stress and disrupt normal signaling. That damage increases the chance that a normal cell begins behaving abnormally.

Reducing exposure, therefore, becomes practical prevention. Clean food, clean water, improved air quality, and removal of stored toxins lower the biological stress placed on cells. When the environment inside the body becomes less hostile, the immune system functions better, and abnormal cells are more likely to be controlled before they multiply.

09:50 Lower Your Cadmium Levels Through DMSA

Cadmium deserves special attention because of how common and how harmful it is. It is classified as a Class 1 human carcinogen. Studies link cadmium exposure to higher rates of prostate cancer, breast cancer, and several other malignancies. The challenge is that cadmium hides inside tissues and does not leave easily.

Testing for cadmium requires a provocative heavy metal test. A chelating agent is given first, which pulls stored metals out of cells and into the urine so they can be measured. Without this step, blood tests often miss the true burden because the metal stays trapped in organs and fat tissue.

Once identified, removal becomes the goal. Dimercaptosuccinic acid, commonly called DMSA, is a prescription chelating agent that binds to certain heavy metals and allows the body to excrete them. Clinical use has shown that repeated dosing over time can lower stored cadmium levels safely when monitored by a clinician. This approach targets the metal directly instead of relying on general “detox” products that lack measurable results.

Lowering cadmium reduces one source of DNA stress inside the body. Removing that burden supports immune function and decreases one of the known contributors to cancer risk. In secondary prevention, small improvements like this add up. Each reduction in toxic exposure creates a healthier internal environment where abnormal cells have less opportunity to grow.

11:22 Lose Percent Body Fat, Not Weight

Body weight is one number, yet that number hides several different tissues. It includes fat, muscle, bone, water, and organ mass, all added together. Because everything is combined, the scale cannot tell you what actually changed. A lower number does not automatically mean better health.

Fat tissue plays an active biological role inside the body. It stores energy, produces inflammatory chemicals, and influences hormones such as insulin and estrogen. Excess body fat creates a chronic inflammatory state that stresses cells and interferes with normal immune surveillance. Over time, this environment increases the likelihood that damaged cells survive and continue dividing.

Large population studies connect higher body fat with increased risk for many cancers. Researchers have identified links across more than a dozen cancer types, including breast, prostate, colon, and pancreatic cancers. In breast cancer survivors, reductions in body fat correlate with lower recurrence rates. Similar findings appear in men with prostate cancer. These patterns repeat across different populations and study designs.

Muscle tissue supports the opposite effect. Muscle improves glucose control, supports metabolism, and helps regulate inflammation. Preserving muscle while reducing fat improves how the body handles energy and strengthens overall resilience. For that reason, the goal focuses on body composition rather than the scale.

13:31 What Are Cancer Cells

Cancer often sounds mysterious, yet the process begins with a simple change inside a single cell. Every day, billions of cells divide to replace old tissue. During this process, DNA must be copied accurately. Small errors sometimes occur. Most of these errors get repaired or the damaged cell is removed.

A cancer cell forms when those protective steps fail. The cell acquires mutations that allow it to ignore normal controls. It continues dividing when it should stop, avoids programmed cell death, and begins multiplying without restraint. One cell becomes two, two become four, and the population expands quietly.

These early cells remain invisible. Imaging tests cannot detect them. Blood tests cannot measure them. Symptoms do not appear. The immune system usually identifies these abnormal cells and destroys them before they gather into a mass. This silent cleanup happens constantly without anyone noticing.

Trouble begins when abnormal cells escape detection and continue doubling. After many cycles of growth, they form a cluster large enough to become a tumor. By that stage, the process has already been underway for years. Understanding this timeline explains why prevention must focus on daily biology rather than waiting for something to show up on a scan.

14:40 Maintaining Immune Health

The immune system protects the body every day by identifying and removing abnormal cells before they grow. This process happens quietly and constantly, and it includes early cancer cells that form long before a tumor can be detected. When immune defenses remain strong, many of these cells are cleared without ever causing symptoms.

Chronic stress, poor sleep, excess body fat, and nutrient deficiencies weaken this protection. Over time, those factors reduce how well immune cells communicate and respond. Simple habits restore that balance. Regular sleep, adequate protein, and nutrients such as vitamin C, vitamin D, and zinc support normal immune signaling and tissue repair.

What to Do:

1. Sleep 7 to 8 hours each night on a consistent schedule
2. Eat regular meals with adequate protein to protect muscle and immune function
3. Keep vitamin C intake around 1,000 to 2,000 mg daily unless otherwise directed
4. Maintain vitamin D levels within a healthy clinical range through testing and guidance
5. Ensure adequate zinc intake through food or supplementation
6. Reduce percent body fat through structured nutrition and resistance training
7. Manage stress through routine movement, sunlight, and recovery time

These daily actions keep immune defenses active and give the body a stronger position against future disease.

17:58 Vitamin C and Its Impact on the Body

Vitamin C plays a direct role in how the body repairs itself and defends against disease. Humans do not produce vitamin C internally, which means every cell depends on a regular supply from food or supplements. Without enough vitamin C, immune function weakens, tissue repair slows, and inflammation increases.

This vitamin supports several basic systems at once. White blood cells use vitamin C during infection control and cellular cleanup. Collagen production also depends on it, and collagen forms the structural framework that holds tissues together. Strong connective tissue helps isolate damaged areas and supports normal healing. These functions create physical barriers that make it harder for abnormal cells to spread.

Laboratory research has also examined vitamin C at higher concentrations. In controlled settings, elevated levels generate oxidative stress inside abnormal cells, which disrupts their survival. Healthy cells tolerate this stress more effectively because their repair systems remain intact. This difference explains why vitamin C has attracted interest in oncology and immune support.

Daily intake provides steady support. Many clinicians recommend around 1,000 to 2,000 mg per day, divided into doses that the body can absorb efficiently. Some programs use periodic intravenous vitamin C to reach higher blood levels under medical supervision. The purpose remains simple and practical, which is to support immune activity and reduce the number of abnormal cells that escape detection.

19:38 Repurpose Drug Therapy

Not every useful therapy starts as a cancer drug. Some medications developed for other conditions demonstrate protective effects when researchers examine them more closely. Using these existing medications for new purposes is known as repurposing.

This strategy has practical advantages. The safety profile is already documented, dosing is established, and costs remain low. Physicians understand how the drugs behave in the body, which allows careful use without unnecessary risk. The focus shifts from aggressive treatment to subtle support of cellular stability.

Several medications have drawn attention in this area. Low-dose naltrexone has been studied for immune modulation and may influence inflammatory signaling. Doxycycline at low doses affects mitochondrial activity in abnormal cells and has been explored for its effects on cancer stem cells. Metformin, commonly prescribed for blood sugar control, has been associated with lower cancer incidence in multiple observational studies and also improves metabolic health.

These medications work quietly in the background. They influence metabolism, inflammation, and cellular growth signals rather than attacking tissue directly. This approach fits well with prevention because it supports normal biology while remaining gentle on the body.

Repurposed drugs, therefore, serve as tools within a larger system. They complement lifestyle habits, nutritional support, and environmental cleanup. Each piece adds another layer of protection without introducing the toxicity associated with conventional chemotherapy.

20:24 Sirolimus and Its Function

Sirolimus, also known as rapamycin, affects a pathway inside cells called mTOR. This pathway regulates growth, energy use, and cellular repair. When mTOR stays overactive, cells receive constant signals to grow and divide. Excess growth increases the chance that damaged cells survive and multiply.

Low-dose sirolimus slows this pathway. Slower signaling encourages maintenance and repair rather than constant expansion. Cells shift attention toward cleaning out damaged components and improving mitochondrial function. This internal housekeeping process, known as autophagy, helps remove dysfunctional structures that could contribute to disease.

Research into aging biology and oncology has highlighted this mechanism. Healthier mitochondria produce energy more efficiently and generate fewer damaging byproducts. Reduced cellular stress lowers mutation rates and supports immune recognition of abnormal cells. These effects align directly with the goals of secondary cancer prevention.

Clinical use typically involves low doses given intermittently, often once weekly under supervision. The intent focuses on modulation rather than suppression. The goal involves guiding cellular behavior toward stability and repair.

Sirolimus fits into the same philosophy as the other measures discussed. It supports internal balance, reduces biological stress, and strengthens the body’s natural defenses. Combined with clean nutrition, lower toxic exposure, healthy body composition, and strong immune function, it becomes another practical layer in a comprehensive prevention plan.

Key Takeaway

Finishing cancer treatment does not mean the risk disappears. Cancer can return years later because abnormal cells may exist long before a tumor becomes visible on scans. That is why daily prevention remains important even when you feel well.

Lower toxic exposures, reduce percent body fat, support immune health, and maintain adequate vitamin levels. Address environmental risks such as heavy metals and use safe, evidence-based therapies when appropriate. These steps strengthen the body’s defenses at a cellular level.

Consistent habits protect long-term health and reduce the chance of recurrence over time.

Continue the Conversation

If this discussion raised new questions for you, there are related episodes that expand on these themes in greater detail:

EP31 – Do Men Really Die From Prostate Cancer? What the Data Actually Shows

EP33 – Testosterone, Aging, and Vitality What Medicine Isn’t Telling You

For a broader explanation of the reasoning behind this perspective, Fight Cancer Like a Man by Dr. Stephen Petteruti presents these principles in a structured and practical format, outlining how to approach cancer prevention, screening, and treatment decisions with clarity.

Fight Cancer Like a Man by Dr. Petteruti: https://www.amazon.com/dp/B0GLZ9TL8N/

If you would like continued access to extended clinical notes and member-only discussions, you can join the Intellectual Medicine Community here:

• Membership: https://tinyurl.com/DrPetterutiMember
• Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
  Instagram: https://www.instagram.com/dr.stephenpetteruti
  Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
• Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To support deeper reflection, referenced studies explore the long-term outcomes of observation compared with intervention. These data examine survival, treatment-related complications, and the biological consequences of biopsy and hormone suppression. Reviewing this literature allows patients and clinicians to move beyond habit and consider a more individualized approach to prostate health.

Suggested Reading

The following peer‑reviewed publications support the discussion in Episode 05, demonstrating environmental, metabolic, immune, and cellular factors involved in secondary cancer prevention.

Ng AK, Travis LB. Second primary cancers: an overview. Hematol Oncol Clin North Am. 2008;22(2):271‑289. doi:10.1016/j.hoc.2008.01.008
PubMed: https://pubmed.ncbi.nlm.nih.gov/18395150/

Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long‑term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2011;29(22):3056‑3064. doi:10.1200/JCO.2011.34.6585
PubMed: https://pubmed.ncbi.nlm.nih.gov/21709189/

Anand P, Kunnumakkara AB, Sundaram C, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097‑2116. doi:10.1007/s11095‑008‑9661‑9
PubMed: https://pubmed.ncbi.nlm.nih.gov/18626751/

Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2024;22(3):499-512.e6. doi:10.1016/j.cgh.2023.07.027

IARC Working Group. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum. 2012;100C:121‑145. PMID: 23189751
PubMed: https://pubmed.ncbi.nlm.nih.gov/23189751/

Lauby‑Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794‑798. doi:10.1056/NEJMsr1606602
PubMed: https://pubmed.ncbi.nlm.nih.gov/27557308/

Nieman DC, Wentz LM. The compelling link between physical activity and the body’s defense system. J Sport Health Sci. 2019;8(3):201‑217. doi:10.1016/j.jshs.2018.09.009
PubMed: https://pubmed.ncbi.nlm.nih.gov/31193280/

Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211. doi:10.3390/nu9111211
PubMed: https://pubmed.ncbi.nlm.nih.gov/29099763/

Keum N, Giovannucci E. Vitamin D and cancer — update 2021. Curr Opin Clin Nutr Metab Care. 2021;24(2):139‑146. doi:10.1097/MCO.0000000000000728
PubMed: https://pubmed.ncbi.nlm.nih.gov/33496525/

Sorup HN, Christensen J, Tjønneland A, et al. Zinc intake, cadmium exposure, and risk of cancer: Danish Diet, Cancer, and Health Study. Br J Nutr. 2020;124(9):951‑959. doi:10.1017/S0007114520002128
PubMed: https://pubmed.ncbi.nlm.nih.gov/32693972/

Maiese K. Targeting molecules to modulate mTOR activity: rapamycin and beyond. Curr Med Chem. 2021;28(7):1491‑1508. doi:10.2174/0929867327666200820142722
PubMed: https://pubmed.ncbi.nlm.nih.gov/32811214/

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are intended to support thoughtful decision-making and improve health literacy. They are not a substitute for individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine By Dr. Stephen Petteruti (Public Version)

Date: 11 March, 2025

Introduction

For many men, the word testosterone brings quiet fear before any facts are discussed. They hear that hormone therapy might cause prostate cancer, so they choose to live with low energy, fading strength, and slower thinking instead of asking questions. Over time, fatigue becomes normal, muscle shrinks, weight increases, and daily life feels harder than it should.

At the same time, testosterone decline happens to every man with age. It is not rare or unusual, and it affects nearly every system in the body. The real issue is not whether levels fall, but what happens when they fall too far and stay there for years without being addressed.

This creates a simple but important question. Should you accept the decline, or should you restore your levels and focus on careful monitoring? That balance is what this discussion is really about.

Rethinking Prostate Cancer Fear

Fear around prostate cancer often begins with the belief that any cancer cell inside the prostate is undoubtedly dangerous. That belief pushes many men toward unnecessary testing and procedures before they understand what those findings mean. As a result, they will be forced to deal with anxiety and take rushed decisions that proper planning would have easily replaced.

The truth is that recent research paints a calmer picture. Medical findings should always be the basis of your reaction and not some random thing you see online, or something you must have heard from a non-medical professional.

What Modern Research Says About Testosterone

Much of the fear about testosterone therapy came from studies published decades ago. At that time, doctors believed that higher testosterone levels directly stimulated prostate cancer growth, and that idea shaped medical practice for many years. As a result, many men were told to avoid therapy even when they clearly had symptoms of deficiency.

Newer research has questioned those assumptions. Clinical trials that followed men receiving properly tells a whole different story from the myth that has been surrounding this topic.

Looking at the Bigger Picture of Health

Hormones do not act alone inside the body. Prostate cells exist within the same environment as every other tissue, so overall health plays a large role in long-term outcomes. When the body is inflamed, poorly nourished, or chronically stressed, disease risk increases across many systems.

Daily habits shape that environment more than most people realize. Excess body fat increases inflammation and disrupts metabolism, while poor sleep weakens immune function and recovery. Over time, these factors create more problems than a single hormone level ever could.

Supporting health through consistent meals, regular strength training, adequate sleep, and lower toxin exposure builds resilience. A stronger body handles abnormal cells more effectively and maintains function as the years pass.

Signs Testosterone May Be Too Low

Low testosterone usually shows up gradually rather than suddenly. Energy drops, workouts feel harder, and muscle mass decreases even when exercise habits stay the same. Body fat often increases around the waist, and recovery becomes slower.

Mental and emotional changes may follow. Many men describe brain fog, reduced motivation, lower confidence, and decreased mood. Libido declines, and sleep becomes lighter and less refreshing.

These changes affect daily life in practical ways. Work feels harder, movement feels heavier, and enthusiasm fades. Lab testing helps confirm the issue, yet symptoms often tell the story first.

Monitoring Without Panic

PSA testing is commonly used to monitor prostate health, but the number alone does not tell the whole story. Infection, inflammation, recent exercise, or even normal aging can temporarily raise the value. Treating one reading as an emergency often creates unnecessary stress.

Looking at trends over time provides more reliable information. Gradual changes usually reflect normal aging, while sudden shifts deserve closer review. A calm and structured approach protects both health and peace of mind.

This kind of monitoring supports better decisions. It allows men to stay informed without rushing into invasive procedures that may not be needed.

A Balanced Perspective

Testosterone therapy is not about chasing extreme levels or quick fixes. It is about restoring hormones to a healthy range so that strength, focus, and energy return to normal. When therapy is supervised and monitored, it becomes part of a structured health plan rather than a risky experiment.

At the same time, regular checkups and prostate monitoring keep safety in view. This combination of restoration and observation creates balance. It supports vitality while respecting long-term health.

When decisions are guided by evidence instead of fear, men gain both clarity and confidence. That mindset often leads to better outcomes than avoiding treatment altogether.

Listen to the Full Episode

You can listen to the full episode here [https://www.youtube.com/watch?v=DZjjeRdxt8I].

If you want access to full transcripts, expanded clinical notes, research references, and practical tools you can use during your own medical visits, those resources are available inside the Intellectual Medicine Membership.

Dr. Stephen Petteruti also explores these topics in greater depth in Fight Cancer Like a Man, where the evidence and clinical reasoning behind this vitality-focused approach are explained in clear, practical terms.

Continue the Conversation

If this discussion raised new questions for you, there are related episodes that expand on these themes in greater detail:

EP09 - Male Sexual Health Explained: Testosterone, Erections, and Long-Term Vitality

EP04 - Testosterone Therapy Explained: Benefits, Risks, PSA, and Prostate Health

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To support deeper reflection, referenced studies explore the long-term outcomes of observation compared with intervention. These data examine survival, treatment-related complications, and the biological consequences of biopsy and hormone suppression. Reviewing this literature allows patients and clinicians to move beyond habit and consider a more individualized approach to prostate health. You can find this information in the Membership section of Intellectual Medicine.

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

EP06 - The Truth About Testosterone: Does It Really Cause Prostate Cancer?

Host: Intellectual Medicine By Dr. Stephen Petteruti (Members Version)

Date: 11 March, 2025

Episode Summary

• Testosterone naturally declines with age, and lower levels affect strength, energy, mood, memory, bone density, and sexual health. Many men avoid treatment because of long-standing fears about prostate cancer, even though these daily functional changes reduce overall quality of life.
• Current clinical research does not show a clear increase in prostate cancer risk among men receiving properly supervised testosterone therapy. Much of the concern came from older studies and assumptions that newer evidence has not confirmed.
• Small prostate cancer cells are common in aging men and often remain confined to the gland without causing symptoms or harm. Careful monitoring, steady habits, and thoughtful decision-making are more helpful than reacting quickly to isolated test results.
• Testosterone therapy, when prescribed and monitored responsibly, focuses on restoring healthy hormone levels and supporting normal body function. Regular follow-up and routine prostate checks allow men to maintain vitality while keeping safety in view.

Quick Decision Checklist

You should check the following boxes for good health and testosterone balance:

☐ Tested total and free testosterone levels with a qualified clinician

☐ Noticed symptoms such as fatigue, low mood, reduced strength, or declining libido

☐ Discussed benefits and risks of testosterone therapy using current evidence, not old assumptions

☐ Monitored PSA periodically and tracked trends instead of reacting to one reading

☐ Avoided rushing into invasive procedures without a clear clinical need

☐ Maintained a healthy percent body fat through regular meals and strength training

☐ Slept consistently and managed daily stress to support immune and hormonal balance

☐ Scheduled routine follow-ups to adjust therapy safely and stay informed

These steps keep decisions calm, structured, and based on long-term health rather than fear.

00:00 Introduction

Will testosterone therapy increase the risk of prostate cancer?

This question has followed men for decades, and it often creates fear before facts are even considered. Many people hear the word “testosterone” and immediately assume that adding hormones must feed cancer growth. Because of that belief, men who feel tired, weak, or mentally slower often avoid treatment even when their hormone levels are clearly low.

At the same time, testosterone decline is not rare or unusual. It happens to every man with age. Levels fall gradually each year, and that drop affects strength, mood, memory, bone density, and sexual health. Muscle becomes harder to maintain, energy decreases, and daily life feels heavier than it should.

The concern about prostate cancer came from older studies and long-standing medical habits. Over time, that concern turned into dogma, even though newer research does not clearly support it. Modern data show that the relationship between testosterone and prostate cancer is far more complex than people were originally taught.

So the real question is not simply whether testosterone is dangerous. The better question is: how do you balance the benefits of healthy hormone levels with the evidence about risk?

03:30 Steps to Take About Prostate Cancer

Fear around prostate cancer often starts with the idea that any cancer cell inside the prostate is automatically dangerous. That belief pushes many men toward immediate testing and procedures before they understand what those findings actually mean. The result is anxiety and rushed decisions rather than careful thinking.

Autopsy studies give a different perspective. When researchers examined men who died from other causes, they found that a large percentage had small prostate cancer cells inside the gland that never caused symptoms during life. Some studies report rates as high as 80 to 90% in older men. These cells existed quietly and never progressed to a harmful disease.

This tells us something important. The presence of cancer cells does not automatically mean illness or shortened life. Many prostate cancers grow slowly and remain confined to the gland for years or decades. Treating every early finding as an emergency does not match how the disease actually behaves.

A practical approach begins with staying calm and avoiding unnecessary procedures. Routine monitoring, maintaining overall health, and focusing on prevention support long-term outcomes more reliably than reacting to every small lab change. The goal is to protect function and quality of life while observing carefully rather than rushing into interventions that carry permanent side effects.

05:11 Dr. Morgentaler’s Investigative Work

Much of the fear about testosterone and prostate cancer came from research published decades ago, when doctors believed that higher testosterone levels directly stimulated cancer growth. That conclusion shaped medical practice for years and led many physicians to avoid testosterone therapy altogether.

Later, researchers began to question those early assumptions. One of the most recognized voices in this area is Abraham Morgentaler, a urologist who carefully reviewed the original data and conducted additional studies. His work looked closely at how testosterone actually behaves inside the body and how the prostate responds to normal hormone levels.

What he found was that the older research had important limitations. The early studies focused on men with advanced or metastatic prostate cancer, which is a very different condition from healthy men with low testosterone. Applying those results to every man created confusion and exaggerated risk.

More recent clinical trials have followed men receiving testosterone therapy and tracked prostate outcomes over time. These studies have not demonstrated higher rates of prostate cancer compared with men who did not receive treatment. Prostate size, PSA levels, and cancer diagnoses remained within expected ranges for age.

This body of evidence does not claim that testosterone removes all risk. No medical decision carries zero risk. It does show that the long-standing belief that testosterone directly causes prostate cancer does not match modern clinical data.

08:19 The Unequivocal Truth

There is one fact that becomes clear when you look at the full picture. Prostate cancer is extremely common with aging, regardless of whether a man uses testosterone therapy. If a man lives long enough, small cancer cells will likely appear in the prostate at some point.

This means testosterone is not the deciding factor. Some men on therapy develop prostate cancer. Some men who never used hormones develop them as well. The background rate is already high, which makes it difficult to blame one specific cause.

At the same time, low testosterone has well-documented consequences. Reduced muscle mass, higher body fat, lower bone density, slower thinking, and reduced vitality all affect independence and daily function. These changes influence how someone feels and moves every day, not just years down the road.

For many men, the decision becomes practical rather than theoretical. Living with healthy hormone levels supports strength, energy, and mental clarity. Monitoring prostate health with regular exams and labs adds an extra layer of safety. Together, these steps create a balanced approach that respects both quality of life and medical caution.

09:03 The Anti-Cancer Lifestyle

Concerns about testosterone often focus on a single hormone while ignoring the larger picture of health. Prostate cells live inside the same body as every other tissue, so the environment around those cells influences how they behave. When the body is strong and stable, abnormal cells struggle to grow or spread.

Daily habits shape that environment. Excess body fat increases inflammation, disrupts insulin signaling, and alters hormone balance in ways that encourage disease. Toxic metals and unnecessary radiation exposure place additional stress on cells and increase DNA damage over time. Poor sleep and chronic stress weaken immune surveillance, which reduces the body’s ability to remove abnormal cells early.

An anti-cancer lifestyle addresses these factors directly. Maintaining healthy percent body fat, eating balanced meals with adequate protein, exercising regularly, and minimizing exposure to toxins create conditions where the body functions efficiently. Immune cells work better, inflammation stays lower, and tissue repair remains active.

This approach does not rely on one treatment or one pill. It relies on consistent daily behavior. When the internal environment supports health, small clusters of abnormal cells are less likely to turn into meaningful disease.

10:48 Signs of Sub-Optimal Testosterone

Testosterone declines gradually with age in every man. This decline affects many systems at the same time because testosterone receptors exist in muscle, bone, brain, and metabolic tissue. When levels drop, the changes appear in everyday life rather than in a single lab number.

Low or sub-optimal levels often present as fatigue that does not improve with rest. Muscle mass decreases even when exercise habits stay the same, and body fat increases around the abdomen. Recovery after workouts slows, joints feel weaker, and strength declines.

Cognitive and emotional changes may follow. Many men report brain fog, lower motivation, reduced confidence, and diminished mood. Libido decreases, sexual performance declines, and sleep quality often worsens. These shifts reduce quality of life and make daily tasks feel harder than they should.

Lab testing provides useful information, yet symptoms carry equal importance. A value that falls inside a “normal for age” range does not guarantee optimal function. Health is measured by how you feel and perform each day, not simply by fitting into an age-adjusted chart.

13:01 The Goal of Testosterone Therapy

Testosterone therapy is not about chasing high numbers or creating unnatural hormone levels. The purpose is restoration. The aim is to return the body to a healthier physiological range where strength, clarity, and energy support normal living.

Adequate testosterone supports muscle preservation, which improves metabolism and protects joints. It helps maintain bone density, which reduces fracture risk later in life. It also supports cognitive speed, mood stability, and cardiovascular function. These effects influence independence and daily performance for years.

The therapy focuses on balance and monitoring. Blood levels are checked regularly, symptoms are reviewed, and dosing is adjusted carefully. This structured approach keeps treatment controlled and reduces unnecessary risk.

When viewed this way, testosterone replacement functions like other forms of hormone support. It corrects a deficiency that develops with time. The goal remains simple and practical, which is to maintain vitality and function while continuing routine medical follow-up.

16:03 Understanding PSA Levels

PSA stands for prostate-specific antigen. It is a protein produced by prostate tissue and released into the blood in small amounts. Doctors use it as a screening tool because higher numbers can sometimes be associated with prostate irritation or disease.

The challenge is that PSA is not specific to cancer. Many everyday situations can raise the number. Infection, inflammation, recent sexual activity, exercise such as cycling, poor sleep, or even normal aging can cause temporary increases. A higher value does not automatically mean cancer is present.

For this reason, PSA should be treated as one piece of information rather than a final answer. The number must be interpreted slowly and in context. Reacting quickly to a single lab value often leads to unnecessary procedures that create stress without improving outcomes.

Long-term observation provides more useful insight. Tracking the trend over time gives a clearer picture than focusing on one isolated result. Gradual changes usually reflect normal aging, while sudden or dramatic shifts deserve closer evaluation and thoughtful follow-up rather than immediate invasive action.

What to Do

1. Check PSA periodically instead of reacting to a single reading.
2. Repeat the test if the value rises before making any decisions.
3. Review recent activities such as illness, cycling, or sexual activity that may affect results.
4. Maintain a healthy percent body fat, regular exercise, and adequate sleep to reduce inflammation.
5. Discuss trends with a qualified clinician before considering imaging or biopsy.

These steps keep the process measured and rational. They protect the quality of life while still respecting the value of monitoring.

18:57 Question the Dogma of Testosterone Therapy

For decades, testosterone therapy carried a strong stigma. Many people were taught that replacing testosterone automatically leads to prostate enlargement or cancer. That belief became common practice long before modern evidence existed.

Current research does not support that fear. Large clinical trials and long-term observations have not demonstrated a clear increase in prostate cancer risk among men receiving monitored testosterone therapy. At the same time, low testosterone is consistently associated with fatigue, muscle loss, higher body fat, reduced bone density, and lower quality of life.

Medicine changes as evidence improves. Ideas that once sounded certain often require revision when better data becomes available. Questioning old assumptions is part of responsible healthcare, especially when those assumptions limit treatments that may improve strength, mood, and daily function.

Testosterone therapy should therefore be approached with balance rather than fear. It requires proper evaluation, medical supervision, and regular follow-up. When used thoughtfully, it becomes one tool for maintaining vitality rather than something to avoid because of outdated beliefs.

Key Takeaway

Testosterone naturally declines with age, and when levels fall too low, the effects show up in everyday life. Energy drops, muscle mass decreases, recovery slows, body fat increases, and focus becomes less sharp. Many men notice these changes gradually and assume they are simply part of getting older, yet much of this decline relates to hormone levels rather than age alone.

Current research does not show that properly supervised testosterone therapy increases the risk of prostate cancer in healthy men. At the same time, persistently low testosterone is linked with poorer strength, reduced vitality, and lower overall well-being. Decisions should therefore be guided by evidence and symptoms rather than fear or outdated assumptions.

Related Episodes

Learning is strongest when ideas connect. Continue exploring these episodes that build on today’s discussion:

EP09 - Don't Biopsy Your Prostate Until You Hear This (Part 2) 

EP04 - Why Early Treatment of Prostate Cancer May Be Ineffective: The Case for Conventional Therapies

Call to Action

For a deeper explanation of the science and reasoning behind this approach, read Fight Cancer Like a Man by Dr. Stephen Petteruti on Amazon— a clear and practical guide to smarter cancer prevention, vitality, and informed decision‑making.

Join the Intellectual Medicine Community

• Membership (exclusive educational content and clinical resources): https://tinyurl.com/DrPetterutiMember
• Sign up for Dr.  Steve’s Email Newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com 

Connect with Dr. Petteruti

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
• Instagram: https://www.instagram.com/dr.stephenpetteruti
• Facebook: https://www.facebook.com/dr.stephenpetteruti 

Subscribe to the Intellectual Medicine Podcast

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
  Spotify:  https://tinyurl.com/DrPetterutiSpotifyPodcast

Extra Reading

The long-standing hesitation surrounding testosterone replacement therapy (TRT) is largely rooted in mid-century medical assumptions that have been fundamentally challenged by modern clinical data. As Dr. Petteruti discusses in this episode, the relationship between hormonal restoration and prostate health is governed by the "Saturation Model," which suggests that physiological levels of testosterone do not inherently drive disease progression in healthy men. The following peer-reviewed studies, including landmark meta-analyses and long-term registry data, provide the evidentiary framework for a shift away from fear-based medicine toward an informed, vitality-focused approach to men’s health.

Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143. doi:10.1038/pcan.2013.60

Gacci M, Sebastianelli A, Salvi M, et al. Obesity, metabolic syndrome, and prostate cancer: a review of systematic reviews. Front Endocrinol (Lausanne). 2017;8:151. doi:10.3389/fendo.2017.00151

Haider A, Haider KS, Saad F, et al. Incidence of prostate cancer and urothelial carcinoma in men receiving testosterone therapy: methods and 10-year outcomes. World J Mens Health. 2020;38(3):377-384. doi:10.5534/wjmh.190035

Kang DY, Li HJ. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement therapy. J Clin Med. 2022;11(8):2131. doi:10.3390/jcm11082131

Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50(5):935-939. doi:10.1016/j.eururo.2006.08.015

Stabile A, Giganti F, Rosenkrantz AB, et al. Low testosterone levels and prostate cancer risk: from neurological mechanisms to clinical implications. Rev Urol. 2016;18(3):130-138. doi:10.3909/riu0735

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

Host: Intellectual Medicine by Dr. Petteruti (Member Version)

Date: 18 March, 2025

Episode Summary

• Early-stage prostate cancer has an extremely low short-term death rate, yet rising PSA levels and routine biopsies often lead to unnecessary diagnoses and procedures that create fear rather than better outcomes.
• Large long-term studies show similar survival between men who undergo surgery or radiation and those who choose observation, while biopsy and aggressive treatment carry real risks, including infection, functional loss, and possible spread of abnormal cells.
• A safer approach focuses on careful monitoring, imaging when appropriate, and strengthening the body through immune support, toxin reduction, healthy body composition, and consistent daily habits that protect long-term vitality.

Quick Decision Checklist

Use this checklist to guide your decisions before agreeing to a prostate biopsy or any invasive prostate procedure.

☐ Review PSA trends over time instead of reacting to one elevated result

☐ Ask how any proposed test or procedure would change long-term survival before agreeing to it

☐ Avoid routine prostate biopsy without a clear and necessary clinical reason

☐ Use imaging such as MRI and structured monitoring to further evaluate

☐ Focus on immune strength through sleep, nutrition, and regular movement

☐ Reduce exposure to known carcinogens, including smoking, heavy metals, and unnecessary radiation

☐ Maintain a healthy percent body fat and preserved muscle through strength training

00:00 Introduction

Few words create more fear in a man’s life than “prostate cancer.” The moment a PSA number rises or a doctor mentions biopsy, the pressure to act feels immediate and urgent. Many men assume that testing quickly and cutting something out must automatically improve survival.

Yet the numbers tell a calmer story. In early-stage prostate cancer, the death rate during the first five years sits close to zero percent, which means most men are not in immediate danger. When risk is already low, aggressive testing and procedures become harder to justify, especially when those procedures carry permanent side effects.

This is where the prostate biopsy enters the conversation. A biopsy sounds simple and harmless, just a needle and a sample, but it can set off a chain reaction that leads to anxiety, repeat testing, surgery, or radiation that may never have been necessary. Before anyone agrees to that step, it makes sense to slow down, understand the evidence, and ask a clear question: Will this test actually improve my health or simply label me with a problem that might never have caused harm?

That question changes everything.

01:58 False Diagnosis Is the Culprit

When people hear that prostate cancer diagnoses keep increasing, they assume the disease itself is becoming more aggressive. The natural reaction is fear. More diagnoses sound like more danger.

The data show a different pattern. Over the past two decades, deaths from prostate cancer have declined, yet the number of men labeled with prostate cancer continues to rise. When diagnosis increases while mortality falls, it suggests that many of these newly discovered “cancers” were never life-threatening to begin with.

Part of the issue lies in how prostate tissue changes with age. As men get older, the prostate commonly develops atypical or irregular cells. Under a microscope, some of these cells resemble cancer. Pathologists may label them malignant even though they might never grow, spread, or affect the man’s lifespan.

Autopsy studies make this point very clear. When researchers examine men who died from unrelated causes, such as heart disease or accidents, they often find small clusters of prostate cancer cells that were never detected during life. In some reports, 70 to 90% of elderly men had these cells present, yet prostate cancer was not what killed them.

This changes how the word “cancer” should be interpreted in this setting. The presence of abnormal cells does not automatically equal a dangerous disease. In many cases, it simply reflects a slow biological change that the body keeps contained for decades.

A biopsy turns this quiet finding into a formal diagnosis. Once the word “cancer” appears on a report, anxiety rises, families worry, and treatment discussions begin. The problem is that the label may create more harm than the cells themselves ever would.

03:50 Studies Conducted

If removing or treating the prostate truly saved lives in early disease, the evidence would be obvious. We would expect to see a clear survival difference between men who received treatment and men who did not. That kind of result is easy to measure over time.

Large, long-term trials have tested exactly this question. In these studies, men with early-stage prostate cancer were divided into two groups. One group had surgery to remove the prostate, and the other group underwent observation without immediate treatment.

Researchers followed these men for many years, in some cases close to two decades. At the end of follow-up, overall death rates looked nearly identical between the groups. Death specifically from prostate cancer also showed little or no meaningful difference.

This finding is important. If removing the gland does not clearly extend life for early-stage disease, then detecting tiny abnormalities earlier does not automatically create a benefit. Discovering more cancer on biopsy does not guarantee better outcomes.

Treatment, however, is not neutral. Surgery carries risks such as urinary leakage, erectile dysfunction, infection, bleeding, and complications from anesthesia. Radiation introduces bowel and bladder irritation, fatigue, and long-term tissue damage. These effects influence daily life in very real ways.

So we end up with a mismatch. The measurable benefit remains uncertain, yet the side effects are immediate and permanent for many men. When that is the case, the value of aggressive diagnosis becomes questionable.

Before ordering any test, a simple rule applies. Ask how the result will change management and whether that change improves survival or quality of life. If the answer is unclear, the test may not be necessary.

06:05 Risks of Biopsy-Related Cancer Spread

A prostate biopsy is often described as minor. The description makes it sound harmless, almost routine. In reality, the procedure involves multiple core needles passing through the gland to collect tissue samples.

Each needle puncture creates bleeding and inflammation. The tissue barrier that may have been containing abnormal cells gets disrupted. From a biological standpoint, piercing a tumor or suspicious area raises a logical concern about spreading cells.

This concern is not theoretical. In other cancers, researchers have observed tumor cells along needle tracks after biopsies. Studies in breast cancer have shown higher rates of local spread in some patients who underwent needle sampling before surgery. While prostate tissue is different, the principle remains the same.

Even when a spread does not occur, the procedure itself carries risks. Men frequently report pain, bleeding in urine or semen, and infection. Some develop fevers or require antibiotics. A small number experience serious complications that lead to hospitalization.

There is also a psychological cost. Once a biopsy shows “cancer,” even if it is low grade and unlikely to progress, many men feel pressure to act immediately. That pressure can push them toward surgery or radiation that may not have been needed.

So the biopsy becomes the trigger. It starts a cascade of decisions based on fear rather than a clear survival benefit. For a disease that often grows slowly and remains confined to the gland, that cascade may cause more harm than protection.

For many men with stable symptoms and modest PSA changes, careful monitoring, imaging, and attention to overall health provide a safer path. Slowing down, gathering information, and avoiding unnecessary needles can preserve both quality of life and peace of mind.

08:30 Alternatives to Biopsy

When PSA rises or an exam feels abnormal, many men are told that a biopsy is the next automatic step. It is presented as the only way to “know for sure.” That framing makes the situation feel urgent, as if there is no safe middle ground.

There is a middle ground. A biopsy is not the only source of useful information. Prostate health can be evaluated through trends, imaging, and clinical observation before any needle enters the gland.

PSA can be repeated over time to look for patterns rather than reacting to a single number. Temporary increases often follow infection, inflammation, recent sexual activity, long bike rides, or poor sleep. When the test is repeated weeks later, the value frequently returns closer to baseline. Watching the trend gives a clearer picture than responding to one isolated spike.

Imaging also adds context. Multiparametric MRI allows doctors to examine the structure of the prostate and identify whether there are suspicious areas. This approach provides anatomical detail without piercing tissue. While imaging is not perfect, it avoids the mechanical trauma and risks that come with biopsy.

Clinical monitoring remains another option. Regular follow-up visits, lab checks, and symptom review allow time to see how the situation evolves. Prostate cancer typically grows slowly. Taking time rarely changes the outcome, yet rushing into a procedure can create permanent consequences.

This approach asks a simple question. If early treatment does not clearly improve survival, then why accept immediate procedural risk? For many men, structured observation provides information while preserving safety.

09:55 Our Bodies Are Fighting Cancer Every Day

Many people think of cancer as something that suddenly appears one day. Biology works differently. Abnormal cells form in the body all the time.

Every day, cells divide, copy DNA, and replace old tissue. During this process, small mistakes happen. Some of those mistakes create cells that look abnormal or behave differently. This is a normal part of life at the cellular level.

The immune system constantly patrols for these changes. Specialized immune cells identify damaged or suspicious cells and remove them before they multiply. In most cases, this process happens quietly and efficiently. You never feel it, and you never know it occurred.

Prostate tissue follows the same rule. Small clusters of atypical cells may form, and the body attempts to wall them off or eliminate them. Many of these clusters remain contained for years or decades. They never grow large enough to cause symptoms or threaten life.

Understanding this changes the mindset. The presence of a few abnormal cells does not mean the body has failed. It often means the body is already managing the situation.

Instead of assuming that every abnormal finding requires cutting or radiation, it makes sense to ask how to support the body’s natural defense systems. Strengthening what already works can be more logical than immediately disrupting tissue with invasive procedures.

11:58 Other Components to Fight Cancer

If the objective is to reduce risk and support long-term health, daily habits become powerful tools. Cancer does not develop in isolation. It develops inside an environment created by metabolism, inflammation, toxins, and immune strength.

Reducing known carcinogens is one practical step. Environmental toxins such as heavy metals accumulate over time and interfere with normal cellular function. Testing and medically supervised detoxification strategies can lower this burden and reduce stress on tissues.

Body composition also plays a central role. Excess body fat increases inflammatory signals and hormonal disruption. Chronic inflammation creates conditions that make abnormal growth more likely. Lowering percent body fat through consistent meals, adequate protein, and strength training improves metabolic stability and immune performance.

Nutrition and micronutrients support cellular repair. Adequate intake of vitamins, minerals, and protein gives immune cells the materials they need to function properly. Sleep allows hormonal regulation and tissue recovery. Regular movement improves circulation and immune surveillance throughout the body.

These actions may sound simple, yet they address the foundation of health. They focus on creating conditions where abnormal cells struggle to survive rather than depending on late-stage intervention after a diagnosis.

When you step back and look at the full picture, prevention becomes a daily practice. Supporting the body, reducing toxic exposure, and monitoring calmly provide a safer path than rushing toward a needle that may never have been necessary in the first place.

14:20 A True Story of a Prostate Cancer Survivor

Statistics help you think clearly, yet real lives often make the lesson stick. Numbers show trends. Stories show what those trends look like day to day.

Consider the example shared in the discussion of an older man who lived with prostate cancer for decades. He chose observation, monitoring, and lifestyle support instead of immediate surgery or radiation. He continued working, stayed active, and kept his normal routine well into his eighties.

His PSA stayed elevated for years. Imaging showed abnormalities inside the gland. By conventional standards, those findings would have pushed many men toward aggressive treatment. Instead, he focused on strength, movement, and consistent medical follow-up.

His life did not revolve around hospital visits or recovery from procedures. He maintained independence, worked daily, and described feeling well. The diagnosis existed on paper, yet it did not control his daily function.

This example does not claim that every case will follow the same path. It shows something practical. A prostate cancer label does not automatically mean decline or immediate intervention. Many men live long, active lives while monitoring their condition carefully.

15:59 Cutting Off the Gland Is Not the Solution

Surgical removal of the prostate often sounds decisive. The reasoning feels simple. Remove the gland and remove the problem.

Long-term studies raise important questions about that assumption. Research following men with early-stage prostate cancer for up to twenty years has shown similar survival rates between those who had surgery and those who chose observation. Death from prostate cancer remained low in both groups.

At the same time, surgery carries permanent consequences. The prostate sits next to nerves and structures that control urination and sexual function. Removing the gland can lead to urinary leakage, erectile dysfunction, pain, and recovery complications. These effects influence daily life immediately and can persist indefinitely.

Radiation carries its own burdens. Nearby tissues such as the bladder and rectum receive exposure, which can result in chronic irritation or long-term discomfort. These outcomes affect quality of life even when the cancer itself was never life-threatening.

When survival remains similar, side effects carry greater weight in decision-making. A treatment that reduces function without extending life deserves careful scrutiny. This is why many clinicians now emphasize thoughtful monitoring for low-risk disease rather than automatic intervention.

17:04 Advice to Patients

Prostate decisions often feel rushed. A lab number rises, fear sets in, and the next step appears urgent. This emotional pressure can push people toward procedures before they understand the full picture.

A calmer approach helps you think clearly. Early-stage prostate cancer usually progresses slowly, which gives you time to gather information and evaluate options. Taking time does not equal neglect. It allows measured decisions based on evidence rather than anxiety.

Medical care works best when you remain involved and informed. Ask what each test will change. Ask how a result will alter management. If the answer does not clearly improve your health or survival, reconsider whether the step is necessary.

What to Do

• Track PSA over time and focus on trends rather than one reading.
• Repeat abnormal tests before making decisions.
• Consider imaging, such as MRI, to assess the gland without puncturing tissue.
• Support your body through strength training, healthy percent body fat, sleep, and balanced meals.
• Reduce exposure to known toxins and address inflammation.
• Discuss every option with a qualified clinician and take time to weigh the benefits and risks before agreeing to a biopsy or surgery.

These steps keep the process rational and structured. They protect function while still respecting the importance of monitoring. The aim is to stay informed, stay steady, and choose interventions only when clear evidence shows they are truly necessary.

Key Takeaway

Prostate cancer often creates fear long before it creates harm. Many early prostate findings grow slowly and remain confined to the gland for years, which means immediate biopsy or surgery is not always necessary. Acting too quickly can introduce complications such as pain, infection, urinary problems, or sexual dysfunction without clearly improving long-term survival.

A more thoughtful approach focuses on careful monitoring, understanding PSA trends, and supporting whole-body health. When you slow down, gather information, and protect your strength and function, decisions become clearer and less reactive. The priority stays simple and practical, which is to preserve quality of life while using evidence to guide each step rather than letting fear dictate the path forward.

Related Episodes

Learning is strongest when ideas connect. Continue exploring these episodes that build on today’s discussion:

• EP09 - Don't Biopsy Your Prostate Until You Hear This (Part 2) 
• EP04 - Why Early Treatment of Prostate Cancer May Be Ineffective: The Case for Conventional Therapies

Call to Action

For a deeper explanation of the science and reasoning behind this approach, read Fight Cancer Like a Man by Dr. Stephen Petteruti on Amazon— a clear and practical guide to smarter cancer prevention, vitality, and informed decision‑making.

Join the Intellectual Medicine Community

• Membership (exclusive educational content and clinical resources): https://tinyurl.com/DrPetterutiMember
• Sign up for Dr.  Steve’s Email Newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com 

Connect with Dr. Petteruti

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
• Instagram: https://www.instagram.com/dr.stephenpetteruti
• Facebook: https://www.facebook.com/dr.stephenpetteruti 

Subscribe to the Intellectual Medicine Podcast

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
  Spotify:  https://tinyurl.com/DrPetterutiSpotifyPodcast

Selected References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

C, Jacklin et al. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.” Cancer treatment and research communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England Journal of Medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122

Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14,2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005

Ladjevardi, Sam et al. “Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.” Disease Markers vol. 2014 (2014): 707529. doi:10.1155/2014/707529

Nead, Kevin T et al. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology vol. 3,1 (2017): 49-55. doi:10.1001/jamaoncol.2016.3662

Sennerstam, Roland B et al. “Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.” Cancer cytopathology vol. 125,10 (2017): 748-756. doi:10.1002/cncy.21909

Wilt, T J, and M K Brawer. “The Prostate Cancer Intervention Versus Observation Trial (PIVOT).” Oncology (Williston Park, N.Y.) vol. 11,8 (1997): 1133-9; discussion 1139-40, 1143.

Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England Journal of Medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

Host: Intellectual Medicine by Dr. Petteruti (Member Version)

Date: 25 March, 2025

Episode Summary

• Screening tests exist to reduce death or serious harm, yet large mammogram studies show that finding cancer earlier does not always change overall survival, and repeated imaging adds radiation exposure and false positives.
• Body awareness plays a strong role in early detection, and simple monthly self-exams often help women notice changes quickly without extra procedures or stress.
• Risk varies by the individual, so age, family history, body type, and lifestyle should guide decisions rather than applying the same rule to everyone.
• A thoughtful, informed approach that weighs benefits, risks, and personal comfort helps protect health while avoiding unnecessary tests and interventions.

Quick Decision Checklist

Use this checklist to guide your thinking before scheduling any breast imaging or screening test. The aim is to stay calm, informed, and intentional so each decision supports your long-term health rather than pressure or routine.

☐ Understand what the screening is expected to change and how it would improve survival or quality of life

☐ Discuss both benefits and risks of mammography, including radiation exposure and false positives

☐ Perform monthly self-breast exams and stay familiar with your normal breast texture and shape

☐ Track personal risk factors such as family history, body fat level, and past exposures before choosing imaging

☐ Consider ultrasound first when appropriate to reduce unnecessary radiation

☐ Avoid rushing into biopsy or additional procedures without a clear clinical need

☐ Focus daily on prevention through healthy body composition, movement, sleep, and reduced toxin exposure

☐ Make the final decision based on informed choice and personal comfort, not pressure or habit

00:00 Introduction

Few topics in women’s health create quiet pressure like breast cancer screening. At some point, nearly every woman hears the same instruction during a clinic visit: book your mammogram and get it done soon. The message often sounds urgent, and the space to ask questions feels small.

That pressure can make the decision feel heavier than it needs to be. Screening gets framed as something you simply comply with, rather than something you think through. When a choice feels rushed, fear often replaces clear thinking.

It helps to slow the pace and separate two ideas that often get mixed together. Screening is not prevention. A mammogram does not stop cancer from forming inside the body. It only looks for changes that may already exist.

Every test comes with trade-offs. Mammograms use ionizing radiation. They can show shadows that turn out to be harmless. Those shadows can lead to repeat scans, biopsies, and days or weeks of worry, even when nothing serious is found.

Breast health decisions should feel calm and informed, not forced. You deserve clear facts, time to reflect, and the freedom to choose what fits your body and your comfort level. Before saying yes to any screening plan, it helps to ask one steady question: What will this test truly change for me?

03:00 What Screening Tests Are Designed to Do

Screening tests were created with a simple purpose. They exist to reduce death and serious illness by finding disease early enough for treatment to make a meaningful difference. The logic sounds reassuring because catching something sooner feels like gaining control, yet the real value of any screening tool depends on one outcome alone, which is whether people actually live longer or live better because of it.

Finding a condition earlier does not automatically improve survival. A test can detect abnormalities, label someone as sick, and still leave the final outcome unchanged. When this happens, the person carries stress, appointments, and procedures without receiving a clear health benefit. This distinction often gets lost because early detection sounds powerful, even when the long-term numbers do not show meaningful improvement.

For that reason, screening must always be judged by results rather than intention. The key question is not whether a test can find something. The real question is whether acting on that information truly changes the course of life in a positive way. When the answer is uncertain, the decision becomes personal rather than mandatory, and thoughtful discussion replaces pressure.

03:18 What the Mammogram Studies Actually Show

Mammograms have been promoted for decades as the standard approach to breast cancer screening. Many women grow up hearing that this test is something they simply must do, often without anyone clearly explaining what the research actually shows. When you slow down and look at the evidence, the picture becomes more nuanced and less absolute than the messaging suggests.

Large population studies have compared women who received regular mammograms with women who did not. In several of these trials, cancers were detected earlier in the screened group, which sounds encouraging at first. Yet when researchers followed both groups for many years, the overall death rates looked very similar. Earlier detection did not consistently translate into fewer deaths from breast cancer.

At the same time, mammography introduces trade-offs that are rarely discussed in everyday conversations. The test uses ionizing radiation, and radiation carries cumulative biological effects. The dose from one study is small, yet repeated exposure over decades adds up, especially when screening begins at a younger age and continues year after year. From a biological standpoint, exposing breast tissue to repeated radiation while searching for cancer creates a tension that deserves honest reflection.

False positives also create a quiet burden. A shadow appears on the image, additional scans follow, and sometimes a biopsy is recommended even when the finding turns out to be harmless. This process can lead to pain, scarring, anxiety, and weeks or months of worry, all without improving health. Many women end up chasing findings that were never dangerous to begin with.

When you look at these details together, mammography stops feeling like a one-size-fits-all rule. It becomes a decision that depends on personal risk, comfort level, and values. Some women may prefer the information despite the downsides, while others may choose different approaches. Both paths can be reasonable when they are grounded in understanding rather than fear.

08:07 The Role of Self-Exams and Body Awareness

In the middle of all the technology, it is easy to forget something simple. No one knows your body better than you do. Body awareness remains one of the most practical and accessible tools available, yet it often receives less attention than machines and imaging.

A monthly self-exam allows you to become familiar with what is normal for you. Breast tissue naturally has texture and variation, so the goal is not perfection or constant searching. Instead, you develop a baseline sense of how things usually feel, which makes a new or unusual change easier to recognize. Over time, this quiet familiarity builds confidence rather than anxiety.

This approach has no radiation, no compression, and no cost. It does not require an appointment or insurance approval, and it places control directly in your hands. Many women have discovered lumps themselves between scheduled screenings, which shows that personal awareness remains relevant regardless of what imaging is used.

Body awareness also changes the emotional tone of health decisions. Instead of feeling commanded to follow a schedule, you become an active participant in your own care. You notice changes, ask questions, and then decide whether further evaluation makes sense. That mindset supports thoughtful choices rather than automatic reactions.

When screening is viewed through this wider lens, the path becomes clearer. Technology can assist when needed, yet it does not replace common sense, observation, and personal knowledge. A balanced approach respects both science and intuition, giving you space to choose what aligns with your health, your comfort, and your life.

09:50 Understanding Individual Risk Factors

Breast cancer risk is often presented as if every woman faces the same situation. In reality, risk looks different from one person to another. Age, family history, body composition, environment, and daily habits all shape the picture. When those differences are ignored, screening starts to feel like a rule instead of a personal decision.

Family history is only one part of the story. Having a parent or sibling with breast cancer can raise risk slightly, and certain gene mutations increase it further, yet most women who develop breast cancer have no strong family history at all. This shows that genes alone rarely explain what happens. Lifestyle and environment often carry just as much influence.

Body structure also affects how useful imaging can be. Women with denser or larger amounts of breast tissue may find that lumps are harder to feel, so imaging can provide added information. Women with smaller or less dense tissue may detect changes earlier through touch and familiarity with their own body. These differences explain why the same screening schedule does not fit everyone equally well.

Environmental exposure adds another layer. Smoking, chronic inflammation, toxic metals, poor sleep, and excess body fat all create stress inside the body. Over time, that stress affects how cells repair themselves and how the immune system responds. Lowering these everyday risks supports health long before any scan is performed.

What to Do

• Learn your personal and family health history
• Maintain a healthy percent body fat through balanced meals and strength training
• Stay physically active and protect consistent sleep
• Reduce exposure to smoking, heavy metals, and unnecessary radiation
• Perform a monthly self-exam to stay familiar with your normal breast tissue
• Discuss your individual risk profile with a clinician before choosing a screening plan

11:56 Making a Thoughtful Screening Decision

Once you understand your own risk, screening becomes easier to approach calmly. The conversation shifts away from pressure and toward clarity. Instead of feeling pushed into a test, you begin to evaluate whether it truly fits your situation.

Many women are told to schedule a mammogram without much explanation. The message often sounds urgent, which creates fear. Yet the research shows that early detection through routine screening does not always change long-term outcomes for every group. When the benefit is uncertain, it makes sense to slow down and think carefully.

A thoughtful decision comes from asking simple questions. What information will this test provide? How might the result change my care? What are the downsides, such as radiation exposure or false alarms that lead to more procedures? Answering these questions helps you weigh the value of the test instead of accepting it automatically.

Personal comfort also matters. Some women feel reassured by imaging. Others feel stressed by repeated testing and prefer observation and self-awareness. Both approaches can be reasonable when they are based on evidence and individual preference. Screening works best when it aligns with how you live and what gives you peace of mind.

When the choice feels intentional, confidence follows. You remain in control of your healthcare decisions, and that sense of control reduces anxiety. Medicine should guide you, not command you.

15:40 Mitochondrial Health and Cancer Biology

Screening looks for disease after it forms, yet prevention begins much earlier inside the cell. Every cell contains mitochondria, small structures that produce energy and regulate repair. When these systems function well, tissues stay stable and resilient. When they weaken, abnormal growth has a better chance to take hold.

This perspective shifts the focus from chasing problems to strengthening the internal environment. A healthy body repairs damage more effectively and removes abnormal cells before they spread. A stressed body struggles to keep up. The difference often comes from daily habits rather than medical procedures.

Nutrition, movement, and sleep all support mitochondrial function. Adequate protein helps rebuild tissue. Regular exercise improves circulation and oxygen delivery. Rest allows hormones and immune cells to reset. These basics sound simple, yet they influence biology at a deep level.

Reducing toxic burden also protects these energy systems. Heavy metals, pollutants, and chronic stress interfere with normal cellular processes. Lowering these exposures helps the body operate efficiently and maintain balance. When the internal environment stays strong, the risk of many chronic diseases, including cancer, decreases naturally.

Over time, these steady habits create a foundation of resilience. Screening then becomes one small part of a larger plan, rather than the only line of defense.

18:55 Your Right to Informed Choice

Healthcare decisions should never feel like orders handed down from above. They should feel like conversations where information is shared clearly and you are given the space to think. When a test is presented as something you “must” do, the pressure often replaces understanding, and that is where confusion begins.

Screening tools, including mammograms, exist to provide information. They do not guarantee safety, and they do not prevent disease by themselves. Each test carries benefits, limits, and trade-offs, which means the decision to proceed should come from your own judgment after hearing the full picture. Without that explanation, consent is not truly informed.

Many women describe feeling rushed during appointments. A recommendation is made, a form is signed, and the moment passes before real questions are asked. Later, doubts appear because the reasoning behind the test was never fully discussed. That experience creates anxiety, even when the intention was to help.

You have the right to slow the process down. You can ask what the test is expected to show, how accurate it is, what risks come with it, and what happens next if something unclear appears. You can also ask whether waiting, repeating an exam later, or using another method such as ultrasound makes sense for your specific situation. These questions are reasonable and responsible.

Choice also means respecting your own comfort level. Some women prefer regular imaging because it provides reassurance. Others prefer self-exams, lifestyle changes, and selective testing based on symptoms or risk factors. Both approaches can be thoughtful when they are based on evidence and personal values rather than fear.

At the center of all of this is autonomy. Your body belongs to you, and your healthcare decisions should reflect your goals, your tolerance for risk, and your understanding of the science. When you stay informed and engaged, screening becomes a tool you choose to use, not a rule you feel forced to follow.

Key Takeaway

Breast cancer screening works best when it is approached with clarity and personal judgment rather than pressure. Tests like mammograms can detect changes, yet detection alone does not guarantee better outcomes, and every screening method carries limits along with potential risks. When you understand what a test can and cannot tell you, the decision becomes calmer and more rational instead of fear-driven.

Your health benefits most from steady daily habits, awareness of your own body, and thoughtful conversations with a clinician who respects your input. Screening should support those foundations, not replace them. The strongest position is one where you stay informed, weigh the evidence carefully, and choose the path that fits your risk profile and your comfort level.

Related Episodes

Learning is strongest when ideas connect. Continue exploring these episodes that build on today’s discussion:

EP17 - Biden's Prostate Cancer: The TRUTH Doctors Don't Want You To Know!

EP31 - Do Men Really Die From Prostate Cancer? What the Data Actually Shows

Call to Action

For a deeper explanation of the science and reasoning behind this approach, read Fight Cancer Like a Man by Dr. Stephen Petteruti on Amazon— a clear and practical guide to smarter cancer prevention, vitality, and informed decision‑making.

Join the Intellectual Medicine Community

• Membership (exclusive educational content and clinical resources): https://tinyurl.com/DrPetterutiMember
• Sign up for Dr.  Steve’s Email Newsletter: https://www.drstephenpetteruti.com
• Learn more about Intellectual Medicine: https://www.intellectualmedicine.com 

Connect with Dr. Petteruti

• LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
• Instagram: https://www.instagram.com/dr.stephenpetteruti
• Facebook: https://www.facebook.com/dr.stephenpetteruti 

Subscribe to the Intellectual Medicine Podcast

• Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
  Spotify:  https://tinyurl.com/DrPetterutiSpotifyPodcast

Selected References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Bennett A, et al. Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline. Syst Rev. 2024;13(1):304. Published December 19, 2024. doi:10.1186/s13643-024-02700-3.

Bleyer A, Welch HG. Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med. 2012;367(21):1998-2005.

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.

Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.

Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2016;164(4):256-267.

Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(4):279-296.

Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med. 2016;375(15):1438-1447.

US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918-1930. doi:10.1001/jama.2024.5534.

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: May 6, 2025

Episode Summary

• Testosterone supports brain speed, mood stability, muscle strength, bone health, sexual function, and long-term vitality.
• Age-related testosterone decline is common, but symptoms such as low energy, reduced libido, loss of muscle, and brain fog should be evaluated rather than dismissed.
• Blood tests establish safety baselines, but free testosterone is the active form and often more important than total levels.
• Properly supervised testosterone therapy does not show increased risk of prostate cancer or heart attack in current research and requires monitoring of PSA, blood count, and estrogen.
• Long-term vitality depends on informed decisions, hormone balance, strength training, and preserving independence with age.

Quick Checklist

Before starting or continuing testosterone therapy, keep the main safety and monitoring steps in view. Testosterone affects the whole body, so decisions should be thoughtful and structured rather than casual. This checklist serves as a clear guide for safe and long-term use:

• Obtain baseline labs before therapy, including PSA, complete blood count, thyroid panel, and both total and free testosterone.
• Evaluate symptoms alongside lab results. Loss of libido, low energy, poor recovery, depressed mood, and reduced strength should be considered during assessment.
• Monitor hemoglobin, hematocrit, and estrogen levels during treatment to prevent complications such as erythrocytosis or hormonal imbalance.
• Preserve testicular function when using testosterone by incorporating appropriate medical support under physician supervision.
• Maintain supportive habits such as strength training, body fat control, adequate sleep, and stress regulation to enhance long-term outcomes.

00:00 Introduction

Testosterone is often treated as if it only affects sex drive or muscle size. In reality, that is only a fragment of the truth. The body uses testosterone to support brain function, mood, strength, bone health, energy, and long-term vitality. Because testosterone levels drop gradually over time, many people hardly notice the change at first, yet the signs are usually present. You may feel tired without a clear reason, think a little slower than before, or notice that recovery after exercise takes longer than it did a few years ago.

Medicine has made decline sound normal. Brain fog is called aging, muscle loss, and low energy are brushed aside and treated like the normal life cycle. Yet when the thyroid gland slows down, doctors replace thyroid hormone. The testicles are also hormone-producing organs. When their output fades, the effect spreads through the entire body.

Testosterone works like a messenger. It helps brain cells communicate, supports muscle and bone strength, and influences mood and motivation. Growing older in years is unavoidable. Withering in strength and clarity does not have to be accepted without asking questions.

02:50 Our body is a self-healing machine

The body has regulatory systems that constantly repair tissue, balance hormones, and maintain internal stability. These systems do not abruptly stop working at midlife. What changes over time is the hormonal environment that supports them. When hormone production declines, repair slows, recovery weakens, and performance drops.

In many clinical settings, decline is labeled as normal aging. Slower recall, reduced muscle mass, lower stamina, and decreased drive are often dismissed rather than investigated. When the thyroid underperforms, replacement therapy is standard practice. When insulin production fails, insulin is prescribed. The testicles also produce hormones that influence multiple organs, including the brain, muscles, bones, and cardiovascular system. Yet declining testosterone is frequently ignored or minimized.

Chronological aging is unavoidable. Functional decline is influenced by biology that can be evaluated and, in many cases, supported. The decision to intervene should be based on symptoms, laboratory data, and long-term health strategy rather than cultural assumptions about what aging should look like.

03:16 Benefits of testosterone

Testosterone functions beyond sexual health. In the brain, it supports neuronal signaling and influences memory formation, processing speed, and concentration. Lower testosterone levels have been associated with reduced cognitive performance and increased risk of mood disturbance. Both men and women rely on adequate testosterone for neurological stability.

Muscle tissue is highly dependent on testosterone. During adolescence, rising testosterone levels drive muscle growth and strength development. Later in life, as testosterone declines, maintaining lean muscle mass becomes more difficult even with regular exercise. Reduced muscle mass contributes to decreased strength, slower metabolism, and higher risk of injury.

Bone density is also influenced by testosterone. Lower levels correlate with weaker bones and increased fracture risk. Joint stability depends in part on muscular support, and many patients report reduced musculoskeletal pain when hormone levels are optimized.

Long-standing fears about testosterone therapy have been reexamined. Current evidence does not show a consistent increase in prostate cancer incidence among men receiving properly monitored therapy. Cardiovascular data remain complex, but large studies have not demonstrated a clear rise in heart attack or stroke risk when treatment is supervised and individualized. Monitoring blood count and other markers remains essential.

06:54 Calming effect of testosterone

Testosterone is often assumed to increase aggression. Clinical observation frequently shows the opposite pattern when testosterone levels are low. Men with inadequate testosterone may present with irritability, low motivation, reduced confidence, and depressed mood.

Restoring testosterone to appropriate levels often improves emotional stability and stress tolerance. Some clinicians have incorporated testosterone therapy into treatment plans for men with persistent depressive symptoms when laboratory findings support deficiency.

It is important to distinguish therapeutic restoration from supraphysiologic dosing. Excessive hormone levels can produce instability. The objective of treatment is physiological balance. When levels are maintained within an appropriate range and monitored carefully, many patients report improved mood, steadier energy, and clearer thinking.

11:55 Truth about blood levels

Blood tests are helpful, but they are not the final decision maker. The first reason to check blood work is to create a starting point. A baseline helps identify whether there are conditions that require caution before beginning therapy.

One important marker is PSA, which stands for prostate-specific antigen. If PSA is very high, such as above 10 and in some cases above 20, it deserves careful review before starting testosterone. This does not always mean therapy cannot be done, but it requires thoughtful supervision.

Another test is a complete blood count. Some men carry a genetic condition called hemochromatosis, which causes the body to store too much iron. Over time, excess iron can damage the liver, kidneys, and brain. Testosterone therapy can increase red blood cell production because it stimulates the kidneys to release a hormone called erythropoietin. This hormone signals the bone marrow to make more red blood cells. A mild rise in blood count is expected, but if it climbs too high, a condition called erythrocytosis can develop. In that case, donating blood may be recommended.

Blood tests also help evaluate heart health, blood sugar, and thyroid function. These systems affect energy, mood, and strength. Lab values provide useful information, but symptoms and clinical judgment carry equal weight.

13:45 Total vs. free testosterone

When testosterone is measured in the blood, two main numbers can be reported: total testosterone and free testosterone. Understanding the difference is essential.

Total testosterone represents the entire amount of testosterone circulating in the bloodstream. However, not all of it is available for the body to use. A large portion of testosterone binds to a protein called sex hormone binding globulin, or SHBG. When testosterone is attached to this protein, it cannot enter cells and perform its function.

Free testosterone is the portion that is not bound. This is the active form. It enters cells, interacts with receptors, and supports brain function, muscle growth, bone density, libido, and mood. A person can have a normal total testosterone level but still feel symptoms of deficiency if free testosterone is low.

This difference explains why some men are told their levels are normal even though they feel tired, lose muscle, or experience reduced libido. If only total testosterone is checked, the picture may be incomplete. Measuring free testosterone provides a clearer understanding of what the body can actually use.

Symptoms that may suggest low free testosterone include reduced sexual desire, difficulty with erections, low energy, decreased motivation, slower recovery after exercise, depressed mood, and loss of muscle mass. These symptoms can overlap with thyroid problems or chronic stress, which is why a broader evaluation is important.

Treatment decisions should not rely on one single lab number. If a patient reports improved energy, better mood, stronger workouts, and improved sexual function, that improvement carries meaning even if the lab value sits in the middle of a reference range. On the other hand, if levels are high but side effects appear, adjustments may be required.

Testosterone therapy also requires monitoring of estrogen. Some testosterone converts into estrogen, which plays a role in bone strength and sexual function. If estrogen rises too high, unwanted effects such as breast tissue growth can occur. If it drops too low, bone and libido may suffer. Many clinicians aim for an estrogen range between 20 and 40, though reference ranges vary by laboratory.

Preserving natural testicular function is another consideration. When external testosterone is given without support, the testicles may shrink over time because they reduce their own production. Medications such as clomiphene, enclomiphene, hCG, or gonadorelin can be used to stimulate the testicles and maintain function under medical supervision.

Understanding total and free testosterone helps prevent oversimplified decisions. It ensures therapy is based on biology, symptoms, and long-term health rather than a single number.

21:26 Creams for hair loss

Some men worry that testosterone therapy will cause hair loss. Hair thinning in men is often related to genetics and a hormone called dihydrotestosterone, or DHT. DHT is a stronger form of testosterone that can shrink hair follicles in men who are genetically sensitive.

Testosterone can increase DHT levels. If a man is already prone to male pattern baldness, therapy may speed up a process that was likely going to happen over time.

There are options to manage this risk. One approach is using topical prescription creams that act directly on the scalp. These treatments target hair follicles with minimal absorption into the bloodstream. Another option is medications such as finasteride, which reduce the conversion of testosterone into DHT. Blocking DHT can help preserve hair, though it must be balanced carefully because DHT also contributes to sexual function in some men.

Hair loss management should be individualized. The decision depends on family history, cosmetic preference, and overall treatment priorities. Monitoring and discussion with a qualified clinician ensures that hormonal therapy supports vitality without ignoring side effects.

22:33 Duration of the treatment

A common question is how long testosterone therapy should continue. The honest answer is that it can be continued for life if it remains safe, affordable, and aligned with personal values. There is no fixed expiration date. Testosterone is a hormone your body naturally produces. When levels fall and symptoms appear, replacing it is similar in principle to replacing thyroid hormone when the thyroid slows down.

Stopping therapy is always a personal decision. Some men may choose to stop for financial reasons or philosophical reasons. Others may prefer to age without intervention. That choice does not make anyone careless or uninformed. The role of a physician is to provide information, monitor safety, and guide decisions, not to impose treatment.

Strength training, maintaining a healthy body fat percentage, and sleeping well can support natural testosterone levels. However, even disciplined and healthy men experience a gradual decline over time. Therapy becomes one available option, not an obligation.

Some clinicians recommend an occasional short break, sometimes called a hormone holiday, such as skipping a scheduled dose every few weeks. The theory is that this may keep hormone receptors responsive over the long term. Most men feel stable during short breaks because testosterone remains in the system for some time. Long-term therapy, when properly monitored, can be sustainable for decades.

24:59 How we live is what we control

Aging in years cannot be stopped, yet the way strength, mobility, and clarity change over time can be influenced. One major cause of disability in older adults is sarcopenia, which means loss of muscle mass. Weak muscles make daily tasks harder. Climbing stairs, opening jars, and getting out of a car all depend on muscle strength.

Testosterone supports muscle maintenance. Strong muscles protect joints, improve balance, and lower the risk of falls. Maintaining muscle also supports bone density, which lowers fracture risk. Brain health is also connected to hormone balance. Lower hormone levels have been linked in research to increased risk of cognitive decline.

Lifestyle choices remain important. Walking regularly, lifting weights, eating balanced meals, and keeping body fat within a healthy range all support vitality. Hormone therapy does not replace these habits. It works alongside them. The central idea is that while death is inevitable, years of unnecessary weakness or decline may be influenced by thoughtful action.

Each person chooses how to approach aging. Some will prefer organic decline. Others will use every safe and credible tool available. What remains constant is personal responsibility in making informed decisions.

26:16 Other side effects

No medical therapy is free from potential side effects, and testosterone is no exception. One common effect is acne, especially on the chest or back. This happens because testosterone can stimulate oil glands in the skin. If acne appears, the dose can often be adjusted. In some cases, dividing the weekly dose into two smaller injections can smooth hormone levels and reduce skin reactions.

Hair thinning is another concern for men who are genetically prone to male pattern baldness. Testosterone can increase levels of DHT, a hormone that influences hair follicles. Monitoring and preventive strategies, such as topical treatments or DHT-modulating medications, can be considered when appropriate.

It is important to distinguish medical testosterone therapy from anabolic steroid abuse. High-dose anabolic steroids used for bodybuilding can damage the brain, heart, and reproductive system. They can suppress natural testosterone production and sometimes cause long-term harm. Medical therapy aims to restore physiological levels, not create extreme muscle growth.

Over-the-counter supplements that claim to “boost” testosterone rarely provide meaningful improvement in men with true deficiency. In most symptomatic men over 40, replacing testosterone itself is the effective treatment when clinically appropriate.

30:16 Motivational story of a patient

A story illustrates the broader message about vitality. Years ago, a patient in his mid-80s with stage four lung cancer was receiving supportive care, including testosterone therapy. During a visit, he was asked about his breathing. He replied that he only became short of breath during intimacy with his wife.

At 85 years old, facing advanced cancer, he remained engaged in life, connection, and intimacy. He passed away a few months later. His final months were not defined by weakness or resignation but by participation in living.

The lesson is not that testosterone cures disease. The lesson is that vitality can be preserved longer than many people expect. Strength, connection, and purpose can continue deep into later years when health is supported intentionally. Aging does not require surrendering energy or identity. It requires informed choices and steady attention to the systems that keep the body functioning well.

Key Takeaway

Testosterone is a foundational hormone that affects the brain, muscles, bones, mood, skin, and sexual health. When it declines, the whole body feels the effect. Slower thinking, lower energy, weaker recovery after exercise, reduced confidence, and changes in libido can all reflect falling testosterone levels rather than unavoidable aging.

Blood work helps create a starting point, yet numbers alone do not determine treatment. Total testosterone shows how much is present in the bloodstream, while free testosterone shows how much is actually available for the body to use. Symptoms, physical function, and overall health must be considered together with laboratory values.

When therapy is used, the focus is on restoration to a healthy physiological range under medical supervision. Monitoring blood count and estrogen keeps treatment balanced and safe. Strength training, body composition control, and cardiovascular health remain essential. The central principle is that growing older does not require surrendering clarity, strength, or vitality without first examining the hormonal foundation that supports them.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP06 – The Truth About Testosterone: Does It Really Cause Prostate Cancer?

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Hackett GI. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. World J Mens Health. 2025;43(2):282-290. doi:10.5534/wjmh.240081

Haider, Ahmad et al. “Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.” The Journal of urology vol. 193,1 (2015): 80-6. doi:10.1016/j.juro.2014.06.071

Kaplan, Alan L et al. “Testosterone Therapy in Men With Prostate Cancer.” European urology vol. 69,5 (2016): 894-903. doi:10.1016/j.eururo.2015.12.005

Keren D, Goshen A, Strauss T and Springer S (2025) Study protocol: associations between hormonal profile and physical and cognitive functions in middle-aged men—a one-year cohort follow-up study. Front. Public Health 13:1654077. doi: 10.3389/fpubh.2025.1654077

Mohammad, Osama S et al. “Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.” Cancers vol. 9,12 166. 6 Dec. 2017, doi:10.3390/cancers9120166

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177(4):471-479. doi:10.1001/jamainternmed.2016.9539

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Petteruti (Member Version)

Date: 08 April, 2025

Episode Summary

• Early prostate cancer carries a very low short-term death rate, yet elevated PSA levels often push men toward biopsy, surgery, or radiation even when these steps have not clearly improved long-term survival.
• Prostate biopsy involves multiple core needle samples that can cause bleeding, infection, pain, and anxiety, and there is concern that disrupting tissue may allow abnormal cells to spread beyond the gland.
• Long-term studies, including research following men for up to twenty years, have shown similar death rates among those who had their prostate removed, received radiation, or chose observation, which challenges the idea that aggressive early treatment always helps.
• A more practical approach focuses on careful monitoring, imaging such as MRI, repurposed drug strategies, immune support, toxin reduction, and healthy body composition so the body stays resilient while unnecessary procedures are avoided.

Quick Decision Checklist

Use this checklist as a simple guide before agreeing to a prostate biopsy, surgery, or radiation. Each point is meant to help you think clearly and protect both your long-term health and your daily quality of life.

☐ Track PSA levels over time and look for patterns instead of reacting to a single rise

☐ Repeat abnormal PSA tests to confirm the result before making any decisions

☐ Ask how a biopsy or procedure would change survival or outcomes before agreeing to it

☐ Consider imaging such as prostate MRI to gather information without puncturing tissue

☐ Avoid routine or repeated biopsies unless there is a clear and necessary clinical reason

☐ Support immune health through sleep, balanced meals, strength training, and regular movement

☐ Reduce exposure to toxins such as smoking, heavy metals, and unnecessary radiation

☐ Maintain a healthy percent body fat and preserve muscle mass to lower overall cancer risk

☐ Discuss non-invasive or supportive options, including monitored observation and medical therapies, with a qualified clinician

☐ Take time to understand every option so decisions come from evidence and comfort rather than fear

00:00 Introduction

No man should ever have his prostate biopsied.

That statement sounds strong at first, yet it comes from years of clinical observation and careful review of the evidence. When you look closely at how prostate cancer is detected and treated, you begin to see that many men are exposed to needles, surgery, and radiation when, really, nobody can prove that those steps will actually help them live longer. And at the end of the day, instead of improving the life of the patient, they end up dealing with unnecessary fear.

Saying an elevated PSA is nothing to worry about is far from the truth. Naturally, when you see those numbers going up, the first thing that comes to mind is the word “cancer.” From there, some doctors would start recommending that you have a biopsy. Years of research have proven that while it is an option, it is not the best option. It is always best to know every option and how they relate to you.

03:09 Mortality Rate of Prostate Cancer

Fear around prostate cancer often comes from the belief that it is an immediate threat to life. The word alone can make any man feel like something dangerous is already happening inside his body. Yet when you step back and look at the numbers, the picture looks very different from the fear that usually surrounds it.

Prostate cancer has one of the highest survival rates of any common cancer. The five-year relative survival rate sits around 98 to 99 percent, and even the ten-year survival rate remains close to 98 percent. In simple terms, most men diagnosed with early or localized prostate cancer are still alive many years later, even when no aggressive treatment is done. That reality makes it very difficult to prove that surgery or radiation actually extended anyone’s life in the first place.

History also adds a perspective that most people never hear. In the 1860s, when one of the first modern prostatectomies was performed in England, the surgeon at the time described prostate cancer as a rare disease. “Rare.” That statement forces an important question: If it was once considered uncommon, how did it suddenly become something that seems to affect nearly every aging man today? The answer likely has more to do with how we label and search for it than with the disease itself becoming more aggressive.

Where outcomes truly change is when cancer spreads outside the gland. Once there is distant metastasis, survival drops sharply, with five-year survival falling closer to 30 to 40 percent. That difference tells us something important. The real danger is not simply finding abnormal cells inside the prostate. The real danger begins only after those cells escape and travel elsewhere.

05:32 The Biopsy Procedures

Despite these high survival numbers, many men are still guided toward biopsy as soon as the PSA creeps upward. The test is often described as small and routine, almost like a quick blood draw, but that description leaves out what really happens.

A prostate biopsy involves repeatedly firing a core needle into the gland to remove tissue samples, usually twelve or more. Each pass removes a small cylinder of tissue, and each pass creates bleeding and inflammation. Men often experience pain, blood in the urine or semen, and sometimes an infection that requires antibiotics or hospital care. This is not a minor step, even though it is presented as one.

The result also does not provide certainty. A negative biopsy simply means nothing was found in the spots that were sampled, not that cancer is absent everywhere. That uncertainty often leads to repeat biopsies over months or years, which keeps men stuck in a cycle of procedures without clear answers.

At this point, the obvious question becomes whether finding cancer earlier and treating it aggressively actually changes survival. That question has been studied directly, and the answer surprises many people.

A major long-term study published in the New England Journal of Medicine followed men who already had diagnosed prostate cancer. These men were divided into three groups. One group had the prostate gland removed, another received radiation therapy, and the third group had no immediate treatment at all.

Researchers tracked them for nearly twenty years. After two decades of follow-up, the death rate from all causes and the death rate from metastatic prostate cancer were essentially the same across all three groups. In other words, removing the gland, irradiating it, or doing nothing produced very similar survival outcomes.

That finding forces you to rethink the rush toward aggressive intervention. If long-term survival remains similar, then exposing men to surgery, radiation, or repeated invasive testing becomes much harder to justify. The benefit is uncertain, while the side effects are very real.

09:06 Cellular Metastasis

The biology of prostate cancer helps explain why this happens. Many abnormal or atypical cells can sit quietly inside the prostate for years without causing harm. As long as those cells stay contained within the gland, they often remain dormant and never threaten life.

Trouble begins when cells escape and travel elsewhere in the body. Metastatic spread is what leads to serious illness and death, not simply the presence of abnormal cells inside the prostate. This distinction is critical because it shows that not every detected cancer behaves the same way.

When you consider that biopsies repeatedly puncture the gland and disrupt tissue barriers, it becomes reasonable to question whether such disruption is always helpful. The goal should be preserving health and function while keeping risk low, rather than automatically moving toward procedures that may not improve survival in the first place.

09:53 Active Monitoring of the Prostate

Once a man receives an elevated PSA or a suspicious finding, many doctors offer what they call “active monitoring” or “active surveillance.” At first glance, this sounds careful and reasonable, as if the situation is being watched closely without rushing into surgery. In practice, however, this approach often means repeated biopsies performed at regular intervals, sometimes every six months or every year, with the idea that sampling the tissue again will reveal whether the cancer has changed.

The problem is that this logic falls apart when you look at what a biopsy can and cannot tell you. A biopsy only shows what is happening in the small pieces of tissue that were removed on that day. It cannot predict the future behavior of those cells, and it cannot confirm whether any cells have already moved outside the gland. In other words, the test provides a snapshot, not a forecast. Yet men are exposed to needles again and again based on information that has limited predictive value.

Biology also explains why this approach may be unnecessary for many men. As long as abnormal or atypical cells remain contained within the prostate, they often stay quiet for years. Dormant cells inside the gland rarely cause harm. The true danger begins only when cancer spreads beyond the prostate and establishes itself elsewhere in the body. That is when the disease becomes life-threatening. Simply detecting cells inside the gland does not automatically place someone at risk.

So if a man feels well, has mild urinary symptoms that are typical of aging, and only shows a gradual PSA rise, repeatedly puncturing the gland does not offer clear protection. It often adds discomfort, bleeding, infection risk, and anxiety without demonstrating that survival improves. When you consider that long-term studies have already shown similar death rates between treatment and observation in many early cases, the value of repeated invasive testing becomes even harder to justify.

There are also broader health considerations that rarely get discussed. Surgical and procedural interventions carry collateral risks, especially in older men. Studies of non-cardiac surgery in patients over 65 have reported silent strokes that show up later as memory loss or cognitive decline. Blood clots, infections, and heart strain are not theoretical problems. They are documented realities. When a treatment has no proven survival benefit, even small risks begin to matter.

For these reasons, active monitoring built around serial biopsies often turns into a cycle of procedures rather than a truly protective strategy. A more rational approach focuses on observation that respects the biology of the disease while minimizing harm to the patient.

11:16 Repurposed Drug Therapy

This is where the philosophy used in Intellectual Medicine takes a different direction. Instead of repeatedly sampling tissue or moving quickly toward surgery or radiation, the focus shifts toward creating an internal environment where cancer struggles to grow or spread. The objective is not passive waiting. The objective is active support of the body’s defenses.

One practical tool is imaging. An MRI of the prostate can evaluate the structure of the gland and track changes over time without piercing tissue. When PSA rises gradually but the MRI looks stable year after year, that information provides reassurance without exposing the patient to needles or trauma. It allows monitoring while preserving function and quality of life.

Another strategy involves what is known as repurposed drug therapy. These are medications originally developed for other medical conditions that have shown anti-cancer or anti-metastatic effects. Many are inexpensive, widely available, and have long safety records. They do not require hospitalization, anesthesia, or invasive procedures, yet they may help reduce the biological conditions that allow cancer to spread.

Examples discussed in this approach include low-dose medications that influence cellular metabolism, mitochondrial health, and inflammatory signaling. Drugs such as sirolimus, low-dose naltrexone, low-dose doxycycline, and DMSA for heavy metal reduction have been studied for their ability to create a less favorable environment for cancer growth. Rather than cutting tissue out, the strategy supports immune surveillance and lowers toxic burden, which addresses cancer risk at the cellular level.

There is also an important perspective shift here. When researchers followed more than 250 men with prostate cancer who ultimately died, only a small fraction died from prostate cancer itself. Most died from heart disease or other common illnesses. That observation suggests that overall health, cardiovascular fitness, and toxin exposure may influence survival just as much, or even more, than aggressive prostate procedures. Focusing only on the gland while ignoring the rest of the body can miss the bigger picture.

Taken together, this approach respects two facts that the evidence keeps repeating. First, many prostate cancers remain contained and never threaten life. Second, aggressive interventions often carry permanent side effects without a clear survival advantage. Supporting the immune system, reducing toxic exposure, improving metabolic health, and monitoring with noninvasive tools offer a path that protects both longevity and day-to-day function.

When you weigh everything carefully, preserving strength, clarity, and quality of life becomes just as important as chasing every abnormal cell. For many men, that balance leads away from repeated biopsies and toward smarter, less traumatic ways of managing risk.

17:03 Biggest Risks of Prostate Cancer

By this stage in the discussion, the focus naturally shifts away from needles, scans, and procedures and toward something much simpler. It becomes clear that the largest drivers of prostate cancer risk are not hidden inside the hospital. They are built into everyday biology and the environment a man lives in over decades.

Age stands at the top of the list.

As men get older, the immune system gradually weakens. Cells that once would have been identified and cleared quickly may linger longer. Small abnormalities that would have been corrected in youth can persist. This quiet change happens slowly, year after year, and it explains why prostate cancer appears more often later in life rather than early adulthood. The passage of time itself alters how the body repairs damage and controls abnormal growth.

There is also the issue of accumulated exposure.

Modern life brings constant contact with substances that the body was never designed to handle. Heavy metals such as cadmium, lead, and arsenic build up in tissues through air, water, and food. These elements are known carcinogens. They sit inside the body for years and quietly interfere with normal cellular function. Over time, that interference increases the likelihood that damaged cells survive when they should have been removed.

Body composition plays a role as well.

Higher percent body fat is consistently associated with increased cancer risk across many types of disease, including prostate cancer. Excess fat tissue promotes chronic inflammation and hormonal disruption. Inflammation creates a biological environment where abnormal cells have an easier time surviving. When inflammation stays elevated for years, the body becomes less efficient at repair and immune surveillance.

When you put these pieces together, a pattern emerges.

The greatest risks are not a single PSA number or a small cluster of cells seen on a microscope slide. The greater risks are weakened immune defenses, toxic accumulation, poor metabolic health, and long-term inflammation. These are slow processes that shape the terrain in which cancer either struggles or thrives.

This understanding changes how prevention should be approached. Instead of focusing only on detecting disease earlier and earlier, it makes more sense to strengthen the body so that disease has fewer opportunities to take hold in the first place. Supporting immune health, improving fitness, and reducing toxic exposure address the root conditions that influence long-term outcomes.

When those foundations are solid, the body becomes less hospitable to cancer. That protection works quietly in the background every day, which often provides greater benefit than any single invasive procedure.

21:32 Things to Avoid

As important as knowing what supports health, it is equally important to recognize which paths tend to create harm without clear benefit. Many of the standard responses to an elevated PSA feel decisive, yet they can introduce lifelong complications while offering little evidence that survival improves. Being aware of these risks allows a man to think clearly and choose carefully rather than reacting out of fear.

What to Do:

☐ Avoid routine prostate biopsy when the only finding is an elevated PSA without symptoms

☐ Avoid rushing into surgery or radiation without long-term evidence that it improves survival for your specific situation

☐ Avoid repeated invasive procedures that cannot predict the future behavior of the disease

☐ Avoid ignoring overall health risks, such as heart disease, while focusing only on the prostate

☐ Avoid exposure to known carcinogens, including smoking, heavy metals, and unnecessary radiation

☐ Avoid excess body fat and inactivity that promotes chronic inflammation

☐ Avoid androgen deprivation therapy unless there is a clear and compelling reason, given its effects on energy, mood, muscle, and bone

These choices do not mean doing nothing. They mean protecting the function and preserving the strength while gathering better information. The idea is to remain thoughtful and deliberate, using evidence to guide each step rather than allowing anxiety to dictate treatment.

Key Takeaway

An elevated PSA often creates immediate fear, yet fear alone is not evidence. When you examine the long-term data, early prostate cancer rarely leads to death within the first several years, and many men live full lives without ever needing surgery, radiation, or repeated biopsies. At the same time, those interventions carry real and permanent consequences, including infection, urinary problems, sexual dysfunction, and complications that affect day-to-day living.

This is why the first response should never be panic or reflexive procedures. A biopsy cannot predict the future behavior of the disease, and removing or irradiating the gland has not consistently shown better survival in early cases. Meanwhile, age, immune strength, toxic exposure, and overall metabolic health quietly influence risk far more than a single lab value.

A calmer and more rational path focuses on monitoring trends, protecting whole-body health, and choosing interventions only when there is clear and meaningful benefit. When decisions are guided by evidence instead of pressure, you protect both longevity and quality of life, which ultimately remains the outcome that matters most.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP09 - Don't Biopsy Your Prostate Until You Hear This (Part 2) 

EP04 - Why Early Treatment of Prostate Cancer May Be Ineffective: The Case for Conventional Therapies

For a deeper explanation of the science and reasoning behind this approach, read Fight Cancer Like a Man by Dr. Stephen Petteruti on Amazon— a clear and practical guide to smarter cancer prevention, vitality, and informed decision‑making.

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

C, Jacklin et al. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.” Cancer treatment and research communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England Journal of Medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122

Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14,2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005

Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025;75(6):485-497. doi:10.3322/caac.70028

Ladjevardi, Sam et al. “Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.” Disease Markers vol. 2014 (2014): 707529. doi:10.1155/2014/707529

Nead, Kevin T et al. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology vol. 3,1 (2017): 49-55. doi:10.1001/jamaoncol.2016.3662

Sennerstam, Roland B et al. “Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.” Cancer cytopathology vol. 125,10 (2017): 748-756. doi:10.1002/cncy.21909

Wilt, T J, and M K Brawer. “The Prostate Cancer Intervention Versus Observation Trial (PIVOT).” Oncology (Williston Park, N.Y.) vol. 11,8 (1997): 1133-9; discussion 1139-40, 1143.

Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England Journal of Medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869

Disclaimer

This podcast and accompanying materials are for educational purposes only and do not replace personalized medical care. The information presented is designed to support informed decision‑making and health literacy, not to diagnose or prescribe. Always consult your own qualified healthcare provider regarding personal health questions or treatment decisions.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without permission is prohibited.

Host: Intellectual Medicine by Dr. Petteruti (Member Version)

Date: 15 April, 2025

Episode Summary

• Prostate cancer screening expanded rapidly after the introduction of PSA testing, yet early detection has not been clearly linked to improved long-term survival in large outcome trials.
• Historical data show that prostate removal became standard before modern imaging or laboratory tools existed, and mortality rates did not fall simply because glands were removed.
• Studies comparing surgery, radiation, and observation over long follow-up periods have shown similar mortality outcomes, challenging the assumption that aggressive treatment guarantees benefit.
• Androgen deprivation therapy is associated with fatigue, muscle loss, metabolic change, cognitive decline, and cardiovascular risk, and its impact on survival in early disease remains uncertain.

Quick Checklist

Before moving forward with any screening test, biopsy, surgery, or hormone therapy, it helps to pause and review the full picture. This checklist is meant to guide thoughtful decision-making so that each choice reflects evidence, context, and your broader health priorities.

• Confirm that an elevated PSA has been repeated under stable conditions before considering further steps
• Review long-term outcome data on surgery and radiation, not just short-term PSA changes
• Consider multiparametric MRI with PI-RADS scoring to establish a baseline before any biopsy discussion
• Ask whether a proposed biopsy will change management in a way that improves survival
• Evaluate cardiovascular health alongside prostate findings, including calcium scoring when appropriate
• Weigh the cognitive, metabolic, and cardiovascular risks before agreeing to androgen deprivation therapy
• Reflect on whether findings may represent dormant atypical cells rather than aggressive disease
• Make decisions based on informed understanding rather than fear of a laboratory number

00:00 Introduction

We sometimes think of science and medicine as cold and purely logical, as if every decision comes from clean numbers and neat charts. In real life, it rarely works that way. When the topic turns to prostate cancer, fear, habit, and old beliefs often guide decisions just as much as evidence does.

Before talking about screening tests or treatment plans, it helps to step back and ask a simple question: Where does this path actually lead? If you follow the PSA test, then the biopsy, then the surgery or radiation, what is the end result for your life, your body, and your long-term health? That endpoint, not the first test, is what truly matters.

There is also a basic biological reality that most men never hear about. Autopsy research has shown that many men, especially as they age, carry small clusters of abnormal or cancer-like cells inside the prostate and never know it. These cells often stay quiet for decades and never cause symptoms or shorten life. Some studies even show that a large portion of men over 50 have these cells, and the majority of men past 90 show them as well, despite dying from completely unrelated causes.

That raises an uncomfortable question. If these cells are so common and so often harmless, are we sometimes labeling a normal age-related change as a dangerous disease? And in our attempt to find cancer early, are we sticking needles into healthy glands and creating problems that might never have existed in the first place?

02:21 Historical Evolution of Prostate Treatment

To understand where we are today, it helps to look at how prostate treatment developed over time. In the mid-1800s, a British surgeon performed one of the first modern prostatectomies and described prostate cancer as a rare disease that you would hardly ever see. That statement stands in sharp contrast to how the condition is described today, where it is often portrayed as common and almost inevitable with aging.

So what changed? The biology of men did not suddenly transform. What changed was our ability to look more closely. As diagnostic tools improved, especially through tissue sampling and later blood tests, more abnormal cells were identified. Over time, atypical or dormant cells were grouped together with aggressive disease under the single label of cancer. The more we searched, the more we found, and the more we found, the more the disease appeared to expand.

By the 1940s and 1950s, removal of the prostate gland became standard practice. This was long before PSA testing, MRI imaging, or advanced pathology grading systems. Decisions were based largely on digital rectal examination and clinical suspicion. Surgeons removed glands in an attempt to cure the disease, and this approach became entrenched. Yet during the decades when prostatectomy became widespread, the death rate from prostate cancer did not clearly decline in proportion to the increase in surgery. That historical detail is important because it challenges the assumption that more aggressive early treatment automatically leads to better long-term outcomes.

In the 1990s, the PSA test entered routine use. It was embraced quickly and gained enormous clinical influence. However, no large prospective trial first proved that widespread PSA screening would reduce death from prostate cancer before it became common practice. The test measures a protein produced by prostate tissue, and that level naturally rises with age as the gland enlarges. While PSA can be elevated in cancer, it can also rise from benign enlargement or inflammation. Even so, it became a trigger for biopsy, and biopsy became a trigger for intervention.

06:35 Pause, Think Long, and Hard

At this point, it becomes necessary to step back and reflect carefully. A prostate biopsy is not a trivial event. It involves multiple large-gauge core needle samples, often a dozen or more punctures into the gland. The procedure can cause pain, bleeding, infection, and in some cases, hospitalization. It is not a simple blood draw.

If a procedure carries risk, then the expected benefit must be meaningful. That requires a thoughtful weighing of outcomes. Large trials such as the ProtecT study and the PIVOT trial compared men who underwent surgery or radiation with men who were observed without immediate treatment. After long-term follow-up approaching two decades, there was not much difference in prostate cancer mortality between the groups. That does not mean no treatment ever has value, but it does mean the benefit is not as straightforward as many assume.

When evidence shows a limited survival advantage, and procedures carry real physical consequences, it becomes wise to think carefully before proceeding. The question is not whether cancer is real. The question is whether every detected abnormality requires aggressive intervention, especially when many prostate cancers grow slowly and remain confined to the gland for years.

07:22 More Pain, More Benefit Theory

There is a basic principle in medicine that if we impose suffering, there should be a proportional gain. If a patient undergoes surgery, radiation, or hormone suppression that affects strength, bladder control, sexual function, and cognition, then there should be a clear and measurable survival benefit to justify that cost.

This principle becomes particularly relevant in prostate care. Surgery can lead to urinary incontinence, erectile dysfunction, infection, cardiovascular stress, and complications from anesthesia. Radiation can affect surrounding tissues and carry delayed consequences. Androgen deprivation therapy alters hormone balance and brings its own long list of side effects. These are not small inconveniences. They reshape daily life.

If these interventions consistently and clearly extended life in early-stage disease, the tradeoff might be easier to accept. However, when long-term data fail to show a dramatic survival difference between active treatment and observation in many cases, the equation becomes less convincing. Causing significant harm without clear proportional benefit does not align with thoughtful medical practice.

The endgame must always remain in view. Every test and every intervention should be evaluated not by how aggressive it sounds, but by whether it meaningfully changes long-term outcomes. Without that clarity, it is easy to follow a path simply because it has become standard, rather than because it has been proven superior.

08:22 PSA Test and Biopsy Utility

The PSA test has become deeply embedded in prostate care. It measures prostate-specific antigen, a protein produced by prostate tissue, and it tends to rise gradually as men age because the gland naturally enlarges. It can also increase in the presence of inflammation, infection, recent sexual activity, cycling, or other forms of irritation. While it may rise in prostate cancer, it does not diagnose cancer by itself.

For that reason, PSA must be interpreted carefully and in context. A single elevated number does not define a disease. It should be repeated, especially if there are possible temporary causes for the rise. Watching the pattern over time provides more insight than reacting to one isolated value.

Where difficulty begins is when PSA becomes a trigger for biopsy. The assumption is that tissue diagnosis provides certainty. Yet even a biopsy only samples small areas of the gland. It cannot reliably predict future behavior. It cannot tell whether abnormal cells will remain confined or eventually spread. And it cannot guarantee that the most aggressive area was even sampled.

At the same time, a biopsy is not harmless. It involves multiple large core needle punctures. Bleeding, infection, pain, and hospitalization are possible. In some cases, men land in the hospital for intravenous antibiotics due to post-biopsy infection. When we place a procedure with real risk against uncertain predictive value, the utility becomes less obvious.

So the PSA has a role, but that role is limited. It can serve as a monitoring tool. It can prompt closer observation. It should not automatically lead to tissue puncture without reflection. The presence of a number does not obligate a needle.

09:26 PI-RADS (Prostate Imaging Reporting and Data System)

If biopsy is not the first step, imaging becomes an important alternative. Multiparametric MRI of the prostate allows physicians to evaluate the anatomy of the gland without penetrating it. This imaging is interpreted using the PI-RADS scoring system, which stands for Prostate Imaging Reporting and Data System.

PI-RADS provides a structured scale, usually from 1 to 5, estimating the likelihood that clinically significant cancer may be present. Lower scores suggest low suspicion. Higher scores suggest greater concern. It functions somewhat like mammography scoring in breast imaging, offering a standardized way to communicate risk.

However, PI-RADS does not provide certainty. It estimates probability. It helps create a baseline. A man may have a PSA of a certain value and an MRI showing a PI-RADS 2 or 3 lesion. That combination offers context and a starting point for longitudinal follow-up. If future imaging remains stable and PSA trends slowly, that stability provides meaningful information without tissue disruption.

MRI also has limitations. It can identify suspicious regions, but it cannot predict with accuracy whether cells will remain dormant or become aggressive. No imaging study can forecast the future. What it does offer is a noninvasive method to observe structure and change over time. In the absence of a clear survival advantage from immediate intervention, the ability to monitor without trauma carries practical value.

11:07 Prostate-Specific Membrane Antigen (PSMA) PET Scan

The PSMA PET scan is another imaging tool, but its role is very different. PSMA stands for prostate-specific membrane antigen. This PET scan uses a tracer that binds to prostate cancer cells and can highlight areas of spread throughout the body.

It is not a screening test. It is not designed for men with only an elevated PSA and no confirmed diagnosis. Its most appropriate use is in men who already have biopsy-proven prostate cancer and need to determine whether the disease has moved beyond the gland. If the scan identifies metastatic lesions outside the prostate, then local treatment of the gland alone becomes less relevant.

For men without tissue confirmation, PSMA imaging is not the starting point. It does not replace careful clinical assessment. It does not substitute for thoughtful decision-making. It is a staging tool, not a screening solution.

Taken together, PSA, MRI with PI-RADS scoring, and PSMA PET imaging form a layered framework. PSA offers biochemical data. MRI provides structural evaluation. PSMA PET helps assess systemic spread when cancer has been established. None of these tools, however, can guarantee outcomes. They can inform, guide, and contextualize risk, but they cannot promise survival advantage from early aggressive action.

This is why every diagnostic step should be tied to the endgame. If a test leads only to interventions that have not clearly improved long-term survival in early disease, then its role must be reconsidered. Information has value, but only when it guides decisions that truly benefit the patient.

14:46 Understanding “Active Surveillance”

Active surveillance is often presented as the balanced option between immediate surgery and doing nothing. On the surface, it sounds reassuring. The word “active” suggests vigilance and control, while the word “surveillance” implies careful oversight.

In practice, active surveillance usually means repeated PSA testing, periodic imaging, and scheduled prostate biopsies over time. The intent is to monitor low-risk disease and intervene only if there are signs of progression. It was developed in response to growing awareness that immediate prostate removal or radiation did not clearly improve survival in many early-stage cases.

However, there is a critical issue at the center of active surveillance. The monitoring still depends heavily on biopsy. A biopsy cannot predict the future behavior of prostate cells. It cannot determine with certainty whether cells will remain confined to the gland or eventually leave it. It offers a snapshot, not a forecast.

Studies examining active surveillance have reached an important conclusion. There is no diagnostic study, whether a blood test, biopsy, imaging, or scoring system, that can reliably predict the aggressiveness of prostate cancer in an individual patient. That means even with surveillance, uncertainty remains.

If the abnormal cells stay inside the gland, they cannot harm you. Harm occurs when the disease extends beyond the prostate. The challenge is that current tools cannot definitively identify which early findings will behave aggressively and which will remain dormant. Active surveillance reduces immediate surgical harm, but it does not eliminate anxiety, repeated procedures, or the risk attached to each biopsy.

So the question becomes practical rather than emotional. If active treatment has not clearly reduced long-term mortality in early disease, and if surveillance still relies on invasive sampling, then each man must weigh whether that pathway aligns with his priorities and tolerance for repeated intervention.

15:24 Gleason Score

The Gleason score is a pathology grading system used after prostate tissue is examined under a microscope. It evaluates how abnormal the prostate cells appear compared to normal tissue. The more irregular and poorly organized the cells look, the higher the Gleason score.

A lower Gleason score generally suggests less aggressive cellular features. A higher score suggests a greater likelihood of aggressive behavior. On paper, this grading system appears logical. It categorizes what the cells look like and assigns a number that correlates with statistical risk patterns.

Yet there is a limitation that is often overlooked. While a higher Gleason score is associated with less favorable prognosis in broad population studies, there is no clear evidence that knowing the score automatically leads to a treatment that changes long-term survival in early-stage disease. In other words, the score describes cellular appearance, but it does not guarantee that intervention based on that appearance will alter the ultimate outcome.

This distinction is important. A Gleason score can inform risk discussions. It can guide how closely someone is monitored. What it cannot do is provide certainty about future behavior or ensure that aggressive therapy will eliminate risk.

When a biopsy is required to obtain the Gleason score, the decision to pursue it should be tied to what will meaningfully change afterward. If the result leads to interventions that carry documented harm without proven survival advantage in early disease, then the utility of obtaining that number deserves thoughtful evaluation.

Understanding active surveillance and the Gleason score requires clarity about what they can and cannot accomplish. They offer information. They do not offer guarantees. And in a condition where long-term outcomes often remain similar across different early treatment paths, the weight of each invasive step must be carefully considered.

16:19 Androgen Deprivation Therapy

Androgen deprivation therapy, often abbreviated as ADT, is commonly described in clinical language as hormone suppression. The phrase sounds technical and controlled, yet in practical terms, it means dramatically lowering or eliminating testosterone. Historically, this approach began in the 1940s when it was observed that men with advanced, painful metastatic prostate cancer sometimes experienced symptom relief when testosterone levels were reduced. In that late-stage setting, the intent was palliative. It was meant to reduce suffering, not to cure disease.

Over time, however, the use of ADT expanded. It began to appear earlier in the treatment pathway, sometimes after surgery or radiation when PSA levels started to rise, and sometimes even in men without symptoms. The reasoning often centers on lowering the PSA number and attempting to delay progression.

The problem is that lowering testosterone has predictable biological consequences. Testosterone supports muscle mass, bone density, cognitive sharpness, motivation, and sexual function. When it is suppressed, fatigue sets in. Muscle mass decreases. Body fat increases. Libido fades. Erectile function declines. Mood changes. Some men develop breast tissue. There is also evidence linking ADT to increased cardiovascular risk, metabolic disruption, cognitive decline, and possible higher rates of dementia.

In other words, the outcomes of testosterone suppression are not hypothetical. They are expected. They are measurable. And they affect daily life in a very real way. When ADT is used in men with advanced metastatic disease who are suffering significant symptoms, those trade-offs may be understandable. When it is used earlier, especially in men who feel well, the equation becomes far less clear.

Lowering a PSA number is not the same as improving survival. A rising PSA after treatment, often called biochemical recurrence, does not automatically predict imminent death from prostate cancer. The number can rise for years without symptoms. Chasing that number with aggressive hormonal suppression can create harm long before there is proof of benefit.

This is why any recommendation for androgen deprivation therapy must be evaluated with precision. What is the stage of the disease? Are there symptoms? What is the evidence that this intervention will meaningfully extend life? And what are the guaranteed consequences to strength, cognition, and quality of life? Those questions deserve honest answers before a man consents to hormone suppression.

19:04 Guaranteed Outcomes

When discussing prostate cancer treatment, one theme emerges repeatedly. The benefits are often uncertain, but the side effects are predictable. Surgery carries known risks. Radiation carries known risks. Androgen deprivation therapy carries known risks.

There is no guaranteed cure for removing the gland. There is no guaranteed cure from radiating the gland. There is no guaranteed survival benefit from suppressing testosterone in early or biochemically recurrent disease. What is guaranteed are the biological effects of each intervention.

If a man undergoes surgery, he faces a measurable risk of urinary leakage, erectile dysfunction, infection, blood clots, cardiovascular strain, and potential long-term complications. If he undergoes radiation, surrounding tissues such as the bladder and rectum may suffer delayed damage, sometimes appearing years later. If he undergoes androgen deprivation therapy, muscle loss, fatigue, metabolic change, cognitive dulling, and sexual dysfunction are expected outcomes.

These realities do not mean treatment is always wrong. They mean treatment should be chosen with clear awareness of what is certain and what is speculative. Guaranteed side effects should be weighed against unproven survival advantage in early-stage disease.

What to Do:

• Ask whether the proposed treatment has demonstrated a clear survival benefit in your specific stage of disease.
• Distinguish between lowering a PSA number and extending meaningful life.
• Clarify whether your disease is confined to the gland or has documented spread before considering aggressive therapy.
• Evaluate cardiovascular health and overall risk factors, since heart disease remains a leading cause of death in men with prostate cancer.
• Preserve muscle mass and metabolic health through strength training and appropriate nutrition.
• Consider imaging and longitudinal monitoring before consenting to invasive or hormone-suppressing treatments.
• Ensure that any decision aligns with your values regarding vitality, cognition, and independence.

At the end of the day, no physician can promise what will happen next. Medicine offers probabilities, not certainties. When outcomes are uncertain and harms are predictable, informed decision-making becomes the most powerful tool a man has.

Key Takeaway

Prostate cancer screening often begins with a PSA number, yet the path that follows can quickly move toward biopsy, surgery, radiation, or hormone suppression without clear proof that these steps extend life. Long-term trials have not demonstrated a meaningful reduction in prostate cancer mortality for many early-stage cases, even when the gland is removed or irradiated.

At the same time, the physical consequences of intervention are predictable. Urinary leakage, sexual dysfunction, metabolic decline, cardiovascular strain, and cognitive changes are documented outcomes. These effects are measurable, while the survival advantage remains uncertain.

The essential question is where each decision leads. Screening should support health and clarity, rather than push a sequence of treatments that carry certain harm with unproven long-term benefit.

Continue the Conversation

If this discussion raised new questions for you, there are related episodes that expand on these themes in greater detail:

EP09 – Don’t Biopsy Your Prostate Until You Hear This (Part 2)

EP10 – Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies

For a broader explanation of the reasoning behind this perspective, Fight Cancer Like a Man by Dr. Stephen Petteruti presents these principles in a structured and practical format, outlining how to approach cancer prevention, screening, and treatment decisions with clarity.

If you would like continued access to extended clinical notes and member-only discussions, you can join the Intellectual Medicine Community here:

Membership: https://tinyurl.com/DrPetterutiMember

Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com

Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:

LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:

Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To support deeper reflection, referenced studies explore the long-term outcomes of observation compared with intervention. These data examine survival, treatment-related complications, and the biological consequences of biopsy and hormone suppression. Reviewing this literature allows patients and clinicians to move beyond habit and consider a more individualized approach to prostate health.

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Anastasiadis A, Zapała L, Cordeiro E, Antoniewicz A, Dimitriadis G, De Reijke T. Complications of prostate biopsy. Expert Rev Anticancer Ther. 2013;13(7):829-837. doi:10.1586/14737140.2013.811056

Martin RM. Commentary: prostate cancer is omnipresent, but should we screen for it?. Int J Epidemiol. 2007;36(2):278-281. doi:10.1093/ije/dym049

Muniyan S, Xi L, Datta K, et al. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188383. doi:10.1016/j.bbcan.2020.188383

Lane, Janet Athene et al. “Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).” BJU international vol. 130,3 (2022): 370-380. doi:10.1111/bju.15739

Sarici H, Telli O, Yigitbasi O, et al. Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6. Can Urol Assoc J. 2014;8(5-6):E342-E346. doi:10.5489/cuaj.1499

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are intended to support thoughtful decision-making and improve health literacy. They are not a substitute for individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: April 22, 2025

Episode Summary

• The goal of prostate cancer treatment should be to offer choices, credible information, and options that promote vitality and health.
• Conventional treatments like surgery, radiation, and chemical castration are widely used but often cause harm without significantly improving survival rates.
• There are alternatives to these aggressive treatments that focus on active monitoring, reducing harm, and enhancing overall health without invasive procedures.
• The Intellectual Medicine approach emphasizes informed decision-making, a deeper understanding of the disease, and focusing on long-term well-being instead of unnecessary interventions.

Quick Checklist

When considering your prostate health, the key is making informed, thoughtful decisions. Here are the essential steps you can take to evaluate and manage your risk, without jumping into aggressive treatments too quickly:

• Evaluate your prostate health with PSA, PHI, and MRI (PIRADS score).
• Consider non-invasive treatments instead of surgery or radiation.
• Look into repurposed drugs.
• Reduce carcinogens with detox methods like DMSA.
• Make informed decisions based on credible research, not emotional pressure.

00:00 Introduction

What a good doctor wants for you is choices, information, things that you can trust, things that you can apply, and things that can be monitored actively. Because in the end, the job of your doctor is to present you with alternatives and treat you based on your choices.

For decades, men have been told that removing or irradiating the prostate makes intuitive sense. If something looks abnormal, take it out. The logic sounds decisive. The outcomes, however, have been disappointing.

If you look at long-term survival data through a wider lens, what it shows for certain is that conventional therapy only guarantees pain, extra expenses, and hardship. And most patients who signed up for them only wanted to be free from the illness they felt was a threat to their lives.

That does not mean doing nothing. One thing science has continuously encouraged is that people should keep on gathering credible information and getting safer options. So, thanks to science, we now have other ways to evaluate elevated PSA and prostate risk that focus on vitality, safety, and active monitoring rather than reflexive intervention.

02:38 Removal Guaranteed Harm

When it comes to prostate cancer treatment, the decision to remove or irradiate the prostate may seem logical, especially when something looks abnormal. However, the long-term survival data have shown that these treatments guarantee harm rather than offering a significant survival benefit. Numerous studies conducted over 15 years reveal that aggressive treatment, such as prostate removal or radiation, does not improve survival rates significantly.

While these treatments are not without merit, the evidence supporting their benefits is weak at best. In the world of medicine, there is a basic principle: "First, do no harm." If a procedure like surgery or a biopsy is going to cause harm, it needs to be backed by a clear, substantial benefit. For prostate cancer, however, these procedures offer little more than pain and additional hardship.

Think about it: What other form of cancer would we continuously stick needles into, identifying cancer cells, and then just keep doing it periodically? This approach begs for a reevaluation of how we’re diagnosing and treating prostate cancer. While urologists have their skillset, which sometimes includes biopsies, surgery, and radiation, they are limited in their approach to the bigger picture. A different perspective is needed, and that’s where alternative treatment strategies come in.

04:10 Chemical Castration

One of the most controversial treatments for prostate cancer is androgen deprivation therapy (ADT), also known as chemical castration. In the judicial system, chemical castration is considered cruel and unusual punishment, and yet, it is still recommended for prostate cancer patients.

You might be wondering what the reason for this is. Androgen deprivation therapy aims to lower testosterone levels in men, slowing the growth of prostate cancer cells. However, this treatment often comes with severe consequences. ADT has been known to lead to debilitating symptoms such as fatigue, muscle loss, depression, and mental fog. Worse still, it is often applied when PSA levels continue to rise despite treatment, creating a situation where patients are subjected to even more harm with no guarantee of improved outcomes.

While it might seem logical to turn to ADT in such cases, the reality is that the rising PSA levels do not necessarily indicate that the cancer is progressing. PSA is an imperfect marker, and its rising levels are often used as a justification for harsh treatments like castration. In the end, patients may experience a reduction in PSA levels, but at the cost of their well-being, without any clear evidence of long-term benefit.

04:36 Understanding PSA Results

PSA, or prostate-specific antigen, is a widely used marker for prostate cancer detection, but it is far from a perfect diagnostic tool. A rising PSA level does not necessarily mean that prostate cancer is progressing. It is not a direct indicator of cancer spread or metastasis, yet it is often used as the primary justification for aggressive treatments like biopsy or castration.

For many men, a rising PSA is treated as an urgent signal to take immediate action. However, this false urgency leads to unnecessary procedures and treatments that can cause more harm than good. The PSA test alone cannot tell the full story of prostate health, and interpreting its results requires caution and a comprehensive understanding of a patient’s overall health, age, and risk factors.

To move beyond this reliance on PSA as the primary indicator for prostate cancer progression, it's important to consider alternative diagnostic tools, such as advanced imaging and non-invasive biomarkers, which can offer a more accurate picture of the cancer’s behavior without subjecting patients to invasive procedures that may cause unnecessary harm.

Next steps to take about your prostate

You don’t need a tissue diagnosis to decide how to proceed. There’s no need to stick a needle in your prostate to make informed decisions. The objective should be to protect your vitality and health. Creating an internal environment that’s inhospitable to cancer is far more effective than reflexively turning to aggressive treatments.

Most prostate cancer cells are not actually cancerous. Instead, they’re atypical dormant cells (ADC). These cells can remain in the prostate gland for a lifetime without causing harm. Research has shown that many men over 90 years old have ADCs in their prostate glands without any signs of cancer. So, another option is to live with these dormant cells without subjecting your body to unnecessary interventions.

The problem is sometimes due to the lack of a definitive test to confirm whether these cells have left the prostate gland. However, advanced imaging techniques can help monitor any changes. A careful, proactive approach can give you the peace of mind that you’re making informed choices while avoiding unnecessary harm.

If you’ve already undergone a biopsy, radiation, or even scheduled prostate surgery, don’t panic. You can still change your course. Take time to reflect and consider alternatives. You’re not stuck with one path, especially if it involves painful procedures with unclear benefits.

Treatment Bias explained

There’s a major bias in the medical field surrounding prostate cancer treatments. For decades, doctors have been under the assumption that aggressive treatments like surgery and radiation improve survival rates. Yet, research has shown no significant difference in survival outcomes between patients who undergo these treatments and those who don’t, particularly in early-stage prostate cancer.

Many patients undergo surgery or radiation, convinced that these treatments will save their lives. However, the reality often doesn’t match the expectation. After surgery, some men face painful side effects such as leaking urine or erectile dysfunction. Despite these negative effects, many attribute their survival to the surgery, even if the outcome was merely a coincidence.

This mindset, known as the “philosophy of regret,” is prevalent in conventional medicine. Patients feel pressured to believe that the suffering was worth it because they survived, while the medical community often feels validated in their decision-making. But what’s often missing from this narrative is the truth: Many of these treatments don’t necessarily provide a survival benefit.

The non-biopsy approach

At Intellectual Medicine, we focus on a non-biopsy approach for evaluating prostate cancer risk. This method involves using biometrics and imaging studies to assess the risk of progression or metastasis, without the need for invasive procedures. By taking a more thoughtful approach, a clearer picture of a man’s prostate health can be provided and can be used to guide the patient through the decision-making process.

Three key factors are considered for a non-invasive evaluation:

1. PSA (Prostate-Specific Antigen): A blood test that can indicate elevated prostate levels.
2. PHI (Prostate Health Index): A more comprehensive biomarker that provides additional insight.
3. Prostate MRI: A scan that helps visualize the prostate and its condition.

For men with low-risk profiles, such as a PSA below 20, a PHI under 55, and a PIRADS score of 0 to 3 from an MRI, no biopsy is recommended. Instead, the Intellectual Medicine pathway can be followed. This includes incorporating lifestyle changes, nutrition, supplementation, and repurposed drug therapy.

The aim of this process is normally to keep cancer cells in the prostate and prevent them from spreading. This method helps monitor prostate cancer and contributes to the overall well-being of the patient. The non-biopsy approach is safe, sustainable, and effective, offering an alternative to aggressive treatments that can cause more harm than good.

11:52 Pathway (stage) one risk criteria

When evaluating prostate cancer risk, the first step is to assess your current status through three key tests. These include the PSA level, which should be under 20, the Prostate Health Index (PHI), which should be below 55, and the MRI of the prostate, with a PIRADS score ranging from 0 to 3. These tests are relatively affordable and often covered by insurance, making them accessible for most men.

At this stage, what you should be focused on is ensuring safety. Like the patients, doctors want treatments that don’t cause harm, which is why repurposed drugs are an important option. Drugs like metformin and serolimus have been shown to have anti-cancer effects and can help improve overall health without introducing significant side effects. Metformin, typically used to control blood sugar, has been associated with lower cancer risks and costs just a few dollars a month. Similarly, serolimus is a drug with anti-aging properties that can support mitochondrial vitality, helping the body fight cancer.

These drugs are generally well-tested and have a known safety profile. In contrast to newer treatments, they are less likely to cause unexpected adverse effects. Additionally, other strategies such as doxycycline (an antibiotic used at low doses for its effects on stem cells) and nalrexone (which helps reduce inflammation) are also valuable in managing prostate cancer at this stage.

16:09 Reducing carcinogens

One of the most important steps in any prostate cancer prevention strategy is reducing exposure to carcinogens. Industrial byproducts like cadmium, arsenic, and lead are all around us, from contaminated food and water to environmental pollution. While it is almost impossible to avoid them, there are ways to mitigate their harmful effects on the body.

One effective method is using DMSA, a prescription drug that helps detoxify the body by removing these carcinogenic metals. The Intellectual Medicine protocol suggests using DMSA in periodic detox cycles, about twice a year for four weeks. Reducing the level of carcinogens in the body lowers the risk of not only prostate cancer but also heart disease and cognitive decline.

By combining this detox strategy with other health-enhancing treatments, cancer can be prevented without resorting to harmful conventional therapies. The key is safety and long-term health improvement, ensuring that the body is not exposed to toxic substances that might fuel cancer growth.

18:06 Pathway two criteria

If your PSA level is over 20, your PHI score exceeds 55, or your PIRADS score from the MRI is greater than 3, this signals a higher risk for prostate cancer. At this stage, the risk profile is higher, but you are still asymptomatic, and there’s no evidence of cancer spread beyond the prostate. In this case, additional treatments come into play to help slow down the cancer’s progression without causing significant harm.

Subcutaneous mistletoe injections are one such treatment. Misteltoe, commonly used in Europe, is an immune system booster that helps your body fight cancer more effectively. This treatment is safe and relatively inexpensive, making it a practical option for many men. Another option at this stage is ivermectin, which has shown some promise in combating cancer at low doses. Both treatments focus on strengthening the body’s natural defenses against cancer and do not carry the same risks as invasive therapies.

It’s important to consult a skilled healthcare provider before starting these treatments. Self-administration of treatments without proper guidance can lead to complications. Make sure to seek professional advice and support as you navigate these options.

20:40 Rely upon deeper research

When it comes to prostate cancer, research is your best tool. There is a growing body of evidence suggesting that treatments like chemical castration and radiation may actually increase risks for heart disease and dementia.

This highlights the importance of turning to deeper research and relying on evidence-based, non-invasive approaches to managing prostate cancer. The plan should be to create a treatment plan that does not cause harm and is based on solid scientific understanding. This is why Intellectual Medicine advocates for approaches that focus on prevention, monitoring, and holistic health instead of relying on conventional treatments with weak evidence of benefit.

Take your time to explore these alternative pathways, as they offer a safer way forward. Focus on maintaining vitality and health by making well-informed, researched choices that benefit your overall well-being. Whether through lifestyle modifications, nutritional changes, or repurposed drug therapy, there’s a path forward that doesn’t involve unnecessary pain or hardship.

21:08 Pathway 3 and its approach

When prostate cancer progresses beyond the prostate gland, it is classified as stage three. At this point, positive imaging studies, such as a bone scan or a PSMA PET scan, can detect lesions in the bones or other organs. The good news is that even at this stage, prostate cancer remains vulnerable and can still be managed.

Prostate cancer tends to move slowly, and the focus should always be on maintaining vitality. Castration therapy, or androgen deprivation therapy, should never be considered for this stage. While it might be applied in cases with symptoms like urinary blockages or severe bone pain, it does not offer any guarantee of curing the cancer. The side effects make this treatment unsuitable for many.

At this stage, it is important to work closely with an oncologist. If prostate cancer has spread to the bones, targeted radiation can help strengthen the bones. However, there should be no radiation or surgery to the prostate itself. Alternative therapies, such as an anti-helminthic drug, may be useful, but they should only be taken under a physician's supervision.

23:45 Possibility of benefits with absence of harm

The treatments advocated in Intellectual Medicine do not cure prostate cancer, but they focus on offering potential benefits without causing harm. Traditional treatments like surgery, radiation, and chemical castration often come with debilitating side effects, such as erectile dysfunction, incontinence, and mental fog. The aim is to focus on preventing harm while still offering a chance for benefits.

While no treatment can guarantee a cure, avoiding unnecessary suffering and preserving quality of life are paramount. The focus of Intellectual Medicine is to ensure that treatments do not cause more harm than benefit, especially when conventional treatments have proven to be ineffective in extending life. The approach centers on vitality and health, providing patients with alternative options that prioritize well-being.

25:07 The importance of having choices

What sets Intellectual Medicine apart is the emphasis on providing patients with choices, empowering them with the information, resources, and strategies to make informed decisions about prostate health. Conventional medicine tends to narrow the options to surgery, radiation, and castration, but these treatments often come with irreversible consequences and uncertain outcomes. Offering alternatives that focus on prevention and holistic well-being is vital.

The priority is always on providing credible, balanced information so that patients can make decisions based on their health and vitality. With continuous research and updated treatments, this approach offers a better way forward, allowing patients to avoid unnecessary pain and hardship while still actively managing their prostate health.

It is very important to provide men with the tools they need to take control of their health. By offering safe, sustainable options, Intellectual Medicine aims to create a nationwide infrastructure for better prostate cancer management. Although the approach may not be suitable for everyone, it is based on real-world outcomes and thoughtfulness, empowering patients to make the right choices for their health.

Key Takeaway

Prostate cancer management doesn’t have to follow the traditional path of surgery, radiation, or chemical castration. By focusing on alternatives that prioritize vitality, safety, and informed decision-making, men can avoid the unnecessary harms of conventional treatments.

The approach of Intellectual Medicine emphasizes non-invasive strategies like repurposed drugs, lifestyle changes, and active monitoring, allowing patients to manage prostate cancer without sacrificing their quality of life. It’s crucial to have choices, gather credible information, and consider safer, more holistic options that focus on long-term well-being instead of immediate, aggressive interventions.

Continue the Conversation

If this discussion raised new questions for you, there are related episodes that expand on these themes in greater detail:

EP15 – Beyond the Hype: Why Ivermectin Isn’t the Answer — and What Might Be

EP28 – Prostate Supplements Explained: What Science Actually Shows vs Common Assumptions

For a broader explanation of the reasoning behind this perspective, Fight Cancer Like a Man by Dr. Stephen Petteruti presents these principles in a structured and practical format, outlining how to approach cancer prevention, screening, and treatment decisions with clarity.

If you would like continued access to extended clinical notes and member-only discussions, you can join the Intellectual Medicine Community here:

Membership: https://tinyurl.com/DrPetterutiMember

Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com

Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:

LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:

Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

C, Jacklin et al. “More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.” Cancer treatment and research communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England Journal of medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122

Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14,2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005

Ladjevardi, Sam et al. “Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.” Disease markers vol. 2014 (2014): 707529. doi:10.1155/2014/707529

Nead, Kevin T et al. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology vol. 3,1 (2017): 49-55. doi:10.1001/jamaoncol.2016.3662

Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England Journal of medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are intended to support thoughtful decision-making and improve health literacy. They are not a substitute for individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr Stephen Petteruti (Member Version)

Date: Apr 29, 2025

00:00 Introduction

For most men, getting an erection is an important physical trait. It is something men value and something many hope to maintain throughout life. Yet male sexuality does not stop at hardness alone. It includes desire, confidence, hormone balance, emotional connection, and long-term vitality.

From puberty, testosterone surges awaken sexual awareness. From that stage, boys begin to experience morning erections, spontaneous desire, and physical curiosity as part of early development. Those early encounters often shape how a man sees himself for decades. When sexual function is strong, confidence tends to follow. So when difficulty with erections begins to creep in, the psychological weight can be significant, even if it is rarely discussed openly.

As this subject gains more public attention, many voices now offer opinions on maintaining and restoring erections and male sexuality in general. It is an area surrounded by both science and misinformation. Getting the wrong guidance can damage sexual confidence and overall health.

01:38 Performance anxiety and psychological impact

Performance anxiety is one of the most common causes of erectile difficulty, especially in younger men, and it often has little to do with physical illness. Men under the age of 30 frequently experience erectile dysfunction because of nervousness, fear of failure, or overwhelming self-consciousness during sexual activity. When anxiety rises, the body shifts into a fight or flight state. In that state, blood is directed toward large muscles and away from the penis. An erection requires calmness and a sense of safety, so when the brain senses pressure or threat, even if that threat is emotional, the body does not respond the way a man expects.

This can create a cycle that feeds on itself. A man worries about whether he will get an erection, and that worry alone makes it harder to achieve one. After one difficult experience, the fear of repeating it can grow stronger. Over time, confidence may begin to decline, and sexual encounters can start to feel like tests rather than moments of connection. In many cases, when the anxiety is addressed and the pressure is reduced, erectile function improves without medication because the underlying issue was psychological, not physical.

As men move into their 30s and 40s, the source of stress often changes. Instead of fear during a new sexual experience, the pressure may come from work, finances, family responsibilities, or lack of sleep. Chronic stress increases cortisol levels, which can interfere with testosterone production and sexual desire. By the time men reach their 50s, ageing of blood vessels and medical conditions such as high blood pressure or diabetes may begin to play a larger role. Emotional events such as retirement or loss of a partner can also affect sexual confidence. Understanding the stage of life you are in helps put erectile difficulty into perspective rather than viewing it as personal failure.

04:18 Communication is vital

Sexual health improves when communication is open and respectful. Many men carry concerns silently, which increases internal tension. That tension can appear during intimacy as hesitation or performance difficulty. When partners communicate honestly about expectations, preferences, and fears, the emotional pressure decreases, and the connection becomes stronger.

Timing influences how well these conversations go. Discussing performance immediately after intimacy can feel like an evaluation, which may increase defensiveness. It is often better to talk in a neutral setting when both partners feel relaxed. Some couples even find that introducing sensitive topics through a written message gives both people time to process their thoughts before responding. The purpose is to understand and support each other.

Your environment also shapes your sexual experience. Privacy and a sense of security support relaxation. For couples with children at home or busy schedules, planning intimate time can actually reduce pressure because both partners enter the moment prepared rather than rushed. As men age, sexual response may require more preparation than it did in early adulthood. Adequate sleep, reduced stress, and moderate alcohol intake all support better performance. Alcohol, which may have felt stimulating at age 20, often weakens erection strength later in life when consumed beyond small amounts. Accepting that the body changes over time helps reduce unrealistic expectations.

06:45 Healthy erection key elements

A healthy erection depends on several systems working together smoothly. Blood flow is central because the penis relies on healthy arteries to fill and maintain firmness. Erectile dysfunction can sometimes appear years before heart disease becomes obvious. For men over 50, evaluating cardiovascular health through blood pressure checks, cholesterol testing, blood sugar assessment, and, in some cases, coronary calcium scoring can provide useful information. If circulation is compromised, erection quality often declines as well.

Hormones are another essential part of the picture. Testosterone supports libido, energy, and erectile response. There is no single number that defines what level is right for every man, which is why symptoms must be considered alongside laboratory results. Reduced desire, fatigue, and weaker erections can signal that testosterone levels are no longer optimal for that individual. Thyroid function and blood sugar control also deserve attention because imbalances in these areas can interfere with sexual performance. Diabetes, in particular, increases the risk of erectile dysfunction due to its effects on nerves and blood vessels.

Physical conditioning strengthens both circulation and hormone balance. Regular cardiovascular exercise improves endothelial function, which supports blood vessel flexibility. Maintaining a healthy body composition reduces strain on the heart and supports metabolic stability. Sexual response also depends on the appropriate stimulus and mental relaxation. Men are often visually stimulated, yet attraction is personal and varies widely. When the nervous system feels safe and relaxed, blood vessels can open properly and support a firm erection.

When anxiety, stress, poor circulation, or hormone imbalance disrupts this balance, erectile difficulty can develop. Instead of reacting with fear, a structured evaluation of heart health, hormone levels, stress load, and lifestyle habits offers clarity. Sexual health reflects overall health, and strengthening the body as a whole supports long-term vitality and confidence.

10:34 PDE-5 drugs: Sildenafil and Tadalafil

The most widely used medications for erectile dysfunction belong to a group called PDE-5 inhibitors. The two most recognized are sildenafil, known by the brand name Viagra, and tadalafil, known as Cialis. These medications increase blood flow to the penis, making it easier to achieve and maintain an erection when sexual stimulation is present.

Tadalafil has gained special attention in recent years because daily low-dose use has been linked in medical literature to additional health benefits. Studies have shown that men who take 5 milligrams of tadalafil daily may experience reduced risk of heart attack, stroke, and even dementia. It also improves urinary flow in men with prostate enlargement. This means that for many men, tadalafil supports vascular health beyond sexual performance.

Some men use tadalafil daily and add sildenafil on occasions when stronger support is needed. Timing plays a role. Sildenafil works best when taken on an empty stomach about one to two hours before intimacy. If the moment passes and sex does not happen, there is no lasting harm beyond minor cost.

Side effects are usually mild and may include headache, nasal congestion, or flushing. Because these medications can lower blood pressure, men who are already on blood pressure medication should work closely with a physician before starting them.

It is important to understand that PDE-5 drugs do not create desire. Sexual stimulation must still be present. If a man is anxious and focused on whether he will perform well, the medication alone may not overcome that mental barrier. The brain must be relaxed enough to allow the medication to work effectively.

13:25 Alprostadil vs Caverject

When oral medications are not enough, injectable therapy can provide reliable support. Alprostadil is a medication injected directly into the base of the penis. Caverject is a branded version of alprostadil. Many clinicians also prescribe a compounded blend called Trimix, which combines three vasodilating agents to improve blood flow.

Although the idea of an injection sounds intimidating, the needle used is extremely small and most men report very little discomfort. The benefit of injectable therapy is speed and reliability. Within five to ten minutes, increased blood flow begins, often before psychological tension has time to interfere. For men dealing with performance anxiety, this early physical response can reduce mental pressure because the erection begins developing regardless of anxious thoughts.

These injections are usually limited to two or three times per week and should not be used on consecutive days. Caution is required if combining injectable therapy with PDE-5 drugs, and medical supervision is important to prevent complications such as prolonged erection.

Trimix is generally affordable and highly effective when used correctly. For men who have struggled with inconsistent results from pills alone, injectable therapy can restore confidence and consistency in sexual performance.

15:45 Peptide therapy

Peptide therapy represents another option, particularly when libido is low rather than blood flow alone being the issue. Two peptides discussed in clinical practice are PT-141 and melanotan. These are non-hormonal agents that act on the brain centers responsible for sexual desire.

PT-141 works by stimulating melanocortin receptors in the brain, enhancing sexual arousal and improving erectile response. Melanotan was originally studied for its potential to increase skin pigmentation and reduce skin cancer risk by stimulating melanin production. An unexpected effect observed during development was increased sexual desire. Some men also report improved erectile quality and enhanced climax.

Both peptides are usually administered by injection. Inhaled forms exist but tend to be less reliable. Melanotan may also influence appetite and weight, though long-term studies remain limited. Importantly, these peptides are not approved by the FDA for erectile dysfunction, and research regarding their long-term safety remains incomplete.

Because of this, they should only be used under the guidance of a clinician experienced in functional or anti-aging medicine. Purchasing these compounds online without supervision carries risks related to dosing accuracy and product purity.

Even with advanced therapies available, it is worth remembering that sexual intimacy does not depend entirely on erection quality. Many couples maintain deeply satisfying sexual relationships through creativity, communication, and mutual stimulation. Penetration is not the primary source of pleasure for many women, and men can achieve orgasm without full rigidity.

Medical support can strengthen performance, but emotional connection, reduced pressure, and mature intimacy often have equal influence on long-term sexual vitality.

18:58 Parallel orgasmic activity

Sexual intimacy does not begin and end with penetration. Many couples place pressure on erection strength, as if that alone determines success. In reality, connection and shared pleasure sustain long-term intimacy. When erection quality fluctuates, there are still meaningful ways to experience closeness and climax together.

Parallel orgasmic activity refers to non-penetrating stimulation where both partners are engaged at the same time. This can involve stimulating a woman’s clitoris while the man stimulates his own penis, or while partners stimulate each other. In many situations, self-stimulation reduces self-consciousness and helps a man stay focused on sensation rather than performance.

The purpose of sexual activity in a committed relationship is bonding. It builds closeness, emotional safety, and connection. Research consistently shows that couples who maintain regular sexual contact report higher relationship satisfaction. The frequency varies. Some couples prefer daily intimacy, while others thrive with less. Clinical observation suggests that roughly once per week serves as a healthy minimum for maintaining physical connection. When intimacy drops to once or twice per month, emotional and physical distance can slowly increase.

Temporary erection challenges should never become a reason to withdraw from physical closeness. Creativity, communication, and shared pleasure preserve intimacy even during periods of adjustment.

20:27 Different types of libido

Libido changes with age, and understanding that shift prevents unnecessary anxiety. There are two main patterns of desire: spontaneous libido and reactive libido.

Spontaneous libido is common in younger men. It appears suddenly and without planning. A visual cue, a passing thought, or a memory can trigger desire immediately. Many men remember adolescence, when erections happened without warning. This type of desire tends to decline gradually over time, even when hormone levels are well supported.

Reactive libido becomes more common in adulthood. This form of desire develops in response to touch, closeness, or anticipation. It builds during foreplay or emotional connection rather than appearing out of nowhere. This transition is normal and does not signal dysfunction.

Men in their forties and beyond often juggle work, family, and responsibilities. Stress competes with desire. Setting aside intentional time for intimacy may feel structured, yet it allows the mind and body to prepare. When both partners expect closeness, reactive libido activates more easily. Recognizing this shift helps men adjust without assuming something is wrong.

What to Do:

• Accept that libido changes with age. A shift from spontaneous to reactive desire is common and does not mean something is broken.
• Schedule intentional time for intimacy when life becomes busy. Preparation reduces stress and supports responsive desire.
• Focus on foreplay and emotional connection to activate reactive libido naturally.
• Manage stress through sleep, exercise, and open communication with your partner.
• If desire remains low despite lifestyle adjustments, evaluate testosterone levels, thyroid health, blood sugar, and cardiovascular status with a qualified clinician.

22:59 Staying vital and prioritizing intimacy

Long-term sexual vitality depends on protecting physical health, hormone balance, and emotional connection. Certain medications interfere with libido and erection quality. Some blood pressure drugs, antidepressants, antipsychotics, and hormone suppression therapies are known to reduce sexual drive. Men who notice changes after starting medication should discuss concerns with the prescribing physician, since adjustments may be possible.

Hormone balance plays a central role. Testosterone supports libido, energy, and erectile response. Chronic stress, untreated medical conditions, and metabolic issues can weaken that system. Cardiovascular health is equally important because erections depend on steady blood flow. Men who protect heart health often protect sexual function at the same time.

Intimacy also requires intention. Couples who value connection create space for it. They communicate clearly about preferences and concerns. They adapt to changes in schedule and energy levels. Sexuality evolves with age, yet it does not disappear unless it is neglected.

Remaining sexually active across decades is achievable. Sexual connection strengthens bonding, emotional stability, and overall well-being. When men care for their health, manage stress, and stay open with their partners, intimacy remains part of life rather than a fading memory.

Key Takeaway

Male sexual health is not defined by erection strength alone. It reflects hormone balance, blood flow, mental state, relationship connection, and overall physical health. When any one of these areas is neglected, sexual performance can suffer, but that does not mean vitality is lost.

Performance anxiety, stress, poor sleep, cardiovascular disease, medication side effects, and declining testosterone can all influence erections and desire. Many of these factors are measurable and treatable. Others require communication, preparation, and maturity rather than medication.

Spontaneous libido often turns into reactive libido with age, and that change is normal. Intimacy can remain strong when couples adapt instead of panicking.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP06 – The Truth About Testosterone: Does It Really Cause Prostate Cancer?

EP14 – Testosterone, Aging, and Vitality: What Medicine Isn’t Telling You

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

How do stress and anxiety affect sexual performance and erectile dysfunction? Healthy Male. December 22, 2023. Accessed Feb 18, 2026. https://healthymale.org.au/health-article/how-do-stress-and-anxiety-affect-sexual-performance-and-erectile-dysfunction

Kaplan, Alan L et al. “Testosterone Therapy in Men With Prostate Cancer.” European urology vol. 69,5 (2016): 894-903. doi:10.1016/j.eururo.2015.12.005

Klap, Julia et al. “The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.” The Journal of urology vol. 193,2 (2015): 403-13. doi:10.1016/j.juro.2014.07.123

Mohammad, Osama S et al. “Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.” Cancers vol. 9,12 166. 6 Dec. 2017, doi:10.3390/cancers9120166

Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England journal of medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: May 6, 2025

Episode Summary

• Testosterone supports brain speed, mood stability, muscle strength, bone health, sexual function, and long-term vitality.
• Age-related testosterone decline is common, but symptoms such as low energy, reduced libido, loss of muscle, and brain fog should be evaluated rather than dismissed.
• Blood tests establish safety baselines, but free testosterone is the active form and often more important than total levels.
• Properly supervised testosterone therapy does not show increased risk of prostate cancer or heart attack in current research and requires monitoring of PSA, blood count, and estrogen.
• Long-term vitality depends on informed decisions, hormone balance, strength training, and preserving independence with age.

Quick Checklist

Before starting or continuing testosterone therapy, keep the main safety and monitoring steps in view. Testosterone affects the whole body, so decisions should be thoughtful and structured rather than casual. This checklist serves as a clear guide for safe and long-term use:

• Obtain baseline labs before therapy, including PSA, complete blood count, thyroid panel, and both total and free testosterone.
• Evaluate symptoms alongside lab results. Loss of libido, low energy, poor recovery, depressed mood, and reduced strength should be considered during assessment.
• Monitor hemoglobin, hematocrit, and estrogen levels during treatment to prevent complications such as erythrocytosis or hormonal imbalance.
• Preserve testicular function when using testosterone by incorporating appropriate medical support under physician supervision.
• Maintain supportive habits such as strength training, body fat control, adequate sleep, and stress regulation to enhance long-term outcomes.

00:00 Introduction

Testosterone is often treated as if it only affects sex drive or muscle size. In reality, that is only a fragment of the truth. The body uses testosterone to support brain function, mood, strength, bone health, energy, and long-term vitality. Because testosterone levels drop gradually over time, many people hardly notice the change at first, yet the signs are usually present. You may feel tired without a clear reason, think a little slower than before, or notice that recovery after exercise takes longer than it did a few years ago.

Medicine has made decline sound normal. Brain fog is called aging, muscle loss, and low energy are brushed aside and treated like the normal life cycle. Yet when the thyroid gland slows down, doctors replace thyroid hormone. The testicles are also hormone-producing organs. When their output fades, the effect spreads through the entire body.

Testosterone works like a messenger. It helps brain cells communicate, supports muscle and bone strength, and influences mood and motivation. Growing older in years is unavoidable. Withering in strength and clarity does not have to be accepted without asking questions.

02:50 Our body is a self-healing machine

The body has regulatory systems that constantly repair tissue, balance hormones, and maintain internal stability. These systems do not abruptly stop working at midlife. What changes over time is the hormonal environment that supports them. When hormone production declines, repair slows, recovery weakens, and performance drops.

In many clinical settings, decline is labeled as normal aging. Slower recall, reduced muscle mass, lower stamina, and decreased drive are often dismissed rather than investigated. When the thyroid underperforms, replacement therapy is standard practice. When insulin production fails, insulin is prescribed. The testicles also produce hormones that influence multiple organs, including the brain, muscles, bones, and cardiovascular system. Yet declining testosterone is frequently ignored or minimized.

Chronological aging is unavoidable. Functional decline is influenced by biology that can be evaluated and, in many cases, supported. The decision to intervene should be based on symptoms, laboratory data, and long-term health strategy rather than cultural assumptions about what aging should look like.

03:16 Benefits of testosterone

Testosterone functions beyond sexual health. In the brain, it supports neuronal signaling and influences memory formation, processing speed, and concentration. Lower testosterone levels have been associated with reduced cognitive performance and increased risk of mood disturbance. Both men and women rely on adequate testosterone for neurological stability.

Muscle tissue is highly dependent on testosterone. During adolescence, rising testosterone levels drive muscle growth and strength development. Later in life, as testosterone declines, maintaining lean muscle mass becomes more difficult even with regular exercise. Reduced muscle mass contributes to decreased strength, slower metabolism, and higher risk of injury.

Bone density is also influenced by testosterone. Lower levels correlate with weaker bones and increased fracture risk. Joint stability depends in part on muscular support, and many patients report reduced musculoskeletal pain when hormone levels are optimized.

Long-standing fears about testosterone therapy have been reexamined. Current evidence does not show a consistent increase in prostate cancer incidence among men receiving properly monitored therapy. Cardiovascular data remain complex, but large studies have not demonstrated a clear rise in heart attack or stroke risk when treatment is supervised and individualized. Monitoring blood count and other markers remains essential.

06:54 Calming effect of testosterone

Testosterone is often assumed to increase aggression. Clinical observation frequently shows the opposite pattern when testosterone levels are low. Men with inadequate testosterone may present with irritability, low motivation, reduced confidence, and depressed mood.

Restoring testosterone to appropriate levels often improves emotional stability and stress tolerance. Some clinicians have incorporated testosterone therapy into treatment plans for men with persistent depressive symptoms when laboratory findings support deficiency.

It is important to distinguish therapeutic restoration from supraphysiologic dosing. Excessive hormone levels can produce instability. The objective of treatment is physiological balance. When levels are maintained within an appropriate range and monitored carefully, many patients report improved mood, steadier energy, and clearer thinking.

11:55 Truth about blood levels

Blood tests are helpful, but they are not the final decision maker. The first reason to check blood work is to create a starting point. A baseline helps identify whether there are conditions that require caution before beginning therapy.

One important marker is PSA, which stands for prostate-specific antigen. If PSA is very high, such as above 10 and in some cases above 20, it deserves careful review before starting testosterone. This does not always mean therapy cannot be done, but it requires thoughtful supervision.

Another test is a complete blood count. Some men carry a genetic condition called hemochromatosis, which causes the body to store too much iron. Over time, excess iron can damage the liver, kidneys, and brain. Testosterone therapy can increase red blood cell production because it stimulates the kidneys to release a hormone called erythropoietin. This hormone signals the bone marrow to make more red blood cells. A mild rise in blood count is expected, but if it climbs too high, a condition called erythrocytosis can develop. In that case, donating blood may be recommended.

Blood tests also help evaluate heart health, blood sugar, and thyroid function. These systems affect energy, mood, and strength. Lab values provide useful information, but symptoms and clinical judgment carry equal weight.

13:45 Total vs. free testosterone

When testosterone is measured in the blood, two main numbers can be reported: total testosterone and free testosterone. Understanding the difference is essential.

Total testosterone represents the entire amount of testosterone circulating in the bloodstream. However, not all of it is available for the body to use. A large portion of testosterone binds to a protein called sex hormone binding globulin, or SHBG. When testosterone is attached to this protein, it cannot enter cells and perform its function.

Free testosterone is the portion that is not bound. This is the active form. It enters cells, interacts with receptors, and supports brain function, muscle growth, bone density, libido, and mood. A person can have a normal total testosterone level but still feel symptoms of deficiency if free testosterone is low.

This difference explains why some men are told their levels are normal even though they feel tired, lose muscle, or experience reduced libido. If only total testosterone is checked, the picture may be incomplete. Measuring free testosterone provides a clearer understanding of what the body can actually use.

Symptoms that may suggest low free testosterone include reduced sexual desire, difficulty with erections, low energy, decreased motivation, slower recovery after exercise, depressed mood, and loss of muscle mass. These symptoms can overlap with thyroid problems or chronic stress, which is why a broader evaluation is important.

Treatment decisions should not rely on one single lab number. If a patient reports improved energy, better mood, stronger workouts, and improved sexual function, that improvement carries meaning even if the lab value sits in the middle of a reference range. On the other hand, if levels are high but side effects appear, adjustments may be required.

Testosterone therapy also requires monitoring of estrogen. Some testosterone converts into estrogen, which plays a role in bone strength and sexual function. If estrogen rises too high, unwanted effects such as breast tissue growth can occur. If it drops too low, bone and libido may suffer. Many clinicians aim for an estrogen range between 20 and 40, though reference ranges vary by laboratory.

Preserving natural testicular function is another consideration. When external testosterone is given without support, the testicles may shrink over time because they reduce their own production. Medications such as clomiphene, enclomiphene, hCG, or gonadorelin can be used to stimulate the testicles and maintain function under medical supervision.

Understanding total and free testosterone helps prevent oversimplified decisions. It ensures therapy is based on biology, symptoms, and long-term health rather than a single number.

21:26 Creams for hair loss

Some men worry that testosterone therapy will cause hair loss. Hair thinning in men is often related to genetics and a hormone called dihydrotestosterone, or DHT. DHT is a stronger form of testosterone that can shrink hair follicles in men who are genetically sensitive.

Testosterone can increase DHT levels. If a man is already prone to male pattern baldness, therapy may speed up a process that was likely going to happen over time.

There are options to manage this risk. One approach is using topical prescription creams that act directly on the scalp. These treatments target hair follicles with minimal absorption into the bloodstream. Another option is medications such as finasteride, which reduce the conversion of testosterone into DHT. Blocking DHT can help preserve hair, though it must be balanced carefully because DHT also contributes to sexual function in some men.

Hair loss management should be individualized. The decision depends on family history, cosmetic preference, and overall treatment priorities. Monitoring and discussion with a qualified clinician ensures that hormonal therapy supports vitality without ignoring side effects.

22:33 Duration of the treatment

A common question is how long testosterone therapy should continue. The honest answer is that it can be continued for life if it remains safe, affordable, and aligned with personal values. There is no fixed expiration date. Testosterone is a hormone your body naturally produces. When levels fall and symptoms appear, replacing it is similar in principle to replacing thyroid hormone when the thyroid slows down.

Stopping therapy is always a personal decision. Some men may choose to stop for financial reasons or philosophical reasons. Others may prefer to age without intervention. That choice does not make anyone careless or uninformed. The role of a physician is to provide information, monitor safety, and guide decisions, not to impose treatment.

Strength training, maintaining a healthy body fat percentage, and sleeping well can support natural testosterone levels. However, even disciplined and healthy men experience a gradual decline over time. Therapy becomes one available option, not an obligation.

Some clinicians recommend an occasional short break, sometimes called a hormone holiday, such as skipping a scheduled dose every few weeks. The theory is that this may keep hormone receptors responsive over the long term. Most men feel stable during short breaks because testosterone remains in the system for some time. Long-term therapy, when properly monitored, can be sustainable for decades.

24:59 How we live is what we control

Aging in years cannot be stopped, yet the way strength, mobility, and clarity change over time can be influenced. One major cause of disability in older adults is sarcopenia, which means loss of muscle mass. Weak muscles make daily tasks harder. Climbing stairs, opening jars, and getting out of a car all depend on muscle strength.

Testosterone supports muscle maintenance. Strong muscles protect joints, improve balance, and lower the risk of falls. Maintaining muscle also supports bone density, which lowers fracture risk. Brain health is also connected to hormone balance. Lower hormone levels have been linked in research to increased risk of cognitive decline.

Lifestyle choices remain important. Walking regularly, lifting weights, eating balanced meals, and keeping body fat within a healthy range all support vitality. Hormone therapy does not replace these habits. It works alongside them. The central idea is that while death is inevitable, years of unnecessary weakness or decline may be influenced by thoughtful action.

Each person chooses how to approach aging. Some will prefer organic decline. Others will use every safe and credible tool available. What remains constant is personal responsibility in making informed decisions.

26:16 Other side effects

No medical therapy is free from potential side effects, and testosterone is no exception. One common effect is acne, especially on the chest or back. This happens because testosterone can stimulate oil glands in the skin. If acne appears, the dose can often be adjusted. In some cases, dividing the weekly dose into two smaller injections can smooth hormone levels and reduce skin reactions.

Hair thinning is another concern for men who are genetically prone to male pattern baldness. Testosterone can increase levels of DHT, a hormone that influences hair follicles. Monitoring and preventive strategies, such as topical treatments or DHT-modulating medications, can be considered when appropriate.

It is important to distinguish medical testosterone therapy from anabolic steroid abuse. High-dose anabolic steroids used for bodybuilding can damage the brain, heart, and reproductive system. They can suppress natural testosterone production and sometimes cause long-term harm. Medical therapy aims to restore physiological levels, not create extreme muscle growth.

Over-the-counter supplements that claim to “boost” testosterone rarely provide meaningful improvement in men with true deficiency. In most symptomatic men over 40, replacing testosterone itself is the effective treatment when clinically appropriate.

30:16 Motivational story of a patient

A story illustrates the broader message about vitality. Years ago, a patient in his mid-80s with stage four lung cancer was receiving supportive care, including testosterone therapy. During a visit, he was asked about his breathing. He replied that he only became short of breath during intimacy with his wife.

At 85 years old, facing advanced cancer, he remained engaged in life, connection, and intimacy. He passed away a few months later. His final months were not defined by weakness or resignation but by participation in living.

The lesson is not that testosterone cures disease. The lesson is that vitality can be preserved longer than many people expect. Strength, connection, and purpose can continue deep into later years when health is supported intentionally. Aging does not require surrendering energy or identity. It requires informed choices and steady attention to the systems that keep the body functioning well.

Key Takeaway

Testosterone is a foundational hormone that affects the brain, muscles, bones, mood, skin, and sexual health. When it declines, the whole body feels the effect. Slower thinking, lower energy, weaker recovery after exercise, reduced confidence, and changes in libido can all reflect falling testosterone levels rather than unavoidable aging.

Blood work helps create a starting point, yet numbers alone do not determine treatment. Total testosterone shows how much is present in the bloodstream, while free testosterone shows how much is actually available for the body to use. Symptoms, physical function, and overall health must be considered together with laboratory values.

When therapy is used, the focus is on restoration to a healthy physiological range under medical supervision. Monitoring blood count and estrogen keeps treatment balanced and safe. Strength training, body composition control, and cardiovascular health remain essential. The central principle is that growing older does not require surrendering clarity, strength, or vitality without first examining the hormonal foundation that supports them.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP06 – The Truth About Testosterone: Does It Really Cause Prostate Cancer?

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Hackett GI. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. World J Mens Health. 2025;43(2):282-290. doi:10.5534/wjmh.240081

Haider, Ahmad et al. “Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.” The Journal of urology vol. 193,1 (2015): 80-6. doi:10.1016/j.juro.2014.06.071

Kaplan, Alan L et al. “Testosterone Therapy in Men With Prostate Cancer.” European urology vol. 69,5 (2016): 894-903. doi:10.1016/j.eururo.2015.12.005

Keren D, Goshen A, Strauss T and Springer S (2025) Study protocol: associations between hormonal profile and physical and cognitive functions in middle-aged men—a one-year cohort follow-up study. Front. Public Health 13:1654077. doi: 10.3389/fpubh.2025.1654077

Mohammad, Osama S et al. “Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.” Cancers vol. 9,12 166. 6 Dec. 2017, doi:10.3390/cancers9120166

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177(4):471-479. doi:10.1001/jamainternmed.2016.9539

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: May 13, 2025

Episode Summary

• Ivermectin and fenbendazole show laboratory evidence against cancer cells, but strong human clinical evidence is limited, and dosing strategies remain unclear.
• Fenbendazole is an animal drug and not approved for human use, while albendazole is a safer, prescribable alternative within the same class that may be considered in advanced cases under supervision.
• Cancer treatment requires a long-term, medically guided plan focused on safety, monitoring, and sustainability rather than reacting to online hype or isolated success stories.

Quick Decision Checklist

Before making a decision about ivermectin, fenbendazole, or albendazole, pause and evaluate the situation carefully. Cancer treatment requires structured thinking, medical supervision, and long-term planning. Use the checklist below to guide a responsible conversation with your clinician before starting any new therapy:

• Confirm the exact type and stage of your cancer and understand the expected course with standard care.
• Review treatments with stronger human clinical evidence before considering experimental or repurposed drugs.
• Never self-dose based on online forums; discuss any plan with a qualified clinician.
• Check baseline labs, including liver function and blood counts, before starting therapy and monitor regularly.
• Clarify the dosing schedule and duration in advance rather than taking medication continuously without structure.
• Weigh safety, cost, and long-term sustainability, since cancer control usually requires ongoing management rather than a short burst of treatment.

00:00 Introduction

Few drugs have created as much noise in recent years as ivermectin and fenbendazole. Some people see them as hidden breakthroughs to cancer, while others dismiss them outright. With a diagnosis like cancer, people tend to get emotional and find themselves running every corner of the world searching for urgent hope. This desperation leads them to all sorts of things, especially online.

Before focusing on any single drug, it helps to think critically and ask the right questions. What are we trying to achieve? At this point, you don’t have the luxury to chase trends. Your priority is to protect vitality, extend meaningful life, and use treatments that are safe, practical, and grounded in solid reasoning.

Ivermectin, fenbendazole, and related drugs belong to a class with interesting laboratory data, but laboratory data is not the same as proven human benefit. The responsible approach is to examine where these agents may fit. Where do they not fit? And how do you approach them with careful judgment?

03:56 Can Ivermectin Help Fight Cancer?

Ivermectin was approved in 1978 as a deworming medicine, and it has been very effective for treating parasitic infections. The scientist who helped develop it even received a Nobel Prize for that work. In laboratory studies, ivermectin has shown that it can interfere with certain signaling pathways inside cancer cells. It may also affect cancer stem cells, which are the cells believed to help tumors grow and return. In petri dish experiments, it can trigger apoptosis, which is a form of programmed cell death.

However, most of this evidence comes from laboratory research. These studies are done on cancer cells in controlled environments, not inside the human body. When evaluating any treatment, there are levels of evidence to consider. First comes cellular research. Then, animal studies. After that come small human studies. The strongest evidence comes from large, placebo-controlled human trials. With ivermectin, the data are largely limited to laboratory findings and a small number of case reports. That places it in a lower tier of clinical certainty.

This does not directly eliminate it from consideration, but it does place it in proper perspective. Anecdotes shared online often involve multiple treatments used together, which makes it difficult to isolate the effect of ivermectin alone. Careful judgment is required before assigning it a central role in cancer care.

06:40 Things to Consider About Ivermectin Treatment

Treatment decisions depend on the type of cancer, the stage, and the available alternatives. If there are therapies with stronger human data and clearer survival outcomes, those options deserve attention first. In clinical practice, ivermectin is generally considered only after other evidence-supported therapies have been used or when disease progression continues despite standard and integrative interventions.

Dose is another serious concern. Ivermectin was designed for short-term use in parasitic infections, often as a single dose or limited weekly schedule. Some individuals are taking it daily or even twice daily for extended periods, which raises concerns about liver strain and other side effects. Cancer therapy often involves cycles rather than constant daily exposure, because the body requires recovery time and monitoring.

There are other repurposed medications with broader safety data and more human experience in oncology, such as metformin or low-dose naltrexone. Subcutaneous mistletoe therapy also has structured clinical use in integrative cancer programs. Ivermectin does not currently sit at the same level of supporting evidence as these agents, which influences how and when it may be considered.

09:07 Phase 2 Treatment

In structured cancer management, treatments are often organized into phases. Phase 1 typically involves foundational therapies that have stronger evidence and established safety patterns. Biomarkers and imaging studies are monitored closely to track response. If progression occurs despite these measures, additional agents may be introduced.

Within that framework, ivermectin may be reserved for what could be described as a second-phase intervention. It is not positioned as a first-line therapy. Even in advanced cancers, many patients can remain stable for extended periods using carefully designed protocols that focus on long-term disease control.

Cancer management requires a sustainable plan. Short, intense treatment programs without long-term follow-through rarely produce durable results. The aim is to maintain function, preserve strength, and suppress progression over time. Any agent considered must fit within that broader strategy and must be monitored for safety, particularly liver function and overall tolerance.

10:57 Long-Term, Sustainable, and Effective Plan

Cancer management cannot be built around short bursts of intensity followed by long periods of neglect. A durable plan must be safe enough to maintain, structured enough to monitor, and practical enough to continue for years if necessary. Traveling for a month of aggressive therapy and then returning home without a structured follow-up plan rarely produces stable long-term control. Cancer biology does not pause simply because treatment pauses.

Any repurposed drug, including ivermectin or medications in the same class, must fit into a broader strategy that includes laboratory monitoring, imaging when appropriate, and ongoing evaluation of liver function and blood markers. These drugs should never be used based on internet dosing suggestions or anecdotal reports alone. Even if a primary oncologist does not prescribe a therapy, it is ethically appropriate for a physician to monitor safety parameters if a patient chooses to proceed. Liver enzymes, blood counts, and symptom patterns must be followed carefully.

The larger objective is steady disease control while preserving strength and daily function. Cancer often behaves as a chronic condition that can relapse if pressure is completely removed. That reality requires a plan designed for sustainability rather than urgency alone.

12:08 Fenbendazole vs. Safer Alternatives

Fenbendazole belongs to the benzimidazole class of drugs. It is widely used in veterinary medicine as a deworming agent for animals, particularly dogs. Laboratory studies show that this class of drugs can interfere with microtubules inside cells, block glucose uptake, and disrupt cancer cell structure. These mechanisms are biologically interesting and explain why attention has grown around fenbendazole.

However, fenbendazole is not approved for human use. That fact alone creates significant challenges. Physicians cannot legally prescribe it, and dosing guidelines for cancer treatment in humans do not exist. While some individuals follow informal protocols, such as the widely discussed three-day-on, four-day-off schedule associated with Joe Tippen, it remains unclear how much of his outcome was related to fenbendazole versus concurrent conventional treatment. He was enrolled in chemotherapy at the same time, which introduces uncertainty.

Safety is another concern. Reports suggest potential neurotoxicity, seizures, balance disturbances, visual changes, and liver enzyme elevations. Because the drug was designed for animals, product purity and consistency when purchased outside regulated channels can vary. Absorption is also inconsistent, which means even if a theoretical effective dose existed, achieving stable blood levels would be difficult.

Within the same drug family, there are human-approved alternatives such as albendazole and mebendazole. These medications share similar mechanisms but have established human dosing history and clearer safety parameters. When comparing options within the same class, human-approved drugs provide a more controlled environment for monitoring and adjustment. That distinction becomes particularly important when managing a serious illness that already carries significant physiological stress.

Fenbendazole may attract attention because of dramatic online testimonials, yet responsible care requires attention to legality, dosing clarity, and organ safety. When safer alternatives with similar biological actions exist, those options deserve priority.

16:07 Albendazole’s/Mebendazol Promise and Dosing Strategy

Albendazole is also a benzimidazole drug, but unlike fenbendazole, it is approved for human use as an antiparasitic medication. Because it is licensed for human prescription, physicians can legally prescribe it off-label and monitor its effects. That distinction alone makes clinical supervision possible.

Mechanistically, albendazole interferes with microtubule formation inside cells and reduces glucose uptake by rapidly dividing cells. It may also impact cancer stem cells, which are thought to contribute to tumor persistence and recurrence. Laboratory data support these mechanisms, and at least one small phase 2 study has evaluated safety in humans, providing limited but meaningful reassurance regarding tolerability.

The challenge lies in defining optimal cancer dosing. Traditional antiparasitic use often involves short treatment courses. In oncology settings, a once-weekly dosing strategy may balance theoretical anticancer activity with safety considerations. Intermittent dosing reduces continuous liver exposure while maintaining biological pressure on cancer cells. Monitoring includes liver function tests and symptom review.

Albendazole is not positioned as a first-line therapy. It is typically reserved for advanced or progressive malignancies where foundational therapies have already been applied. In that context, it may serve as an additional strategic layer rather than a primary intervention.

The key advantage of albendazole compared with fenbendazole is clinical control. The drug can be prescribed, dosed thoughtfully, monitored legally, and adjusted based on laboratory findings. When working within complex cancer care, that level of structure significantly improves safety.

18:22 Who Should Consider Albendazole Treatment?

Albendazole is not designed for someone with early-stage cancer that is stable and responding well to foundational treatment. It is generally reserved for situations where the disease is aggressive, advanced, or progressing despite structured first-line strategies. In many practices, this means stage four disease, rapidly rising tumor markers, or imaging that shows new growth despite ongoing care.

In prostate cancer management, for example, phase one therapy may control the disease for years through metabolic control, repurposed medications with stronger human data, immune support, and lifestyle intervention. As long as biomarkers remain stable and imaging is reassuring, escalation is unnecessary. Albendazole enters the conversation when measurable progression occurs or when pathology at diagnosis suggests a high-risk pattern.

This approach prevents unnecessary exposure to drugs before they are needed. Cancer care should follow a stepwise model, where each layer is added based on objective findings rather than fear. Albendazole becomes a strategic reserve option for patients facing limited conventional solutions, especially when prognosis is poor and maintaining quality of life is central to decision-making.

Even in advanced disease, it should be prescribed with supervision, laboratory monitoring, and clear expectations. It is not a miracle agent. It is one possible tool within a broader, structured treatment plan.

22:18 Functional Medicine vs. Pharma Priorities

Functional medicine and pharmaceutical-driven oncology operate under different incentives and timelines. Large pharmaceutical trials require massive funding, extended follow-up, and regulatory approval pipelines. Drugs that are off-patent or generic rarely receive that level of financial backing, even if laboratory data suggests potential benefit. That funding reality shapes which therapies are studied extensively and which remain underexplored.

For example, intravenous vitamin C has shown signals of benefit in small studies for pancreatic cancer, including improved survival in certain controlled settings. Enthusiasm grew in integrative circles, yet large-scale funding did not continue once a new proprietary drug entered the market. The absence of expanded trials does not automatically mean the absence of value. It often reflects economic priorities.

Functional medicine physicians operate differently. They assess available mechanistic data, safety profiles, affordability, and clinical experience, then integrate therapies thoughtfully when risk is acceptable. This approach requires caution, transparency, and ongoing monitoring. It does not reject conventional oncology, but it does recognize that innovation does not always flow through pharmaceutical pipelines alone.

Patients should understand that skepticism toward repurposed drugs can stem from limited large-scale trials rather than definitive proof of ineffectiveness. At the same time, limited funding does not equal automatic validation. Careful reasoning remains essential.

23:28 Avoiding Hype and Acting with Caution

Cancer creates urgency, and urgency can cloud judgment. Online forums, viral protocols, and emotional testimonials often sound convincing, especially when someone feels they are running out of time. However, acting without structure can expose you to unnecessary risk, liver injury, financial strain, or interactions with other treatments. Laboratory evidence does not equal proven human benefit, and anecdotal stories do not replace controlled studies.

Careful judgment means weighing mechanism, safety, dosing clarity, affordability, and clinical supervision. It also means knowing where a drug fits within a broader treatment plan instead of treating it as a standalone rescue solution. Cancer care must remain organized and strategic rather than reactive.

What to Do:

• Speak openly with a qualified clinician before starting any repurposed drug.
• Request liver function tests and blood monitoring if using ivermectin or albendazole.
• Avoid copying internet dosing schedules or Reddit-based protocols.
• Use escalation strategies only when disease progression is documented.
• Choose treatments that are sustainable, supervised, and financially realistic in the long term.
• Keep expectations grounded in the current level of evidence.

Key Takeaway

Ivermectin and fenbendazole attract attention because they promise a possibility in situations that feel urgent and frightening. Laboratory studies show that these drugs can interfere with cancer cell signaling and growth in controlled settings. However, laboratory findings are different from proven benefits in people. Human evidence remains limited, and dosing strategies are not clearly defined, especially for fenbendazole, which is not approved for human use.

Albendazole belongs to the same drug class and can be prescribed legally. It has clearer safety data and defined monitoring pathways, yet it is typically reserved for later stages when structured treatment plans require additional options. It is not the first step in most cases.

The central message is that cancer care requires careful planning, medical supervision, and long-term strategy. Decisions should be based on safety, evidence, and sustainability rather than urgency or online momentum.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP12 – Fight Prostate Cancer Like a Man: Avoid Regret, Reclaim Your Power Using Repurposed Drug Therapy

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Antoszczak, Michał et al. “Old wine in new bottles: Drug repurposing in oncology.” European journal of pharmacology vol. 866 (2020): 172784. doi:10.1016/j.ejphar.2019.172784

Ciwun M, Tankiewicz-Kwedlo A, Pawlak D. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy. Cancers (Basel). 2024;16(6):1240. Published 2024 Mar 21. doi:10.3390/cancers16061240

Dalgleish AG, Liu WM. The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients. Oncol Lett. 2022;24(2):247. Published 2022 Jun 7. doi:10.3892/ol.2022.13367

Nappi L, Aguda AH, Nakouzi NA, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020;130(2):699-714. doi:10.1172/JCI130819

Juarez M, Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, Diaz-Chavez J, Duenas-Gonzalez A. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol. 2020;85(6):1153-1163. doi:10.1007/s00280-020-04041-z

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: May 20, 2025

Episode Summary

• The body forms abnormal cells every day, and the immune system removes most of them before they grow into cancer. Prevention begins with strengthening that natural defense system.
• Excess body fat and chronic inflammation increase cancer risk by creating a constant internal stress that damages cells and weakens immune control.
• Environmental exposures such as processed foods, nitrates, alcohol, tobacco, microplastics, and heavy metals add cumulative strain over time, which can raise long-term cancer risk.
• Screening tools can detect disease early, but they carry limitations and risks. Long-term prevention depends on daily habits that reduce metabolic stress and support immune balance.

Quick Decision Checklist

Review these points carefully. If several boxes remain unchecked, prevention needs closer attention.

• Maintain a healthy body weight and monitor waist circumference regularly.
• Control portion sizes and avoid chronic overeating that fuels inflammation.
• Limit alcohol, avoid tobacco, and reduce intake of processed meats and nitrates.
• Filter drinking water and minimize daily exposure to plastics and environmental toxins.
• Prioritize restorative sleep and consistent physical activity each week.
• Approach screening tests thoughtfully, weighing both potential benefit and procedural risk before proceeding.

00:00 Introduction

People do not realize that the body is fighting cancer every single day. As your cells divide and carry out their normal functions, small errors can occur in their DNA. This is part of normal biology. When those abnormal cells appear, the immune system identifies them and removes them before they grow into something dangerous. This process happens quietly and continuously.

Cancer becomes a clinical problem when the body can no longer keep up with that task. If inflammation is constant, if excess body fat is present, if blood sugar remains poorly controlled, or if the body is repeatedly exposed to toxins, the internal environment changes. Under those conditions, damaged cells have a greater chance of surviving and multiplying instead of being cleared.

This is why prevention must begin at the cellular level. If we only focus on detecting cancer after it forms, we overlook the biological conditions that allowed it to grow. Screening has value, and we will discuss it carefully. However, long-term protection begins with strengthening the systems that control abnormal cell growth every day.

03:28 – Excess Body Fat, Inflammation, and Cancer Risk

One of the strongest and most consistent links to cancer risk is excess body fat. This is not about appearance. Fat tissue is biologically active. It produces inflammatory chemicals, alters hormone balance, and influences insulin signaling. When body fat increases, especially around the abdomen, inflammatory markers tend to rise as well.

Every time we eat, the body generates a temporary surge of oxidative stress in order to process nutrients. That response is normal. The issue begins when meal size and frequency remain high over many years. Larger and more frequent meals create repeated inflammatory waves. Over time, that pattern can disturb the internal environment and increase cellular stress.

Chronic inflammation creates a setting where abnormal cells are more likely to survive. Gastrointestinal tissues are especially vulnerable because they are in direct contact with food, additives, alcohol, and digestive byproducts. This partly explains why cancers of the colon, pancreas, and esophagus correlate with obesity.

Prevention in this area does not require complicated diet theories. It begins with volume control, stable body composition, and consistent metabolic health. Maintaining healthy body fat, managing blood sugar, and ensuring adequate vitamin D levels are practical interventions that support immune surveillance.

If you remove excess fat and reduce inflammatory load, you strengthen the very system that keeps microscopic cancers from progressing. That foundation must be addressed before discussing any screening test or procedure.

06:17 – Environmental Toxins, Processed Foods, and Hidden Carcinogens

Cancer risk is shaped by repeated exposure to environmental irritants. The gastrointestinal tract, skin, and lungs are surfaces that interact directly with the outside world. Whatever touches those surfaces again and again can influence how cells behave over time.

Processed foods often contain nitrates, preservatives, artificial additives, and stabilizers. Even products labeled as natural can contain compounds that convert into carcinogenic substances during digestion or high-heat cooking. The concern is not a single exposure. The concern is cumulative load. Small exposures repeated daily for decades increase biological stress.

Cooking methods influence risk as well. Charring meat at high temperatures produces compounds that irritate intestinal tissue. Alcohol directly irritates the lining of the digestive tract. Tobacco introduces carcinogens that affect multiple organs. These exposures are known and modifiable.

Environmental toxins extend beyond food. Non-stick cookware can release chemical residues when overheated. Heavy metals may contaminate water supplies. Microplastics are increasingly detected in bottled water and food packaging. Complete avoidance is unrealistic, but reducing total exposure lowers long-term tissue irritation.

Prevention at this level focuses on lowering cumulative toxic burden so the immune system can continue doing its work. When tissue is constantly inflamed or chemically stressed, immune surveillance becomes less efficient over time. Reducing repeated irritation protects cellular stability long before any screening test is performed.

10:45 – Screening, procedural bias, and risk vs. benefit

Screening sounds simple on the surface. Detect disease early and prevent a bad outcome. In practice, it requires careful thought because every screening tool carries both measurable benefit and measurable risk.

Take Barrett’s esophagus as an example. The annual rate of progression from Barrett’s to esophageal cancer is estimated at roughly 0.1% to 0.5% per year. That risk is real, but it is not high. Upper endoscopy, or EGD, is often used to monitor for change. Yet serious complications from EGD that require hospitalization also occur in about 0.1% of cases. When the complication rate begins to approach the progression rate, the decision to repeat the procedure routinely deserves reflection rather than automatic scheduling.

Colonoscopy follows a similar pattern. It allows direct visualization of the colon and removal of adenomas, which are precancerous polyps. That is a real strength. At the same time, data show that approximately 27,000 emergency room visits per year in the United States are linked to colonoscopy-related complications. These include bleeding, perforation, sedation-related problems, and cardiovascular events, particularly in older adults.

Another important detail is operator variability. Detection rates depend on bowel preparation quality and the thoroughness of the physician performing the procedure. A fast examination can miss lesions hidden behind folds. The theoretical advantage of seeing the colon directly depends heavily on execution.

Noninvasive screening tools now exist. The fecal immunochemical test detects hidden blood in the stool and can be done yearly. Stool DNA testing combines blood detection with analysis of abnormal DNA shed from polyps or cancer. These tests involve no sedation, no perforation risk, and no recovery period. A positive result then justifies a colonoscopy for diagnostic clarification.

Screening decisions should reflect individual risk. Prior adenomas, strong family history, persistent symptoms, or unexplained bleeding justify a different approach than a healthy, low-risk individual without symptoms. Screening is part of prevention, but it is not prevention itself. Lifestyle, metabolic health, and immune support remain foundational to reducing long-term cancer risk.

15:18 – Practical prevention strategies that actually matter

Cancer prevention does not begin in an operating room. It begins in the body long before any scan or procedure. The internal environment you create each day influences how well your immune system finds and destroys abnormal cells.

Excess body fat plays a strong role in cancer risk. Fat tissue is active. It releases inflammatory chemicals and changes hormone balance. Long-term inflammation increases the chance that damaged cells survive when they should be removed. For many adults who do not smoke, carrying extra body fat is one of the strongest controllable risk factors for several cancers, including gastrointestinal, breast, and prostate cancer. Reducing portion size, avoiding constant snacking, and maintaining a healthy body weight lowers the inflammatory load placed on the body.

Every time you eat, your body creates oxidative stress in order to digest food. This process is normal, yet very large meals increase that stress. Eating moderate portions and allowing time between meals helps the body recover and maintain balance.

Sleep also supports cancer defense. During deep sleep, the immune system restores itself. Cells that patrol for abnormal growth work more effectively when sleep is consistent and restorative. Chronic sleep disruption weakens that protection.

Environmental exposure accumulates gradually. Processed meats containing nitrates and nitrites increase cancer risk whether those compounds come from synthetic additives or so-called natural sources. Alcohol consumption increases cancer risk in a dose-related pattern. Tobacco remains a direct carcinogen. Non-stick cookware, contaminated water, heavy metals, and microplastics add to long-term exposure. Complete avoidance is unrealistic, yet reducing repeated contact lowers cumulative burden.

Persistent gastrointestinal symptoms require attention. Long-term use of acid-suppressing medications without identifying the cause of reflux may mask irritation instead of correcting it. Elevating the head of the bed, moderating meal timing, and identifying trigger foods can reduce reflux without lifelong dependence on medication.

Vitamin D status also influences immune regulation. Maintaining an appropriate blood level through monitored supplementation supports cellular health.

Daily habits shape the internal terrain in which cancer either struggles or survives. Screening tools help detect disease, yet long-term protection begins with managing body weight, inflammation, sleep, and environmental exposure.

21:57 – The philosophy of prevention and living without fear

Many people see cancer as something that suddenly appears without warning. In reality, the body is constantly identifying and removing abnormal cells. This process happens quietly every day. The immune system works in the background, correcting errors before they develop into visible disease. Understanding this changes how prevention is viewed.

Fear can push people toward repeated testing and rapid procedures. Fear can also cloud judgment. Clear thinking begins with recognizing that health is influenced daily by sleep, body composition, inflammation levels, toxin exposure, and metabolic balance. When these systems are supported, immune surveillance remains strong.

Screening plays a role in modern medicine. It can identify disease at an earlier stage. At the same time, every screening test has limits. No test captures everything. Every procedure carries potential complications. Decisions about screening require a calm review of individual risk, symptom patterns, age, and overall health status.

A normal screening result reflects the condition of the body at that moment. It does not replace healthy living. Long-term cancer risk is shaped by ongoing habits. Maintaining a stable weight, limiting excess alcohol, avoiding tobacco, reducing processed food intake, filtering water, and minimizing exposure to environmental toxins all influence cellular health.

Living without fear means taking responsibility for controllable factors while accepting that absolute certainty does not exist in biology. Health is strengthened through consistent daily choices, informed decisions about screening, and an understanding of how the body protects itself.

What to Do:

When the topic of cancer prevention feels overwhelming, clarity helps. Instead of reacting to fear, focus on steady actions that support your body over time.

• Maintain a healthy body weight by reducing portion sizes and avoiding frequent overeating, since excess body fat increases inflammation and cancer risk.
• Prioritize restorative sleep each night so your immune system can repair and regulate abnormal cells effectively.
• Limit alcohol intake and completely avoid tobacco, as both directly increase the risk of several cancers.
• Reduce exposure to common environmental toxins by filtering drinking water, storing food in glass or stainless steel instead of plastic, and avoiding heavily processed foods with added preservatives such as nitrates.
• Address persistent digestive symptoms rather than masking them with long-term medication, and work with a clinician to correct the underlying cause.
• Use screening thoughtfully based on your individual risk profile, and discuss benefits and risks clearly before agreeing to invasive procedures.

Key Takeaway

Cancer does not usually appear out of nowhere. The body forms abnormal cells every day, and the immune system works daily to remove them before they become dangerous. Prevention, therefore, begins with supporting that internal defense through healthy body weight, controlled inflammation, clean nutrition, proper sleep, and reduced toxin exposure.

Screening has value when it is used thoughtfully and based on individual risk. However, screening alone does not create protection. Long-term health depends on daily habits that reduce irritation, metabolic strain, and environmental burden. When prevention is handled with calm reasoning rather than fear, it becomes a steady practice that supports strength and longevity over time.

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP14 – Testosterone, Aging, and Vitality: What Medicine Isn’t Telling You

EP05 - How to Prevent Prostate Cancer Recurrence: What Your Oncologist Isn't Telling You

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Bonn, Stephanie E et al. “Body mass index and weight change in men with prostate cancer: progression and mortality.” Cancer causes & control : CCC vol. 25,8 (2014): 933-43. doi:10.1007/s10552-014-0393-3

Eklund M, Nordström T, Aly M, et al. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. Eur Urol Focus. 2018;4(5):707-710. doi:10.1016/j.euf.2016.10.009

Pernar, Claire H et al. “The Epidemiology of Prostate Cancer.” Cold Spring Harbor perspectives in medicine vol. 8,12 a030361. 3 Dec. 2018, doi:10.1101/cshperspect.a030361

Schröder, Fritz H et al. “Screening and prostate-cancer mortality in a randomized European study.” The New England journal of medicine vol. 360,13 (2009): 1320-8. doi:10.1056/NEJMoa0810084

Zhang, Liang et al. “Cadmium Levels in Tissue and Plasma as a Risk Factor for Prostate Carcinoma: a Meta-Analysis.” Biological trace element research vol. 172,1 (2016): 86-92. doi:10.1007/s12011-015-0576-0

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: May 23, 2025

Episode Summary

• Biden’s diagnosis raises a larger question about how advanced prostate cancer is managed and why aggressive hormone suppression remains the default response.
• “Hormonally sensitive” means testosterone will be suppressed, a decision that affects the heart, brain, bones, and overall strength in aging men.
• Survival statistics for metastatic prostate cancer have improved only modestly over decades, even as treatments have intensified.
• PSA levels alone do not define danger, and many prostate cancer cells remain dormant for years, allowing space for careful monitoring in selected cases.

Quick Decision Checklist

Before moving forward with hormone suppression or any major prostate cancer intervention, walk through these points carefully:

• Confirm whether the diagnosis is based on imaging, symptoms, and overall clinical picture, not PSA alone.
• Ask whether there is documented metastatic disease on imaging, or if treatment is being proposed due to a rising lab value.
• Understand the full-body effects of androgen deprivation, including muscle loss, bone thinning, metabolic strain, and cognitive changes.
• Review the actual survival data behind the recommended drug, including how many months of median benefit were shown in trials.
• Clarify whether treatment is urgent due to pain or organ involvement, or whether there is room to monitor while preserving strength and mental clarity.
• Consider long-term vitality, independence, and fall risk alongside cancer control before committing to irreversible hormone suppression.

00:00 – Introduction

Biden ruled America from 2021 to 2025, but before he stepped down, reports from credible sources confirmed that he had been diagnosed with prostate cancer. Now we are in 2026, and there has been no announcement of his death from the disease. That reality alone should prompt deeper thinking.

Is this simply the advantage of access to high-level medical care, the kind available to former presidents? Or does it suggest that prostate cancer, even when described as advanced, does not always behave the way the public is led to believe?

For decades, men have been told that once prostate cancer spreads, aggressive hormone suppression is the only responsible path. Yet survival statistics have barely moved over many years, even as treatments have grown more intensive. That disconnect deserves careful examination.

One thing is certain: the public conversation often leaves out the full picture. If we are going to talk honestly about prostate cancer, we must examine what “hormonally sensitive” really means, what testosterone suppression actually does to the aging male body, and whether the standard pathway always serves long-term vitality.

00:39 – What “Hormonally Sensitive” Really Means

When doctors describe prostate cancer as “hormonally sensitive,” they are using a specific medical term. In conventional practice, it means the cancer is expected to respond to androgen deprivation therapy. In simple language, that means suppressing testosterone to very low levels.

The long-standing belief is that testosterone fuels prostate cancer growth. Based on that assumption, lowering testosterone is expected to slow the disease. This approach has shaped prostate cancer treatment for decades and remains the foundation of care once cancer is described as advanced or metastatic.

However, the phrase “hormonally sensitive” can sound reassuring to the public. It creates the impression that the cancer is controllable and that the treatment is straightforward. What often goes unspoken is that testosterone is not just a reproductive hormone. It plays a central role in brain function, muscle strength, bone density, mood regulation, immune resilience, and overall metabolic health.

When testosterone is suppressed, the entire body feels the effect. Understanding that reality is essential before accepting the idea that hormone suppression is a simple or harmless solution.

02:18 – Castration Risks: Heart, Brain, and Bone Decline

When testosterone is suppressed through androgen deprivation therapy, the changes in the body are not subtle. Testosterone supports muscle mass, bone strength, red blood cell production, mood stability, and cognitive clarity. Removing it affects every system that depends on it.

One of the first consequences is muscle loss. As muscle mass declines, balance weakens and the risk of falls increases. In older men, a fall followed by a hip fracture can mark the beginning of rapid physical decline. Bone thinning also accelerates under hormone suppression, which increases the likelihood of fractures.

The cardiovascular system is also affected. Lower testosterone levels are linked with higher rates of metabolic dysfunction, increased body fat, insulin resistance, and a greater risk of heart disease. In elderly patients, this becomes clinically relevant.

The brain does not remain untouched. Many men report fatigue, low motivation, brain fog, and mood changes during hormone suppression. Research has linked long-term androgen deprivation to increased risk of cognitive impairment.

When discussing treatment, it is important to look beyond tumor response. A therapy that reduces cancer activity but weakens the heart, brain, and skeletal system must be examined in full context.

05:28 – Outdated Dogma Still Drives Treatment

The idea that testosterone feeds prostate cancer has guided treatment since the mid-1900s. Early clinical observations showed that lowering testosterone could shrink prostate tumors in certain cases. From that point forward, androgen deprivation therapy became the backbone of care for advanced disease.

As years passed, this concept was rarely challenged. Medical training reinforced it. Drug development focused on stronger and more precise ways to suppress testosterone. Hospitals built treatment systems around it. Over time, what began as an observation evolved into a fixed rule.

However, when long-term national statistics are examined, the results are less dramatic than many assume. Mortality rates for metastatic prostate cancer have remained relatively steady across many years. Five-year survival has improved slightly, but not to a degree that reflects a major breakthrough in outcome.

At the same time, the side effects of testosterone suppression are well documented. Muscle loss, bone thinning, metabolic decline, cardiovascular risk, and cognitive changes are common consequences. When a treatment produces significant physiologic strain yet delivers only modest survival change, it becomes reasonable to reassess the framework guiding its use.

Medical history contains many examples where early conclusions shaped decades of practice before being reexamined. Prostate cancer therapy sits at a similar crossroads. The question is not whether androgen deprivation can lower PSA or shrink tumors. The deeper question is whether the long-standing assumption about testosterone and cancer progression fully reflects modern evidence, especially when vitality and long-term health are part of the discussion.

09:00 – Role of Enzalutamide

Enzalutamide is a drug designed to block the androgen receptor. Even when testosterone is present in the blood, the medication prevents prostate cancer cells from using that signal to grow. It is commonly added when standard hormone suppression begins to lose effect or when the disease is described as advanced.

Public summaries of major trials often highlight that the drug improves survival. In one widely cited study, the median survival for men taking enzalutamide was 32.4 months, compared with 30.2 months for those on placebo. That difference is a little over two months. The improvement reached statistical significance, which means the numbers were unlikely due to chance. However, statistical significance and life experience are not the same thing.

Most headlines stop at the survival number. They do not describe what daily life looks like during treatment. Enzalutamide can increase fatigue. It can affect concentration and memory. It may raise the risk of falls. Blood pressure can rise. Some men experience weakness and reduced stamina. In older patients, these changes can alter independence and physical safety.

When a therapy adds months on paper, the discussion must include how those months are lived. A man who cannot think clearly, who feels physically depleted, or who struggles to maintain balance is living a very different life from the one he had before treatment. Survival curves do not show that reality.

Enzalutamide is often presented as evidence that major progress has been made in advanced prostate cancer. A closer reading of the data shows modest extension of time, accompanied by meaningful physiologic strain. Any decision to use it should involve a clear understanding of both the numerical benefit and the full body consequences.

10:23 – Quality of Life vs. Survival Statistics

When advanced prostate cancer is discussed in the media or in medical summaries, the focus almost always centers on survival numbers. Five-year survival. Median survival. Months gained on therapy. These figures appear precise and reassuring because they are measurable. However, numbers alone do not describe the lived experience of the person behind the statistic.

A survival statistic simply tells us how long a group of patients lived after starting treatment. It does not tell us how they felt during that time. It does not explain whether they remained physically strong, mentally sharp, emotionally stable, or independent. For an aging man, those details shape daily life far more than a number printed in a study.

Take metastatic prostate cancer as an example. In 1975, the five-year survival rate for cancer that had spread to the bone was approximately 30 percent. By 2020, that number had increased to about 37 percent. That change reflects some improvement, yet it is modest. During those decades, treatment intensity increased dramatically. Hormone suppression became more aggressive. New drugs were added. Combination regimens expanded. Hospital visits increased. Monitoring intensified.

The key question is not simply whether survival curves moved upward. The question is what happened to muscle mass, bone density, cardiovascular risk, cognition, mood, and independence during that time. Androgen deprivation therapy lowers testosterone to very low levels. Testosterone supports muscle strength, bone stability, red blood cell production, mood regulation, and brain function. When it is removed, predictable consequences follow.

Muscle mass declines. Balance weakens. Bone density decreases, increasing fracture risk. Fat mass increases. Insulin resistance may develop. Fatigue becomes common. Some men report mental fog, slowed thinking, or depressed mood. These changes are not rare complications. They are expected physiologic responses to long-term testosterone suppression.

When studies report survival benefit, they often use endpoints such as overall survival or progression-free survival. These are important measurements, yet they do not capture the complexity of human function. A man may technically be alive at 36 months, but if he has experienced repeated falls, cognitive decline, or loss of autonomy, that outcome carries a cost not reflected in the survival percentage.

There is also the issue of how “progression” is defined. In many trials, a rising prostate-specific antigen level qualifies as progression, even if the patient has no symptoms and imaging shows no new lesions. That definition can trigger treatment escalation. The therapy then lowers PSA levels, and the study records improvement. However, PSA suppression does not always correlate with meaningful clinical improvement. It represents a laboratory response, not necessarily a functional one.

Another layer to consider is age. Many men diagnosed with advanced prostate cancer are in their seventies or eighties. At that stage of life, preserving mobility, cognition, and cardiovascular stability may determine whether they remain independent or require assisted care. A treatment that slightly extends survival but accelerates frailty must be evaluated in that context.

Quality of life is difficult to measure precisely. It includes energy levels, clarity of thought, emotional resilience, physical capability, sleep, sexual function, and social engagement. These factors shape how a person experiences each day. When treatment discussions focus exclusively on tumor size or PSA trends, these broader elements can be overlooked.

It is also important to understand how statistics are presented. A two-month median survival increase means that half the treated group lived two months longer than half the control group. It does not mean every patient gains two months. Some may gain more, some none at all. Meanwhile, side effects can occur across the entire treatment population.

This does not imply that survival data are meaningless. They provide valuable insight into treatment effects. However, survival must be interpreted alongside the physiologic burden of therapy. For many men, the central concern is not simply length of life but the character of that life.

An informed conversation requires acknowledging both dimensions. What is the expected extension of survival? What is the likelihood of fatigue, weakness, fracture, cognitive decline, or cardiovascular strain? How will treatment alter independence? How does that align with the patient’s values and priorities?

When evaluating advanced prostate cancer therapy, the balance between statistical survival and daily vitality becomes central. Numbers describe duration. Quality of life describes experience. Both deserve equal attention before deciding how to proceed.

13:19 – Exploring Bipolar Androgen Therapy

For many years, the dominant idea in prostate cancer treatment has been simple. Lower testosterone and the cancer slows down. That idea shaped hormone therapy for decades. Men with advanced disease are placed on continuous androgen deprivation, which means their testosterone is driven down to very low levels and kept there.

Over time, doctors noticed something important. In many men, the cancer eventually begins growing again even though testosterone remains extremely low. This stage is called castration-resistant prostate cancer. The name itself reveals the problem. The cancer has adapted to survive in a low-testosterone environment. When that happens, stronger hormone blockers are often added, yet long-term control remains difficult.

This pattern forced researchers to ask a different question. If cancer cells adapt to constant suppression, what happens if the environment changes dramatically instead of remaining low all the time? That question led to the development of bipolar androgen therapy, often shortened to BAT.

Bipolar androgen therapy does not keep testosterone low continuously. Instead, it cycles hormone levels. A man receives a high dose of testosterone, which raises blood levels sharply. After a set period, medication lowers testosterone again. This cycle is repeated under close supervision. The word “bipolar” refers to these two opposite hormonal states, high and low, alternating in a controlled way.

The reasoning behind this approach is based on how cancer cells behave. When testosterone is suppressed for long periods, prostate cancer cells often increase the number of androgen receptors they carry. These receptors detect testosterone. By increasing receptor numbers, the cells attempt to survive in a low-hormone environment. However, when testosterone is suddenly raised to high levels, those heavily loaded receptors can become overwhelmed. Laboratory studies suggest this surge may disrupt cell division, damage cancer cell DNA repair processes, and interfere with growth signals. Some cancer cells slow down. Some undergo programmed cell death.

Early clinical trials explored this strategy in men whose cancer had already progressed despite standard hormone suppression. These were small studies conducted at major research centers. In several of them, roughly 40 to 50 percent of participants experienced meaningful declines in PSA during treatment cycles. While PSA is an imperfect marker, those declines suggested biological activity. In addition, many men reported improved energy, clearer thinking, better mood, and increased physical strength during the high-testosterone phases. These quality-of-life changes were measurable and noticeable to patients.

These studies were not large enough to provide final answers. They do not prove that bipolar androgen therapy extends life. They do show that raising testosterone in selected men did not automatically cause rapid or catastrophic progression. That finding alone challenges the long-standing belief that testosterone always fuels prostate cancer in a simple and predictable way.

Continuous hormone suppression produces well-documented physical effects. Muscle mass declines. Bone density decreases. Body fat increases. Balance becomes less stable. Cognitive performance may weaken. Mood disturbances are common. In older men, these changes increase the risk of falls, fractures, and cardiovascular strain. When treatment affects the heart, brain, and skeleton, those outcomes must be weighed carefully in the overall plan of care.

Bipolar androgen therapy attempts to introduce biological instability into cancer cells while allowing intervals of hormonal restoration. It is still considered investigational and requires careful monitoring with blood tests and imaging. It is not appropriate for every patient. However, it represents a serious scientific effort to rethink a model that has remained largely unchanged for decades.

For men facing decisions about hormone suppression, understanding this evolving research expands the conversation. It introduces the possibility that prostate cancer biology may be more complex than the simple idea that lower testosterone always equals better control.

18:19 – PSA Isn’t a Reliable Progression Marker

A rising PSA creates panic. It is often treated as proof that the cancer is advancing and must be attacked immediately. But PSA is a laboratory number. It is not a direct measurement of where the cancer is or what it is doing inside the body.

There is a weak correlation between PSA level and actual disease burden. A PSA can rise while the cancer remains contained within the prostate capsule. Imaging, especially advanced scans such as PSMA PET, gives a clearer picture than PSA alone.

An example was described of a patient whose PSA rose from 100 to 300. On paper, that number looks alarming. Yet bone scans and PSMA imaging showed no metastatic spread. The cancer remained localized. No androgen deprivation therapy was initiated. The patient felt well and maintained strength and clarity.

Treating a lab value instead of a clinical condition can expose a man to severe side effects without a proven survival benefit. Androgen deprivation almost guarantees muscle loss, bone thinning, cognitive decline, and increased cardiovascular risk. Once started, resistance develops over time. When resistance appears, the therapy loses effectiveness.

PSA elevation alone does not automatically justify castration. Imaging, symptoms, and overall health status must guide decision-making. Acting solely on a number can lead to irreversible harm.

18:19 – PSA Isn’t a Reliable Progression Marker

A rising PSA creates panic. It is often treated as proof that the cancer is advancing and must be attacked immediately. But PSA is a laboratory number. It is not a direct measurement of where the cancer is or what it is doing inside the body.

There is a weak correlation between PSA level and actual disease burden. A PSA can rise while the cancer remains contained within the prostate capsule. Imaging, especially advanced scans such as PSMA PET, gives a clearer picture than PSA alone.

An example was described of a patient whose PSA rose from 100 to 300. On paper, that number looks alarming. Yet bone scans and PSMA imaging showed no metastatic spread. The cancer remained localized. No androgen deprivation therapy was initiated. The patient felt well and maintained strength and clarity.

Treating a lab value instead of a clinical condition can expose a man to severe side effects without a proven survival benefit. Androgen deprivation almost guarantees muscle loss, bone thinning, cognitive decline, and increased cardiovascular risk. Once started, resistance develops over time. When resistance appears, the therapy loses effectiveness.

PSA elevation alone does not automatically justify castration. Imaging, symptoms, and overall health status must guide decision-making. Acting solely on a number can lead to irreversible harm.

23:42 – Let the Atypical Dormant Cells Sleep

By the time a man reaches 90 years old, studies show that 60 to 80 percent of men will have prostate cancer cells inside the gland. Most of these cells are small, quiet, and inactive. They are often called dormant or atypical cells. They exist, but they are not spreading rapidly or causing harm.

This changes how prostate cancer should be viewed in older men. If something is present in the majority of aging males, it begins to look less like a rare emergency and more like a common biological event. Many of these cells never wake up. They stay contained within the prostate capsule for years.

Intervening aggressively in every case may disturb a situation that could have remained stable. Biopsies, radiation, or hormone suppression can trigger complications that affect quality of life.

Sometimes the wiser path is careful monitoring. Let the quiet cells remain quiet. Preserve strength, memory, balance, and independence for as long as possible

Continue the Conversation

If this discussion sparked new thoughts, there are other episodes that build on these ideas and examine them from different angles:

EP01 – Why Modern Healthcare Is Failing Prevention | How to Actually Improve Your Health

EP05 - How to Prevent Prostate Cancer Recurrence: What Your Oncologist Isn't Telling You

For a deeper and more structured look at this philosophy, Fight Cancer Like a Man by Dr. Stephen Petteruti walks through prevention, screening, and treatment decisions in a practical and direct way. It lays out the reasoning behind prioritizing vitality, safety, and informed choice.

If you would like access to extended clinical notes and member-only discussions, join the

Intellectual Medicine Community:
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.drstephenpetteruti.com
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

C, Jacklin et al. “More men die with prostate cancer than because of it” – an old adage that still holds true in the 21st century.” Cancer Treatment and Research Communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer. 2015;137(12):2795-2802. doi:10.1002/ijc.29408

Martin RM. Commentary: prostate cancer is omnipresent, but should we screen for it?. Int J Epidemiol. 2007;36(2):278-281. doi:10.1093/ije/dym049

Newcomb, Lisa F et al. “Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.” Urology vol. 75, 2 (2010): 407-13. doi:10.1016/j.urology.2009.05.050

Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5-10. doi:10.1111/j.1464-410X.2007.07138.x

Disclaimer

This podcast and its accompanying materials are for educational purposes. They are designed to support thoughtful decision-making and improve health literacy. They do not replace individualized medical advice, diagnosis, or treatment. Always consult your qualified healthcare professional regarding personal medical concerns.

© 2026 Stephen Petteruti, DO | All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: June 23, 2025

00:00 – Introduction

For many years, men have been told that the PSA test is a simple way to protect their health. The message sounds straightforward: test early, find prostate cancer early, treat it early, and you reduce the risk of dying from it. On the surface, that reasoning appears sensible. However, the prostate is not like other organs, and prostate cancer does not behave like many other cancers.

Since the PSA test became widely used in the 1990s, millions of men have entered a medical pathway that often begins with a blood test and quickly moves toward biopsy, surgery, or radiation. During that same period, the overall death rate from prostate cancer has not fallen in proportion to the number of procedures performed. That gap between expectation and outcome deserves careful attention.

Before deciding whether to undergo PSA screening, it is important to understand how the test was discovered, how its numbers are interpreted, and what typically happens once a result is labeled “elevated.”

00:45 – The Discovery of PSA and the Rise of Prostatectomy

In the early 1970s, Dr. Richard Ablin, an immunologist, identified a protein produced by prostate tissue that later became known as prostate specific antigen, or PSA. His laboratory discovery allowed scientists to measure this protein in the blood. Dr. Ablin consistently warned that PSA was not designed to serve as a broad screening test for prostate cancer. He explained that PSA levels can rise for several noncancerous reasons, including benign prostate enlargement, inflammation, infection, or even recent sexual activity. In other words, an elevated PSA does not automatically mean a dangerous cancer is present.

Despite those warnings, PSA testing expanded widely in the late 1980s and 1990s. The reasoning appeared simple. If PSA increases, cancer might be present, and early detection should help men live longer. However, PSA does not reliably distinguish between slow-growing cells that may never cause harm and aggressive tumors that require urgent care. That limitation was central to Dr. Ablin’s concern.

To understand how this became standard practice, it helps to look back at the 1950s, when radical prostatectomy became widely adopted. Surgeons began removing the entire prostate gland under the assumption that eliminating the organ would eliminate the cancer. At that time, long-term randomized trials showing a clear reduction in prostate cancer death were not available. The procedure spread because it appeared logical.

From the 1950s through the 1990s, prostatectomy rates increased steadily. Over much of that period, national death rates from prostate cancer did not show a dramatic decline. More recent data from 2012 through 2023 show that the per capita death rate has remained relatively stable.

When PSA testing entered routine care, it reinforced this surgical pathway. An elevated PSA often led to biopsy, and a positive biopsy frequently led to surgery or radiation. This sequence became deeply embedded in medical practice. Dr. Ablin later wrote extensively, including in The Great Prostate Hoax, arguing that PSA had been transformed from a laboratory marker into a driver of intervention.

Understanding this history clarifies how a biological discovery evolved into a large screening and treatment system that continues to shape prostate cancer care today.

03:00 – Biopsy Trap and Hidden Risks

A prostate biopsy is rarely an isolated decision. It usually follows a rising PSA level, and once tissue is sampled and labeled as cancer, the pressure to intervene increases rapidly. Even when the cells identified are slow-growing and unlikely to threaten life, the diagnosis itself shifts the psychological landscape. Fear enters the room, and fear tends to drive action.

At that stage, many men move toward surgery or radiation without fully understanding that early-stage prostate cancer carries an extremely high five-year survival rate, often around 99 percent. The emotional weight of the word cancer can overshadow the statistical reality.

Before agreeing to a biopsy, a man should understand that the procedure is not simply diagnostic. It can set in motion a chain of decisions that carry permanent consequences for urinary control, sexual function, and overall quality of life. A thoughtful pause at this point reflects careful judgment rather than denial.

05:00 – PSA Profits Over Prostate Health

Once PSA testing became routine, an entire medical economy formed around it. A blood test leads to imaging. Imaging often leads to a biopsy. Biopsy leads to surgery or radiation. Each step generates revenue for laboratories, device manufacturers, hospitals, and pharmaceutical companies. This does not require a conspiracy. It reflects a system in which financial incentives and clinical decisions become closely linked.

In 2023, a major study published in the New England Journal of Medicine followed men with localized prostate cancer for about 20 years. The findings were sobering. Men who underwent surgery or radiation had a similar risk of dying from prostate cancer as men who were monitored without immediate intervention. After two decades, the difference in prostate cancer–specific mortality between groups was small. That type of data should have prompted a national reassessment of how aggressively early disease is treated.

Instead, the screening cycle continues. New biomarker tests are introduced. New imaging technologies are promoted. Each advancement is framed as progress, yet the long-term death rate from prostate cancer has remained relatively flat in recent years. If removing glands and irradiating tissue were dramatically altering the course of the disease, population-level mortality curves would reflect that shift.

Corporate involvement extends beyond treatment. Companies such as Kimberly-Clark, which manufactures absorbent products used by men with post-surgical incontinence, actively support prostate cancer awareness campaigns. Public awareness itself is not harmful. However, when awareness messaging intensifies fear without equal discussion of treatment risks and long-term outcomes, it can push men toward procedures that permanently alter urinary and sexual function.

The central issue is not whether industry should exist. Innovation requires investment. The issue is whether financial structures subtly reinforce a pathway in which screening almost automatically progresses to intervention, even when long-term survival benefit remains limited. When billions of dollars depend on a treatment model, it becomes difficult for that model to be questioned from within.

Men deserve to see the full data, including 20-year outcomes, complication rates, and quality-of-life consequences. Only then can they decide whether a rising PSA should lead to immediate action or careful observation.

09:40 – Truth Behind Prostate Cancer “Awareness”

Prostate cancer awareness campaigns are widely promoted through media, fundraising events, and public messaging. These campaigns often highlight that prostate cancer is the second leading cause of cancer death in men after lung cancer. While that statement is accurate, it is usually presented without explaining how prostate cancer behaves in most men.

Many older men carry small prostate cancer cells that never spread and never cause harm. Autopsy studies have shown that a large percentage of men in their eighties and nineties have prostate cancer cells in the gland, even though they died from other causes. This tells us that the presence of cancer cells does not automatically mean a life-threatening disease.

Awareness messaging often focuses on early detection and urgency. When a man hears the word cancer, fear naturally follows. That fear can lead to rapid decisions about biopsy, surgery, or radiation. After treatment, if the cancer does not progress, it is commonly assumed that the intervention prevented death. In reality, many early-stage prostate cancers have a 99 percent five-year survival rate even without aggressive treatment.

True awareness should include this full biological context. It should explain how common slow-growing prostate cancer is, what the real risk of death looks like, and what the side effects of treatment may involve. Without that balanced information, awareness can unintentionally push men toward interventions that may not improve long-term survival while clearly affecting quality of life.

11:57 – Risk of Dying from Prostate Cancer

When early-stage prostate cancer is diagnosed, the five-year survival rate is about 99 percent. That number is rarely emphasized during the first conversation after diagnosis. Instead, the focus often turns immediately toward action. Surgery. Radiation. Hormone therapy. Yet a 99 percent five-year survival rate means that the overwhelming majority of men with localized disease will still be alive five years later, regardless of aggressive intervention.

This is where perspective becomes essential. Many prostate cancers grow slowly. Some remain confined to the gland for years. In older men, especially those in their late seventies or eighties, other health risks such as heart disease, stroke, or general age-related decline are statistically more likely causes of death.

Consider President Biden. Reports confirmed a prostate cancer diagnosis before he left office. Now, in 2026, there has been no announcement that he has died from the disease. That alone reflects an important biological reality. Even when prostate cancer is described as advanced, it does not automatically mean imminent death.

The emotional weight of the word cancer can distort statistical truth. A man who hears that he has prostate cancer may assume that immediate removal of the gland will save his life. However, long-term studies have shown that, in many cases, men who undergo surgery or radiation have similar prostate cancer–specific death rates twenty years later compared to those who were monitored carefully.

This does not mean no one dies from prostate cancer. Some men do, and when the disease becomes aggressive and symptomatic, treatment decisions become different. The key point is proportionality. If early-stage prostate cancer carries a 99 percent five-year survival rate, then the decision to accept permanent side effects such as impotence or incontinence must be weighed against that statistical reality.

Risk must be understood clearly before irreversible action is taken.

16:58 – Don’t Sacrifice Your Vitality

When men hear the words “you have prostate cancer,” fear takes over quickly. That reaction is understandable. Cancer is a serious diagnosis. However, early-stage prostate cancer carries a 99 percent five-year survival rate. That means nearly every man diagnosed at an early stage will still be alive five years later, regardless of immediate aggressive intervention.

At the same time, surgery and radiation carry predictable risks. Removal of the prostate can lead to urinary leakage and erectile dysfunction. Radiation can injure nearby organs, including the bladder and rectum. These outcomes are not rare events. They are known complications.

The central issue becomes clear. If early-stage prostate cancer rarely threatens life in the short term, but treatment almost guarantees permanent side effects, the decision must be approached with caution. President Biden’s case brought attention to this reality. An older man with a prostate nodule does not automatically face imminent death. Age, overall health, and cancer behavior all influence outcome.

Vitality includes strength, continence, sexual function, cognitive clarity, and independence. Once lost, many of these functions do not fully return. Preserving them has real value.

What to Do

• Do not rush into a biopsy or treatment based solely on fear.
• Ask for full survival statistics specific to your stage and age group.
• Request imaging, such as an MRI, before agreeing to invasive procedures.
• Understand the documented rates of impotence and incontinence for any proposed treatment.
• Consider structured monitoring if the cancer is low-grade and localized.
• Make decisions based on long-term function, not emotional pressure.

20:08 – Do Your Own Research

If you decide to get a PSA test, the most important step comes after the number is reported. A PSA value by itself does not diagnose cancer, and it does not measure how dangerous a condition may be. PSA can rise because the prostate is enlarging with age. It can rise from inflammation. It can arise from infection. It can even rise temporarily after certain activities. Treating a single laboratory value as a crisis can lead to decisions that cannot be reversed.

Many men assume that once they enter a specialist’s office, the path forward is fixed. In reality, recommendations are shaped by training, tradition, and financial structure within the system. A urologist is trained to biopsy. A surgeon is trained to operate. A radiation center is built to radiate. That does not mean these physicians act in bad faith. It means the system has momentum.

Doing your own research does not mean rejecting medical care. It means asking deeper questions like: What is the true risk of dying from this stage of disease? What is the probability of urinary leakage? What is the likelihood of erectile dysfunction? What are the cardiovascular and metabolic consequences if hormone therapy is proposed later?

Seek multiple perspectives. Read original study summaries when possible. Ask for absolute risk numbers, not just relative improvements. Understand what five-year survival means in practical terms. Knowledge reduces panic, and calm decision-making protects long-term health.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP10 – Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies

EP21 – Prostate Cancer Alert: What to Ask Your Doctor When Your PSA Is High

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749-1757. doi:10.1002/ijc.29538

Kimberly-Clark. Stand Strong for Men's Health. Depend website. Published September 1, 2025. Accessed February 23, 2026. https://www.depend.com/en-us/stand-strong

Lane, Janet Athene et al. “Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).” BJU international vol. 130,3 (2022): 370-380. doi:10.1111/bju.15739

Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5-10. doi:10.1111/j.1464-410X.2007.07138.x

Wilt, T J, and M K Brawer. “The Prostate Cancer Intervention Versus Observation Trial (PIVOT).” Oncology (Williston Park, N.Y.) vol. 11,8 (1997): 1133-9; discussion 1139-40, 1143.

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: June 10, 2025

Episode Summary

• Testosterone developed a negative reputation because of early beliefs linking it to prostate cancer and heart disease. Those ideas were built on limited evidence. Current research and clinical experience have challenged that foundation and show that properly monitored therapy does not automatically increase those risks.
• Testosterone receptors are present in the brain, muscle, heart, and reproductive organs. When levels decline, people may experience fatigue, reduced strength, brain fog, mood changes, and loss of libido. Restoring appropriate levels can improve cognitive clarity, physical resilience, and overall function in both men and women.
• Large studies, including research published in the New England Journal of Medicine, have not demonstrated increased rates of heart attack or stroke in men receiving supervised testosterone therapy. The prostate saturation model also explains why therapeutic levels do not necessarily stimulate prostate cancer growth.
• Testosterone therapy in clinical practice should be based on symptoms, free and total testosterone evaluation, and careful monitoring of red blood cell levels and estrogen balance. Decisions should reflect both scientific evidence and the patient’s lived experience rather than long-standing fear.

Quick Decision Checklist

Use this as a structured reflection before starting or adjusting testosterone therapy:

• Persistent symptoms are present, including low energy, reduced strength, decreased libido, brain fog, mood instability, or slowed recovery. These symptoms have been ongoing and are affecting daily function.
• Total and free testosterone levels have been measured, and the results were interpreted in context. Free testosterone was reviewed carefully, since it represents the biologically active portion of the hormone.
• Other contributing causes of fatigue or mood change have been considered, including thyroid imbalance, sleep quality, nutritional deficiencies, and chronic stress.
• Cardiovascular health has been evaluated, including blood pressure, lipid profile, and baseline hemoglobin or hematocrit levels, so that monitoring can occur safely during therapy.
• PSA has been reviewed appropriately in men, and any elevation has been interpreted rationally rather than automatically linked to testosterone use.
• The decision to begin therapy is based on both evidence and functional impact, with a clear plan for follow-up labs and symptom reassessment after initiation.

00:00 – Introduction

Testosterone may be one of the most misunderstood hormones in modern medicine. It is often spoken about with suspicion, as if it exists mainly to create aggression, impulsive behavior, or health risk. Cultural narratives have shaped that image for decades, linking testosterone to excess rather than balance. As a result, many people approach the topic with hesitation before they ever look at the science.

In reality, testosterone is essential to human physiology in both men and women. Receptors for this hormone exist throughout the body, including in the brain, heart, muscles, and bones. It influences cognitive clarity, emotional stability, metabolic function, and physical strength. When levels decline, the effects are not limited to libido. Fatigue increases, resilience decreases, and mental sharpness can fade.

The purpose of this discussion is to separate long-standing fear from measurable evidence. Understanding how testosterone works at the cellular level, how it should be dosed responsibly, and how it interacts with PSA and prostate health allows a more grounded conversation about vitality and long-term well-being.

01:40 – Why Testosterone Has a Bad Reputation

Testosterone carries a reputation that has been shaped by culture as much as by science. For many years, it has been associated with aggression, impulsive behavior, and what people now call toxic masculinity. In women, it has been linked with fears of unwanted physical changes, such as facial hair or voice deepening. These images are powerful, and they tend to overshadow the biological role of the hormone itself.

Much of this fear grew from earlier medical assumptions that connected testosterone to cancer risk, especially prostate cancer in men and breast cancer in women. That connection was built on limited early observations that later became fixed beliefs. Once a concept becomes embedded in medical training, it can remain in place for decades, even as new research challenges it.

The result is a hormone that is often viewed with suspicion rather than balance. Instead of asking how to use testosterone safely and thoughtfully, the conversation has often centered on avoiding it altogether. To understand whether that caution is justified, it is necessary to look beyond reputation and examine how testosterone actually behaves in the body.

03:05 – Testosterone and Cellular Behavior

Yes, testosterone has a big role in sexual activities, and that’s why it is being referred to as a sex hormone. But what nobody is telling you is the fact that it interacts with receptors located in nearly every tissue of the body. These receptors are found in the brain, skeletal muscle, heart, bone, fat tissue, and reproductive organs. When testosterone binds to these receptors, it influences how cells function, repair themselves, and communicate with one another.

In the brain, testosterone supports neuronal signaling. Adequate levels are associated with sharper cognition, better verbal fluency, improved mood stability, and stronger motivation. When levels decline, some individuals report slower thinking, reduced resilience under stress, irritability, and decreased drive. These changes are often attributed to aging, yet hormonal shifts can play a measurable role.

And in muscle tissue, testosterone promotes protein synthesis, which supports muscle mass and strength. In bone, it contributes to mineral density and structural integrity. In red blood cell production, it stimulates the bone marrow. These are fundamental biological processes, not optional enhancements.

At the cellular level, testosterone does not act as a reckless growth signal. Research increasingly shows that its behavior is regulated and tissue-specific. In certain contexts, it may even demonstrate anti-proliferative effects, meaning it can limit abnormal cell growth. Understanding this cellular behavior is essential before accepting long-standing fears about universal cancer stimulation.

05:05 – Proper Dosing vs Misuse

Much of the fear surrounding testosterone therapy comes from misuse rather than responsible medical treatment. There is a clear difference between supervised hormone replacement and supraphysiologic dosing used in bodybuilding culture. When testosterone is given in excessive amounts, side effects such as acne, mood instability, elevated red blood cell count, and fluid retention can occur. That is not therapeutic medicine. That is pharmacologic excess.

In clinical practice, dosing is individualized and monitored. Blood work includes hemoglobin and hematocrit to ensure red blood cell levels remain within safe range. Estradiol levels are also observed, since testosterone can convert to estrogen. These markers are manageable when tracked appropriately.

A major study published in the New England Journal of Medicine examining testosterone therapy in men. That study did not show an increased incidence of heart attack or stroke among treated men. It did demonstrate improvements in lean body mass, strength, and sexual function. Despite these findings, the published conclusion remained cautious, reflecting persistent institutional hesitation rather than demonstrated harm.

Another key physiologic fact discussed is the distinction between total and free testosterone. Total testosterone includes hormones bound to carrier proteins and therefore biologically inactive. Free testosterone represents the fraction available to bind cellular receptors. With aging, binding proteins increase, which can produce “normal” total levels while free testosterone remains low. Treating solely by total lab number can therefore mislead clinicians.

Therapeutic testosterone aims to restore physiologic function, not exceed it. Dosing decisions are guided by symptom response alongside laboratory monitoring. When managed carefully, complications are uncommon and reversible. The problems most often cited in public debate typically arise from improper dosing, lack of supervision, or misunderstanding of hormone physiology rather than from responsible clinical replacement.

07:04 – Who Is a Candidate for Testosterone Therapy

Testosterone therapy should be considered when a person has persistent symptoms that align with low hormone levels and those symptoms are affecting daily function. The decision does not begin with a lab number alone. It begins with how the person feels and how the body is performing.

In men, common indicators include reduced sexual desire, difficulty maintaining erections, ongoing fatigue, loss of muscle strength, increased abdominal fat, slower recovery after physical activity, low motivation, and reduced mental clarity. These symptoms often develop gradually. Many men assume they are simply aging, yet blood testing may reveal low or borderline testosterone levels that correlate with their decline in vitality.

In women, low testosterone can present as diminished libido, irritability, reduced resilience to stress, midsection weight gain, and a sense of emotional flattening. The transcript emphasized that testosterone is biologically active in women and supports mood, cognition, and physical strength. Careful physiologic replacement, when indicated, can restore balance without producing masculinizing effects when properly managed.

A suitable candidate is someone whose symptoms are consistent, whose laboratory findings support deficiency, and who is willing to undergo monitoring. Hemoglobin, hematocrit, estradiol levels, and overall metabolic markers require periodic review to maintain safety.

Testosterone therapy is a medical decision grounded in symptom relief, physiologic restoration, and careful supervision.

10:05 – Testosterone Use in Clinical Practice

In clinical practice, testosterone therapy is handled as hormone restoration, not as enhancement and not as experimentation. The process begins with a careful review of symptoms. Low energy, reduced libido, loss of muscle strength, brain fog, slower recovery, and mood changes are documented in detail. These symptoms are then evaluated alongside laboratory values, including total testosterone, free testosterone, hemoglobin, hematocrit, and in men, PSA.

Total testosterone alone does not tell the full story. Only free testosterone is biologically active and able to bind to receptors inside cells. As men and women age, a larger portion of testosterone becomes bound and inactive. This can produce a situation where total testosterone appears “okay” on paper while free testosterone is insufficient for proper cellular function. That distinction guides dosing decisions.

Therapy is started at a measured dose and adjusted gradually. The adjustment is based on symptom response and safety markers. Hemoglobin and hematocrit are monitored because testosterone can increase red blood cell production. If levels rise excessively, dosing can be modified. Estrogen levels are monitored when indicated, since testosterone can convert to estradiol. In men, PSA trends are followed over time without assuming that testosterone is driving change.

12:10 – Testosterone and Heart Health

Concerns about testosterone and the heart have circulated for years, yet the clinical data described earlier do not support the claim that properly monitored testosterone therapy increases heart attack or stroke risk. In a study published in the New England Journal of Medicine, men receiving testosterone therapy were followed for cardiovascular outcomes. The findings showed no increased incidence of heart attack or stroke compared with control groups. At the same time, men receiving therapy demonstrated improved lean body mass, improved strength, and improved sexual function.

From a physiologic standpoint, testosterone supports muscle tissue, including cardiac muscle. It also influences body composition. When testosterone is deficient, fat mass tends to increase and muscle mass declines. Increased visceral fat is associated with insulin resistance and metabolic dysfunction, both of which are recognized contributors to cardiovascular disease. Restoring testosterone to appropriate physiologic levels can improve body composition and insulin sensitivity, which are relevant to long-term cardiovascular health.

Strength and balance also influence survival in older adults. Falls leading to hip fractures carry significant mortality risk within the following year. Testosterone contributes to bone density and muscle strength, both of which reduce fracture risk. When discussing heart health, these broader physiologic effects must be considered alongside laboratory cardiovascular endpoints.

14:07 – Why Fear Persists

Fear around testosterone has deep historical roots. Decades ago, a single clinical observation linking testosterone to prostate cancer growth shaped medical teaching for generations. That early report became embedded in textbooks, training programs, and clinical culture. Once a belief is integrated into professional identity, it becomes difficult to revisit, even when newer data challenge it.

Another factor is structural. Testosterone therapy does not fit neatly into the traditional disease model. It often aims to restore vitality, cognitive clarity, muscle strength, and sexual function rather than treat an immediately life-threatening condition. Conventional systems are structured around diagnosing pathology and prescribing interventions that prevent acute events. Hormone optimization aimed at improving daily function can be viewed as elective or cosmetic rather than medical, even when deficiency is measurable.

There is also discomfort around misuse. Supraphysiologic dosing in athletic doping and bodybuilding has shaped public perception. When testosterone is administered in excessive amounts, side effects occur. That misuse influences how therapeutic dosing is viewed, even though clinical replacement under supervision is fundamentally different from abuse.

Finally, many clinicians lack formal training in hormone optimization. Without familiarity, caution can turn into avoidance. When providers rely solely on age-adjusted laboratory ranges and do not integrate symptom assessment, patients with genuine deficiency may be dismissed. Fear persists not because evidence shows widespread harm at therapeutic levels, but because long-standing assumptions are slow to change.

15:44 – Total vs Free Testosterone Explained

When testosterone is measured in blood, two main values appear on the report: total testosterone and free testosterone. Understanding the difference between these two numbers is essential for making sense of symptoms and dosing decisions.

Total testosterone represents all testosterone circulating in the bloodstream. However, a large portion of that total is bound to proteins, primarily sex hormone–binding globulin and albumin. When testosterone is bound to these proteins, it cannot enter cells or activate testosterone receptors. In other words, it is present in storage form but not biologically active.

Free testosterone is the fraction that is not bound. This is the portion that can enter cells, bind to receptors in the brain, muscle, bone, and heart, and produce physiologic effects. Free testosterone drives energy, strength, libido, cognitive clarity, and metabolic function.

As people age, levels of sex hormone–binding globulin often increase. When that happens, total testosterone can appear normal or even high while free testosterone remains low. This creates a misleading lab picture. A patient may feel fatigued, weak, or cognitively dull while being told that the total number is within range.

For that reason, clinical decisions should not rely on total testosterone alone. Both values should be reviewed together, and they must be interpreted alongside symptoms. A laboratory reference range adjusted downward for age does not automatically represent optimal function.

18:22 – Cultural and Medical Resistance to Testosterone

Resistance to testosterone therapy did not develop overnight. It formed over decades through cultural bias, early assumptions, and repetition in medical training. Once an idea becomes embedded in textbooks and guidelines, it can persist long after the original evidence has been questioned.

For many years, testosterone was linked to aggression, impulsivity, and uncontrolled behavior. In men, it became associated with dominance and excess. In women, it was framed as something unnatural or dangerous. These cultural impressions blended with early medical theories that connected testosterone to prostate cancer based largely on limited data. One early report tied testosterone to cancer progression in a single patient. That observation spread quickly and became accepted as general truth.

Over time, that belief shaped clinical caution. Doctors were trained to associate testosterone with risk rather than restoration. Even when later research showed that men with low testosterone often have higher rates of illness and that therapeutic dosing does not appear to increase prostate cancer incidence, the older narrative remained influential.

Institutional medicine also moves slowly. Treatment standards are built around large guideline committees, insurance reimbursement structures, and established prescribing patterns. A therapy aimed at improving vitality, cognition, strength, and sexual function does not always fit neatly into disease-focused reimbursement models. If a patient is not in immediate danger, the system often views intervention as optional rather than medically necessary.

Fear also persists because many clinicians are not deeply trained in hormone optimization. Without familiarity with dosing nuance, monitoring strategies, and receptor biology, uncertainty grows. Uncertainty easily turns into avoidance.

Yet clinical experience and expanding research continue to challenge the older fears. Testosterone receptors exist throughout the body. Adequate levels support muscle integrity, bone density, cognitive performance, and metabolic health. When therapy is applied thoughtfully, with proper monitoring of hemoglobin, hematocrit, estrogen balance, and symptoms, it can restore function without destabilizing other systems.

Changing long-standing medical attitudes takes time. It requires updated education, careful review of modern data, and honest discussion about where early assumptions may have been overstated. As understanding improves, resistance gradually weakens. In that space, patients and physicians can approach testosterone therapy with clarity instead of inherited fear.

20:19 – Rethinking Vitality and Fear-Based Medicine

At the center of this discussion is a simple question. Should health care focus only on preventing death, or should it also protect strength, clarity, energy, and independence? Many medical systems are designed to respond to crisis. They treat heart attacks, strokes, infections, and advanced disease. Yet long before those events occur, people often experience gradual decline in muscle mass, memory, mood stability, and sexual function. Low testosterone can contribute to that decline in both men and women.

Fear-based medicine tends to magnify rare risks while minimizing daily functional loss. Testosterone has been viewed through that lens for decades. The result is hesitation, even when evidence shows that carefully monitored therapy does not increase prostate cancer incidence, does not raise heart attack rates in large studies, and can improve lean body mass and cognitive performance. When fear dominates the conversation, patients may be denied a therapy that could restore resilience.

Reframing vitality means recognizing that aging does not require surrendering strength or mental sharpness. It means evaluating real data instead of inherited assumptions. It also means understanding that no therapy is completely free of risk, but risk must be weighed against benefit in a rational way.

What to Do

• Evaluate persistent symptoms such as fatigue, brain fog, low libido, loss of muscle mass, or depressed mood with a qualified clinician who understands hormone physiology.
• Measure both total and free testosterone rather than relying on total levels alone. Free testosterone reflects the biologically active portion.
• Base dosing decisions on symptom improvement combined with laboratory monitoring, including hemoglobin, hematocrit, and estradiol levels.
• Monitor PSA in men, but interpret changes thoughtfully rather than reacting automatically to minor fluctuations.
• Reassess regularly. Hormone therapy is not static. Dose adjustments should reflect how the body responds over time.
• Make decisions grounded in current research and personal health priorities, not cultural fear or outdated dogma.

Key Takeaway

Testosterone is a biologically essential hormone that supports brain function, muscle strength, bone density, mood stability, sexual health, and overall resilience in both men and women. Much of the fear surrounding testosterone therapy grew from early assumptions about cancer and heart disease that were based on limited data and later challenged by broader research.

Current evidence discussed in this episode shows no consistent proof that properly monitored testosterone therapy increases prostate cancer risk, breast cancer risk, or cardiovascular events. At the same time, clinical experience and published studies show improvements in energy, lean body mass, libido, cognitive clarity, and overall function when therapy is used appropriately.

The decision to use testosterone should not be driven by fear or by lab numbers alone. It should be guided by persistent symptoms, careful monitoring, individualized dosing, and a clear understanding of both potential risks and documented benefits.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP53 – Prostate Cancer and Testosterone: What Men Are Never Told

EP33 – Testosterone, Aging, and Vitality What Medicine Isn’t Telling You

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Hackett GI. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. World J Mens Health. 2024;43(2):282-290. doi:10.5534/wjmh.240081

Haider, Ahmad et al. “Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.” The Journal of urology vol. 193,1 (2015): 80-6. doi:10.1016/j.juro.2014.06.071

Kaplan, Alan L et al. “Testosterone Therapy in Men With Prostate Cancer.” European urology vol. 69,5 (2016): 894-903. doi:10.1016/j.eururo.2015.12.005

Keren D, Goshen A, Strauss T and Springer S (2025) Study protocol: associations between hormonal profile and physical and cognitive functions in middle-aged men—a one-year cohort follow-up study. Front. Public Health 13:1654077. doi: 10.3389/fpubh.2025.1654077

Mohammad, Osama S et al. “Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.” Cancers vol. 9,12 166. 6 Dec. 2017, doi:10.3390/cancers9120166

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177(4):471-479. doi:10.1001/jamainternmed.2016.9539

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: June 24, 2025

Episode Summary

• Watchful waiting often translates into doing nothing, which leaves men anxious and without a structured plan. Active surveillance should involve informed, deliberate monitoring rather than passive delay.
• Biopsies and Gleason scores provide limited predictive value and carry risks, while modern MRI and consistent biomarker tracking offer safer ways to monitor change over time.
• Early-stage prostate cancer carries a 99 percent five-year survival rate, which means rushed intervention rarely improves short-term outcomes and can permanently affect quality of life.
• Proactive management includes metabolic health, maintaining body fat at or below 20 percent, optimizing vitamin D levels between 50 and 100 ng/mL, and working with an independent clinician who prioritizes long-term function and autonomy.

Quick Decision Checklist

Before agreeing to watchful waiting or active surveillance, review these points carefully and make sure each one has been addressed clearly and calmly.

• Confirm the exact stage and Gleason score, and ask how that score was determined and how consistent the interpretation is among pathologists.
• Ask whether non-biopsy monitoring with MRI and consistent biomarkers can replace repeat biopsies.
• Clarify your actual five-year and ten-year risk of death from prostate cancer based on your age and health status.
• Evaluate your current metabolic health, including percent body fat and vitamin D level, and correct deficiencies that increase long-term risk.
• Consider whether your doctor is financially or institutionally tied to surgical or radiation pathways.
• Decide whether your plan preserves strength, sexual function, continence, and cognitive clarity while monitoring disease progression responsibly.

00:00 – Introduction

A diagnosis of prostate cancer often leads to a recommendation that sounds calm and reassuring. Many men are told that their disease appears slow-growing and that watchful waiting or active surveillance is appropriate. On the surface, this approach seems reasonable because it avoids the immediate risks of surgery or radiation. However, the language can mask a deeper concern about whether passive monitoring truly serves the patient’s long-term interest.

For years, prostate surgery and radiation have carried well-documented risks such as impotence, incontinence, and bowel dysfunction, while overall mortality statistics have shown only modest improvement. In response to those limitations, medicine developed a more conservative pathway. Instead of intervening right away, doctors monitor PSA levels, repeat imaging, and sometimes perform additional biopsies over time.

The central question is whether simply observing cancer cells inside the gland is sufficient or whether a more informed and proactive strategy should be considered from the beginning.

01:10 – Watchful Waiting vs Informed Decision-Making

When a doctor recommends watchful waiting, it usually means that immediate surgery or radiation is being deferred. The cancer is described as low risk or slow growing, and the patient is told that careful monitoring is enough for now. This recommendation often reflects uncertainty within the medical system. On one hand, aggressive treatment can cause permanent harm. On the other hand, doing nothing feels unsettling once the word cancer has entered the conversation.

Watchful waiting sometimes factors in age and overall health, even if that is not stated openly. A physician may assume that an older man with heart disease or lung disease is unlikely to die from prostate cancer within the next few years. In that context, intervention may appear unnecessary. However, that judgment is being made on behalf of the patient, often without a detailed discussion about long-term health strategy.

Informed decision-making is different. It requires understanding the biology of prostate cancer, the limits of surgery and radiation, the psychological burden of carrying a diagnosis, and the available options beyond simple observation. It means asking what actions can be taken to support immune function, metabolic health, and risk reduction rather than accepting a passive plan. Watchful waiting avoids immediate harm, but informed care asks whether there are constructive steps that can improve resilience while monitoring the disease.

03:40 – The Ethical Problem with “Do Nothing” Medicine

When a man hears the words “you have prostate cancer,” it immediately changes how he sees his future. Cancer carries weight, and it’s difficult news to deal with. Yet in many cases, the next statement from the doctor is that no immediate action is required. The recommendation becomes watchful waiting or active surveillance. That contrast creates psychological strain. The patient is told something serious is present, yet he is asked to live as though nothing is happening.

From a clinical standpoint, the hesitation to operate makes sense. Removing the prostate gland or radiating it carries well-known risks. Impotence, urinary leakage, bowel irritation, and long-term discomfort are documented consequences. Research over decades has shown that aggressive treatment does not always reduce long-term mortality in early-stage disease. In fact, some long-term studies have demonstrated similar prostate cancer death rates twenty years later, whether a man had surgery, radiation, or conservative management. When the survival difference is small or uncertain, restraint becomes understandable.

However, restraint is not the same as inaction. The ethical tension arises when “doing nothing” becomes the entire strategy. If a physician knows that excess body fat increases inflammatory signaling, that low vitamin D levels correlate with higher malignancy rates, and that metabolic dysfunction weakens immune surveillance, then silence about these factors leaves the patient without direction. The principle of medicine has always included two parts: avoid harm and provide benefit where possible. If a benefit can be pursued through non-invasive means, it should be discussed.

There is also the psychological burden to consider. Living with a known cancer without a structured plan can create chronic stress. Chronic stress affects sleep, cortisol balance, immune regulation, and overall resilience. A passive framework may unintentionally increase anxiety while offering no roadmap for improvement. Ethical care should acknowledge that biology and psychology are linked. A patient deserves more than reassurance that nothing drastic will be done.

The issue is not that conservative management is wrong. It is conservative management should still be active in intent. Monitoring PSA trends, using MRI when appropriate, tracking biomarkers consistently, addressing vitamin D status, reducing body fat to 20 percent or less in men, and strengthening metabolic health all represent meaningful actions. These steps carry low risk and may improve overall outcomes beyond prostate cancer alone.

When medicine limits the conversation to surgery, radiation, or waiting, it narrows the patient’s agency. Ethical care expands the discussion. It explains the evidence behind survival statistics, clarifies the limits of biopsy interpretation and Gleason scoring, and introduces safe, proactive strategies. A man facing prostate cancer should not be left suspended between fear and passivity. He should be guided toward thoughtful monitoring combined with deliberate efforts to improve the internal environment in which those cancer cells exist.

06:40 – Why Passive Care Is Not Risk-Free

Watchful waiting sounds calm and suggests safety. It implies that by avoiding surgery or radiation, harm has been avoided. In reality, passive care carries its own set of risks, even if those risks are quieter and less visible.

First, prostate cancer is not static biology. A biopsy gives a snapshot. It describes what a cluster of cells looked like at one moment in time. The Gleason score is a visual grading system based on how the cells appear under a microscope. Different pathologists can interpret the same slide differently. It is a description, not a prediction. A low-grade pattern today does not guarantee stable behavior tomorrow. Cancer biology evolves.

Second, repeated biopsies are often built into active surveillance protocols. Each biopsy involves inserting multiple needles through the prostate capsule. That process causes bleeding and inflammation. There is also a theoretical concern about cell disruption and dissemination, even though this risk remains debated. Beyond that, repeated procedures increase infection risk and psychological stress. Surveillance that relies heavily on invasive sampling is not biologically neutral.

Third, passive care often fails to address modifiable risk factors. Excess body fat is associated with inflammatory signaling that can stimulate cancer growth. Low vitamin D levels correlate with higher rates of malignancy in several studies. Insulin resistance and poor metabolic control create a biochemical environment that favors cellular proliferation. If these elements are left unaddressed, the internal terrain remains unchanged. The cancer cells are simply being observed, not challenged.

Fourth, psychological stress has physiologic consequences. A man told that he has cancer but is instructed to “wait and see” may live in chronic tension. Elevated stress hormones can impair immune surveillance. Sleep may suffer. Mood may shift. None of this is captured in a surveillance protocol that measures PSA and schedules biopsies.

Passive care avoids immediate procedural harm, which is valuable. However, the absence of intervention does not equal the absence of risk. The disease may progress silently. The body’s metabolic environment may remain unfavorable. The patient may experience ongoing anxiety without structured guidance.

True risk reduction requires engagement. Monitoring should be consistent and non-invasive where possible. MRI imaging can evaluate anatomy without puncturing tissue. Biomarker trends over time provide more information than a single measurement. Body composition, vitamin D levels, metabolic health, and inflammatory markers can be optimized.

When surveillance becomes an excuse for inaction, it fails the patient. When surveillance becomes a framework for deliberate health improvement combined with careful monitoring, it becomes a thoughtful strategy. The difference lies in whether the plan simply watches biology unfold or actively supports the body while keeping harm to a minimum.

08:40 – What Active Surveillance Really Involves

Active surveillance is often presented as the responsible middle ground. It is described as careful monitoring instead of immediate surgery or radiation. On the surface, that sounds reasonable. However, what it involves in practice deserves close examination.

Traditional active surveillance protocols rely heavily on repeat PSA testing and scheduled biopsies. A biopsy may be performed at diagnosis, then again within months, and then at regular intervals. Each time, multiple needles are inserted through the prostate to sample tissue. The tissue is examined, graded, and compared with prior results. If the Gleason score changes or the volume of cancer appears larger, treatment is often recommended.

The problem is that a biopsy samples only small portions of a gland that contains millions of cells. The prostate is not a smooth, uniform structure. It has folds, compartments, and areas that may not be captured in a needle sample. A stable biopsy does not guarantee that microscopic change is not occurring elsewhere. Likewise, a slightly higher Gleason score does not automatically mean the disease is accelerating in a clinically meaningful way. The interpretation still depends on subjective grading.

PSA testing is another pillar of surveillance. PSA is influenced by gland size, inflammation, infection, and benign enlargement. Many men experience gradual PSA increases with age due to normal growth of prostate tissue. A rising number can trigger an alarm even when imaging shows no spread beyond the gland. Acting on PSA alone can lead to unnecessary escalation.

True active surveillance should involve more than repeating invasive procedures. Magnetic resonance imaging offers a way to evaluate anatomy without disrupting tissue. Serial MRIs can identify structural change over time. Biomarker panels may add additional information about biological activity. The key is consistency in measurement so that trends, not single data points, guide decisions.

Active surveillance should also address the host environment. Cancer cells do not exist in isolation. They respond to metabolic signals, inflammatory pathways, hormone balance, and immune function. Percent body fat, vitamin D levels, insulin sensitivity, and cardiovascular health influence the internal terrain. Surveillance that ignores these elements is incomplete.

When active surveillance becomes a cycle of periodic biopsies and anxious waiting, it falls short. When it combines structured monitoring with deliberate health optimization, it transforms into a proactive strategy. The difference is whether the patient is simply being observed or actively strengthening the biological environment in which the disease exists.

10:09 – The Limitations of Biopsies and Gleason Scoring

Once a biopsy confirms prostate cancer, much of the treatment discussion revolves around the Gleason score. The Gleason system is based on how the sampled cells look under a microscope. A pathologist studies the shape and arrangement of the cells and assigns a grade that reflects how abnormal they appear. The two most common patterns are added together to produce the final score.

This system has value, but it has limits that are rarely explained clearly to patients. A Gleason score is not a direct measurement of how the cancer will behave over time. It is a visual interpretation of cell structure at a single moment, taken from small tissue fragments. Two pathologists can sometimes assign slightly different grades to the same specimen. That alone tells you there is a degree of subjectivity involved.

A prostate biopsy also samples only portions of the gland. Typically, 10 to 12 cores are taken, yet the prostate contains far more tissue than those cores represent. Cancer can be unevenly distributed. One area may appear low grade while another region, not sampled, behaves differently. Conversely, a small cluster of more irregular cells may be identified and labeled as higher grade, even if the broader disease remains slow-moving.

Another issue is timing. A biopsy does not reveal a trajectory. Cancer biology is dynamic. What matters is what the cells look like and how they change over months and years. Repeating biopsies to chase that information introduces cumulative risk. Each procedure carries the possibility of bleeding, infection, inflammation, and theoretical spread of cells beyond the capsule.

The Gleason score can inform discussion, but it should not dictate automatic action. When interpreted alongside imaging trends, biomarkers, and overall health status, it becomes one data point among several. When treated as absolute truth, it can drive decisions that permanently alter the quality of life based on incomplete information.

13:40 – Non-Biopsy Monitoring with MRI and Biomarkers

If repeated biopsies are not the ideal way to monitor prostate cancer, the question becomes practical. How should the condition be followed over time?

Magnetic resonance imaging, particularly multiparametric MRI, changed this conversation. From 2012 to 2015, prostate MRI became widely available with improved resolution. It allows physicians to examine the anatomy of the gland without inserting needles. Areas that look suspicious can be visualized, measured, and compared over time. The value is not in a single scan. The value is in sequential comparison. If a lesion remains stable in size and appearance over months or years, that stability carries meaning. If it changes, that shift provides information without cutting into tissue again.

MRI is not perfect. It cannot detect every microscopic cluster of cells. However, it offers a structural context that a lab test cannot provide. It shows location, size, and whether there is extension beyond the capsule. That level of detail adds perspective that a biopsy core alone cannot give.

Biomarkers add another layer. PSA, when interpreted in isolation, can be misleading. When measured consistently and evaluated over time, trends become more informative than a single number. Additional markers, such as the Prostate Health Index, can refine interpretation. The key principle is consistency. The same lab, the same method, and the same intervals allow comparison that is meaningful.

Monitoring through imaging and biomarkers shifts surveillance from repeated tissue disruption to structured observation. It reduces procedural harm while still tracking change. It also places responsibility on pattern recognition rather than reacting to one isolated data point.

This approach reframes the risk. Instead of asking whether cancer is present, which is already known, the focus becomes whether the condition is evolving in a way that justifies intervention. That distinction is central to thoughtful care.

16:10 – Vitamin D, Metabolic Health, and Risk Modulation

If a man chooses surveillance, the discussion should not end with imaging schedules and lab intervals. The biological environment in which prostate cells live plays a major role in how those cells behave over time. That environment is influenced by metabolic health, body composition, and micronutrient status.

Excess body fat is not metabolically neutral. Adipose tissue produces inflammatory signals and alters hormone balance. Chronic low-grade inflammation creates a setting that favors cellular stress and genetic instability. In men with higher body fat percentages, insulin resistance is also more common. Elevated insulin and related growth signals can promote cellular proliferation. Reducing body fat to 20 percent or lower, as often recommended in this context, is not cosmetic advice. It is metabolic risk management.

Vitamin D status is another modifiable factor. Observational studies have shown correlations between low vitamin D levels and higher rates of several malignancies, including prostate cancer. Some analyses suggest that maintaining a serum vitamin D level above 50 ng/mL is associated with lower cancer incidence and reduced risk of severe infection. While correlation does not prove causation, vitamin D plays a role in immune regulation, cellular differentiation, and inflammation control. These mechanisms are biologically plausible in cancer modulation.

In clinical practice, daily supplementation of 5,000 international units of vitamin D3 is commonly used to maintain levels in the desired range, with concurrent vitamin K2 intake in the range of 200 to 300 micrograms per day to support proper calcium handling. Serum levels should be measured to ensure adequacy and safety.

These interventions are inexpensive and broadly beneficial. Improving body composition enhances cardiovascular health, glucose regulation, mobility, and overall resilience. Optimizing vitamin D supports bone health and immune balance. Within the framework of active surveillance, such measures represent active biological engagement rather than passive observation.

Surveillance that ignores metabolic terrain is incomplete. Surveillance that includes body composition, nutrient status, and systemic health transforms the strategy from waiting to conditioning the internal environment toward stability.

19:10 – Choosing Proactive Thinking Over Passive Fear

A diagnosis of prostate cancer should never push a man into panic or passivity. Active surveillance must be structured and intentional. It requires ongoing evaluation, metabolic correction, and informed decision-making. The goal is steady management of risk while maintaining strength, clarity, and independence.

What to Do

• Confirm the stage and risk category of the cancer using consistent PSA tracking and high-quality prostate MRI rather than relying on a single biopsy result.
• Monitor PSA trends over time and interpret them alongside imaging findings instead of reacting to one elevated value.
• Maintain body fat at or below 20 percent, since excess adipose tissue influences inflammatory pathways and hormonal balance.
• Test vitamin D levels and maintain a range between 50 and 100 ng/mL, using vitamin D3 with vitamin K2 when appropriate.
• Prioritize resistance training, metabolic stability, and blood sugar control to strengthen immune resilience.
• Work with a clinician who understands non-biopsy monitoring strategies and is comfortable discussing options beyond automatic surgical or radiation pathways.

Active surveillance should reflect structured oversight and active health optimization. When approached thoughtfully, it becomes a disciplined plan rather than passive waiting.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP04 – Why Early Treatment of Prostate Cancer May Be Ineffective: The Case for Conventional Therapies

EP11 – Is It Really Prostate Cancer? Rethinking Diagnosis, Biopsies, and the Gleason Score

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

C, Jacklin et al. “More men die with prostate cancer than because of it” – an old adage that still holds true in the 21st century.” Cancer Treatment and Research Communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Blas, Leandro et al. “Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.” Cancers vol. 14,17 4161. 27 Aug. 2022, doi:10.3390/cancers14174161

Eggener, Scott E et al. “Predicting 15-year prostate cancer specific mortality after radical prostatectomy.” The Journal of urology vol. 185,3 (2011): 869-75. doi:10.1016/j.juro.2010.10.057

Epstein JI. Bad grades for Gleason. The Pathologist. Published November 20, 2017. Accessed October 15, 2025. https://thepathologist.com/issues/1117/bad-grades-for-gleason

Landy, Rebecca et al. “Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.” Cancer prevention research (Philadelphia, Pa.) vol. 13,4 (2020): 367-376.

Okubo, Yoichiro et al. “Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment.” Archivos espanoles de urologia vol. 76,9 (2023): 633-642. doi:10.56434/j.arch.esp.urol.20237609.78

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: July 01, 2025

Episode Summary

• A high PSA does not require an immediate specialist referral or biopsy. Primary care physicians can monitor PSA trends, use MRI imaging, and apply biomarkers before moving toward invasive procedures.
• Prostate biopsy has limits and risks, including inaccuracy and potential spread. MRI, consistent biomarker tracking, calcium scoring, circulating tumor cell testing, and PSMA PET imaging can provide a broader risk context before major decisions are made.
• Most early prostate cancer carries a very high survival rate, so urgency should not override careful thinking. Ask direct questions, review heart risk and overall health, and take ownership of decisions that affect long-term function and quality of life.

Quick Decision Checklist

Before agreeing to further testing or referral, review these points carefully:

• Confirm the exact PSA value and review prior PSA results to understand the trend over time rather than reacting to a single number.
• Ask whether monitoring with repeat PSA testing and prostate MRI is reasonable before considering a biopsy.
• Request a clear explanation of the potential risks and benefits of a biopsy, including accuracy limits and possible complications.
• Evaluate overall health risk by checking the coronary calcium score and cardiovascular status, since heart disease often poses a greater immediate threat than early prostate cancer.
• Discuss advanced imaging, such as PSMA PET scan or circulating tumor cell testing if cancer has already been diagnosed and major treatment is being considered.
• Clarify whether any financial relationships or ownership interests could influence referral or treatment recommendations, so decisions remain centered on long-term health and function.

00:00 Introduction

Preparation determines the quality of the decisions that follow. When a man is told his PSA is elevated, the conversation can quickly move toward referrals, scans, or biopsy. If he walks into that appointment without clarity, he may agree to steps he has not fully examined.

An elevated PSA is a laboratory signal. It is not a diagnosis. Even when cancer cells are found, the situation is rarely urgent. Prostate conditions often move slowly, which gives space for careful thought. The danger comes from panic and rushed decisions, not from the number itself.

Before seeing a specialist, before agreeing to a procedure, a man should know what to ask. The right questions protect his health, his independence, and his quality of life.

00:34 Do You Really Need a Urologist?

An elevated PSA often triggers a reflex referral to a urologist. That pathway feels routine, but routine does not mean required. A primary care physician is fully capable of evaluating an elevated PSA, repeating the test, reviewing trends, and discussing non-invasive options before involving a surgical specialist.

Specialists are trained to do procedures. That is their focus. A urologist’s daily work centers on biopsies, surgeries, and interventions. When you enter that environment, the discussion naturally moves toward procedural next steps. That does not mean the recommendation is malicious. It means it is aligned with their training and workflow.

A thoughtful first step is to ask your primary care doctor whether the PSA can be monitored over time. PSA values often rise gradually with age as the prostate enlarges. A single elevation does not define a crisis. Repeating the test, evaluating velocity, and reviewing other health risks may provide context without immediate referral.

Seeing a urologist remains an option. It is not an obligation. The key is entering any consultation prepared, informed, and clear about what you want to avoid and what you are willing to consider.

01:19 Biopsy Is an Option

An elevated PSA does not create a mandate for a biopsy. A biopsy is a choice, and every choice in medicine should be weighed against benefit, risk, and available alternatives.

Prostate biopsies became standard practice in the 1980s. The technique has remained largely the same for decades. A needle is inserted into the gland multiple times to collect tissue samples. Those samples are examined under a microscope to determine whether cancer cells are present. While this method can detect cancer, it is invasive and not without consequence.

Research and clinical experience show that biopsies carry risks, including bleeding, infection, and inflammation. There is also an ongoing debate about whether repeatedly disrupting the prostate capsule could contribute to spread if cancer cells are present. That concern has not been fully resolved, yet it deserves acknowledgment during informed consent.

Accuracy is another limitation. A biopsy samples small areas of a gland that has many compartments. Cancer cells can exist in locations not captured by the needle. A negative biopsy does not guarantee the absence of disease. A positive biopsy confirms cells are present but does not always predict behavior or outcome.

Magnetic resonance imaging of the prostate has improved significantly since it became widely used between 2012 and 2015. High-quality MRI can identify suspicious areas and provide anatomical detail without puncturing the gland. Combined with serial PSA measurements and other biomarkers, imaging can offer meaningful information before deciding on tissue sampling.

If insurance does not cover an MRI without prior biopsy, some patients choose to pay out of pocket. The average cost is often in the range of several hundred dollars, which for many men is preferable to undergoing an invasive procedure prematurely.

Before consenting to a biopsy, it is reasonable to ask whether imaging and careful monitoring could provide sufficient clarity first. A biopsy may still be chosen, but it should follow discussion, not fear.

03:28 What’s Your Calcium Score?

When a PSA is elevated, attention often locks onto the prostate, and everything else fades into the background. That narrow focus can distort judgment. Many men with early-stage prostate cancer live long lives, and the more common cause of death in this group is cardiovascular disease. If risk is going to be assessed honestly, the heart must be part of the discussion.

A coronary artery calcium score is a specialized CT scan that measures calcified plaque inside the coronary arteries. It does not evaluate the prostate. It evaluates the arteries that supply blood to the heart. In men over 60, a calcium score above 100 has been linked to a meaningful ten-year risk of death from heart disease and other causes. Early-stage prostate cancer, by contrast, carries a five-year survival rate close to 99 percent.

These numbers frame priorities. Before moving toward invasive prostate procedures, it is reasonable to ask whether vascular risk presents the more immediate threat to lifespan. A calcium score provides objective data that helps guide the decision.

04:40 Lifestyle Changes That Are Necessary

When a PSA rises, the conversation usually turns toward imaging, biopsy, and procedures. Very little time is spent on the biological environment in which prostate cells live. That gap is significant. Prostate tissue does not exist in isolation. It responds to hormones, inflammation, insulin levels, body fat, sleep quality, and metabolic health. If those factors are ignored, the focus becomes narrow and reactive.

Body fat plays a direct role in hormone balance and inflammation. Fat tissue increases aromatase activity, which alters the balance between testosterone and estrogen. Excess visceral fat is also linked with higher insulin levels and chronic low-grade inflammation. Both conditions create a metabolic setting that favors cellular stress. For men with elevated PSA, maintaining body fat near or below 20 percent reduces inflammatory signaling and improves metabolic stability.

Vitamin D status is another variable often overlooked. Lower vitamin D levels have been associated in observational studies with higher rates of several cancers, including prostate cancer. Vitamin D supports immune regulation and cellular differentiation. Many laboratories report a “normal” vitamin D level beginning around 30 ng/mL. Some clinicians aim for levels above 50 ng/mL in order to support broader immune resilience. This does not replace medical therapy, but it reflects a modifiable factor that influences overall health.

Exercise directly affects prostate health through multiple mechanisms. Resistance training preserves muscle mass and insulin sensitivity. Cardiovascular exercise improves endothelial function and reduces inflammatory markers. Sedentary behavior, on the other hand, contributes to metabolic dysfunction and weight gain. A structured exercise plan that includes strength training at least two to three times per week and regular aerobic movement improves systemic health in ways that extend beyond the prostate.

Diet also influences inflammatory tone. Highly processed foods, excessively refined carbohydrates, and high sugar intake worsen insulin resistance and promote fat accumulation. Diets rich in whole foods, vegetables, fiber, healthy fats, and adequate protein support metabolic balance. While no single food cures prostate cancer, dietary patterns influence the internal environment in which cells function.

Sleep quality and stress management further affect hormonal balance. Chronic sleep deprivation lowers testosterone, increases cortisol, and impairs immune surveillance. Persistent psychological stress maintains elevated stress hormones, which influence inflammatory pathways. Consistent sleep and structured stress reduction are part of comprehensive risk management.

These interventions are not dramatic. They do not generate headlines. However, they directly modify the terrain in which prostate cells exist. When a PSA is elevated, asking about lifestyle factors is not a distraction. It is a rational step toward strengthening the whole system while decisions about imaging or procedures are being made.

07:00 Mohs Surgery and the Limits of Targeting

When discussing prostate biopsy and targeted treatment, it helps to understand how cancer behaves in other tissues. In dermatology, a technique called Mohs surgery is used for certain skin cancers. During that procedure, the surgeon removes very thin layers of tissue and examines each layer under a microscope in real time. The reason for this careful process is simple. Skin cancers often extend in irregular microscopic patterns that cannot be seen with the naked eye. If even a small portion is left behind, the cancer can recur.

The prostate gland has a similar structural complexity. It is not a smooth, solid mass. It contains ducts, glands, and microscopic channels. Cancer cells within the prostate may not form a single clean, round nodule. They can exist in scattered areas or extend in patterns that are invisible to imaging and impossible to define precisely with a needle.

This raises an important biological question. If skin cancer requires careful layer-by-layer assessment to ensure complete removal, how confident can anyone be that inserting a needle into one visible area of the prostate captures the full picture? An MRI may highlight a suspicious region, but MRI resolution has limits. A biopsy samples a fraction of the gland, not the entire structure.

The same logic applies to focal radiation or focal ablation therapies that attempt to treat only a visible lesion. If cancer cells exist beyond the visible boundary, targeting a single spot may not address the broader biological field. The prostate is not a solid marble with a single defect. It is a living organ with complex internal architecture.

This does not mean imaging has no value. MRI can provide useful anatomical information. Biomarkers can provide trend data over time. The limitation lies in assuming that a single targeted intervention fully defines or resolves the condition. Cancer biology is often more diffuse and less predictable than a clean image suggests.

Understanding this complexity helps frame better questions when PSA is elevated. Instead of assuming that a needle or beam precisely isolates the problem, it becomes reasonable to ask how accurate that targeting truly is and what margin of uncertainty remains.

10:00 Calcium Score Resources

When PSA rises, attention often turns quickly to the prostate. Yet the broader context of health should be part of the same conversation. A coronary artery calcium score measures calcified plaque in the arteries that supply the heart. It is obtained through a non-contrast CT scan and provides a numerical score that reflects cardiovascular risk.

Why does this belong in a discussion about prostate cancer? Because cardiovascular disease remains the leading cause of death in men. Many men diagnosed with early-stage prostate cancer are statistically more likely to die from heart disease than from their prostate condition. Ignoring that reality distorts risk assessment.

For example, a calcium score above 100 in a man over 60 correlates with a substantially increased ten-year risk of death from all causes, including heart disease. In contrast, early-stage prostate cancer carries an extremely high five-year survival rate, often around 99 percent. Those numbers do not eliminate prostate risk, but they place it in perspective.

Calcium scoring is widely available, relatively low-cost, and typically does not require contrast. It provides actionable information about arterial health. Lifestyle interventions, lipid management, metabolic control, and inflammation reduction can meaningfully affect cardiovascular trajectory.

When speaking with a physician about an elevated PSA, asking about calcium score shifts the conversation from a narrow organ focus to a whole-body evaluation. It reflects an understanding that longevity depends on more than one lab value. Prostate monitoring and cardiovascular risk assessment should proceed together, because lifespan is influenced by both.

10:54 Galleri Test

Another question worth raising involves circulating tumor cell testing. One example is the Galleri test, developed by Grail. This blood test looks for fragments of tumor-related DNA that may be circulating in the bloodstream. It is designed to detect cancer signals from multiple organs, including the prostate.

A biopsy answers one question. It tells you whether cancer cells are present inside the prostate gland. A circulating tumor cell test asks something different. It looks for evidence that cancer-related material has entered the blood. If tumor DNA or circulating cells are detected, that suggests biological activity beyond the gland itself.

That distinction has consequences. Surgery and radiation are local treatments. They focus on tissue within the prostate. If disease activity has moved beyond that boundary, local intervention does not address the full picture.

The limits of this test must also be understood. Early stage prostate cancer often does not shed measurable tumor DNA into the bloodstream. A negative result does not eliminate risk. It simply means no circulating signal was detected at that time.

Even with those limits, this type of testing adds another layer of information before major decisions are made. It broadens the discussion from identifying cancer in the prostate to evaluating whether there is measurable activity elsewhere in the body.

12:00 PSMA PET Scan

Another question to raise before any aggressive intervention is whether a PSMA PET scan has been performed. PSMA stands for prostate-specific membrane antigen. This imaging study is designed to detect prostate cancer cells that express this surface protein, even when they are located outside the prostate gland.

Traditional imaging, such as bone scans or CT scans, often identifies disease only after it becomes structurally obvious. PSMA PET scanning works at a molecular level. It highlights prostate cancer cells based on their biological signature, which can reveal spread that would otherwise remain invisible.

This information changes categories of care. If the scan shows disease confined strictly to the gland, that is one discussion. If it identifies lymph node involvement or distant spread, that is a different discussion entirely. Local treatments such as surgery or radiation do not address systemic disease.

Before committing to irreversible procedures, understanding whether cancer activity extends beyond the prostate provides clarity. It shifts the focus from reacting to a lab number toward evaluating the true biological footprint of the disease.

15:10 Your Family Doctor Should Guide You

Your primary care doctor is trained to look at the whole picture. That includes your heart health, metabolic status, bone strength, body composition, medications, and overall life expectancy. A prostate lab value does not exist in isolation. It sits inside a larger health framework.

Specialists focus on organs. Family doctors focus on people. An elevated PSA may draw attention to the prostate, yet your long-term outcome may depend more on cardiovascular risk, diabetes control, inflammation, or body fat percentage. A calcium score, blood pressure pattern, lipid profile, and metabolic markers often carry greater predictive value for lifespan than a small focus of prostate cells inside the gland.

Empowering your family doctor to coordinate monitoring creates balance. PSA trends, MRI findings, biomarkers, and overall health metrics can be tracked together. That approach avoids tunnel vision and reduces pressure to rush toward procedures.

A collaborative primary care physician can help interpret changes over time, frame risk accurately, and maintain perspective while decisions are made thoughtfully.

16:00 Own Your Life

A high PSA or a biopsy report can create emotional pressure. That pressure often drives urgency, and urgency can lead to decisions that cannot be reversed. In most early cases, prostate cancer grows slowly. That usually allows time to think clearly, gather information, and weigh options carefully.

No one else will live with the long-term effects of surgery, radiation, or hormone therapy. Those outcomes affect urinary control, sexual function, muscle strength, and daily independence. That reality alone justifies taking the time to ask direct questions and to demand clear answers.

You Might Want to Consider:

• Writing down your questions before the visit, so the conversation stays focused.
• Asking for exact numbers regarding risk, including five- and ten-year survival data.
• Requesting copies of PSA trends, imaging reports, and pathology findings.
• Seeking a second opinion before agreeing to a biopsy, surgery, or radiation.
• Reviewing heart risk, calcium score, metabolic health, and body fat percentage alongside prostate findings.
• Allowing yourself time to decide, since early-stage prostate cancer rarely requires immediate intervention.

Decisions about the prostate should be deliberate, informed, and aligned with long-term health priorities.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP43 – PSA Rising? Ask These 3 Questions

EP48 – Rising PSA Explained: When to Watch, When to Act, and When to Wait

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Cassell, Ayun, and Solomane Konneh. “Unlocking the potential in vitamin D in prostate cancer prevention.” World Journal of Clinical Oncology vol. 15, 2 (2024): 169-174. doi:10.5306/wjco.v15.i2.169

Hantusch, Brigitte et al. “Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.” International journal of molecular sciences vol. 25,17 9245. 26 Aug. 2024, doi:10.3390/ijms25179245

Okubo, Yoichiro et al. “Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment.” Archivos espanoles de urologia vol. 76,9 (2023): 633-642. doi:10.56434/j.arch.esp.urol.20237609.78

Landy, Rebecca et al. “Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.” Cancer prevention research (Philadelphia, Pa.) vol. 13,4 (2020): 367-376.

llic, Dragan et al. “Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.” BMJ (Clinical research ed.) vol. 362 k3519. 5 Sep. 2018, doi:10.1136/bmj.k3519

Petteruti SJ, Frazzini V. Reduction of Calcium Scores Using Intravenous Chelation: A Retrospective Pilot Study. Cureus. 2023;15(9):e44657. Published 2023 Sep 4. doi:10.7759/cureus.44657

Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5-10. doi:10.1111/j.1464-410X.2007.07138.x

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: July 08, 2025

Episode Summary

• Prostate enlargement is common with aging and becomes important only when it interferes with urinary function, sleep, or bladder emptying.
• Inflammation, metabolic health, and gradual hormonal changes influence symptoms, and steady monitoring over time gives better guidance than reacting to a single test result.
• Supplements, targeted medications, and lifestyle adjustments can improve urinary flow and reduce nighttime urination, though results often require months of consistency.
• Procedures such as laser enucleation, thermal therapy, or other interventions should be considered carefully, with attention to long-term outcomes, sexual side effects, and the experience level of the treating center.

Quick Decision Checklist

Before choosing medication or a procedure, take a moment to look at the basics. Review these points carefully before moving forward:

• Urinary flow allows you to empty your bladder without significant strain or prolonged dribbling.
• Nighttime urination is manageable and does not severely disrupt sleep quality.
• A post-void residual test has confirmed whether the bladder is emptying effectively.
• Non-surgical options, such as supplements or medication, have been given enough time to show measurable effects.
  The size of the prostate has been evaluated in the context of symptoms, not treated as a problem on its own.
• More than one procedural opinion has been obtained before committing to surgery.

00:00 – Introduction

An enlarged prostate is one of the most predictable changes in a man’s body as he ages. If you live long enough, your prostate will grow. That growth is not a disease. It reflects time and biology.

Size alone does not determine whether something is wrong. What truly determines whether attention is needed is how the gland affects urination and daily comfort. Many men hear that their prostate is enlarged and immediately assume danger. In most cases, the issue is mechanical, not life-threatening.

The focus should be simple and practical. Is urine flowing well enough for you to live without constant interruption, discomfort, or sleep disruption? That is where the conversation begins.

01:59 – Factor to Check: Can You Pee?

Urinary function is the central issue in prostate enlargement. The gland surrounds the urethra, which is the tube that carries urine from the bladder out of the body. As the prostate grows, it can compress that channel. The effect is not determined by overall size alone, but by where the growth occurs. If the enlargement presses inward toward the urethra, flow becomes restricted. If it expands outward, symptoms may be minimal even if the gland measures large on imaging.

The practical way to assess this is through function, not fear. Ask yourself how well you empty your bladder. A strong stream that empties comfortably suggests that the bladder and outlet are working in coordination. A weak stream, hesitancy, straining, dribbling, or the feeling that urine remains trapped after voiding indicates obstruction. These are functional signs that deserve attention.

Nighttime urination also provides useful information. Waking once per night may be manageable. Waking three or four times and feeling exhausted the next day signals that bladder performance is being affected. The issue is not simply how often you wake, but whether sleep remains restorative. Chronic sleep disruption alters energy, mood, metabolism, and cardiovascular health. That makes urinary symptoms more than a minor inconvenience.

Urgency is another clue. A sudden, intense need to urinate, especially if it feels difficult to delay, suggests the bladder muscle has thickened from pushing against resistance over time. The bladder adapts to obstruction by becoming stronger and more forceful. That adaptation eventually produces the sensation of pressure and urgency. In advanced cases, incomplete emptying increases the risk of infection or acute retention.

Clinical evaluation can provide additional clarity. A post-void residual test measures how much urine remains in the bladder after urination. If a significant amount is left behind, it indicates that the obstruction is affecting emptying efficiency. This measurement offers more insight than prostate size alone because it reflects how the urinary system is performing as a whole.

The decision to intervene should rest on the quality of life and objective function. A large prostate without symptoms does not require aggressive action. A moderate enlargement that disrupts sleep, causes repeated infections, or leads to retention deserves structured management. Function guides treatment. Numbers and measurements support the decision, but they do not replace it.

04:18 – Be Patient With Your State

Prostate enlargement develops gradually over the years. It reflects aging tissue, hormonal shifts, and cumulative inflammatory exposure. Because it evolves slowly, improvement also tends to occur slowly. This is where many men make a mistake. Symptoms begin to interfere with comfort, and the instinct is to fix the problem quickly. Rushing toward an invasive solution without first allowing conservative strategies time to work often leads to regret.

The prostate does not shrink overnight. Supplements require months before a measurable change occurs. Prescription medications such as tadalafil, finasteride, or dutasteride alter physiology over time, not days. Even symptom improvement can be gradual as the bladder adjusts and inflammation settles. Expecting immediate transformation sets up frustration and unnecessary escalation.

Patience also applies to the interpretation of PSA levels. A larger prostate commonly produces a higher PSA because there is more glandular tissue generating the protein. That elevation does not automatically signal cancer or demand invasive investigation. Watching trends over time provides more meaningful information than reacting to a single reading.

There is also the emotional component. Urinary changes can feel unsettling because they affect privacy, sleep, and confidence. Anxiety can amplify symptoms, especially urgency and frequency. Calm, structured monitoring creates stability. Tracking how often you wake at night, how strong the stream feels, and whether emptying improves with therapy gives you real data.

Conservative care is not passive. It includes dietary adjustments, weight management, reducing evening fluid intake, supporting antioxidant status, and using medications appropriately. These strategies protect function while preserving sexual health and minimizing complications. Surgical procedures remain available if needed, but they should follow thoughtful progression rather than impatience.

06:08 – Prostate Gland and Inflammation Connection

Benign prostatic enlargement is not simply a matter of tissue growing larger with age. A major driver of symptom fluctuation is inflammation within the gland. The prostate is highly vascular and sensitive to systemic inflammatory signals. Even modest increases in inflammatory mediators can cause temporary swelling, increased vascular permeability, and tissue congestion. That swelling may be small in absolute size but significant in functional effect because the gland surrounds the urethra. A few millimeters of inward pressure can meaningfully alter urinary flow.

Inflammation may originate locally or systemically. Local triggers include bacterial prostatitis, pelvic floor tension, or urinary tract irritation. Systemic triggers include viral illness, metabolic stress, sleep deprivation, psychological stress, obesity, and oxidative burden. For example, long-haul air travel exposes the body to higher oxidative stress and circadian disruption. In a man with an already enlarged gland, that additional inflammatory load can precipitate acute urinary retention. The prostate does not enlarge permanently in that scenario; it becomes acutely inflamed and congested.

Free radicals and oxidative stress are central to this process. Reactive oxygen species increase inflammatory signaling pathways such as NF-kB activation, which in turn increases cytokine production. These cytokines promote vascular dilation and tissue edema. The prostate’s stromal and epithelial components respond to these signals by increasing fluid content and cellular activity. The result is tighter urethral compression and worsened symptoms.

This is why antioxidant support is often discussed. Vitamin C, for example, functions as a water-soluble antioxidant that neutralizes free radicals in circulation. At doses around 1,000 to 2,000 milligrams per day, it is generally well tolerated in healthy individuals and may blunt acute inflammatory surges. Dividing doses improves absorption and reduces gastrointestinal discomfort. The mechanism is not direct prostate shrinkage; it is the reduction of oxidative load that may otherwise worsen congestion.

Non-steroidal anti-inflammatory drugs such as ibuprofen reduce prostaglandin synthesis by inhibiting cyclooxygenase enzymes. Prostaglandins contribute to inflammatory swelling and pain signaling. Short-term, low-dose use in selected individuals may reduce acute inflammatory exacerbations of urinary symptoms. However, chronic use carries risks including gastrointestinal bleeding, renal impairment, and cardiovascular concerns. Any repeated or long-term strategy requires physician supervision.

Chronic low-grade inflammation is also associated with metabolic factors. Excess visceral fat produces inflammatory cytokines such as TNF-alpha and IL-6. Insulin resistance amplifies systemic inflammation and oxidative stress. These factors may contribute to progressive stromal proliferation within the prostate. Therefore, body composition, glycemic control, and physical activity indirectly influence prostate behavior. Weight reduction in overweight men has been associated with improvement in lower urinary tract symptoms, likely through reduced inflammatory signaling and improved hormonal balance.

It is important to distinguish inflammation from structural hyperplasia. Benign prostatic hyperplasia involves increased cellular proliferation in both glandular and stromal components. Inflammation can coexist with and worsen this process, but it is not identical to it. Anti-inflammatory strategies may reduce congestion and symptom severity without dramatically altering total gland volume. That distinction explains why some men experience significant symptomatic relief without measurable reduction in prostate size on imaging.

Infection represents another inflammatory pathway. Bacterial prostatitis can cause dramatic swelling, pain, fever, and obstructive symptoms. Even subclinical infections may contribute to chronic irritation. In such cases, targeted antibiotic therapy is required. Empirical or repeated antibiotic use without a clear indication is not advisable due to resistance and microbiome disruption. Proper evaluation with urinalysis, culture, and clinical assessment is necessary.

Systemic inflammatory states such as autoimmune disease, chronic stress, and poor sleep quality can also amplify urinary symptoms. Cortisol dysregulation affects immune signaling. Sleep fragmentation increases sympathetic tone, which can worsen urinary urgency. The bladder and prostate are influenced by autonomic nervous system balance, so inflammatory and neurohormonal factors intersect.

The connection between inflammation and prostate symptoms explains why symptom severity may fluctuate independently of gland size. A man may have stable imaging findings yet experience variable urinary flow based on inflammatory status. Monitoring patterns over time helps differentiate transient inflammatory exacerbation from progressive structural obstruction.

Managing inflammation, therefore, becomes part of functional management. This includes optimizing body weight, maintaining regular physical activity, moderating alcohol intake, ensuring adequate micronutrient status, supporting sleep quality, and addressing infections promptly. These measures do not replace procedural options in severe obstruction, but they influence day-to-day symptom control and long-term trajectory.

09:19 – Supplements That May Shrink the Prostate

Nutritional support plays a gradual role in managing prostate enlargement. These interventions do not act quickly, and expectations should be measured in months rather than weeks. The gland typically enlarges over many years, so any reduction in volume or symptom improvement develops slowly. Most supplement strategies aim to influence hormonal metabolism, inflammation, or oxidative stress rather than physically removing tissue.

Saw palmetto is one of the most widely used compounds. It is believed to reduce the conversion of testosterone to dihydrotestosterone, or DHT. DHT is one of the hormones associated with gradual prostate enlargement. Results across studies are mixed, yet some men report improvement in urinary flow and nighttime frequency. Benefits, if present, tend to appear after several months of consistent use.

Other compounds are often combined in multi-ingredient formulas. Pygeum africanum extract may reduce inflammation and improve urinary symptoms. Stinging nettle root has been studied for its potential effects on urinary flow and prostate tissue signaling. Beta-sitosterol has shown modest improvement in symptom scores in some trials. Zinc supports normal prostate function, although excessive intake should be avoided, and daily amounts generally should not exceed 30 milligrams unless supervised.

Lycopene, found in tomatoes, is another commonly discussed nutrient. Dark red tomatoes, especially plum varieties, contain higher concentrations. Several servings per week provide dietary lycopene along with other beneficial plant compounds.

12:17 – Medical Options That Avoid Surgery

Medication is often the next step when urinary symptoms remain bothersome despite lifestyle changes and supplements. These treatments aim either to relax the urinary pathway or to gradually reduce prostate size. They do not remove tissue, and they do not require anesthesia. Their effectiveness depends on symptom severity, prostate size, and individual response.

Tadalafil, commonly known for erectile support, is approved in a daily 5 milligram dose for urinary symptoms related to prostate enlargement. It works by relaxing smooth muscle in the prostate and bladder neck, which can improve urinary flow. Some men notice benefits within a few weeks. The same medication has also been associated in observational research with lower rates of cardiovascular events, though it is still a prescription drug and must be used under supervision.

Finasteride and dutasteride work differently. These medications reduce the conversion of testosterone to dihydrotestosterone. Over several months, this hormonal adjustment can shrink prostate volume. Studies show average reductions in size of about 20 to 25 percent after six to twelve months of consistent use. These agents are typically recommended for men with clearly enlarged glands rather than mild symptoms. Sexual side effects are reported in a minority of patients, though real-world experiences vary.

Tamsulosin belongs to a group called alpha blockers. It relaxes the muscle fibers around the urethra, allowing urine to pass more easily. It does not shrink the gland. Relief can occur within days. Side effects may include dizziness or changes in ejaculation.

Before choosing medication, assessment should include symptom scoring, post-void residual testing, and evaluation of prostate size. Medical therapy is often effective and may delay or eliminate the need for procedures when symptoms are moderate.

14:28 – HOLep: Holmium Laser Enucleation of the Prostate

Holmium Laser Enucleation of the Prostate, commonly called HOLep, is a surgical technique designed to remove obstructing prostate tissue through the urethra without making an external incision. It is typically recommended for men with significantly enlarged glands who have persistent urinary retention, repeated infections, or severe symptoms that have not improved with medication.

During the procedure, a laser is used to separate enlarged prostate tissue from the surrounding capsule. The removed tissue is pushed into the bladder and then broken into smaller pieces so it can be extracted. Because the laser cauterizes as it cuts, bleeding risk is generally lower than with older resection methods. Hospital stays are usually short, and catheter time is often brief.

HOLep has been studied for many years and is considered durable. Long-term follow-up shows low retreatment rates compared with several other minimally invasive techniques. It can be performed even in very large prostates, which is a major advantage.

However, retrograde ejaculation is common after the procedure. This means semen travels backward into the bladder instead of exiting normally. Erectile function is usually preserved, but ejaculation changes are frequent.

Operator experience is critical. Outcomes vary significantly depending on how often the surgeon performs the procedure. High-volume centers generally report better results and fewer complications.

17:27 – Comparing HOLep, REZUM, and UroLift

Choosing a procedure for urinary obstruction depends on prostate size, symptom severity, and personal priorities such as preserving ejaculation. Each option works in a different way, and each has strengths and limits.

HOLep removes obstructing tissue with a laser. It works well for small, moderate, and very large prostates. Long-term retreatment rates are low. Hospital stay may be overnight. Retrograde ejaculation is common. For men with severe obstruction or very large glands, it is often the most durable option.

REZUM uses controlled steam injections to damage excess prostate tissue. Over weeks, the body reabsorbs the treated tissue and the channel opens. It is usually done as an outpatient procedure with lighter anesthesia. Ejaculatory function is often preserved. Improvement is gradual and may take several weeks. It is generally better suited for small to moderate enlargement, and retreatment rates are higher than HOLep.

UroLift places small implants that pull prostate tissue away from the urethra. It avoids cutting or heating tissue and typically preserves sexual function. However, it leaves permanent material inside the body. Some men later require additional procedures, and long-term durability is still being evaluated.

22:23 – How to Maintain Prostate Function Naturally

Maintaining prostate function is less about chasing a specific prostate size and more about reducing the factors that irritate and inflame the gland. The prostate responds to systemic stress. Illness, metabolic dysfunction, poor sleep, excess body fat, and oxidative stress can all worsen urinary symptoms. Over time, these influences affect how well the bladder empties and how stable urinary flow feels.

Body composition plays a role. Higher visceral fat levels are associated with greater inflammation and hormonal shifts that can influence prostate growth. Bringing body fat into a healthy range supports better urinary function and overall metabolic stability. Nutrition also contributes. Regular intake of whole foods rich in antioxidants, including tomatoes for natural lycopene, supports tissue health. Zinc intake should remain moderate, generally not exceeding 30 mg per day unless medically supervised.

Hydration timing affects nighttime symptoms. Reducing fluid intake several hours before bed may reduce nocturia. Caffeine and alcohol can irritate the bladder and worsen urgency in susceptible men.

Inflammation control is central. Short-term use of vitamin C during periods of physical stress, such as travel or acute illness, may help blunt inflammatory spikes. Non-steroidal anti-inflammatory drugs, when used cautiously and under medical guidance, may temporarily ease symptom flares in select cases.

The monitoring function is practical and objective. Track how often urination occurs during the day and night. Note changes in stream strength, urgency, and sense of bladder emptying. These patterns provide more meaningful feedback than prostate size alone.

What to Do

• Track urinary frequency and nighttime awakenings for several weeks to identify patterns.
• Maintain body fat at a healthy level through diet and resistance training.
• Include natural lycopene sources such as dark red tomatoes several times per week.
• Limit evening fluids and reduce caffeine or alcohol if urgency is present.
• Consider physician-guided daily tadalafil if urinary flow and erectile function are both concerns.
• Reassess symptoms over a three to six-month period before considering procedural intervention.

23:10 – Desmopressin

Nighttime urination, also called nocturia, is not always caused only by prostate size. In many older men, the kidneys continue producing urine at night at levels similar to daytime production. This creates repeated awakenings even if the prostate obstruction is mild. In those cases, treating the prostate alone does not fully solve the problem.

Desmopressin, also known as DDAVP, is a synthetic version of antidiuretic hormone. This hormone signals the kidneys to reduce urine production. When taken at bedtime under medical supervision, it can decrease the volume of urine formed overnight. The result for some men is fewer awakenings and longer uninterrupted sleep cycles.

This medication does not shrink the prostate. It does not improve flow mechanics. Its role is specific. It reduces nighttime urine production. That distinction is important. If nocturia is driven mainly by high nighttime urine output rather than severe obstruction, desmopressin may provide relief.

Monitoring is necessary. Desmopressin can lower sodium levels in the blood. Sodium should be checked before starting and periodically afterward, especially in older adults. Proper patient selection and dosing are essential.

For men whose main complaint is waking three to five times nightly despite reasonable flow during the day, this medication can sometimes restore sleep quality without surgery. It is a targeted tool for a specific problem and should be used thoughtfully under physician guidance.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP31 – Do Men Really Die From Prostate Cancer? What the Data Actually Shows

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Kaltsas A, Giannakas T, Stavropoulos M, Kratiras Z, Chrisofos M. Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives. Diseases. 2025;13(2):53. Published 2025 Feb 11. doi:10.3390/diseases13020053

Lan TY, Chiang CH, Chen JW, Chang TT. Potential beneficial impacts of tadalafil on cardiovascular diseases. J Chin Med Assoc. 2025;88(4):267-272. doi:10.1097/JCMA.0000000000001205

Özkaptan O, Sevinç C, Çanakcı C, et al. Comparison of outcome for holmium laser enucleation prostate and Rezum system in benign prostate hyperplasia: a matched pair analysis. World J Urol. 2025;43(1):242. Published 2025 Apr 22. doi:10.1007/s00345-025-05644-y

Kim JH, Yang HJ, Kim SY, Song YS. Risk factors for hyponatremia associated with desmopressin use. Transl Androl Urol. 2024;13(6):923-929. doi:10.21037/tau-24-4

Zhou Z, Liu G, Ji J, Liu Y, Liao L. Association of Sarcopenic Obesity with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms: A Nationwide Cross-sectional Study. Eur Urol Open Sci. 2025;82:81-87. Published 2025 Oct 25. doi:10.1016/j.euros.2025.10.005

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: July 15, 2025

Episode Summary

• Brain fog is a slowdown in clarity, recall, and mental speed. It can happen at any age and is usually linked to how the brain is functioning, not permanent damage.
• The brain depends on hydration, proper nutrition, gut balance, sleep, and daily movement. Even small problems in these areas can reduce focus and sharpness.
• Hormone changes, especially shifts in testosterone and progesterone, can affect memory, confidence, and processing speed, even when routine lab results appear “normal.”
• Inflammation after infections, certain medications, alcohol, and metabolic strain are common contributors. Identifying and correcting these factors can restore clear and steady thinking.

Quick Decision Checklist

Before starting supplements, hormones, or advanced therapies, review the basics carefully:

• Am I sleeping at least seven hours with consistent bedtime and minimal nighttime interruptions?
• Am I well hydrated throughout the day, not just when I feel thirsty?
• Have I reviewed my medications for possible cognitive side effects?
• Is my diet supplying adequate protein, B vitamins, vitamin D, and omega-3 fatty acids?
• Have I recently recovered from an infection that may still be affecting inflammation levels?
• Am I physically active most days of the week?
• Have hormone levels been evaluated in context of symptoms, not just lab reference ranges?
• Has alcohol or cannabis use increased during this period of fogginess?

If several of these areas are off balance, correct them first. Many cases of brain fog improve once foundational factors are stabilized.

00:00 – Introduction

Brain fog is not dementia or a sign of stroke. And contrary to popular belief, it is not an indicator of permanent decline. It is that frustrating state where your thinking slows down, your words do not come as quickly, and your mental sharpness feels dulled.

Many people blame stress, aging, or a busy life. Those factors can contribute, but the brain is still an organ made of living cells. When those cells lack proper fuel, hydration, hormones, sleep, or recovery after illness, it falls short of optimal performance. Just like a muscle.

If your focus has weakened, your memory feels unreliable, or your confidence at work is slipping because your mind is not firing the way it used to, that deserves careful evaluation. Brain fog has causes, and most of them are correctable when approached in a structured, biological way.

01:05 – What Is Brain Fog?

Brain fog is a slowdown in cognitive performance without structural brain disease. It is not progressive dementia, and it is not mild cognitive impairment. It is a functional decline in clarity, speed, and mental sharpness.

People describe it as delayed recall, difficulty finding the right word, slower processing of numbers, reduced focus, and mental fatigue that appears earlier in the day than it should. Confidence in thinking often drops because the brain does not respond as quickly as before.

This state can occur at any age. It may follow stress, infection, medication use, sleep disruption, nutrient deficiency, or hormonal shifts. The key distinction is reversibility. Brain fog reflects impaired function, not irreversible damage. The task is to identify what is interfering with cellular performance and correct it methodically.

01:54 – How to Care for Your Brain

The brain is a living organ made of cells that require oxygen, water, nutrients, hormonal balance, and proper circulation. When any of these inputs fall short, cognitive performance declines. Brain fog often reflects basic physiologic strain rather than structural disease.

Hydration is foundational. Even mild dehydration can reduce attention span, increase irritability, and slow reaction time. The brain is highly sensitive to fluid balance because blood volume directly affects oxygen and nutrient delivery. A steady intake of water across the day supports stable function more effectively than large, infrequent amounts.

Movement is equally important. Physical activity increases cerebral blood flow, improves oxygen delivery, and stimulates the production of brain-derived neurotrophic factors that support neuronal resilience. Regular walking, especially outdoors with light exposure, helps regulate circadian rhythm and improves cognitive clarity. Light exposure influences melatonin and cortisol patterns, which directly affect alertness and sleep quality.

Nutrition must support mitochondrial activity. The brain consumes a significant portion of daily glucose and depends on micronutrients such as B vitamins for energy metabolism. Inadequate intake of B12, B6, folate, and vitamin C can impair neurotransmitter synthesis and reduce neuronal efficiency. Protein intake also supports neurotransmitter production, particularly dopamine and serotonin pathways involved in focus and mood stability.

The gut–brain connection plays a measurable role. Gastrointestinal inflammation or microbiome imbalance can influence neuroinflammation through immune signaling pathways. Chronic reliance on acid-suppressing medications, particularly proton pump inhibitors, may alter gut flora and reduce nutrient absorption, indirectly affecting cognition. In these cases, restoring nutritional balance and supporting the microbiome can improve clarity.

Medication review is critical. Certain drugs commonly used for blood pressure, mood, or gastric reflux may contribute to cognitive dullness. Evaluating necessity, dosage, and alternatives can remove hidden contributors to brain fog.

04:15 – Multivitamin Feeds the Brain

The brain depends on a steady nutrient supply to function well. B vitamins help convert food into usable energy and support communication between nerve cells. Low levels of B12, B6, folate, or niacin can slow processing speed, reduce focus, and increase mental fatigue. The change may be subtle, but over time it becomes noticeable.

Vitamin C supports antioxidant protection inside brain tissue, helping reduce cellular stress. Vitamin D influences mood regulation, immune balance, and cognitive performance. Suboptimal levels are often linked with reduced clarity and lower mental stamina.

A well-formulated multivitamin can help correct mild deficiencies, particularly in people with inconsistent diets, digestive issues, or long-term medication use. Formulation quality matters. Excess supplemental calcium is usually unnecessary, and copper balance should be considered carefully. Supplements support a solid diet. When nutrient gaps are corrected, mental sharpness often improves.

07:13 – Post-Infectious Inflammation and Recovery

A lot of people deal with brain fog after traumatic incidence or even an infection. It does not have to be severe. A bad flu, COVID, pneumonia, or even a strong sinus infection can leave behind lingering inflammation. The infection may be gone, but the immune response can remain active for weeks or months. That lingering inflammation can affect how brain cells communicate, which slows thinking and reduces mental sharpness.

This happens because infections trigger inflammatory chemicals called cytokines. These chemicals are useful during illness, but if they stay elevated, they can interfere with focus, memory speed, and mental stamina. Many people describe it as feeling “not quite themselves” long after recovery.

Supporting recovery means calming inflammation and restoring cellular energy. Nicotinamide riboside, a precursor to NAD, is often used for two to three months at doses around 300 to 500 milligrams daily. Omega-3 fatty acids, especially EPA and DHA, can also support brain cell membranes. Vitamin C adds antioxidant support.

10:55 – Hormones Cause Fogginess

Hormones play a direct role in how clearly the brain functions. They influence neurotransmitters, electrical signaling between neurons, blood flow, and even confidence in decision-making. When hormone levels decline or fluctuate outside an individual’s optimal range, cognitive speed and mental sharpness can drop.

Testosterone is especially important for both men and women. It supports neuronal signaling and enhances the transmission of electrical impulses between brain cells. Lower levels are often associated with slower recall, reduced focus, lower motivation, and decreased mental stamina. Many people notice they can still think, but the speed and confidence are not the same.

In women, hormonal shifts can begin years before menopause. Subtle declines in testosterone may occur during the perimenopausal window and can contribute to irritability, reduced clarity, and mood instability. Progesterone fluctuations can also disturb sleep, which then compounds cognitive dullness. Standard blood tests may not always reflect how the brain is responding, because receptor sensitivity and tissue response vary from person to person.

In men, gradual testosterone decline over time can affect processing speed, assertiveness, and mental resilience. Chronic stress, excess body fat, poor sleep, and certain medications can accelerate this decline.

Evaluating hormones requires clinical judgment rather than relying on a single lab value. After hydration, nutrition, inflammation, and medication effects are addressed, a carefully monitored therapeutic trial may clarify whether hormonal insufficiency is contributing to cognitive slowdown.

13:48 – Causes of Inadequate Testosterone

Low testosterone does not appear out of nowhere. It usually reflects strain on the body over time. In men, levels naturally decline with age, but lifestyle factors can accelerate that process. Poor sleep, chronic stress, excess body fat, insulin resistance, heavy alcohol use, and lack of resistance training all suppress healthy production. The body senses stress and shifts resources toward survival rather than optimal hormone output.

Sleep disruption is one of the strongest contributors. Testosterone is largely produced during deep sleep. If sleep is fragmented or shortened night after night, hormone production falls. This alone can create mental dullness, reduced motivation, and slower cognitive processing.

In women, testosterone declines earlier than many expect. It often begins dropping in the late thirties or early forties, even before traditional menopause. This shift can affect mental sharpness, mood stability, and drive. Birth control pills, chronic stress, and certain medications may further suppress natural production.

Excess body fat also plays a role in both sexes. Fat tissue converts testosterone into estrogen through an enzyme called aromatase. As body fat increases, available testosterone decreases. Over time, this imbalance can contribute to fogginess, low energy, and reduced mental confidence.

Identifying the cause requires looking at sleep quality, stress load, metabolic health, medication use, and age-related changes together. Testosterone levels rarely decline in isolation. They respond to the overall state of the body.

16:05 – Sleep Is Important

Sleep is when the brain repairs itself. It is not just lying down and closing your eyes. While you are asleep, the brain clears out waste that builds up during the day. If you do not sleep long enough, that waste stays behind. Over time, this can make thinking slower and less clear.

Research shows that men who sleep less than five to six hours a night can see a drop in testosterone within one week. Lower testosterone can lead to poor focus, low motivation, and slower mental processing. In women, poor sleep can disturb progesterone levels, which may cause more night waking and daytime mental fatigue.

Sleep also controls cortisol, the body’s main stress hormone. High cortisol late at night makes it harder to stay asleep. When this pattern repeats, memory and concentration suffer.

Keeping a regular bedtime, reducing screen light before bed, limiting alcohol at night, and sleeping in a dark, cool room can improve brain clarity. Consistent, deep sleep supports memory, attention, and steady mental performance.

20:22 – Practice Physical Activities

The brain depends on movement. Physical activity increases blood flow to brain tissue, which improves oxygen delivery and nutrient supply. It also stimulates the release of brain-derived neurotrophic factor, often called BDNF. BDNF supports the growth and repair of brain cells and strengthens connections between them. Stronger connections improve memory, focus, and processing speed.

Studies show that even moderate walking for 20 to 30 minutes a day can improve executive function and reduce mental fatigue. Movement also improves insulin sensitivity. When blood sugar swings are reduced, the brain functions more steadily throughout the day. Regular activity lowers inflammation markers as well, which is important because chronic inflammation is linked to cognitive slowing.

Physical activity does not need to be intense. Consistency is more important than intensity. Walking, light resistance training, cycling, or swimming can all support mental clarity. Outdoor activity adds another benefit because sunlight helps regulate circadian rhythm and vitamin D production, both of which influence brain performance.

What to Do

• Walk for at least 20 to 30 minutes daily, preferably outdoors.
• Include resistance training two to three times per week to support hormone balance.
• Break up long sitting periods with short movement every hour.
• Aim for steady, moderate activity rather than extreme workouts.
• Maintain consistency for at least eight to twelve weeks to assess cognitive improvement.

Continue the Conversation

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP57 – Colon Cancer Under 50: Putting the James Van Der Beek Headlines into Perspective

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Buskbjerg CR, Gravholt CH, Dalby HR, Amidi A, Zachariae R. Testosterone Supplementation and Cognitive Functioning in Men-A Systematic Review and Meta-Analysis. J Endocr Soc. 2019;3(8):1465-1484. Published 2019 Jun 6. doi:10.1210/js.2019-00119

Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner's Guide. Neurochem Res. 2015;40(12):2583-2599. doi:10.1007/s11064-015-1581-6

Khan Z, Mehan S, Saifi MA, Gupta GD, Narula AS, Kalfin R. Proton Pump Inhibitors and Cognitive Health: Review on Unraveling the Dementia Connection and Co-morbid Risks. Curr Alzheimer Res. 2024;20(11):739-757. doi:10.2174/0115672050289946240223050737

Rico-González M, González-Devesa D, Gómez-Carmona CD, Moreno-Villanueva A. Exercise as Modulator of Brain-Derived Neurotrophic Factor (BDNF) in Children: A Systematic Review of Randomized Controlled Trials. Life (Basel). 2025;15(7):1147. Published 2025 Jul 21. doi:10.3390/life15071147

Zhao K, Zhang Y, Yang S, et al. Neuroinflammation and stress-induced pathophysiology in major depressive disorder: mechanisms and therapeutic implications. Front Cell Neurosci. 2025;19:1538026. Published 2025 Apr 23. doi:10.3389/fncel.2025.1538026

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: July 22, 2025

Episode Summary

• Prostate biopsy samples less than 1 percent of the gland and provides a graded estimate of cellular appearance, not a guaranteed prediction of how the disease will behave over time. MRI and structured monitoring offer additional data without immediate tissue disruption.
• Long-term studies such as the PIVOT trial show that for many men with localized, low-risk prostate cancer, surgery does not significantly improve prostate cancer–specific survival compared with observation. Treatment decisions should be matched to risk category rather than fear of the label.
• The Gleason score reflects microscopic architecture and carries inter-observer variability. A higher score increases statistical risk, yet individual outcomes still vary widely and require interpretation alongside PSA trends and imaging findings.
• Rushing into irreversible treatment can permanently affect urinary, sexual, and overall functional health. Sequential monitoring, second opinions, and careful review of personal priorities provide a more balanced path forward.

Quick Decision Checklist

Before agreeing to a biopsy or moving toward treatment, review these points carefully and make sure each one has a clear answer:

• Have you asked how much of the prostate the biopsy will actually sample and how that affects certainty of the result?
• Have you reviewed your PSA pattern over time instead of reacting to a single number?
• Have you had a high-quality prostate MRI, and has someone explained the PIRADS score in plain language?
• If cancer is found, have you clarified how your specific Gleason score changes long-term survival based on published data?
• Have you asked how treatment could affect urinary control, sexual function, and daily quality of life?
• Have you considered getting the pathology reviewed by a second, independent pathologist?
• Have you decided in advance what you would do with a positive result versus a negative one?
• Have you given yourself time to reflect instead of making a decision during the first consultation?

00:00 – Introduction

Prostate biopsy is commonly recommended after a rise in PSA or a concerning imaging finding, and it is often described as the clearest way to confirm whether cancer cells are present. Many men are told that once tissue is examined under a microscope, uncertainty will disappear and the next step will be obvious. In reality, the situation is more layered than it first appears.

A biopsy samples only a small fraction of the prostate, and the result is interpreted through a grading system that estimates how abnormal the cells look, not how they will behave over time. Even with a definitive report, uncertainty about progression and long-term outcome remains. Once a diagnosis is documented, however, the pace of decision-making often accelerates.

Here, we examine what a biopsy truly provides, where its limitations lie, and how to approach the result with careful thought before committing to interventions that cannot be reversed.

00:50 – Risks of Cancer Spreading from the Biopsy

A prostate biopsy involves inserting multiple needles through the rectal wall or perineum into the prostate gland to extract tissue samples. Each needle pass disrupts tissue architecture, causes bleeding, and creates microscopic channels within the gland. From a biological standpoint, any time a tumor is penetrated, cells can be dislodged. The key question is not whether cells can enter circulation, but whether that event translates into clinically meaningful spread.

Research has shown that prostate cellular material can be detected in the bloodstream shortly after biopsy in some men. A 2014 Swedish study identified circulating prostate cells following the procedure, sometimes measurable up to 30 minutes later. This finding does not automatically translate into metastasis, but it confirms that tissue disruption can mobilize cellular fragments. For metastasis to occur, those cells must survive immune defenses, attach to distant tissue, and develop their own blood supply. Most circulating cells fail to complete that sequence.

Prostate cancer biology further complicates interpretation. Many prostate tumors are multifocal and dispersed rather than contained within a single capsule-like structure. Biopsy needles pass through multiple tissue planes, potentially intersecting benign and malignant areas. The procedure samples less than one percent of the total gland volume, meaning it is both disruptive and incomplete.

The realistic framing is this: biopsy does introduce biological disturbance, and circulating cells have been documented. Whether that disturbance meaningfully changes long-term outcomes remains debated. That uncertainty should be part of informed decision-making rather than dismissed outright.

02:20 – MRI vs. Biopsy for Detection

Systematic prostate biopsy has been used for decades and typically removes 10 to 12 core samples from different parts of the gland. Even with that approach, those cores represent less than 1 percent of total prostate volume. That limitation alone explains why false negatives occur. Cancer can be present in unsampled areas, particularly because prostate tumors are often multifocal and scattered rather than forming one clean mass.

Multiparametric MRI has changed the diagnostic landscape. The PROMIS trial, published in The Lancet in 2017, studied 576 men with elevated PSA. MRI demonstrated 93 percent sensitivity for clinically significant prostate cancer, compared with 48 percent for standard transrectal biopsy. That difference is substantial.

The PRECISION trial, published in The New England Journal of Medicine in 2018, showed that MRI-guided pathways detected more clinically significant cancers, 38 percent versus 26 percent with standard biopsy, while also reducing detection of low-risk disease, 9 percent versus 22 percent.

MRI does not eliminate uncertainty, but it evaluates the entire gland without puncturing it and allows more selective decision-making before invasive sampling is considered.

05:28 – Psychological Impact of Cancer Labeling

The moment the word “cancer” appears on a pathology report, perception shifts. Even when the finding is a Gleason 6 lesion with a low statistical risk of progression, the emotional response can be immediate and intense. Many men describe a sudden increase in worry, difficulty sleeping, and heightened awareness of normal bodily sensations. Thoughts begin to circle around worst-case scenarios, even when the medical data suggest a slow-moving condition.

Clinical research supports this response. Studies published in the Journal of Clinical Oncology report that men placed on active surveillance for low-risk prostate cancer experience measurable anxiety, particularly during the first year after diagnosis. Depending on the cohort studied, between 15 and 30 percent report significant psychological distress. This occurs even when physicians explain that ten-year prostate cancer–specific survival rates for low-grade disease exceed 95 percent.

Long-term outcome data add perspective. The PIVOT trial in The New England Journal of Medicine followed men for nearly two decades and found no significant difference in prostate cancer mortality between surgery and observation for many with localized disease. Despite these findings, many men proceeded to surgery shortly after diagnosis. The label itself carried weight that statistics struggled to counterbalance.

A Gleason score reflects how cells look under magnification. It estimates relative risk; it does not map out an exact future. Once a diagnosis is attached, momentum can build quickly toward treatment. Recognizing the psychological force of that label is essential before making decisions that permanently affect urinary, sexual, and overall quality of life.

06:00 – PIVOT Study: Surgery vs. Watchful Waiting

In 2012, The New England Journal of Medicine published results from the Prostate Cancer Intervention Versus Observation Trial, widely known as the PIVOT study. The trial enrolled 731 men with localized prostate cancer across multiple Veterans Affairs centers in the United States. Participants were randomly assigned either to radical prostatectomy or to observation, which meant monitoring without immediate surgery. They were then followed for up to 20 years.

The findings were sobering. After nearly two decades of follow-up, overall mortality was similar in both groups. Roughly 61 percent of men in the surgery group had died from any cause, compared with about 67 percent in the observation group. When researchers looked specifically at deaths from prostate cancer, the difference was small and not statistically significant for men with low-risk disease. In other words, removing the prostate did not clearly improve long-term survival for many men whose cancer was detected early.

Subgroup analysis showed that men with higher PSA levels or higher-risk features might derive some benefit from surgery. However, for low-risk disease, especially Gleason 6 cancers, the survival curves overlapped. At the same time, surgery carried well-documented consequences. Rates of erectile dysfunction after radical prostatectomy have been reported between 40 and 70 percent, depending on age and technique. Urinary leakage requiring pads persists in a smaller but meaningful percentage of men.

The study does not argue that surgery has no place. It does show that early removal of the gland does not guarantee longer life for a large portion of men with localized disease. That reality should temper the urgency that often follows a biopsy result. Decisions deserve careful review of risk category, age, other medical conditions, and personal priorities rather than reflex movement toward intervention.

07:10 – Understanding the Gleason Score

The Gleason scoring system was introduced in the 1960s by Dr. Donald Gleason as a way to classify prostate cancer cells based on how they look under a microscope. Pathologists examine the architectural pattern of the cells and assign two grades, each ranging from 3 to 5, representing the most common and the second most common patterns seen in the tissue. These two numbers are then added together to produce a total score between 6 and 10.

A Gleason score of 6, written as 3+3, represents cells that still resemble normal prostate tissue in structure, even though they are classified as malignant. Scores of 7, such as 3+4 or 4+3, indicate a higher degree of disorganization. Scores of 8 to 10 reflect markedly abnormal architecture and are associated with a higher statistical risk of progression. The distinction between 3+4 and 4+3 is clinically important because the dominant pattern influences estimated risk.

It is essential to understand that the Gleason score reflects cellular appearance, not behavior over time. Two men with identical scores can experience very different clinical courses. Studies have shown that men with Gleason 6 disease have prostate cancer–specific survival rates exceeding 95 percent at 10 to 15 years, particularly when the disease is confined to the gland. Even among higher scores, progression varies widely based on PSA level, tumor volume, age, and overall health.

Inter-observer variability also plays a role. Research has demonstrated that when biopsy slides are reviewed by different pathologists, Gleason grading can shift, especially between adjacent categories such as 6 and 7. That variability does not mean the system lacks value, but it does reinforce that the score represents an informed interpretation rather than an absolute measurement.

The Gleason score provides a framework for risk stratification. It does not function as a prediction of personal destiny. Interpreting it responsibly requires combining the number with imaging findings, PSA trends, clinical staging, and individual context before moving toward any permanent treatment decision.

09:23 – Uncertainty in Cancer Progression

Cancer behavior is defined by change over time, not by a single snapshot. A biopsy provides one data point collected on one day from a small portion of tissue. That information may describe how certain cells look under a microscope, but it does not demonstrate how those cells will behave months or years later. Progression requires comparison. Without a second and third measurement, there is no trajectory.

Large autopsy studies have shown that a significant percentage of men over the age of 70 harbor microscopic prostate cancer that never caused symptoms during life. Some reports estimate this silent presence in 60 to 70 percent of older men. These findings support the reality that cellular abnormality and clinical disease are not always the same thing. The presence of cancer cells does not automatically translate into harm.

Long-term observational trials reinforce this uncertainty. In addition to the PIVOT trial, other active surveillance cohorts have followed men for more than a decade with low to intermediate-risk disease. Many of these men did not progress to metastatic cancer, and prostate cancer–specific mortality remained low. The variation in outcomes demonstrates that biological potential differs from person to person, even within the same Gleason category.

Imaging and biomarkers allow repeated assessment without repeated tissue injury. PSA trends measured every three to six months can reveal velocity and doubling time. Multiparametric MRI assigns a PI-RADS score from 1 to 5, offering a structured way to observe anatomical changes. A rising PSA combined with an increasing PI-RADS score carries different implications than a stable pattern over time.

Uncertainty cannot be eliminated. It can, however, be managed through sequential monitoring rather than immediate irreversible action. Time provides information that a single biopsy cannot.

12:20 – Vitality Over Withering: The Goal of Care

Every treatment decision in prostate cancer carries a trade-off between risk reduction and quality of life. Radical prostatectomy and radiation therapy aim to control or eliminate disease within the gland, yet both carry measurable consequences. Long-term data show that erectile dysfunction develops in a substantial percentage of men after surgery, often ranging between 40 and 70 percent depending on age and nerve preservation. Persistent urinary incontinence, though less common, remains a life-altering complication for a subset of patients. Radiation therapy carries its own profile, including bowel irritation, urinary urgency, and delayed sexual dysfunction that may evolve gradually over years.

When survival outcomes are similar for certain low-risk categories, preserving vitality becomes central. Vitality refers to physical function, sexual health, urinary control, mental clarity, and independence. Large observational cohorts of men on active surveillance demonstrate that many maintain stable disease for years without intervention, while retaining baseline function. In several surveillance registries, prostate cancer–specific survival exceeds 95 percent at 10 to 15 years for carefully selected low-risk patients.

This does not suggest ignoring aggressive disease. Higher Gleason scores, rapid PSA doubling time, and radiologic progression may justify intervention. The key distinction lies in matching intensity of treatment with documented biological behavior. Treatment can be escalated later if progression becomes evident. Function, once lost through surgery or radiation, cannot be fully restored.

The long view of care places sustained quality of life at the center of decision-making. Survival statistics matter, but so does the condition in which those years are lived.

14:00 – Why Rushing Into Treatment Can Harm

A prostate cancer diagnosis often creates pressure to act quickly. The emotional weight of the word alone can make delay feel dangerous. In most cases of localized prostate cancer, especially low- to intermediate-risk disease, there is time to think. Prostate cancer typically grows slowly. PSA doubling time is often measured in years, not weeks. Large surveillance registries have shown that many men remain stable for long periods before any escalation becomes necessary. Immediate intervention is rarely an emergency in early-stage disease.

Surgery and radiation are permanent interventions. Once the prostate is removed, it cannot be restored. Once radiation is delivered, tissue changes are irreversible. Complications such as erectile dysfunction, urinary leakage, and bowel irritation may persist long term. These risks should be weighed against the measurable survival benefit in a specific risk category, not against fear alone.

What to Consider

• Your exact Gleason score, PSA level, and clinical stage, not just the word “cancer.”
• Whether imaging findings show progression over time or a stable pattern.
• Your PSA doubling time and overall health status.
• Published survival data for your specific risk category.
• The functional risks of surgery or radiation in men of your age group.
• The possibility of active surveillance with structured monitoring.
• A second pathology review if a biopsy has already been performed.
• Consultation with more than one specialist before committing to treatment.

Taking time to review these elements does not increase danger in most localized cases. It increases clarity. Decisions grounded in data and personal values tend to age better than decisions driven by urgency alone.

16:12 – Final Thoughts: Reflect, Research, Partner Up

Uncertainty is part of prostate cancer care, whether a biopsy is performed or not. Tissue sampling does not remove uncertainty. Surgery does not eliminate it either. Long-term follow-up studies have shown that recurrence can occur even after prostate removal, and men managed conservatively can live just as long in selected risk categories. That reality calls for reflection rather than reflex.

Reflection means understanding your numbers, your pathology report, and your imaging results in context. Research means reading beyond headlines and reviewing long-term outcome data, not short-term PSA responses. Partnering up means building a team that includes a primary care physician and, when appropriate, a urologist or oncologist who is willing to discuss options without urgency.

The prostate cannot be restored once removed, and radiation changes tissue permanently. Decisions should follow careful evaluation of risk, personal priorities, and measurable data. Slow, structured thinking protects both longevity and quality of life far better than speed driven by fear.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP46 - One Habit That Cuts Prostate Cancer Death Risk by 61%

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

C, Jacklin et al. "More men die with prostate cancer than because of it" - an old adage that still holds true in the 21st century.” Cancer treatment and research communications vol. 26 (2021): 100225. doi:10.1016/j.ctarc.2020.100225

Hamdy, Freddie C et al. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.” The New England Journal of Medicine vol. 388,17 (2023): 1547-1558. doi:10.1056/NEJMoa2214122

Kishan, Amar U, and Patrick A Kupelian. “Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects.” Brachytherapy vol. 14,2 (2015): 148-59. doi:10.1016/j.brachy.2014.11.005

Ladjevardi, Sam et al. “Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material.” Disease Markers vol. 2014 (2014): 707529. doi:10.1155/2014/707529

Nead, Kevin T et al. “Association Between Androgen Deprivation Therapy and Risk of Dementia.” JAMA oncology vol. 3,1 (2017): 49-55. doi:10.1001/jamaoncol.2016.3662

Sennerstam, Roland B et al. “Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.” Cancer cytopathology vol. 125,10 (2017): 748-756. doi:10.1002/cncy.21909

Wilt, T J, and M K Brawer. “The Prostate Cancer Intervention Versus Observation Trial (PIVOT).” Oncology (Williston Park, N.Y.) vol. 11,8 (1997): 1133-9; discussion 1139-40, 1143.

Wilt, Timothy J et al. “Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.” The New England Journal of Medicine vol. 377,2 (2017): 132-142. doi:10.1056/NEJMoa1615869

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: July 29, 2025

Episode Summary

• Cancer cannot be eliminated by fasting or cutting out sugar. The body regulates blood glucose internally, and extreme restriction often increases physiological stress rather than improving outcomes.
• Percent body fat has a clear relationship with cancer risk, hormone balance, and immune function. Gradual fat reduction through structured meal timing and portion control supports metabolic stability.
• Protein distribution across three to four measured meals per day helps preserve muscle mass while reducing fat. Oversized portions, especially in restaurants, contribute to excess calorie intake even when the food is high quality.
• Certain foods such as tomatoes, cruciferous vegetables, green tea, olive oil, and fatty fish provide supportive compounds for prostate health, yet long-term consistency and portion awareness remain the dominant drivers of metabolic improvement.

Quick Decision Checklist

Before changing your eating pattern in response to a cancer diagnosis or fear of cancer progression, review these points carefully:

• Have you focused on reducing excess body fat through consistent meal timing and controlled portions rather than extreme restriction?
• Are you eating protein in measured amounts, around 25 to 35 grams per meal, spaced across three to four feedings per day to protect muscle mass?
• Have you eliminated oversized restaurant portions and habitual snacking outside predetermined meal times?
• Are you adding supportive foods such as tomatoes, cruciferous vegetables, green tea, olive oil, and fatty fish into a sustainable weekly routine?
• Are your dietary changes realistic enough to maintain for years without creating stress, misery, or social isolation?
• Are you avoiding crash diets, prolonged fasting experiments, and food fear that may elevate stress hormones and disrupt sleep?

If most of these answers are aligned, your nutritional plan is structured for long-term metabolic stability rather than short-term intensity.

00:00 – Introduction

The idea of starving cancer through nutrition is appealing. If cancer cells use sugar, then cutting out sugar should weaken them. If certain foods fuel growth, then avoiding those foods should slow progression. That line of thinking sounds logical and gives a sense of control.

Biology is not that simple. The human body maintains blood glucose even during prolonged fasting because the brain depends on it. The liver can manufacture glucose from stored substrates, whether carbohydrates are eaten or not. Cancer cells adapt. They draw energy from multiple pathways, including amino acids and fats. Eliminating one nutrient does not deprive them of fuel.

The more important question is how nutrition shapes the internal environment. Body fat, metabolic stress, hormone balance, and immune resilience all influence cancer biology. Rather than focusing on extreme restriction, the real discussion centers on fat reduction, portion control, stress management, and sustainable eating patterns that support long-term health.

02:54 – Stress Is Cancer’s Elixir

Long-term stress changes how the body works. When a person feels stressed for weeks or months, the body releases higher amounts of stress hormones like cortisol and adrenaline. These hormones are helpful in short bursts, but when they stay elevated, they can disturb sleep, raise blood sugar, and strain the immune system. The immune system plays a key role in identifying and clearing abnormal cells, including early cancer cells. If it is constantly under pressure, it may not function at its best.

Stress also affects inflammation. The body uses inflammation as a defense tool, but when it becomes ongoing, it can create an internal environment that is less stable. Chronic inflammation has been linked in research to several diseases, including heart disease and cancer. This does not mean stress causes cancer directly, but it does influence the terrain in which cells live.

Severe dieting, rigid fasting, or constant fear about food can add another layer of stress. A steady, realistic eating pattern that supports stable blood sugar and good sleep is far more supportive of long-term health.

03:56 – Truths About Body Fat

Body fat plays a major role in cancer risk, including prostate cancer. Fat tissue is active. It produces hormones and inflammatory chemicals that influence the entire body. Higher levels of body fat are associated with increased levels of insulin and insulin-like growth factor 1, both of which can stimulate cell growth. Fat tissue also converts certain hormones into forms that may encourage tumor development.

Large population studies have shown a clear association between excess body fat and a higher risk of several cancers, including aggressive prostate cancer. Men with higher body mass index and greater waist circumference tend to have worse outcomes when prostate cancer is present. This relationship has been observed across multiple countries and long-term follow-up studies.

Body fat also affects inflammation. Adipose tissue releases cytokines that promote a low-grade inflammatory state. Over time, that environment influences immune regulation and metabolic balance. When insulin levels remain elevated due to excess body fat, cellular growth signals remain active more often than necessary.

Reducing excess body fat improves insulin sensitivity, lowers inflammatory markers, and stabilizes hormone patterns. The focus shifts away from starving cancer and toward improving the internal environment. Sustainable fat reduction supports overall health, including heart health and metabolic function, while also influencing cancer risk in a meaningful way.

05:00 – Two Principles to Shrink Fat

Shrinking body fat requires structure. Relying on hunger alone does not work well because hunger is influenced by many signals beyond true energy need. Stress, boredom, habit, and emotional cues can all feel like hunger. If eating is guided only by that sensation, portion size often increases over time.

The first principle is consistency in meal timing. Eating at regular, planned intervals helps prevent extreme hunger later in the day. When long gaps occur between meals, appetite hormones rise, and food choices tend to become less controlled. Research on appetite regulation shows that predictable eating patterns help stabilize blood sugar and reduce overeating episodes.

The second principle is portion control. Fullness is delayed. It can take around 20 to 30 minutes for the brain to register that enough food has been consumed. Large portions consumed quickly often exceed true metabolic need before satiety signals are felt. Studies on energy intake consistently show that larger portions lead to greater calorie consumption, even when people believe they are eating “normally.”

Shrinking fat does not require eliminating food groups. It requires planned meals and measured portions. A protein-focused meal, controlled in size, supports muscle while allowing fat stores to gradually decrease. Over time, this approach improves metabolic markers and supports a healthier internal environment.

05:58 – The Role of Ghrelin

Ghrelin is often called the “hunger hormone.” It is produced mainly in the stomach and sends signals to the brain that it is time to eat. Its levels rise before meals and fall after food reaches the stomach. This system works well when meals are spaced in a predictable rhythm. Problems begin when eating becomes irregular.

If someone skips meals during a busy day, ghrelin continues to rise. The brain may not fully register the signal at first because attention is focused elsewhere. Later, when activity slows down, the accumulated hunger can feel overwhelming. At that point, food choices are often driven by urgency rather than intention. Research shows that extreme hunger increases total calorie intake and reduces impulse control around food.

There is also a delay between eating and the brain receiving the message that enough food has been consumed. This delay can last about 20 to 30 minutes. If large amounts of food are eaten quickly, ghrelin remains elevated during that window, which can lead to overeating before satiety signals catch up.

07:30 – Losing Fat Is the Goal

Body weight and body fat are often treated as the same thing, yet they represent different biological realities. The scale measures total mass, which includes muscle, bone, water, and fat. Cancer risk, insulin resistance, and chronic inflammation are influenced primarily by excess body fat, especially visceral fat stored around the organs. Research consistently links higher body fat percentages with increased rates of prostate cancer progression, cardiovascular disease, and metabolic disorders.

Fat tissue is biologically active. It produces inflammatory chemicals called cytokines and alters hormone balance. In men, excess fat increases the conversion of testosterone into estrogen through an enzyme called aromatase. That hormonal shift affects immune function and metabolic stability. Fat tissue also influences insulin levels. Chronically elevated insulin promotes cellular growth signals, including pathways such as mTOR, which regulate cell proliferation. While these pathways are essential for normal repair and muscle growth, persistent overstimulation can create an environment that favors abnormal cell behavior.

Reducing fat mass improves several systems at once. Insulin sensitivity increases, inflammatory markers decline, and hormone balance becomes steadier. Studies show that modest reductions in body fat can lower C-reactive protein, a marker of inflammation, and improve lipid profiles. These changes support overall resilience rather than targeting a single disease in isolation.

Sustainable fat reduction depends on consistency. Regular meal timing helps stabilize hunger hormones such as ghrelin. Adequate protein intake preserves lean muscle mass during fat loss, which maintains metabolic rate. Portion control plays a central role because chronic excess intake, even of high-quality foods, raises inflammatory and metabolic load.

Muscle mass should be preserved during fat reduction. Muscle supports glucose control and metabolic flexibility. Resistance training and daily physical movement protect muscle tissue while encouraging fat utilization.

The objective is a lower body fat percentage while maintaining strength and energy. This approach supports immune balance, hormone stability, and long-term metabolic health.

11:08 – Living Life With Joy While Managing Risk

Chronic fear and constant restriction can wear down the same immune system you are trying to protect. The body responds to long-term emotional strain by raising stress hormones and disturbing sleep, appetite control, and blood sugar balance. Over time, that internal strain influences inflammation and immune surveillance. A person who feels trapped in rigid food rules may experience ongoing tension around every meal. That tension carries biological consequences.

Enjoyment, connection, and pleasure influence physiology as well. Positive social interaction improves parasympathetic nervous system activity, which supports digestion, hormone balance, and recovery. Laughter and meaningful relationships correlate with lower inflammatory markers in population studies. Moderate enjoyment of food or an occasional alcoholic drink, within reasonable limits, does not erase the benefits of a well-structured nutritional pattern. What drives metabolic risk is repeated excess, especially excess body fat, rather than a single celebratory meal.

The body thrives on rhythm and sustainability. If a dietary approach produces misery, resentment, or isolation, adherence usually declines and rebound behaviors follow. Long-term health depends on patterns that can be maintained without psychological strain.

What to Consider

• Is the eating pattern sustainable for years without constant frustration or social isolation?
• Does it support stable body fat reduction while preserving muscle and energy?
• Are meals structured in a way that prevents rebound overeating later in the day?
• Is alcohol intake moderate and consistent rather than saved up for large episodes?
• Does the plan allow social connection and enjoyment without guilt?
• Are stress levels improving as health habits improve?

13:00 – Foods Worth Eating

Certain foods consistently show supportive effects in prostate and metabolic health research. These foods do not act as cures, yet they contribute to a healthier internal environment when included regularly and in reasonable portions.

Tomatoes are one example. They contain lycopene, a carotenoid that has been studied for its association with lower rates of aggressive prostate cancer. Several observational studies suggest that men who consume tomato products regularly have a reduced risk of advanced prostate disease. Cooked tomatoes, such as those in sauces, may improve lycopene absorption because heat releases it from plant fibers.

Cruciferous vegetables, including broccoli, cauliflower, Brussels sprouts, and kale, contain compounds such as sulforaphane and indole-3-carbinol. These compounds support detoxification pathways in the liver and influence cellular signaling related to inflammation. Population studies have associated a higher intake of cruciferous vegetables with a lower risk of certain cancers.

Green tea contains catechins, particularly EGCG, which have antioxidant and anti-inflammatory properties. Some studies link regular green tea consumption with improved metabolic markers and potential protective effects in prostate health.

Olive oil provides monounsaturated fats and polyphenols that support cardiovascular health and reduce oxidative stress. Fatty fish such as salmon offer omega-3 fatty acids, which influence inflammatory balance and insulin sensitivity.

The common theme across these foods is nutrient density and moderation. Including them regularly within a structured eating pattern supports overall health while body fat is gradually reduced. The broader nutritional context matters more than any single ingredient.

16:45 – Eating Schedules vs. Eating When Hungry

Many people rely on hunger as the primary signal for eating. Hunger, however, is influenced by several factors beyond true energy need. It is shaped by hormones such as ghrelin, by sleep quality, by stress levels, and by habit. After long gaps without food, hunger hormones rise sharply. When that delayed signal finally becomes noticeable, it often feels urgent, which increases the likelihood of overeating.

Research on appetite regulation shows that irregular meal timing can lead to greater total calorie intake over the course of a day. When meals are skipped, blood sugar can fluctuate more widely, and the next eating episode tends to be larger and faster. Because it takes roughly 20 to 30 minutes for fullness signals to reach the brain, rapid eating during peak hunger often results in consuming more than the body requires.

A structured eating schedule reduces this volatility. Planned meals at consistent times help regulate hunger hormones and stabilize blood sugar. This approach does not require constant snacking, nor does it demand extreme restriction. It simply establishes predictable feeding windows, which makes portion control more manageable.

Consistency also protects lean muscle mass. When protein intake is spread across regular meals, muscle protein synthesis is better supported. Preserving muscle while reducing fat improves metabolic health and insulin sensitivity.

Eating by structure rather than by impulse encourages steadier energy, better portion awareness, and more controlled fat reduction. Over time, this rhythm becomes habitual, reducing reliance on fluctuating hunger cues.

17:58 – Nutritional Incrementalism

Long-term change rarely happens through sudden extremes. Sustainable nutrition tends to develop through gradual adjustments that can be maintained for years. This is the principle behind nutritional incrementalism. Instead of overhauling everything at once, small changes are introduced, stabilized, and then built upon.

Clinical experience in weight management consistently shows that aggressive crash diets lead to rapid weight loss followed by rebound gain. The body responds to severe calorie restriction by lowering metabolic rate and increasing hunger signals. When normal eating resumes, fat is regained quickly, often exceeding the starting point. This cycle creates frustration and metabolic instability.

A gradual strategy avoids that pattern. For example, one might begin by standardizing meal timing before altering portion size. Once meal timing feels consistent, protein distribution can be adjusted. After that, portion control can be refined. Each step is simple and measurable.

Portion awareness is central. Many restaurant meals contain double or triple the protein required in a single sitting. A four-ounce portion of meat provides roughly 28 to 30 grams of protein, which is sufficient for most adults per meal. Reducing oversized portions alone can meaningfully decrease total daily calorie load without eliminating food categories.

This approach also protects muscle mass. Adequate protein at regular intervals supports muscle maintenance while fat is gradually reduced. Body composition improves, which is a stronger predictor of metabolic health than scale weight alone.

20:21 – Protein Portioning

Protein plays a central role in preserving muscle mass while body fat is reduced. Muscle tissue supports metabolic health, improves insulin sensitivity, and increases daily energy expenditure. When calorie intake is reduced without adequate protein, the body may lose both fat and muscle. Loss of muscle slows metabolism and makes long-term fat reduction more difficult.

Research on muscle protein synthesis suggests that most adults stimulate optimal muscle repair with approximately 25 to 35 grams of protein per meal. For many people, that amount corresponds to about four ounces of meat, poultry, or fish. Larger portions do not proportionally increase muscle-building response because the body has a threshold for effective utilization at each feeding.

Spacing protein across multiple meals supports steadier muscle maintenance. Three to four protein-centered meals per day tend to produce better preservation of lean mass than concentrating intake in a single large meal. This distribution also stabilizes blood sugar and reduces large hunger swings.

Portion awareness remains critical. Restaurant servings often exceed eight or twelve ounces of meat, which doubles or triples the typical physiological need for one sitting. Consistently oversized portions increase total calorie intake and can contribute to fat accumulation even when the food source is high quality.

Protein portioning works best within a structured eating pattern. Each meal includes a measured amount of protein, moderate healthy fats, and controlled carbohydrates. Over time, this pattern supports gradual fat reduction while maintaining strength and metabolic stability.

Key Takeaway

Cancer cannot be starved by eliminating a single food or by following extreme dietary rules. The body maintains blood sugar even during fasting, and cancer cells adapt to available fuel. Sustainable progress comes from improving the internal environment in which the body functions every day.

Percent body fat strongly influences cancer risk, hormone balance, and immune performance. Gradual fat reduction through consistent feeding times, controlled portions, and adequate protein supports metabolic health without creating stress. Severe restriction, crash dieting, and food fear often raise stress hormones and disrupt sleep, which can weaken immune regulation.

Food quality still plays a role. Tomatoes, cruciferous vegetables, green tea, olive oil, and fatty fish provide compounds linked to prostate health. Portion control remains central, since excessive volume increases inflammatory signaling and metabolic strain.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP37 – The Truth About Prostate Supplements: My A–C Grades on What Really Works

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested Reading

To encourage deeper review, referenced studies examine long-term outcomes of observation compared with intervention. These data explore survival patterns, treatment complications, and the biological impact of biopsy and hormone suppression. Reviewing this literature supports a more individualized approach to prostate health.

Jacquet P, Stéphanou A. Beyond the Warburg Effect: Modeling the Dynamic and Context-Dependent Nature of Tumor Metabolism. Cancers (Basel). 2025;17(21):3563. Published 2025 Nov 3. doi:10.3390/cancers17213563

Saha A, Hamilton-Reeves J, DiGiovanni J. White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions. Cancer Metastasis Rev. 2022;41(3):649-671. doi:10.1007/s10555-022-10056-0

Feijó M, Fonseca LRS, Kiss-Toth E, Socorro S, Correia S. Obesogens in Prostate Cancer: An Endocrine and Metabolic Threat. Curr Obes Rep. 2026;15(1):14. Published 2026 Feb 25. doi:10.1007/s13679-026-00690-y

Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S. doi:10.3945/ajcn.114.084038

Talukdar J, Megha, Choudhary H, et al. The Interplay of Chronic Stress and Cancer: Pathophysiology and Implications for Integrated Care. Cancer Rep (Hoboken). 2025;8(5):e70143. doi:10.1002/cnr2.70143

Yin S, Xu X, Li Y, Fang H, Ren J. Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review). Oncol Lett. 2025;30(4):462. Published 2025 Jul 28. doi:10.3892/ol.2025.15208

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: August 12, 2025

Episode Summary

• Sexual vitality after forty is influenced by circulation, hormone balance, stress levels, and relationship dynamics, not by age alone. Changes in erection quality or libido often reflect modifiable health factors rather than irreversible decline.
• PDE-5 inhibitors such as tadalafil and sildenafil improve blood flow and can be safely integrated into care when medically supervised, while testosterone therapy and peptide treatments may be considered in selected cases based on symptoms and clinical judgment.
• Performance anxiety and poor communication can interfere with erection quality even when physiology is adequate. Open conversations outside the bedroom reduce pressure and improve satisfaction for both partners.
• Maintaining vitality requires consistent attention to cardiovascular health, resistance training, sleep, body composition, and emotional connection. Sexual health after forty evolves, yet it remains responsive to thoughtful, proactive care.

Quick Decision Checklist

Before starting medication, hormone therapy, or advanced treatments, review these points carefully:

• Are your symptoms consistent and affecting daily life, or are they occasional fluctuations that may respond to stress reduction and lifestyle changes?
• Have you evaluated cardiovascular health, sleep quality, body composition, and exercise habits, since these directly influence erectile function and testosterone levels?
• Were testosterone levels measured properly, including morning testing and repeat confirmation if low?
• Have you discussed expectations and concerns openly with your partner outside of intimate moments to reduce performance pressure?
• If considering PDE-5 inhibitors, have you reviewed heart medications and blood pressure status with your clinician?
• If exploring testosterone or peptide therapy, are you working with a knowledgeable physician who can monitor PSA, hematocrit, and overall safety markers?

Clear decisions begin with full information. Review the fundamentals before adding new interventions.

00:00 – Introduction

As some men enter their forties, their sexual performance begins to decline. If they hold on to traditional beliefs about aging, they may accept it as just another unavoidable change that comes with getting older. Over time, they may notice that intimacy feels different, that erections are less reliable than they once were, and that the quiet confidence they carried in their younger years does not feel as steady.

At the same stage of life, routine medical visits begin to place greater emphasis on prostate health and hormone balance. Blood work is reviewed with closer attention, and conversations about PSA and testosterone become part of the broader picture. When these discussions unfold alongside changes in sexual function, it can create the impression that vitality is fading in a single direction.

That conclusion deserves a deeper look. Sexual health after forty is influenced by circulation, hormones, metabolic stability, psychological well-being, and communication within a relationship. Even in the presence of prostate concerns, there are practical ways to preserve libido, performance, and intimacy with clarity and intention.

02:56 – Testosterone Levels and Overall Health

Testosterone plays a broader role in male health than many realize. It supports libido, erectile quality, muscle mass, bone density, mood stability, and metabolic function. As levels decline with age, men may experience reduced sexual desire, slower recovery from exercise, increased body fat, lower motivation, and diminished confidence. These changes are gradual, which makes them easy to normalize.

Research has shown that men with lower testosterone levels often have higher rates of metabolic syndrome, type 2 diabetes, and cardiovascular disease. There is also data suggesting that men with low testosterone may have a higher incidence of more aggressive prostate cancer. This does not mean that raising testosterone eliminates risk, but it challenges the long-held assumption that testosterone is inherently dangerous in the context of prostate health.

The relationship between testosterone and prostate cancer is complex. The idea that testosterone fuels cancer growth in a simple, linear way has been questioned in recent years. Some clinicians now work with carefully monitored testosterone therapy even in men with elevated PSA or stable prostate cancer, particularly when quality of life is significantly affected.

The decision to pursue testosterone therapy requires informed discussion and careful monitoring. It involves weighing symptom relief, sexual vitality, metabolic health, and prostate risk together rather than viewing them in isolation.

03:45 – The Role of PDE-5 Inhibitors

Phosphodiesterase type 5 inhibitors, commonly known as PDE-5 inhibitors, are medications developed to improve erectile function by enhancing blood flow to the penis. Drugs such as tadalafil and sildenafil work by relaxing smooth muscle in blood vessel walls, allowing increased circulation during sexual stimulation. They do not create desire, and they do not initiate arousal on their own. Their role is mechanical and vascular. They support the physical process that follows sexual interest.

Erectile function depends heavily on vascular health. The penile arteries are small, and even mild endothelial dysfunction can reduce blood flow enough to impair firmness. For that reason, erectile difficulty can serve as an early signal of broader cardiovascular strain. Studies have shown that men with erectile dysfunction often have a higher risk of future heart disease, which places erectile health within the larger context of vascular integrity.

Tadalafil has a longer half-life than sildenafil and can be taken daily in lower doses. Daily use has been associated with improved erectile reliability, better urinary flow in men with benign prostatic enlargement, and potential cardiovascular benefits through improved endothelial function. Sildenafil, typically taken on demand, acts more quickly but for a shorter duration. Some clinicians use both strategically, depending on the pattern of sexual activity and overall health profile.

These medications are generally safe when prescribed appropriately, though they must be avoided in men using nitrate medications for heart disease due to the risk of dangerous drops in blood pressure. Headache, facial flushing, and nasal congestion are common side effects, usually mild.

PDE-5 inhibitors address blood flow. They do not treat low testosterone, psychological performance anxiety, or relationship strain. For many men, they are part of a broader strategy that includes hormone evaluation, cardiovascular optimization, stress reduction, and open communication with a partner.

05:25 – Performance Anxiety and Self-Awareness

Erectile difficulty is not always a mechanical problem. Even when blood flow and hormone levels are adequate, the mind can interrupt the process. Sexual arousal depends on a delicate balance between the parasympathetic nervous system, which supports erection, and the sympathetic nervous system, which activates during stress. Anxiety activates the sympathetic response. When that system dominates, erection quality often declines.

Performance anxiety can begin subtly. A single episode of erectile inconsistency may create doubt. The next encounter carries a layer of self-monitoring. Instead of being present, attention shifts inward toward evaluation. That internal pressure increases adrenaline, which constricts blood vessels and works against erection. The result reinforces the fear, and a cycle forms.

This dynamic is common in midlife because expectations remain tied to earlier years. Many men measure performance against a younger version of themselves rather than adjusting to biological changes in responsiveness. Spontaneous arousal may become less frequent with age, while responsive arousal, which develops through touch and connection, remains strong. When this difference is misunderstood, it can be misinterpreted as decline.

Open communication plays a stabilizing role. Discussing preferences, concerns, and expectations outside the bedroom reduces pressure during intimacy. Studies in sexual medicine consistently show that couples who communicate directly about sexual needs report higher satisfaction and lower anxiety.

Addressing performance anxiety often requires shifting focus from outcome to experience. Erections are part of intimacy, yet they are not the sole measure of connection. When attention returns to pleasure, touch, and emotional closeness, physiological response often improves without force or urgency.

07:57 – Why Conversations About Intimacy Matter

Sexual health after forty is shaped by biology, but it is sustained by communication. Many men focus on erections, testosterone levels, or medications, yet overlook the simple fact that intimacy is shared. When changes begin to appear, silence often fills the space. A man may notice that erections take longer to develop or require more stimulation, but instead of discussing it, he carries the concern internally. That internal pressure increases stress hormones, which can interfere with arousal and make the situation worse.

Open conversation reduces that pressure. When partners speak honestly about what feels good, what feels different, and what feels uncertain, the nervous system settles. The body responds best in a relaxed state. Erection depends on the parasympathetic nervous system, which functions during calm and connection. Anxiety activates the opposing system, which redirects blood flow away from sexual organs. Clear communication helps maintain the relaxed state required for arousal.

Intimacy also changes in pattern with age. In younger years, desire often appears suddenly and intensely. As men mature, desire frequently becomes responsive. It builds through touch, closeness, and emotional connection rather than appearing without context. When couples understand this shift in pattern, they stop interpreting it as decline and begin treating it as evolution. Foreplay becomes central rather than optional.

Research in sexual medicine shows that couples who talk openly about sex report higher satisfaction and fewer performance concerns. Many women require clitoral stimulation to achieve orgasm, and penetration alone is often insufficient. When couples expand their approach to include manual stimulation, oral stimulation, or the use of devices, pressure around the erection decreases. The focus moves from performance to shared pleasure.

These conversations are usually best held outside the bedroom. A neutral setting allows both partners to speak without feeling evaluated. Sexual vitality after forty is maintained through teamwork, adaptability, and honesty. Medications and hormone therapy can support function, yet communication remains the foundation that allows those tools to work effectively.

11:00 – Practical Strategies to Maintain Vitality

Sexual vitality after forty requires attention to the body as a whole. Erections depend on blood flow, nerve function, hormone balance, and cardiovascular health. When circulation declines, erectile quality often follows. The same arteries that supply the heart also supply the penis, which means erectile difficulty can sometimes appear before overt heart symptoms. For that reason, maintaining vascular health is central to maintaining sexual function.

Regular resistance training supports testosterone levels and preserves muscle mass. Muscle tissue improves insulin sensitivity and metabolic stability, both of which influence hormone balance. Men who engage in strength training at least three times per week often maintain stronger baseline testosterone compared to sedentary peers. Cardiovascular exercise also improves endothelial function, which supports blood vessel dilation during arousal.

Sleep plays a measurable role in testosterone production. Most daily testosterone release occurs during deep sleep cycles. Chronic sleep restriction reduces total testosterone levels and increases cortisol, a stress hormone that interferes with libido and erectile reliability. Seven to eight hours of consistent sleep remains a foundational strategy.

Body composition matters. Higher body fat percentages correlate with lower testosterone and increased inflammation. Adipose tissue converts testosterone into estrogen through the enzyme aromatase. Reducing excess body fat can therefore improve hormonal balance without medication.

Alcohol intake should remain moderate. Excess consumption depresses central nervous system function and disrupts erection physiology. Smoking, including nicotine vaping, impairs vascular health and reduces nitric oxide availability, which is required for penile blood flow.

Stress management is equally important. Chronic psychological stress elevates sympathetic tone, which constricts blood vessels and suppresses sexual responsiveness. Mindfulness practices, structured relaxation, and direct communication with a partner reduce this effect.

Maintaining vitality after forty is not dependent on a single intervention. It is built through consistent lifestyle practices that support circulation, hormone balance, and emotional connection.

12:12 – Peptide Therapy Overview

As men explore ways to preserve libido and sexual responsiveness, some look beyond traditional medications. Peptide therapy has entered that conversation. Peptides are short chains of amino acids that act as signaling molecules in the body. They communicate with specific receptors and can influence processes such as hormone release, blood flow, and neural activation.

Two peptides discussed in clinical circles for sexual vitality are melanotan derivatives and PT-141, also known as bremelanotide. These compounds act centrally in the brain rather than directly on blood vessels. While PDE-5 inhibitors such as tadalafil and sildenafil improve blood flow to the penis, PT-141 works on the hypothalamus, the area involved in sexual desire and arousal signaling. This distinction matters because libido and erection are related but separate processes. A man can have adequate blood flow yet low desire, or strong desire with inconsistent erection quality.

PT-141 is typically administered by subcutaneous injection several hours before anticipated sexual activity. Some clinical observations suggest that its effects can last up to 24 hours. Reported side effects may include nausea, flushing, or temporary increases in blood pressure. Melanotan compounds may increase sexual responsiveness while also stimulating melanin production, which darkens skin pigmentation. Nausea is also a known side effect with higher doses.

These therapies require physician supervision. They are often compounded through regulated pharmacies and are not first-line treatments. Long-term data remains limited compared to established medications.

Peptides are considered adjunct tools rather than replacements for foundational strategies such as cardiovascular health, testosterone optimization, and open communication. For carefully selected individuals under medical guidance, they may provide additional support in maintaining sexual vitality.

15:14 – Reframing Male Aging and Vitality

Male aging is often framed as a steady decline in testosterone, libido, and performance. That narrative creates quiet resignation. The reality is more complex. While hormone levels may decrease gradually with age, many elements of sexual vitality remain responsive to health choices, medical support, and relationship dynamics.

Testosterone levels naturally fall at an average rate of about 1 percent per year after the age of 30. That does not mean every man will experience symptoms. Some men maintain strong libido and erectile function well into their seventies. Others experience fatigue, reduced desire, and slower recovery in their forties. Lab numbers provide context, yet symptoms determine whether intervention is appropriate.

Erections may take longer to develop compared to earlier decades. This reflects changes in vascular elasticity and nerve sensitivity rather than loss of masculinity. Sexual response becomes more intentional and less impulsive. When that change is understood, it feels manageable rather than alarming.

Longitudinal studies show that sexual satisfaction in long-term partnerships often improves with age because communication increases and expectations become realistic. Emotional connection becomes a stronger driver of intimacy than novelty or performance metrics.

Vitality after forty is therefore not defined by comparison to youth. It is defined by adaptability, self-awareness, and proactive care.

Things to Consider:

• Review cardiovascular health regularly, since erectile changes can reflect vascular status.
• Evaluate testosterone levels in the context of symptoms rather than numbers alone.
• Discuss sexual expectations openly with a partner outside of intimate moments.
• Use medications or adjunct therapies under medical supervision, especially when combining treatments.
• Maintain resistance training, sleep hygiene, and body composition as long-term foundations.
• Accept that evolution in sexual response is normal and can still support a satisfying intimate life.

Final Thoughts

Men’s vitality after forty is often reduced to numbers on a lab report or the reliability of an erection. That view is incomplete. Sexual health sits at the intersection of circulation, hormones, emotional connection, mental state, and lifestyle habits. When one area weakens, it influences the others. When several areas are supported together, function often improves in ways that surprise men who had assumed decline was inevitable.

PSA levels, testosterone readings, and imaging results provide useful information, yet they do not define identity or capacity for intimacy. A diagnosis, an elevated lab value, or a temporary performance issue does not require surrendering sexual vitality. Many men continue to maintain active, satisfying intimate lives while monitoring prostate health or addressing age-related changes.

The consistent theme across physiology and psychology is intentional care. Circulatory health, sleep, strength training, stress control, communication, and appropriate medical support all contribute to long-term function. Medications and advanced therapies can play a role, yet they work best when built on stable foundations.

Aging does not eliminate desire or connection. It changes how they are expressed. Men who remain engaged in their health, honest in their relationships, and proactive with medical guidance often find that vitality after forty is different from youth, yet still strong, purposeful, and deeply fulfilling.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP25 – Male Sexual Health Explained: Testosterone, Erections, and Long-Term Vitality

EP27 -Testosterone, Aging, and Vitality: What Medicine Isn’t Telling You

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Hackett GI. Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study. World J Mens Health. 2025;43(2):282-290. doi:10.5534/wjmh.240081

Haider, Ahmad et al. “Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.” The Journal of urology vol. 193,1 (2015): 80-6. doi:10.1016/j.juro.2014.06.071

Kaplan, Alan L et al. “Testosterone Therapy in Men With Prostate Cancer.” European urology vol. 69,5 (2016): 894-903. doi:10.1016/j.eururo.2015.12.005

Keren D, Goshen A, Strauss T and Springer S (2025) Study protocol: associations between hormonal profile and physical and cognitive functions in middle-aged men—a one-year cohort follow-up study. Front. Public Health 13:1654077. doi: 10.3389/fpubh.2025.1654077

Mohammad, Osama S et al. “Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.” Cancers vol. 9,12 166. 6 Dec. 2017, doi:10.3390/cancers9120166

Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177(4):471-479. doi:10.1001/jamainternmed.2016.9539

Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2008;101(1):5-10. doi:10.1111/j.1464-410X.2007.07138.x

Wilt, T J, and M K Brawer. “The Prostate Cancer Intervention Versus Observation Trial (PIVOT).” Oncology (Williston Park, N.Y.) vol. 11,8 (1997): 1133-9; discussion 1139-40, 1143.

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: August 15, 2025

Episode Summary

• Sexual function can change after prostate cancer treatment because surgery, radiation, and hormone therapies may affect nerves, blood flow, and hormonal balance. Recovery often takes time, and several medical strategies exist to help restore circulation, tissue health, and sexual responsiveness.
• Treatments such as tadalafil, vacuum therapy, injectable medications like Trimix or alprostadil, and compounds that support nitric oxide production can help maintain erectile tissue health and improve blood flow during the recovery process.
• Libido and overall sexual vitality can also be supported through therapies that act on the brain and hormonal pathways, while regenerative options such as shockwave therapy and advanced solutions like penile implants provide additional pathways for restoring function and confidence.

Quick Decision Checklist

Before choosing a treatment approach for sexual recovery after prostate cancer therapy, take a moment to review the following considerations carefully:

• Confirm the type of prostate cancer treatment you received and how it may affect nerves, blood vessels, and hormone levels. Recovery strategies often depend on whether the treatment involved surgery, radiation, or hormone suppression.
• Review current medications with your physician, especially drugs that can reduce libido or interfere with erectile function. Some antidepressants and other commonly prescribed medications can affect sexual performance.
• Evaluate circulation and vascular health. Erectile function depends heavily on blood flow, so conditions such as diabetes, high blood pressure, obesity, and smoking history should be addressed alongside sexual recovery strategies.
• Discuss early rehabilitation strategies such as PDE-5 inhibitors, vacuum devices, or nitric oxide–supporting supplements to maintain tissue health while the body heals.
• Consider whether additional therapies such as injectable medications, libido-support treatments, shockwave therapy, or penile implants are appropriate based on the level of recovery achieved so far.
• Work with clinicians who have specific experience in men’s sexual health and post-prostate cancer recovery, since treatment options often require specialized knowledge and careful monitoring.

00:00 – Introduction

Sexual function often changes after prostate cancer treatment, whether the treatment involved surgery, radiation, or another localized approach. Men may notice that erections feel different, desire feels lower, or sensation does not respond the way it once did. When these changes begin without explanation, they can feel confusing and difficult to process.

These changes have clear biological reasons. Cancer treatment can affect the nerves, blood vessels, and hormones that support sexual response. Even when treatment works as intended, the body often needs time and support to adjust. Without proper context, it is easy to assume that these changes are permanent.

Clarity changes how men respond. When the physical causes are understood, decisions about recovery feel calmer and more intentional. Sexual health becomes part of the healing process rather than something quietly set aside.

02:30 – Role of Tadalafil in Recovery

One of the earliest medical strategies used after prostate cancer treatment involves medications that improve blood flow to the penis. Tadalafil, commonly known by the brand name Cialis, belongs to a group of drugs called PDE-5 inhibitors. These medications support the circulation needed for erections, which is especially important after treatments that disturb the nerves and blood vessels surrounding the prostate.

When surgery removes the prostate gland, the nearby nerves that control erection may become irritated, stretched, or temporarily weakened. Radiation therapy can also affect blood vessels over time. In both situations, erections may become difficult because the normal signals between the brain, nerves, and penile tissue are disrupted. Medications like tadalafil help counter this problem by relaxing the blood vessels that supply the penis, allowing more blood to enter the erectile tissue.

Some clinicians introduce tadalafil before surgery and continue it afterward as part of what is often called penile rehabilitation. The idea is to maintain healthy circulation while the nerves recover. Even if a full erection does not occur immediately, increased blood flow keeps the erectile tissue oxygenated and active. This helps prevent long-term tissue damage that can develop when the penis remains inactive for extended periods.

Another important point is that PDE-5 inhibitors do not stimulate prostate cancer growth. Research and clinical experience show that these medications act on vascular pathways rather than cancer biology. For this reason, they are widely considered safe for men recovering from prostate procedures when used under medical supervision.

Recovery of erectile function can take months or even longer, depending on age, nerve preservation, and overall health. During this time, medications like tadalafil can serve as an early foundation for restoring circulation and maintaining tissue health while the body heals.

04:08 – Preserving Penile Tissue Health

After prostate surgery or radiation therapy, the body often needs time to recover nerve signaling and blood flow. During this period, erections may not occur as regularly as they once did. When erectile tissue remains inactive for long periods, the internal structure of the penis can begin to change. Blood circulation becomes weaker, oxygen delivery declines, and the smooth muscle that supports erection may gradually lose elasticity.

The penis is a vascular organ that depends on regular blood flow to maintain healthy tissue. During a natural erection, oxygen-rich blood fills the erectile chambers and keeps the tissue flexible. When this process is interrupted for months, the lack of oxygen can lead to fibrosis, which is the development of scar-like tissue inside the erectile chambers. Fibrosis reduces the ability of the penis to expand and maintain rigidity.

For this reason, many physicians recommend strategies that keep blood circulating through the penile tissue during recovery. Vacuum erection devices are often used for this purpose. The device creates gentle negative pressure around the penis, drawing blood into the erectile chambers. This process helps maintain tissue oxygenation and prevents the structural changes that can occur when erections are absent for extended periods.

These devices can be used during sexual activity with the help of a constriction ring, but they are also commonly used as part of a rehabilitation routine. Even without sexual activity, periodic engorgement helps maintain the health of the erectile tissue while the nerves recover from treatment.

After prostate cancer treatment, recovery rarely follows a straight timeline. Some men regain erectile function gradually over many months, and in certain cases, recovery continues even years after surgery. Maintaining tissue health during that time creates better conditions for the body to restore function whenever nerve signaling improves.

05:00 – Citrulline, Nitric Oxide, and Circulatory Support

Blood flow is the central mechanism behind erection. When sexual stimulation occurs, the nerves surrounding the penis signal the release of nitric oxide. This molecule relaxes the smooth muscle inside the penile arteries and allows blood to rush into the erectile chambers. When nitric oxide levels are strong and circulation is healthy, the penis can fill with blood and maintain rigidity.

After prostate cancer treatment, this signaling pathway may become weaker. Nerve irritation or vascular changes can reduce nitric oxide activity, which limits the body’s ability to generate adequate blood flow. For this reason, some clinicians look at nutritional compounds that support nitric oxide production as part of a broader recovery strategy.

L-citrulline is one of the compounds often discussed in this context. It is an amino acid that the body converts into L-arginine, which then participates in nitric oxide production. By increasing the availability of this pathway, citrulline can help promote vasodilation, meaning the widening of blood vessels that improves circulation.

Typical doses used for circulatory support range from about 2,000 milligrams to 6,000 milligrams per day. Some individuals take it daily, while others use it a few hours before sexual activity or exercise. The compound is also widely used in sports nutrition because increased nitric oxide production improves blood delivery to muscles during training.

For sexual recovery, citrulline is sometimes used alongside medications such as PDE-5 inhibitors. The medication enhances blood flow by affecting vascular signaling, while citrulline supports the body’s nitric oxide pathway. When used together under medical supervision, these approaches may provide complementary support for circulation.

It is important to understand that citrulline does not directly create an erection on its own. Its role is to support the biological conditions that make healthy blood flow possible. When circulation improves and nerve recovery progresses, the body becomes better equipped to restore erectile function over time.

05:44 – Trimix and Alprostadil

When oral medications and circulation-support strategies are not enough to restore erections, doctors sometimes introduce therapies that act directly inside the penile tissue. Two of the most established options are alprostadil and Trimix. These treatments work through a local mechanism, which means they act directly on the blood vessels of the penis rather than relying on nerve signals from the brain.

Alprostadil is a synthetic version of prostaglandin E1, a compound that causes blood vessels to relax and widen. When it is injected into the base or side of the penis using a very small needle, it triggers strong vasodilation inside the erectile chambers. Blood rapidly fills the corpora cavernosa, which are the sponge-like structures responsible for erection. Because the drug works locally, the erection can occur even when nerve pathways have been weakened by prostate surgery or radiation.

Trimix works on the same principle but combines three medications instead of one. The mixture usually contains alprostadil, papaverine, and phentolamine. Each component contributes to the same physiological outcome by relaxing smooth muscle and expanding the blood vessels that supply the penis. The combined effect often produces a stronger and more reliable erection than alprostadil alone, which is why Trimix is frequently used when other treatments have failed.

One advantage of injectable therapy is that it bypasses the nerve-dependent pathway that oral medications rely on. PDE-5 inhibitors require some degree of intact nerve signaling to trigger nitric oxide release. Injectable medications create the vascular response directly inside the erectile tissue. This makes them particularly useful for men recovering from prostatectomy, where nerve function may take a long time to return.

The injections are typically administered about ten minutes before sexual activity. The needles used are extremely fine, usually around a 30–31 gauge insulin-type needle, which allows the medication to be delivered with minimal discomfort. The dosage can be adjusted gradually under medical supervision so that the erection is strong enough for intercourse without lasting too long.

One potential complication is a prolonged erection known as priapism, which occurs when the erection persists for several hours. Although uncommon when doses are carefully managed, this condition requires medical attention because extended blood trapping can damage tissue. Physicians, therefore, guide patients through dose adjustments to find the lowest effective amount.

For many men, injectable therapies restore a sense of control during the recovery period after prostate cancer treatment. Even if natural erections return slowly over time, these medications provide a reliable way to maintain sexual activity and preserve confidence while the body continues to heal.

09:20 – Bremelanotide and Libido Recovery

Loss of sexual desire can become a significant challenge after prostate cancer treatment. Surgery, radiation, and certain medications can disrupt hormonal balance, nerve signaling, and psychological confidence. When libido declines, erectile treatments alone may not solve the problem because the brain’s interest in sexual activity is part of the response that initiates the entire process.

Bremelanotide, also known as PT-141, is a medication designed to act on the brain rather than the blood vessels of the penis. It works by stimulating melanocortin receptors in the central nervous system. These receptors influence sexual desire and arousal, which means the medication targets the motivational component of sexual activity rather than the mechanical component.

Unlike drugs that increase blood flow locally, bremelanotide acts at the level of the brain’s sexual response center. When administered as a small injection several hours before sexual activity, it can increase sexual desire and improve the body’s responsiveness to stimulation. Some men also report improved erectile firmness because heightened arousal can amplify the normal physiological signals involved in erection.

The medication is currently approved in the United States for female sexual arousal disorder, yet clinicians sometimes explore its use in men under medical supervision. Because it acts through a neurological pathway rather than a hormonal pathway, it does not directly alter testosterone levels or interfere with prostate cancer biology. This makes it a potential option for individuals who have experienced loss of libido following surgery, radiation therapy, or long periods of illness.

The effects usually begin within a few hours of administration and can last through the day. Some men describe an increased sense of sexual awareness or responsiveness during that time. The treatment can be used occasionally rather than daily, which allows flexibility depending on personal circumstances.

Like any medication, it carries potential side effects. The most commonly reported include nausea, mild flushing, or temporary drops in blood pressure. These effects are typically manageable when dosing is supervised by a clinician who understands how the drug interacts with other medications.

In the broader context of sexual recovery, therapies that address libido help restore the psychological and neurological components of intimacy. When desire, circulation, and confidence are supported together, the path toward rebuilding sexual health after prostate cancer treatment becomes more complete.

10:28 – Impact of Androgen Deprivation Therapy

Androgen deprivation therapy, often called ADT, is a treatment used to lower testosterone levels in men with prostate cancer. The therapy is sometimes introduced when cancer spreads beyond the prostate or when doctors want to slow the growth of aggressive disease. By reducing testosterone, the treatment removes a major hormonal signal that prostate cancer cells rely on for growth.

While this strategy can be effective for controlling cancer progression, the biological consequences are significant because testosterone supports many systems in the male body. Sexual desire, erectile strength, muscle mass, bone density, and overall energy levels are all influenced by testosterone. When levels drop sharply, men often notice a rapid decline in libido and sexual responsiveness.

The impact on sexual health can be profound. Many men report that the natural interest in intimacy fades, erections become difficult to achieve, and orgasm intensity changes. These effects are not purely psychological. Testosterone plays a direct role in maintaining nerve signaling, blood flow, and brain pathways involved in sexual motivation.

Beyond sexual function, long-term testosterone suppression can affect metabolism and cardiovascular health. Reduced testosterone is associated with increased body fat, decreased muscle strength, and reduced bone density. Some men experience fatigue, mood changes, and difficulty maintaining physical activity. Because of these broader effects, doctors carefully weigh the benefits and risks before recommending androgen deprivation therapy.

For men who require ADT, strategies to maintain quality of life become important. Exercise, resistance training, and careful nutritional habits help protect muscle mass and metabolic health. Some individuals also explore supportive therapies that address libido and circulation, although these approaches must be coordinated carefully with the oncology team.

Understanding the effects of androgen deprivation therapy helps men prepare for the changes it can bring. When expectations are realistic and supportive strategies are in place, it becomes easier to maintain physical health, emotional stability, and meaningful relationships during treatment.

12:46 – Shockwave Therapy

Low-intensity shockwave therapy is a regenerative treatment that has gained attention in the management of erectile dysfunction, including cases that develop after prostate cancer treatment. The therapy uses controlled acoustic waves that pass through the penile tissue and stimulate biological repair processes. Unlike medications that temporarily increase blood flow, this approach aims to improve the underlying vascular environment.

The mechanism centers on micro-mechanical stimulation of the tissue. When the acoustic waves pass through the penis, they create small mechanical stresses within the erectile structures. These stresses activate cellular signaling pathways that promote angiogenesis, which is the formation of new blood vessels. Increased capillary density improves blood supply to the erectile chambers and supports healthier tissue oxygenation.

The treatment also stimulates activity within the smooth muscle cells and endothelial lining of blood vessels. These cells play a central role in maintaining the elasticity of erectile tissue and regulating blood flow. When their function improves, the penis becomes better able to trap blood during sexual arousal, which helps restore erectile rigidity.

Shockwave therapy is usually delivered through a handheld device that applies acoustic pulses along different regions of the penis. Sessions typically last around fifteen to twenty minutes and are repeated over several weeks depending on the treatment protocol. Because the energy levels are low, the procedure does not involve surgery or injections, and most patients tolerate it well without anesthesia.

Regenerative treatments take time to show results because the body must build new vascular structures. Improvements in erection quality often develop gradually over several months rather than immediately after treatment. For this reason, clinicians sometimes space treatments at longer intervals so that the biological repair process can unfold.

The effectiveness of shockwave therapy varies depending on the underlying cause of erectile dysfunction. Men whose difficulties stem primarily from reduced blood flow tend to benefit the most. When nerve damage is severe, additional treatments may still be necessary. Even so, improved circulation can support other therapies and contribute to overall tissue health.

14:47 – Penile Implants and Advanced Options

When medications, injections, and regenerative therapies do not restore reliable erections, penile implants become one of the most effective long-term solutions. A penile implant is a surgically placed device inside the penis that allows a man to create an erection whenever he chooses. Modern implants are hydraulic systems made of cylinders placed within the erectile chambers, a fluid reservoir inside the abdomen, and a small pump located in the scrotum. When the pump is pressed, fluid moves into the cylinders and produces an erection that feels firm and natural enough for intercourse.

Unlike medications that depend on nerve signals or blood vessel responsiveness, implants work mechanically. This makes them especially useful for men who have experienced significant nerve damage following prostate surgery or who have persistent erectile dysfunction after radiation therapy. Because the device replaces the natural erectile mechanism, it can provide a reliable erection regardless of the underlying cause of the dysfunction.

Implants have evolved considerably over the years. Modern devices are designed to remain concealed within the body and allow erections to be produced gradually during intimacy. When sexual activity is finished, the fluid is released, and the penis returns to a relaxed state. Many men report high satisfaction because the device restores spontaneity and removes the uncertainty surrounding erection quality.

What to Consider

• Penile implants require surgery, which means careful evaluation by an experienced urologic surgeon is essential.
• The procedure is typically recommended only after other treatments such as medications, injections, or rehabilitation strategies have been explored.
• Recovery time varies, and sexual activity is usually resumed several weeks after surgery once healing is complete.
• Infection risk is low, but must be discussed before the procedure, particularly in individuals with diabetes or other medical conditions.
• Choosing a surgeon who performs implant procedures regularly improves outcomes and reduces complications.

Final Word

Recovery after prostate cancer treatment is often framed around survival statistics, imaging results, and PSA levels. Sexual health rarely receives the same level of attention, even though it plays a major role in the quality of life for many men. When sexual function changes after treatment, the lack of open conversation can make the experience feel isolating and confusing.

Sexual recovery rarely follows a straight timeline. Nerves can regain function gradually, circulation can improve with supportive therapies, and confidence often returns as men learn how their bodies respond after treatment. Medical tools exist for each stage of that process, ranging from circulation-support medications to injections, rehabilitation devices, regenerative therapies, and surgical solutions.

What often shapes recovery is the decision to stay engaged with the process. Men who ask questions, seek experienced medical guidance, and remain open to different options frequently discover that sexual health can be rebuilt in ways they did not expect. Long-term well-being after prostate cancer includes disease control, physical strength, emotional stability, and the preservation of intimacy and connection.

Continue the Conversation

If this episode raised new questions for you, there are earlier discussions that explore related themes in greater depth.

EP13 – Male Sexual Health Explained: Testosterone, Erections, and Long-Term Vitality

For readers who want a more detailed framework, Fight Cancer Like a Man: A Breakthrough Treatment for Prostate Cancer Without Surgery, Radiation, or Sacrificing Your Manhood by Dr. Stephen Petteruti presents a structured look at prevention, screening, and treatment decisions. The book explains the reasoning behind prioritizing vitality, safety, and informed medical choice in clear and practical terms.

If you would like access to extended clinical notes and member discussions, you can join the:

Intellectual Medicine Community
Membership: https://tinyurl.com/DrPetterutiMember
Sign up for Dr. Steve’s email newsletter: https://www.intellectualmedicine.com/newsletter
Learn more about Intellectual Medicine: https://www.intellectualmedicine.com

Connect with Dr. Petteruti:
LinkedIn: https://www.linkedin.com/in/drstephenpetteruti
Instagram: https://www.instagram.com/dr.stephenpetteruti
Facebook: https://www.facebook.com/dr.stephenpetteruti

Subscribe to the Intellectual Medicine Podcast:
Apple Podcasts: https://tinyurl.com/DrPetterutiApplePodcast
Spotify: https://tinyurl.com/DrPetterutiSpotifyPodcast

Suggested References

Don't just take my word for it. The following research challenges the 'standard of care' by highlighting the data on survival and the real cost of overtreatment. These studies are the map for moving away from blind protocols and toward biological precision.

Baran, Caner, and Mehmet Gokhan Culha. “Comment on: Comparison of the efficacy of the early LI-SWT plus daily tadalafil with daily tadalafil only as penile rehabilitation for postprostatectomy erectile dysfunction.” International journal of impotence research vol. 35,5 (2023): 494-495. doi:10.1038/s41443-022-00588-y

Ückert S, Bannowsky A, Albrecht K, Kuczyk MA. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opin Investig Drugs. 2014;23(11):1477-1483. doi:10.1517/13543784.2014.934805

Kim S, Cho MC, Cho SY, Chung H, Rajasekaran MR. Novel Emerging Therapies for Erectile Dysfunction. World J Mens Health. 2021;39(1):48-64. doi:10.5534/wjmh.200007

Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917. doi:10.1097/AOG.0000000000003514

Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol. 2001;3(3):113-119.

Ribé N, Rajmil O, Bassas L, Jurado C, Pomerol JM. Respuesta a la administración intracavernosa de tres fármacos diferentes en el mismo grupo de pacientes con disfunción eréctil [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction]. Arch Esp Urol. 2001;54(4):355-359.

Vlaicu AG, Mirvald C, Najjar S, et al. Intracavernous Injection Therapy as Second-Line Treatment for ED After Radical Prostatectomy: A Literature Review. Medicina (Kaunas). 2026;62(1):111. Published 2026 Jan 4. doi:10.3390/medicina62010111

Disclaimer

This podcast and its accompanying materials are intended for educational purposes. They aim to support informed discussion and health literacy. They are not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding individual medical concerns.

© 2026 Stephen Petteruti, DO. All rights reserved. Reproduction or distribution without written permission is prohibited.

Host: Intellectual Medicine by Dr. Stephen Petteruti (Member Version)

Date: August 19, 2025

Episode Summary

• The human immune system constantly identifies and destroys abnormal cells, including potential cancer cells. Nutritional status influences how well this system functions, which is why micronutrients and overall metabolic health often appear in discussions about cancer prevention and supportive care.
• Research on supplements varies widely in strength. Laboratory studies, animal research, observational data, and controlled clinical trials each offer different levels of evidence. Understanding these layers helps prevent overconfidence in early findings while still recognizing areas that deserve further investigation.
• Vitamin D remains one of the most frequently studied nutrients in cancer research. Adequate blood levels, often supported by supplementation and paired with vitamin K2 for calcium balance, may contribute to immune regulation and overall health, even though definitive proof of cancer prevention remains limited.
• Many popular supplements carry weaker evidence than commonly assumed. Saw palmetto shows minimal benefit as a standalone product, high doses of vitamin B6 can cause nerve problems, and apricot seeds present real toxicity risks. Careful evaluation and medical guidance remain essential when considering supplements.

Quick Decision Checklist

Before adding supplements to a prostate health plan, take a moment to review the fundamentals. Careful evaluation helps prevent unnecessary risk and keeps the focus on strategies that support long-term health.

You should make sure you tick the following boxes:

• Confirm that the supplement has at least some human research behind it, not only laboratory or animal studies.
• Prioritize nutrients that support overall physiology, such as immune regulation or metabolic health, rather than products marketed with single dramatic claims.
• Verify the correct dosage range and check total intake if the same nutrient appears in multiple supplements.
• Avoid substances associated with toxicity risk or unsupported cancer claims, such as apricot seed products.
• Discuss supplement plans with a knowledgeable clinician who can review medications, medical history, and potential interactions.

00:00 – Introduction

Many people assume that supplements can play a powerful role in preventing or treating prostate cancer. The idea is appealing. If certain nutrients support the immune system and overall health, it seems reasonable to believe that the right combination of supplements might help the body control cancer as well.

The reality is more complicated. Some supplements have biological mechanisms that suggest potential benefit, while others are widely promoted despite very limited evidence. Much of the confusion comes from how research is interpreted, how studies are designed, and how quickly conclusions spread once they appear in medical headlines.

Understanding the difference between scientific evidence, early laboratory findings, and real clinical outcomes helps clarify what supplements may realistically contribute. Some nutrients support immune function and overall health, which indirectly influences cancer risk. Others are popular mainly because of marketing or a misunderstanding of early research. Looking carefully at the evidence allows patients to make decisions that are grounded in science rather than assumptions.

02:07 – Immune System Basics and Cancer Defense

The human body constantly identifies and removes abnormal cells, including cells that carry the early characteristics of cancer. This surveillance is handled by the immune system, which functions through two major layers of protection known as the innate immune system and the adaptive immune system.